losartan has been researched along with Hypertension in 1807 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "In this multicenter, randomized, double-blind, noninferiority trial in China, patients 18 to 65 years of age with mild essential hypertension were randomly allocated to receive either SXC or losartan for 8 weeks." | 9.51 | Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. ( Cao, R; Chen, Y; Ding, R; Dong, G; Dong, Z; Du, J; Fan, J; Gao, Y; Hua, Q; Jiang, W; Lai, X; Li, Z; Mao, J; Wang, X; Wu, S; Wu, W; Wu, Z; Xiong, S; Xu, Y; Yuan, H; Zhang, G; Zhang, J; Zhen, H; Zhou, X, 2022) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion." | 9.41 | Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2021) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 9.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared." | 9.41 | Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. ( Bryant, CE; Hogg, RJ; Rajai, A; Webb, NJA, 2021) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 9.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 9.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of stage I hypertension." | 9.22 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. ( Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; de Alencastro, PR; de Mello, RB; de Sousa, MR; E Silva, RP; Filho, DC; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Neto, AA; Neto, JA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 9.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 9.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 9.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 9.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "The purpose of this study was to compare the effects of benazepril and losartan on endothelial function and vascular stiffness, in patients with diabetes mellitus and hypertension." | 9.20 | Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 9.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| " We aimed to assess the effect of two widely used long-acting drugs: perindopril and losartan in the treatment of hypertension comparing the once-daily (evening) vs." | 9.20 | Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan. ( Csajági, E; Major, Z; Pavlik, G; Szauder, I; Ujhelyi, G, 2015) |
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 9.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 9.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "The purpose of this trial was to assess the efficacy and tolerability of add-on nebivolol, a vasodilatory β-blocker, in patients with untreated or poorly controlled hypertension, receiving stable therapy with lisinopril (an angiotensin-converting enzyme inhibitor) or losartan (an angiotensin II receptor blocker)." | 9.17 | Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. ( Lin, Y; Stapff, M; Weiss, RJ, 2013) |
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 9.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| "Nine hundred thirty-nine participants in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy had measurable LVM at enrolment." | 9.17 | Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurigemma, GP; Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Køber, L; Roman, MJ; Wachtell, K, 2013) |
| "To observe the effects of Jinshuibao Capsule (JC) combined losartan potassium on some indices of early renal damage of hypertension patients of yin and yang deficiency syndrome (YYDS), such as levels of serum cystatin C (Cys C), beta2-microglobulin (beta2-MG), hypersensitive C-reactive protein (hs-CRP), uric acid (UA), blood pressure, blood lipids, and fasting blood glucose (FBG), and to explore their protective effects on early renal damage of hypertension patients and on the metabolisms of blood lipids and blood glucose." | 9.17 | [Jinshuibao capsule combined losartan potassium intervened early renal damage of hypertension patients of yin and yang deficiency: a clinical research]. ( Ge, ZM; Wang, YQ; Xin, Q; Yin, JQ; Zhang, CQ, 2013) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 9.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension." | 9.17 | [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. ( Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013) |
| "The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension." | 9.16 | Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. ( Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012) |
| "The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension." | 9.16 | Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. ( Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H, 2012) |
| " We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12." | 9.16 | Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2012) |
| "The Aichi Research on Combination therapy for Hypertension Study was a multicenter, open-label, prospective observational study that investigated the efficacy and safety of 1-year treatment with the losartan-hydrochlorothiazide (HCTZ) combination tablet in patients with hypertension uncontrolled by either ARB monotherapy or combination therapy with a calcium channel blocker (CCB)." | 9.16 | Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. ( Adachi, M; Kinoshita, A; Koh, N; Maeda, K; Miura, Y; Murohara, T, 2012) |
| "An exploratory subgroup analysis of a prospective, randomized, double-blind, forced-titration study comparing the efficacy and safety of once-daily olmesartan medoxomil (OM) and losartan potassium (LOS) in patients with stage 1 or stage 2 hypertension is reported." | 9.16 | Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. ( Chavanu, KJ; Flack, JM; Graff, A; Li, W, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 9.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "A predefined exploratory analysis of a prospective, randomized, double-blind, forced-titration study of olmesartan medoxomil (OM) versus losartan potassium (LOS) in subjects with hypertension not previously or previously treated with antihypertensive medication is reported." | 9.16 | Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. ( Chavanu, KJ; Lewin, A; Li, W; Punzi, HA, 2012) |
| "The objective of this study is to examine the effects of thiazide diuretics, plus medium-dose losartan versus maximal-dose angiotensin II receptor blockers (ARBs) on blood pressure (BP) in Japanese patients with uncontrolled hypertension despite the use of medium-dose ARBs." | 9.16 | Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. ( Emoto, N; Hirata, K; Inoue, Y; Ishida, T; Kitagawa, Y; Miki, T; Nishimura, K; Nonaka, H; Suematsu, M; Toh, R, 2012) |
| "There are limited data on the results of Russia's use of losartan in clinical practice for the treatment of patients with arterial hypertension (AH)." | 9.16 | [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. ( Glezer, MG; Saĭgitov, RT, 2012) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 9.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| "To evaluate the comparative efficacy and safety of once-daily olmesartan medoxomil (OM) and losartan potassium (LOS) in patients with hypertension." | 9.15 | A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. ( Chavanu, KJ; Dubiel, R; Flack, JM; Li, W; Punzi, HA; Stoakes, KA; Weir, MR, 2011) |
| "The Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial randomised 465 hypertensive overweight subjects with LVH to the direct renin inhibitor aliskiren 300 mg, losartan 100 mg or the combination and followed patients for 9 months." | 9.15 | Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. ( Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 9.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| "Losartan, enalapril and amlodipine reduced the number of premature ventricular contractions (PVCs) in patients with essential hypertension as well as blood pressure." | 9.14 | Losartan decreased premature ventricular contractions in patients with hypertension. ( Kuroyanagi, A; Matsubara, H; Sakamoto, T; Shiraishi, H; Shirayama, T, 2009) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 9.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "We randomized 465 patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m(2) to receive aliskiren 300 mg, losartan 100 mg, or their combination daily for 9 months." | 9.14 | Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. ( Appelbaum, E; Berglund, T; Cherif Papst, C; Dahlöf, B; Lukashevich, V; Manning, WJ; Smith, BA; Solomon, SD; Verma, A, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 9.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| " The primary objective of this randomized, multicenter, comparative, 3-month, open-label study was to evaluate the antihypertensive efficacy of losartan/chlorthalidone versus losartan/hydrochlorothiazide in mild-to-moderate essential hypertension." | 9.14 | A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. ( Basavanagowdappa, H; Chandurkar, N; Kumar, A; Pareek, A; Zawar, S, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 9.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 9.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35." | 9.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 9.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "We examined risks of cardiovascular death, all-cause death, and stroke following MI or coronary revascularization in hypertensive patients with left ventricular hypertrophy (LVH) enrolled in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)." | 9.14 | Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. ( Cicala, S; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Kjeldsen, SE; Lindholm, LH, 2010) |
| "In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly." | 9.14 | Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). ( Ambrosioni, E; Bombelli, M; Cerasola, G; Cipollone, F; Ferri, C; Grazioli, I; Leprotti, C; Mancia, G; Melzi, G; Mugellini, A; Mulè, G; Palasciano, G; Salvetti, A; Trimarco, B, 2010) |
| "This study investigated the effectiveness and tolerability of barnidipine 10 or 20 mg added to losartan 50 mg versus losartan 100 mg alone in patients with mild to moderate essential hypertension whose BP was uncontrolled by losartan 50-mg monotherapy." | 9.14 | Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-grou ( Cagnoni, F; Destro, M; Giglio, A; Grandi, AM; Lonati, L; Maresca, AM; Monza, M; Omboni, S; Parati, G; Pini, C; Ricci, AR; Venco, A, 2010) |
| "The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome." | 9.14 | Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Zoppi, A, 2010) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 9.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 9.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS)." | 9.13 | [Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome]. ( Kumova, TA; medvedev, iN; Simonenko, VB, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 9.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 9.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 9.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with left ventricular hypertrophy (LVH), mainly due to a highly significant 25% reduction in the relative risk of stroke compared with an atenolol-based regimen, for a similar reduction in blood pressure." | 9.12 | Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, G; McInnes, G, 2006) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 9.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 9.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| " The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension." | 9.12 | Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. ( Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "This double-blind, randomised, controlled study compared the efficacy of candesartan cilexetil 8 mg (n = 87) and losartan 50 mg (n = 89), once daily for 6 weeks, relative to placebo (n = 80) in patients with mild-to-moderate essential hypertension (diastolic blood pressure (DBP): 95-115 mmHg)." | 9.12 | A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. ( Asmar, R; Baguet, JP; Mallion, JM; Mouret, S; Nisse-Durgeat, S, 2006) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 9.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 9.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "5 mg in Asian patients with essential hypertension whose blood pressure had previously been treated with but not controlled by valsartan 80 mg." | 9.12 | Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. ( Chiang, CE; Coloma, R; Feig, P; Guptha, S; Ke, Y; Kim, D; Massaad, R; Sun, N; Tseng, CD; Vala, M; Watanabe, LA; Wei, M, 2006) |
| "Patients with essential hypertension (EHT) were randomized to treatment prospectively with losartan (50-100 mg/d) or amlodipine (5-10 mg/d) for 3 months." | 9.12 | The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. ( Fukuoka, T; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Murakami, K; Okura, T; Watanabe, S, 2006) |
| "To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension." | 9.12 | [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. ( Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 9.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 9.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 9.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 9.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 9.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicenter observational study that was designed to enroll hypertensive Japanese patients (>30,000 subjects)." | 9.12 | Design and baseline characteristics of an observational study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH). ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2007) |
| " This multicenter, randomized, double-blind study was aimed at testing the efficacy and safety of the combination of low-dose nifedipine GITS 20 mg/ losartan 50 mg compared with either monotherapy in patients with grade 1 to 3 hypertension over an eight-week period." | 9.11 | Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. ( Bendersky, M; Grassi, G; Guzman, L; Kuschnir, E; Mancia, G; Pañart, MS; Plotquin, Y; Resk, J; Wagener, G, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| " We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 9.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 9.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 9.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 9.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 9.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 9.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 9.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 9.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "To investigate the relationship between serum asymmetric dimethylarginine (ADMA) and blood pressure as well as target organ damage in essential hypertension, and to evaluate the effects of enalapril and losartan on them." | 9.11 | [Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment]. ( Chen, BM; Tao, LJ; Xiong, Y; Zhang, WR, 2005) |
| "In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens." | 9.11 | Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. ( Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 9.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "This 16-week, multicenter, double-blind, active-controlled, parallel-group, titration-to-effect trial compared the blood pressure and neurohumoral responses of the selective aldosterone blocker eplerenone (100-200 mg/d; n = 86) with those of the angiotensin receptor blocker losartan (50-100 mg/d; n = 82) in patients with low-renin hypertension (active renin < or = 25 pg/mL [< or = 42." | 9.11 | Effects of eplerenone versus losartan in patients with low-renin hypertension. ( Davidson, RC; Krause, SL; MacDonald, TM; Patrick, JL; Roniker, B; Ruilope, LM; Weinberger, MH; White, WB, 2005) |
| "A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens." | 9.10 | Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002) |
| "The Losartan Vascular Regression Study (LAARS) was a double-blind, parallel-group, randomized, controlled, multicenter study designed to compare the effects of the AII antagonist losartan and the beta-blocker atenolol on ultrasonographically determined intimamedia thickness (IMT) of the common carotid artery (CCA) in patients with mild to moderate essential hypertension." | 9.10 | Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. ( Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U, 2002) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 9.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 9.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "Both lercanidipine and losartan attenuate LDL oxidation in patients with type 2 diabetes mellitus and hypertension." | 9.10 | Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. ( Levi, Z; Rachmani, R; Ravid, M; Zadok, BS, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "According to a prospective, randomized, cross-over design, 30 hypertensive patients with a previous history of stroke (25 hemorrhage, 5 infarction) were assigned randomly to receive losartan (50 mg) or quinapril (10 mg) once daily for 4 weeks." | 9.10 | Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor. ( Fujiwara, N; Kato, T; Konta, Y; Metoki, N; Okuguchi, T; Okumura, K; Osanai, T, 2002) |
| "To compare the efficacy and safety of losartan with enalapril, in mild to moderate hypertension." | 9.10 | An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. ( Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002) |
| "To evaluate the effect of losartan and amilodipine on the platelet activation and renal function, and to study the relationship between the platelet activation and hypertensive renal damage in patients with mild and moderate hypertension." | 9.10 | [Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension]. ( Xie, XM; Yu, GL; Zhou, P, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 9.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 9.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| "One hundred eighteen patients with mild-to-moderate essential arterial hypertension were randomized to treatment with 10 mg/d of amlodipine (group 1), 20 mg/d of quinapril (group 2), or 2 x 50 mg/d of losartan (group 3)." | 9.10 | Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. ( Kawecka-Jaszcz, K; Klocek, M; Rajzer, M, 2003) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 9.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "A prospective, randomised, double-blind, parallel group study was carried out to compare the efficacy, safety and tolerability of telmisartan 40 mg once daily with losartan 50 mg once daily in Indian patients with mild to moderate hypertension." | 9.10 | Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. ( Ballary, C; Desai, A; Dongre, N; Samra, SS, 2003) |
| " We aimed to clarify the effects of losartan and its combination with hydrochlorothiazide on 24-h blood pressures (BPs), central hemodynamics and microcirculation in essential hypertension (EH)." | 9.10 | Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. ( Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003) |
| "The antihypertensive efficacy and tolerability of losartan/hydrochlorothiazide (HCTZ) and losartan monotherapy as initial treatment were compared in a double-blind trial in Chinese patients with mild to moderate essential hypertension." | 9.10 | A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. ( Chen, L; Gao, R; Jiang, B; Li, J; Li, Y; Liu, G; Su, L, 2003) |
| "With a usual antihypertensive dose, both losartan and quinapril had a little suppressive effect on the cardiac sympathetic activity in essential hypertension." | 9.10 | Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. ( Doi, O; Ishikawa, J; Nawada, R; Obayashi, K; Sakata, K; Tamekiyo, H; Yoshida, H, 2002) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 9.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 9.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "The article presents data on effects of losartan (Cozaar of the Merck-Sharp-Dohme firm, USA) on neurohumoral indices in patients with mild to moderate forms of hypertension." | 9.09 | [Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan]. ( Belovol, AN; Koval', SN; Masliaeva, LV; Miloslavskiĭ, DK; Mysnichenko, OV, 1999) |
| "The antihypertensive efficacy and tolerability profiles of the selective AT1 receptor antagonists telmisartan and losartan were compared with placebo in a 6-week, multinational, multicentre, randomised, double-blind, double-dummy, parallel-group study of 223 patients with mild-to-moderate hypertension, defined as clinic diastolic blood pressure (DBP) >/=95 and /=140 and /=85 mm Hg." | 9.09 | ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. ( Lacourcière, Y; Mallion, J; Siche, J, 1999) |
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 9.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 9.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 9.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "Nineteen untreated patients with mild essential hypertension (47+/-2 years, range 30 to 65 years; 57% male) were randomly assigned in double-blind fashion to losartan or atenolol treatment for 1 year." | 9.09 | Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. ( Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM, 2000) |
| " The aim of this study was to evaluate if the efficacy of losartan in hypertension could be enhanced by providing patients with a device for home BP measurement." | 9.09 | Influence of self-measurement of blood pressure on the responder rate in hypertensive patients treated with losartan: results of the SVATCH Study. Standard vs Automatic Treatment Control of COSAAR in Hypertension. ( Brignoli, R; Hess, L; Vetter, W, 2000) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 9.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "To compare the regression of left ventricular hypertrophy in patients with moderate hypertension treated with enalapril, losartan or a combination of the two drugs at lower doses." | 9.09 | Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. ( Avanza, AC; El Aouar, LM; Mill, JG, 2000) |
| "In this case-control study in uncomplicated subjects with essential hypertension, losartan and enalapril, alone or combined with a diuretic, effectively and equally lowered office and ambulatory blood pressure and induced a significant reduction in left ventricular mass during long-term treatment." | 9.09 | Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. ( Benemio, G; Bruni, B; Porcellati, C; Reboldi, GP; Sacchi, N; Schillaci, G; Verdecchia, P, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 9.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, in which hypertensive patients with ECG LV hypertrophy (Cornell voltage-duration product, > 2440 mm x ms and/or SV1 + RV(5-6) > 38 mm) were randomized to > or = 4 years double-blinded treatment with losartan or atenolol." | 9.09 | Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2000) |
| "The efficacy, safety and side-effects of treatment with losartan (Ocsaar) was studied for the first time in Israel in a large group of patients with mild to moderate hypertension in several community clinics." | 9.09 | [Israeli experiences of treatment of hypertension with losartan (Ocsaar)--summary of the treatment of 421 patients in community health centers]. ( Zimlichman, R, 1999) |
| "Losartan reduces blood pressure in patients with essential hypertension, but the long-term central hemodynamic effects at rest and during exercise are not known." | 9.09 | Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. ( Gerdts, E; Lund-Johansen, P; Myking, OL; Omvik, P, 2000) |
| "The chronopharmacodynamics of angiotension-converting enzyme (ACE) inhibitors, such as ramipril (R), enalapril (E), acetene (A), caposide-50 (C-50) and the effect of the epiphyseal neurohormone melatonin used alone and in combination with cozaar (Co) and cintome (Ci) in the randomized groups including 124 patients with arterial hypertension (AH)." | 9.09 | [Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension]. ( Biiasilov, N; Komarov, FI; Makarova, LA; Narmanova, OZh; Shakirova, AN; Zaslavskaia, RM, 2000) |
| "After a 4-week placebo run-in period, 268 patients with mild-to-moderate hypertension were allocated randomly to groups to receive placebo, candesartan cilexetil (8 mg once daily) or losartan (50 mg once daily), for 4 weeks." | 9.09 | A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. ( Asmar, R; Lacourcière, Y, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 9.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 9.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 9.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| "To study the effect of losartan potassium in the treatment of mild to moderate hypertension and to compare its efficacy and adverse effect profile with enalaparil maleate." | 9.09 | Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. ( Babu, A; Bhaduri, J; Kamath, S; Kumar, TR; Raju, BS; Rao, M; Shobha, JC, 2000) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 9.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "To test the hypothesis that the hypercoagulable state in hypertension is significantly altered by anti-hypertensive therapy, we conducted a pilot prospective randomised double-blind trial of 40 untreated hypertensive patients (30 males, mean age 59 years) who were treated with either enalapril (10-20 mg per day) or losartan (50-100 mg per day) for 8 weeks." | 9.09 | Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. ( Beevers, DG; Li-Saw-Hee, FL; Lip, GY, 2001) |
| "625 mg (P/I) compared with the angiotensin II antagonist losartan 50 mg (L50) in the treatment of essential hypertension." | 9.09 | Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. ( Chanudet, X; De Champvallins, M, 2001) |
| "The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism." | 9.09 | Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. ( Atanassova, I; Natchev, E; Orbetzova, M; Tzingilev, D; Zacharieva, S, 2001) |
| "Patients > or = 21 years of age with mild to moderate hypertension, defined as a trough sitting diastolic blood pressure (SiDBP) between 95 and 115 mm Hg, were randomized to receive once-daily losartan (50 mg) or valsartan (80 mg) for 12 weeks." | 9.09 | Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. ( Calhoun, DA; DeLucca, PT; Elliott, WJ; Gazdick, LP; Kerns, DE; Zeldin, RK, 2001) |
| "The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in African American adults with mild to moderate hypertension." | 9.09 | Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. ( Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 9.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| "625 mg indapamide in essential hypertension." | 9.09 | Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. ( Laurent, S, 2001) |
| "This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function." | 9.09 | [Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan]. ( Badowski, R; Cieślik, P; Haczkiewicz, P; Hefczyc, J; Hrycek, A; Scieszka, J, 2001) |
| "In this multinational, double-blind, randomized, parallel study, the efficacy and tolerability of once-daily losartan (50 mg) versus once-daily ACE inhibitor (captopril; 50 mg) was evaluated in 163 patients with mild to moderate hypertension." | 9.08 | Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. ( Bradstreet, DC; Goldberg, AI; Halasz, S; Lim, NY; Madonna, O; Makris, L; Mallion, JM; Sweet, CS, 1995) |
| "To review the efficacy and safety of losartan and hydrochlorothiazide compared to losartan alone, hydrochlorothiazide alone or placebo in the treatment of mild to moderate hypertension in a clinical trial." | 9.08 | Losartan with hydrochlorothiazide in the treatment of hypertension. ( Schoenberger, JA, 1995) |
| "To compare the incidence of cough with the angiotensin II antagonist losartan, the angiotensin converting enzyme inhibitor lisinopril, and hydrochlorothiazide in hypertensive patients with previous angiotensin converting enzyme inhibitor cough." | 9.08 | Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. ( Ramsay, LE; Yeo, WW, 1995) |
| "The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension." | 9.08 | Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. ( Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS, 1995) |
| "The efficacy and safety of various doses of losartan potassium, a specific and selective angiotensin II receptor antagonist, were compared with those of placebo and enalapril maleate 20 mg in patients with mild to moderate essential hypertension in a randomized, double-blind, parallel study." | 9.08 | A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. ( Arcuri, KE; Goldberg, AI; Gradman, AH; Ikeda, LS; Nelson, EB; Snavely, DB; Sweet, CS, 1995) |
| "This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension." | 9.08 | Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. ( Arcuri, KE; Goldberg, AI; MacKay, JH; Snapinn, SM; Sweet, CS, 1996) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 9.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "One hundred and thirty five non-smoking hypertensive patients with ACE inhibitor cough confirmed by lisinopril rechallenge and placebo dechallenge were recruited into a double-blind random parallel-group comparison of losartan 50 mg, lisinopril 20 mg and hydrochlorothiazide 25 mg each given once daily for a maximum of 8 weeks." | 9.08 | ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. ( Ramsay, LE; Yeo, WW, 1995) |
| "To compare the efficacy and safety of a regimen of losartan potassium (losartan) and a regimen of enalapril maleate (enalapril) in a randomized trial of patients with severe hypertension in which the initial treatments were blinded." | 9.08 | Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. ( Berman, R; Gazdick, LP; Goldberg, AI; Ruff, D; Sweet, CS, 1996) |
| "The pharmacokinetic and pharmacodynamic alterations of multiple doses of losartan, an angiotensin II receptor antagonist, were examined in nine patients with essential hypertension." | 9.08 | Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. ( Ebihara, A; Fujimura, A; Harada, K; Sasaki, M; Sunaga, K, 1996) |
| " Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension." | 9.08 | Effects of losartan on insulin sensitivity in hypertensive subjects. ( Karjalainen, L; Laakso, M; Lempiäinen-Kuosa, P, 1996) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 9.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "The antihypertensive activity and safety of losartan, a specific and selective antagonist of angiotensin II (subtype 1) receptors, was evaluated in 100 inpatients with mild to moderate essential hypertension." | 9.08 | An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. ( Bradstreet, TE; Byyny, RL; Merrill, DD; Sweet, CS, 1996) |
| "To evaluate the blood pressure lowering efficacy as well as tolerability and safety of the angiotensin II antagonist losartan compared with that of the angiotensin converting enzyme inhibitor enalapril in patients with mild-to-moderate essential hypertension." | 9.08 | Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. ( Jensen, HA; Omvik, P; Tikkanen, I, 1995) |
| "In a 12-week, randomized, double-blind study, 24 patients with essential hypertension were given the angiotensin II antagonist losartan, or the beta-adrenoceptor blocker atenolol." | 9.08 | Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. ( Bergbrant, A; Hansson, L; Himmelmann, A; Svensson, A, 1996) |
| "This study compared the incidence of cough with the angiotensin-converting enzyme (ACE) inhibitor lisinopril and the diuretic metolazone with angiotensin II receptor antagonist losartan in elderly hypertensive patients with previous histories of ACE inhibitor-induced cough." | 9.08 | Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. ( Chan, P; Huang, TY; Ko, JT; Lee, YS; Lin, TS; Tomlinson, B, 1997) |
| "A double-blind, randomized, 12 weeks study of the effects on enalapril 20 mg (n = 46) vs losartan 50 mg daily (n = 47) on blood pressure, albuminuria, fasting blood glucose, and lipids in 57 male and 36 female patients with essential hypertension." | 9.08 | Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. ( Dollerup, J; Jensen, HA; Mogensen, CE; Nielsen, B; Nielsen, S, 1997) |
| " Twenty patients with essential hypertension were included in a randomized, double-blind, placebo-controlled crossover study of 4 weeks' treatment with losartan, a selective type 1 angiotensin (AT1) receptor antagonist." | 9.08 | Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo. ( Arnesen, H; Aspelin, T; Kjeldsen, SE; Moan, A; Seljeflot, I; Tønnessen, T, 1998) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 9.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| "The antihypertensive efficacy and safety of losartan, a specific and selective angiotensin II (AII) receptor antagonist, was compared to captopril in patients with mild or moderate essential hypertension." | 9.08 | A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. ( Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997) |
| " Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design." | 9.08 | Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. ( Beissner, P; Lerch, M; Schneider, M; Shaw, SG; Teuscher, AU; Weidmann, P, 1998) |
| "The primary objectives of this double-blind study were to compare the antihypertensive efficacy and tolerability of irbesartan and losartan, two angiotensin II (AT1 subtype) receptor antagonists with different pharmacokinetic profiles in patients with mild-to-moderate hypertension." | 9.08 | Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. ( Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 9.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 9.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 9.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| "The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives." | 9.08 | Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 9.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic)." | 9.07 | Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. ( Brunner, H; Dobbins, TW; Faison, EP; Irwin, R; Karlberg, BE; Lacourcière, Y; Nelson, EB; Ramsay, LE; Snavely, DB, 1994) |
| "Patients with a history of an ACE inhibitor-associated dry cough confirmed by a second challenge with lisinopril were enrolled into an international, multicenter, randomly allocated, double-blind, parallel-group, controlled trial, to be treated with losartan, lisinopril or hydrochlorothiazide." | 9.07 | Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. ( Faison, EP; Lacourcière, Y; Lefebvre, J; Nakhle, G; Nelson, EB; Snavely, DB, 1994) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 8.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| " Several clinical trials have compared candesartan with losartan in the management of essential hypertension." | 8.87 | A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. ( , 2011) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 8.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "Hypertension is a major risk factor for cardiovascular disease, and data regarding the efficacy and tolerability of telmisartan compared with losartan on blood pressure (BP) control in patients with hypertension." | 8.84 | Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. ( Cheng, JW; Lu, GC; Xi, GL, 2008) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 8.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 8.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility." | 8.82 | Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. ( Volpe, M, 2005) |
| "The clinical efficacy and tolerability of losartan were studied in clinical trials in Japanese patients with essential hypertension." | 8.79 | The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. ( Ogihara, T; Yoshinaga, K, 1996) |
| "Losartan is the first drug of a new therapeutic class, the angiotensin II (A II)-receptor antagonists, to be clinically studied and become available for the management of hypertension." | 8.79 | Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. ( Goldberg, AI; Mallion, JM, 1996) |
| " Experience with losartan, the first of the selective AII receptor antagonists to be approved for clinical use, indicates that this approach is efficacious in all grades of hypertension and offers a more attractive and acceptable tolerability profile than other forms of antihypertensive medications." | 8.79 | Angiotensin II antagonism: a new avenue of hypertension management. ( Gavras, H, 1997) |
| "Losartan potassium, an angiotensin II receptor antagonist, is the first of a new class of agents to be introduced for the treatment of hypertension." | 8.79 | Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. ( Caffe, SE; McIntyre, M; Michalak, RA; Reid, JL, 1997) |
| "The co-administration of losartan and puerarin in hypertension rat models was investigated aiming to evaluate their interaction and potential mechanism." | 8.31 | Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan. ( Huang, Y; Xue, M, 2023) |
| "To describe a case of angioedema associated with increasing the dose of HMG-CoA reductase inhibitor (atorvastatin) from 20 to 40 mg daily in a patient previously stable on angiotensin II receptor blocker (losartan) and calcium channel blocker (amlodipine) as antihypertensive agents." | 8.12 | Dose-dependent atorvastatin associated with angioedema. ( Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA, 2022) |
| " We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension." | 8.12 | Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022) |
| "Losartan prescription in some conditions such as hypertension or ERT could worsen RBF and RVR responses to Ang II." | 8.12 | Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats. ( Choopani, S; Nematbakhsh, M, 2022) |
| "A MassARRAY approach was used to detect single nucleotide polymorphism (SNP) loci in the URAT1 and CYP2C9 genes (16 and 2 loci, respectively) in 111 patients with hypertension and hyperuricemia taking losartan and in 121 healthy controls." | 8.02 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. ( Fan, Y; Li, Z; Mao, D; Wang, Y; Wu, L; Zhuang, W, 2021) |
| " The present study aims to examine whether COX-1 and COX-2 were implicated in endothelial dysfunction in hypertension and calcitriol, an active form of vitamin D preserved endothelial function through regulating COX expression." | 8.02 | Calcitriol inhibits COX-1 and COX-2 expressions of renal vasculature in hypertension: Reactive oxygen species involved? ( Dong, J; Gao, M; Li, Y; Liu, Y; Suo, Z; Xu, C, 2021) |
| "We investigated the therapeutic effects of losartan, an angiotensin II type 1 receptor blocker, on prostatic hyperplasia in spontaneously hypertensive rats (SHRs)." | 8.02 | Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats. ( Higashi, Y; Karashima, T; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2021) |
| "In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)." | 8.02 | Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021) |
| " Considering the causal relationship between hypertension and AD and that targeting cerebrovascular pathology with ARBs does not necessarily require their systemic effects, we tested intranasal losartan in the rat model of chronic hypertension (spontaneously hypertensive stroke-prone rats, SHRSP)." | 7.91 | Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats. ( Beer-Hammer, S; Buadze, M; Danielyan, L; Davtyan, T; Drews, HJ; Frey, WH; Gleiter, CH; Kabisch, D; Lourhmati, A; Petschak, S; Schwab, M; Verleysdonk, S; Yenkoyan, K, 2019) |
| " We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation." | 7.85 | Aliskiren reduces albuminuria after kidney transplantation. ( Biedunkiewicz, B; Chamienia, AL; Debska-Slizien, AM; Heleniak, Z; Lizakowski, S; Małgorzewicz, S; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2017) |
| "Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)." | 7.85 | Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017) |
| "Stroke-prone spontaneously hypertensive (SHRSP) rats were administered losartan, amlodipine or saline for 6 or 16weeks at the onset of prehypertension." | 7.85 | Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model. ( He, DH; Lin, JX; Xie, Q; Xu, CS; Zhang, LM, 2017) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 7.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 7.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| "Spontaneous rectus sheath haematomas and cough secondary to losartan are individually rare conditions." | 7.83 | Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy. ( Ahmed, S; Sweigart, J; Talari, G; Talari, P, 2016) |
| "With regard to the medications, Atorvastatin, Losartan and Captopril were administered more in patients (groups 1, 2 and 3) than the patients without hypertension and CAD." | 7.83 | Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. ( Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M, 2016) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is involved in hypertension." | 7.81 | Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. ( Hsu, CN; Huang, LT; Lee, CT; Tain, YL, 2015) |
| "To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensive patients with hyperuricemia and the uricosuric action of losartan therapy among hypertensive patients with hyperuricemia." | 7.81 | URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. ( Lou, XY; Peng, Y; Qu, J; Qu, Q; Sun, H; Wang, G; Zeng, Y, 2015) |
| "We determined whether the blood pressure response to losartan in an older Chinese population with essential hypertension was associated with apelin gene polymorphisms." | 7.81 | Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension. ( Jia, J; Men, C; Tang, KT; Zhan, YY, 2015) |
| "Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis." | 7.80 | Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 7.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| " In the present study, we tested the hypothesis that the B1 kinin receptor (B1R) contributes to vascular hypertrophy in angiotensin II (ANG II)-induced hypertension, through a mechanism involving reactive oxygen species (ROS) generation and extracellular signal-regulated kinase (ERK1/2) activation." | 7.80 | An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies. ( Akamine, EH; Barreto-Chaves, ML; Carvalho, MH; Ceravolo, GS; Chopard, RP; Costa, TJ; Fernandes, DC; Fortes, ZB; Jordão, MT; Laurindo, FR; Montezano, AC; Takano, AP; Tostes, RC; Touyz, RM, 2014) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 7.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension." | 7.78 | Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. ( Inoue, A; Mitsutake, R; Miura, S; Saku, K; Shiga, Y; Uehara, Y, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 7.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 7.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 7.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "To investigate the effect of losartan on prostatic hyperplasia in spontaneous hypertension rats (SHRs) and its pathophysiological mechanism." | 7.78 | [Inhibitory effect of losartan on prostatic hyperplasia in spontaneous hypertension rats and its pathophysiological mechanism]. ( Dong, LN; Qu, XB; Shen, F; Zeng, XF; Zhang, XY; Zhao, XK, 2012) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 7.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 7.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| "The clinical course of losartan potassium/hydrochlorothiazide (Preminent(®))-induced hyponatremia has not been described." | 7.77 | Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients. ( Fujiki, K; Kinoshita, H; Kobayashi, K; Koga, N; Tomiyama, J; Yaguramaki, T; Yakushiji, F; Yasuda, M, 2011) |
| " Diminished PAME release and its vasorelaxing activity and increased release of angiotensin II in the PVAT suggest a noble role of PVAT in pathogenesis of hypertension." | 7.77 | Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. ( Chang, HH; Chen, MF; Chen, PY; Chiang, CL; Kuo, JS; Lee, TJ; Lee, YC; Liu, CH; Yeh, JI, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "Hypertension caused by chronic infusion of angiotensin II (Ang II) in experimental animals is likely to be mediated, at least in part, by an elevation of ongoing sympathetic nerve activity (SNA)." | 7.76 | Does enhanced respiratory-sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II-salt hypertension? ( Fink, GD; Osborn, JW; Pedrino, GR; Toney, GM, 2010) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 7.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 7.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 7.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "A case of anaphylaxis and angioedema induced by angiotensin II receptor blocker (ARB), losartan is reported." | 7.76 | Losartan associated anaphylaxis and angioneurotic oedema. ( Kazim, SF; Shahid, M, 2010) |
| "To evaluate 24-hour efficacy of losartan in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index." | 7.76 | [The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome]. ( Frána, P; Plachý, M; Rihácek, I; Schwarz, D; Soucek, M, 2010) |
| "We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke." | 7.75 | Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "To investigate the effects of losartan on left ventricular hypertrophy (LVH) and plasma transforming growth factor-beta1 (TGF-beta1) in elderly patients with essential hypertension (EH)." | 7.75 | [Effects of losartan on left ventricular hypertrophy and plasma transforming growth factor-beta1 in elderly patients with hypertension]. ( Bai, SC; Huang, P; Lai, WY; Li, Y; Su, L; Wu, ZL; Xu, DL, 2009) |
| "The effects of endogenous angiotensin II (Ang II) and neuronal nitric oxide synthase (nNOS) on tonic sympathetic activity were studied in salt-sensitive hypertension-induced heart failure." | 7.75 | Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure. ( Kato, K; Kemuriyama, T; Maruyama, S; Nishida, Y; Ohta, H; Sato, Y; Tandai-Hiruma, M, 2009) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| " We prospectively compared MWS derived from linear echocardiographic dimensions with MR strain(in) in septal and posterior locations in 27 subjects with ECG LV hypertrophy in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 7.74 | Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. ( Bella, JN; Biederman, RW; Calhoun, D; Dell'Italia, LJ; Devereux, RB; Doyle, M; Kortright, E; Oparil, S; Perry, G; Pohost, GM; Young, AA, 2008) |
| " We investigated long-term effects of losartan on serum concentrations of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS) by serial measurements over 6 months." | 7.74 | Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. ( Aso, Y; Hara, K; Inoue, T; Inukai, T; Nakano, T; Node, K; Sakai, Y; Shimizu, M; Takayanagi, K; Takebayashi, K; Uchida, T, 2008) |
| "The different protein spots expression may play important roles in Losartan's effective protection to hypertension rats renal tissue." | 7.74 | [Losartan's effects on the protein expression of the kidney of spontaneous hypertension rat]. ( Chen, JZ; Du, YX; Li, SP; Wang, XX; Yu, M, 2008) |
| "The mechanisms by which chronic infusion of an initially subpressor low dose of angiotensin II (ANG II) causes a progressive and sustained hypertension remain unclear." | 7.74 | Investigation of the mechanisms by which chronic infusion of an acutely subpressor dose of angiotensin II induces hypertension. ( Cochrane, T; Hood, SG; May, CN; McKinley, MJ, 2007) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 7.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 7.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicentered, observational study that was designed to enroll 30,000 hypertensive Japanese patients from more than 3,000 private practitioners." | 7.74 | Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| " The patient experienced cough 3 days following the initiation of losartan treatment." | 7.74 | Cough induced by losartan with resolution after substitution with enalapril. ( Ahmadi, F; Dashti-Khavidaki, S; Faghihi, T; Khalili, H, 2008) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 7.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 7.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 7.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 7.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "Our objective was to compare the efficacy and duration of action of 4 angiotensin II receptor blockers (ARBs)--losartan (25-100 mg), candesartan (2-12 mg), valsartan (40-80 mg), and telmisartan (10-40 mg)-in patients with essential hypertension using self-measurement of blood pressure at home (home BP) and to examine the differential effect of the four ARBs on home pulse pressure (home PP)." | 7.73 | Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. ( Asayama, K; Hashimoto, J; Imai, Y; Kikuya, M; Metoki, H; Nishimura, T; Ohkubo, T; Totsune, K, 2005) |
| "These results suggest that reversal of high fructose-induced hypertension and insulin resistance by chronic losartan treatment is not dependent on AT2R activation and that functional activation of AT1R plays a major role in the pathogenesis of high fructose-induced hypertension and insulin resistance." | 7.73 | Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. ( Hsieh, PS, 2005) |
| " To assess the relations of LV mass and function with Hgb delivery (ie, the physiological carrier of oxygen), we calculated the product of Hgb concentration and Doppler-derived cardiac output in 864 hypertensive participants with electrocardiographic LVH (359 women) in the Losartan Intervention for End Point Reduction in Hypertension echocardiography substudy." | 7.73 | Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Fyhrquist, F; Gerdts, E; Hoieggen, A; Narayan, P; Nieminen, MS; Papademetriou, V; Wachtell, K, 2006) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| " Here we asked whether this defect represents a prime determinant in genetic hypertension or whether it is secondary to angiotensin II (Ang II) and/or the mechanical forces exerted on the vascular wall." | 7.73 | Abnormal renovascular parathyroid hormone-1 receptor in hypertension: Primary defect or secondary to angiotensin ii type 1 receptor activation? ( Barthelmebs, M; Coquard, C; Fiaschi-Taesch, N; Helwig, JJ; Massfelder, T; Schordan, E; Welsch, S, 2006) |
| "Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production." | 7.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 7.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "Losartan attenuates BSO-induced hypertension, which appears to be mediated, in part, by angiotensin II and the prostanoid endothelium-derived factors." | 7.72 | Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Silvestrov, N; Socci, RR, 2003) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 7.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "Hypertension caused by angiotensin II (Ang II) infusion is associated with oxidative stress in the peripheral vasculature and kidney." | 7.72 | Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. ( Davisson, RL; Lazartigues, E; Sharma, RV; Zimmerman, MC, 2004) |
| "Losartan treatment prevents the development of hypertension but not all vascular changes observed after ouabain treatment." | 7.72 | Ouabain-induced hypertension alters the participation of endothelial factors in alpha-adrenergic responses differently in rat resistance and conductance mesenteric arteries. ( Alonso, MJ; Balfagón, G; Rossoni, LV; Salaices, M; Vassallo, DV; Xavier, FE, 2004) |
| " This study was designed to determine whether our newly developed technique of color-coded TDI may be a useful means of quantifying the improvement in regional left ventricular (LV) myocardial contractility and relaxation after treatment with losartan in patients with hypertension." | 7.72 | Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique. ( Harada, K; Ishimoto, T; Ito, S; Kimura, E; Oishi, Y; Oki, T; Tabata, T; Tanaka, H; Yamada, H, 2004) |
| "To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system." | 7.72 | Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective. ( Burnier, M; Erne, P; Szucs, TD, 2004) |
| "The study sought to determine whether treatment with the angiotensin II type 1 receptor antagonist losartan would restore the normal dilation of the left main coronary artery (LMCA) by cold pressor test in patients with essential hypertension, as shown by echocardiography." | 7.71 | Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension. ( Chang, Q; Deng, YB; Li, CL; Yang, HY, 2002) |
| "Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II." | 7.71 | Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002) |
| "To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)." | 7.71 | Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002) |
| "To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)." | 7.71 | [Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001) |
| "The effects of angiotensin II receptor antagonist losartan on elastic properties of aorta in patients with mild to moderate essential hypertension were assessed." | 7.71 | Assessment of effect of angiotensin II receptor antagonist losartan on aortic distensibility in patients with essential hypertension by echocardiography. ( Bi, X; Chang, Q; Deng, Y; Li, C; Pan, M; Yang, H, 2002) |
| "Sympathetic hyperactivity and hypertension caused by chronic treatment with ouabain or sodium-rich artificial cerebrospinal fluid (aCSF) can be prevented by central administration of an angiotensin type 1 (AT(1)) receptor blocker." | 7.71 | AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. ( Leenen, FH; Zhang, J, 2001) |
| "To investigate whether brain AT1 receptor stimulation contributes as a hypertensive mechanism to deoxycorticosterone acetate (DOCA)-salt hypertension, losartan (1 mg/4 microL) or artificial cerebrospinal fluid (aCSF) was injected into the lateral cerebral ventricle in conscious control uninephrectomized Wistar rats or rats with DOCA-salt for 2 or 4 weeks, and mean arterial pressure (MAP) and heart rates (HR) were recorded." | 7.71 | Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. ( Leenen, FH; Park, CG, 2001) |
| "We examined the effect and safety of combination therapy with low-dose diuretics (hydrochlorothiazide: HCTZ) and angiotensin II receptor antagonist (losartan) in elderly cases of hypertension, using ambulatory blood pressure monitoring (ABPM)." | 7.71 | [Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension]. ( Abe, I; Eto, K; Iida, M; Tsuchihashi, T, 2002) |
| "To test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist losartan would restore the normal dilation of the left main coronary artery to the cold pressor test in patients with essential hypertension, as assessed by echocardiography." | 7.71 | Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography. ( Deng, YB; Li, CL; Wang, DW; Yang, HY, 2002) |
| "The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in untreated patients with moderate-to-severe essential hypertension or patients with uncontrolled hypertension despite treatment with monotherapy or low-dose combination." | 7.71 | Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. ( Coca, A; de la Sierra, A; Felip, A; Mínguez, A; Pelegrí, A; Plana, J; Sobrino, J; Soler, J; Vila, J, 2002) |
| "Angiotensin II type 1 receptor-mediated constrictor effects may be modulated by hypertension-related vascular changes, changes in receptor function and in neurohumoral activity." | 7.70 | Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. ( Baan, J; Chang, PC; Pfaffendorf, M; van Zwieten, PA; Vermeij, P, 1998) |
| "The influence of losartan and the endothelin A and B receptor antagonist, bosentan was assessed on the alterations in renal hemodynamic and function as well as urinary albumin excretion (taken as an index of renal lesions) associated with L-NAME hypertension." | 7.70 | [Renal alterations in L-NAME hypertension: influence of losartan and bosentan]. ( Demeilliers, B; Herizi, A; Jover, B; Mimran, A, 1998) |
| "The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors." | 7.70 | Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| "To investigate the role of angiotensin II in the pathogenesis of hyperinsulinemia-induced hypertension in rats." | 7.70 | Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. ( Fang, TC; Huang, WC, 1998) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 7.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "This study was designed to investigate the effects of chronic inhibition of NO synthesis as well as chronic angiotensin receptor blockade with losartan in the development of hypertension, on mesenteric arterial bed reactivity as well as on the development of cardiac and kidney hypertrophy in deoxycorticosterone-salt (DOCA) hypertension." | 7.70 | Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. ( Cardinal, R; de Champlain, J; K-Laflamme, A; Oster, L, 1998) |
| ") was compared to that of Cozaar combination with melatonin (3 mg before sleep) in 21 patients with hypertension stage II (mean age 62 years)." | 7.70 | [Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension]. ( Goncharov, LF; Goncharova, ZF; Komarov, FI; Makarova, LA; Zaslavskaia, RM, 1998) |
| "Losartan is the first recently approved drug against hypertension disease that competes with the biological action of angiotensin II (AII) at the AT1 receptor." | 7.70 | An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. ( Kolocouris, A; Matsoukas, J; Mavromoustakos, T; Roumelioti, P; Weisemann, R; Zervou, M, 1999) |
| "To report a case of angioedema associated with losartan administration." | 7.70 | Losartan-induced angioedema. ( Rivera, JO, 1999) |
| "Since the effects of angiotensin II receptor antagonism on arterial function in nitric oxide (NO)-deficient hypertension are unknown, we investigated the influence of losartan therapy (20 mg kg-1 day-1) on the control of arterial tone in NG-nitro-L-arginine methyl ester (L-NAME; 20 mg kg-1 day-1)-induced hypertension." | 7.70 | Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. ( Holm, P; Hutri-Kähönen, N; Jolma, P; Kähönen, M; Kalliovalkama, J; Pörsti, I; Tolvanen, JP; Wu, X, 1999) |
| " ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study." | 7.70 | Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. ( Dahlöf, B; Devereux, RB; Jern, S; Kjeldsen, SE; Okin, PM, 2000) |
| "We assessed the role of angiotensin (Ang) II type 1 receptor (AT1) and endothelin type A and B (ETA & ETB) receptor in cardiovascular hypertrophy associated with angiotensin II-induced hypertension (200 ng/kg." | 7.70 | [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan]. ( Belabbas, H; Herizi, A; Jover, B; Mimran, A, 2000) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 7.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| "This small open study in elderly patients with essential hypertension investigated the effects of the angiotensin II AT1 receptor antagonist on red blood cell haematology and haemorheology." | 7.69 | Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. ( Bailey, RR; Gilchrist, NL; Nicholls, MG; Shand, BI, 1995) |
| "This study investigated the ability of the selective angiotensin II (AII)-type (AT)1 receptor antagonist losartan to reverse the fast (< 30 sec) pressor effect of AII, and the hypertension produced by chronic (2 weeks) i." | 7.69 | Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. ( Fink, GD; Gorbea-Oppliger, VJ; Melaragno, MG; Petit, RL; Potter, GS, 1994) |
| " To test the hypothesis that endogenous angiotensin II (Ang II) in the AHA also plays a role in blood pressure regulation and in NaCl sensitive hypertension in the SHR-S, Type 1 Ang II (AT1) receptors in the AHA were blocked by local microinjection of losartan, a selective nonpeptide AT1 receptor antagonist, and the effects of the intervention on blood pressure were observed." | 7.69 | Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. ( Berecek, KH; Chen, SJ; Jin, HG; Meng, QC; Oparil, S; Wyss, JM; Yang, RH, 1994) |
| " In these studies, we produced chronic NO blockade by oral administration of the NO synthesis inhibitor nitro-L-arginine methyl ester (L-NAME), which produced sustained hypertension and increased renal vascular resistance (RVR) in conscious rats." | 7.69 | Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. ( Baylis, C; Engels, K; Qiu, C, 1994) |
| "We tested the hypothesis that angiotensin II-induced hypertension is associated with an increase in vascular ." | 7.69 | Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. ( Freeman, BA; Griendling, KK; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Tarpey, M, 1996) |
| "Angioedema has not been associated with losartan therapy in hemodialysis patients, as it has been with angiotensin converting enzyme (ACE) inhibitors." | 7.69 | Angioedema associated with angiotensin II receptor antagonist losartan. ( Sharma, PK; Yium, JJ, 1997) |
| " Treatment with either losartan (25 mg x kg(-1) x d(-1)) or hydralazine (15 mg x kg(-1) x d(-1)), both of which prevented the Ang II-induced hypertension, blocked HO-1 mRNA upregulation." | 7.69 | Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. ( Alexander, RW; De Keulenaer, G; de León, H; Fukui, T; Griendling, KK; Ishizaka, N; Laursen, JB; Wilcox, JN, 1997) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 7.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| "We examined the chronic effects of losartan (DuP 753), a novel orally active angiotensin II receptor antagonist, on blood pressure and renal function in eight hospitalized patients with essential hypertension." | 7.68 | Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. ( Abe, K; Hagino, T; Imai, Y; Misawa, S; Omata, K; Tsunoda, K; Yoshinaga, K, 1993) |
| "We examined the chronic effects of MK954, a novel orally active angiotensin II receptor antagonist, on blood pressure and renal function in 8 patients with essential hypertension for 2-4 weeks." | 7.68 | [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension]. ( Abe, K; Hagino, T; Tsunoda, K; Yoshinaga, K, 1992) |
| "Inhibitors of angiotensin converting enzyme, renin, and the angiotensin II (Ang II) receptor lower the blood pressure of spontaneously hypertensive rats (SHR) used as a model of essential hypertension." | 7.68 | Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy. ( Higuchi, K; Inagami, T; Murakami, T; Nakajo, S, 1991) |
| "The aim of current study was to assess the effectiveness of losartan 50 mg in reducing blood pressure among post-dialysis euvolemic hypertensive patients, observing their survival trends and adverse events during the course of study." | 6.84 | Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial. ( Adnan, AS; Aftab, RA; Khan, AH; Khan, TM; Sulaiman, SAS, 2017) |
| "Ninety-one patients with untreated hypertension underwent a home sleep study (55 were found to have OSA; 36 were not)." | 6.82 | Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. ( Manhem, K; Peker, Y; Rosengren, A; Thunström, E, 2016) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 6.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "Morning hypertension is an established risk factor for cardiovascular events." | 6.80 | Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study. ( Anegawa, T; Aoki, Y; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Uchiwa, H; Ueda, T, 2015) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 6.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 6.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 6.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "A significant white coat hypertension was noticed in both the arms." | 6.78 | A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension. ( Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J, 2013) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 6.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| "Hypertension is associated with endothelial dysfunction and activated Rho-associated kinases (ROCKs)." | 6.77 | Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. ( Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2012) |
| "Many patients with hypertension have difficulty achieving their target blood pressure (BP)." | 6.77 | Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study. ( Inou, T; Kobayashi, K; Kubara, I; Meno, H; Nakamura, Y; Ota, T; Shiga, Y; Tanaka, M; Tsuchiya, Y, 2012) |
| " This study examined the practical efficacy of a combination therapy of ARB with thiazide diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy in patients with morning hypertension administered an ordinal dosage of ARB." | 6.77 | Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension. ( Hanayama, Y; Makino, H; Nakamura, Y; Uchida, HA, 2012) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 6.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| " Clinical and laboratory adverse events were reported for 29 patients (11%), but serious abnormalities were not observed." | 6.75 | One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2010) |
| "As arterial hypertension is the most important risk factor for ischemic stroke, the relevant guidelines recommend rigorous treatment to normalize blood pressure." | 6.73 | [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)]. ( Bestehorn, K; Diener, HC; Haller, H; Jung, C; Lüders, S; Schmieder, RE; Schrader, J; Smolka, W; Wahle, K, 2008) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 6.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Amiloride 40 mg was as effective as the other diuretics." | 6.73 | The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. ( Ashby, MJ; Brown, MJ; Hood, SJ; Taylor, KP, 2007) |
| " There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group." | 6.73 | Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. ( Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 6.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| " During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12." | 6.71 | Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. ( Byrne, M; Gil-Extremera, B; Lacourcière, Y; Mueller, O; Williams, L, 2003) |
| " Both drugs provided effective control over the 24-h dosing interval." | 6.71 | Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. ( Kolloch, RE; Meinicke, TW; Neutel, JM; Plouin, PF; Schumacher, H, 2003) |
| "Aliskiren was well tolerated at all doses studied." | 6.71 | Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. ( Jensen, C; Nussberger, J; O'Brien, E; Stanton, A, 2003) |
| "001) and the other periods of the 24-h interval compared with the levels achieved by the previous treatment, indicating a clear dose-response relationship." | 6.71 | Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. ( Lacourcière, Y; Poirier, L, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 6.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 6.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system predisposing to a procoagulant state." | 6.71 | Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. ( Hatzizacharias, A; Krespi, P; Makris, TK; Papadopoulos, DP; Stavroulakis, G; Tsoukala, C; Votteas, VE; Zilidis, A, 2004) |
| " Adverse events with the two treatments were comparable (telmisartan vs." | 6.71 | Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. ( Bai, J; Cai, NS; Cheng, NN; Fan, WH; Guo, JX; Guo, JZ; Ke, YN; Lu, ZY; Sheng, LH; Tang, B; Zhu, JR, 2004) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 6.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "and enalapril 20 mg o." | 6.70 | A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. ( Fagard, R; Lijnen, P; Pardaens, K; Thijs, L; Vinck, W, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "In losartan-treated patients, both cardiomyocyte and noncardiomyocyte apoptosis decreased (P<0." | 6.70 | Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. ( Díez, J; Fortuño, MA; González, A; Larman, M; López, B; Querejeta, R; Ravassa, S, 2002) |
| "Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase." | 6.70 | A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. ( Abellan, J; Cucalón, JM; Fernández-Vega, F; Gómez de la Cámara, A; Maceira, B; Sanz de Castro, S, 2001) |
| "Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity." | 6.69 | Losartan in Cushing's syndrome. ( Andrewa, M; Angelova-Gateva, P; Natchev, E; Orbetzova, M; Torbova, S; Tzingilev, D; Vergilova, J; Wipperrnann, M; Zacharieva, S, 1998) |
| " Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary." | 6.69 | Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. ( Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999) |
| "Losartan is a selective, competitive antagonist of the thromboxane A2 receptor in experiments performed in isolated vascular strips and in human and rat platelet-enriched plasma." | 6.69 | Inhibition of platelet aggregability by losartan in essential hypertension. ( Brosnihan, KB; Ferrario, CM; Levy, PJ; Owen, J; Smith, R; Yunis, C, 2000) |
| "Losartan appears to be an effective anti-hypertensive agent in patients with mild to moderate hypertension." | 6.68 | Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. ( Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995) |
| " A dose-response relationship to losartan was observed in this patient population." | 6.68 | Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. ( Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " The acute pharmacodynamic actions of intravenous (i." | 6.67 | Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. ( Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 6.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 6.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 6.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| " The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval." | 6.43 | Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros ( Lacourcière, Y; Neutel, JM; Schumacher, H, 2005) |
| "Losartan (Cozaar) is an angiotensin AT1 receptor antagonist." | 6.43 | Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Moen, MD; Wagstaff, AJ, 2005) |
| "Losartan 50-100 mg/day was compared with atenolol 50-100 mg/day in patients with essential hypertension and left ventricular hypertrophy (LVH) [n = 9,193] in the randomized, double-blind Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 6.42 | Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy. ( Keating, GM; Waugh, J, 2003) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 6.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| " Further data are needed on the use of losartan potassium in patients with renal impairment before accepting the recommendation that dosage adjustment is not necessary." | 6.40 | A risk-benefit assessment of losartan potassium in the treatment of hypertension. ( Burrell, LM, 1997) |
| "Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist." | 6.39 | Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. ( Goa, KL; Wagstaff, AJ, 1996) |
| " Once-daily dosing with losartan has been documented to be safe." | 6.39 | Losartan: first of a new class of angiotensin antagonists for the management of hypertension. ( Carr, AA; Prisant, LM, 1996) |
| "The renin-angiotensin system, through the effects of angiotensin II, may be involved in the pathogenesis of essential hypertension and associated left ventricular hypertrophy." | 6.18 | [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist]. ( Kjeldsen, SE; Omvik, P, 1996) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| " Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models." | 5.56 | Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. ( Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020) |
| "In this multicenter, randomized, double-blind, noninferiority trial in China, patients 18 to 65 years of age with mild essential hypertension were randomly allocated to receive either SXC or losartan for 8 weeks." | 5.51 | Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. ( Cao, R; Chen, Y; Ding, R; Dong, G; Dong, Z; Du, J; Fan, J; Gao, Y; Hua, Q; Jiang, W; Lai, X; Li, Z; Mao, J; Wang, X; Wu, S; Wu, W; Wu, Z; Xiong, S; Xu, Y; Yuan, H; Zhang, G; Zhang, J; Zhen, H; Zhou, X, 2022) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The aim is to explore the treatment effect of coronary artery disease (CAD) and hypertension on plasma levels of renalase activity and also the possible association of renalase rs10887800 gene polymorphism with CAD and hypertension." | 5.51 | Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. ( Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S, 2019) |
| " High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies." | 5.48 | Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. ( Anegawa, T; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Kajimoto, H; Uchiwa, H, 2018) |
| "Spontaneous seizures were video- and EEG-monitored in spontaneously hypertensive rats (SHRs) for a 16-week period after SE." | 5.43 | Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy. ( Atanasova, D; Ivanova, N; Kortenska, L; Lazarov, N; Lozanov, V; Mitreva, R; Pechlivanova, DM; Stoynev, A; Tchekalarova, JD, 2016) |
| "Losartan is a selective angiotensin II receptor type 1 blocker and a substrate of drug efflux transporter MDR1 (ABCB1)." | 5.43 | Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. ( Babaoglu, MO; Bozkurt, A; Cevik, L; Göktaş, MT; Gumus, E; Guven, GS; Kalkışım, S; Karaca, Ö; Pepedil, F; Yasar, U, 2016) |
| "The diagnosis of primary aldosteronism (PA) among the older-aged population has posed a crucial challenge." | 5.42 | The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old. ( Balakrishnan, P; Chen, YM; Chueh, SC; Hsein, YC; Kuo, CC; Wang, MJ; Wu, KD; Wu, VC, 2015) |
| "The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion." | 5.41 | Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2021) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 5.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared." | 5.41 | Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. ( Bryant, CE; Hogg, RJ; Rajai, A; Webb, NJA, 2021) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 5.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Treatment with losartan lowered systolic arterial pressure in S-P467L (132." | 5.40 | Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension. ( Carrillo-Sepulveda, MA; Davis, DR; Grobe, JL; Keen, HL; Sigmund, CD, 2014) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 5.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| " Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)." | 5.37 | Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). ( Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011) |
| "Treatment with Losartan and PD123319 in controls reduced MKP-1 and elevated ERK1/2 phosphorylation to the level observed in BS/GS patients treated with PD123319." | 5.36 | Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. ( Calò, LA; D'Angelo, A; Davis, PA; Mormino, P; Pagnin, E; Pessina, AC; Schiavo, S, 2010) |
| "Losartan treatment for 4-8 weeks reduced blood pressure of SHR to the normal levels seen in WKY." | 5.36 | Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. ( Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010) |
| " The medicated films were evaluated for physical properties, in vitro drug release studies, in vitro skin permeation studies, and pharmacodynamic studies." | 5.36 | Pharmacodynamics of a losartan transdermal system for the treatment of hypertension. ( Alam, MI; Ali, A; Aqil, M; Shams, MS; Sultana, Y, 2010) |
| "Hypertension is a lifestyle-related disease which often leads to serious conditions such as heart disease and cerebral hemorrhage." | 5.35 | Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension. ( Fukamizu, A; Ichino, T; Ishida, J; Koyama, T; Matsumoto, H; Mura, E; Nakamura, K; Ohno, O; Ohno, T; Uemura, D; Yamada, K; Yamaguchi, K; Yazawa, K; Ye, M, 2008) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 5.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 5.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "In this randomized double-blind double-simulation controlled trial, 300 patients with stage I or II hypertension will be recruited and randomly allocated in a 1:1:1 ratio to group A (treatment with SQG and placebo instead of Losartan), group B (treatment with Losartan and placebo instead of SQG), and group C (treatment with SQG and Losartan)." | 5.34 | Effects of sang-qi granules on blood pressure and endothelial dysfunction in stage I or II hypertension: study protocol for a randomized double-blind double-simulation controlled trial. ( Huang, L; Jing, R; Li, L; Li, R; Liu, L; Qiao, J; Shi, H; Sun, R; Yang, D; Zhu, C, 2020) |
| "Hyperkalemia is a complications of the use of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and aldosterone antagonists." | 5.33 | [Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. ( Kauffmann, R; Orozco, R; Venegas, JC, 2005) |
| "Hypertension is commonly associated with Wilms tumor, but hypertension secondary to renin-secreting Wilms tumor is uncommon." | 5.32 | Treatment of Wilms tumor-related hypertension with losartan and captopril. ( Mauger, D; Wong, W, 2004) |
| "Losartan was administered for a period of 14." | 5.31 | Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. ( Calviño, J; Lens, XM; Romero, R; Sánchez-Guisande, D, 2000) |
| "Apparently, when hypertension is sustained, reappearance of target organ damage may not be entirely dependent on angiotensin." | 5.31 | Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 5.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "Losartan-treated ANG II-infused rats exhibited normalized apoptosis, bax, caspase 3 activity, and AT(1) receptors." | 5.31 | Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. ( Diep, QN; El Mabrouk, M; Schiffrin, EL; Yue, P, 2002) |
| "But losartan potassium has been found to be more effective with fewer side effects when compared to enalapril maleate." | 5.31 | A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension. ( Arora, P; Neki, NS, 2001) |
| "Pretreatment with losartan (40 mg/kg/d) did not improve insulin action in the SHR." | 5.30 | Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. ( Caldiz, CI; de Cingolani, GE, 1999) |
| " Losartan is as effective as other commonly used antihypertensive agents, but it permits convenient dosing and is better tolerated." | 5.29 | The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension. ( Lacourcière, Y, 1995) |
| "Treatment with Losartan (10 mg/kg per day) lowered blood pressure markedly." | 5.28 | Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. ( Fukuchi, S; Hashimoto, S; Mizuno, K; Niimura, S; Ohtsuki, M; Sanada, H; Tani, M; Watanabe, H, 1992) |
| "9 years-old, with stage I hypertension at baseline and after 18 months of treatment with chlorthalidone/amiloride or losartan." | 5.27 | Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study. ( Bertoluci, C; Branchi, TV; Foppa, M; Fuchs, FD; Fuchs, SC; Santos, ABS, 2018) |
| "Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis." | 5.27 | Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. ( Nafar, M; Samavat, S; Shahraki, E, 2018) |
| "The aim of the study is to compare the effects of hydrochlorothiazide and indapamide on the kidney in patients with hypertension inadequately controlled with losartan." | 5.24 | Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. ( Chen, X; Li, J; Liu, K; Meng, Q; Shi, D; Shi, R; Wang, S; Zhang, X; Zhou, X, 2017) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 5.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| "9 years follow-up in 9193 patients with hypertension randomized to losartan- or atenolol-based regimens." | 5.24 | Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. ( Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM, 2017) |
| "Baseline estimated GFR (eGFR) and change in eGFR during follow-up were examined in relation to average on-treatment SBP in 8778 hypertensive patients with ECG left ventricular hypertrophy (LVH) randomly assigned to losartan- or atenolol-based treatment." | 5.22 | Impact of achieved systolic blood pressure on renal function in hypertensive patients. ( Devereux, RB; Kjeldsen, SE; Okin, PM, 2016) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 5.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of stage I hypertension." | 5.22 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. ( Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; de Alencastro, PR; de Mello, RB; de Sousa, MR; E Silva, RP; Filho, DC; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Neto, AA; Neto, JA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 5.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 5.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 5.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study." | 5.20 | TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. ( Argiolas, G; Barlassina, C; Boerwinkle, E; Braga, D; Carpini, SD; Chapman, AB; Chittani, M; Citterio, L; Condorelli, G; Cooper-Dehoff, RM; Cusi, D; Dominiczak, AF; Donner, KM; Frau, F; Fresu, G; Glorioso, N; Glorioso, V; Gong, Y; Hiltunen, TP; Johnson, JA; Kontula, KK; Lanzani, C; Manunta, P; Melander, O; Ortu, MF; Padmanabhan, S; Piras, DA; Pozzoli, S; Rivera, NV; Salvi, E; Simonini, M; Trimarco, B; Troffa, C; Turner, ST; Velayutham, D; Zaninello, R, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 5.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "The purpose of this study was to compare the effects of benazepril and losartan on endothelial function and vascular stiffness, in patients with diabetes mellitus and hypertension." | 5.20 | Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 5.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS)." | 5.20 | Marfan Sartan: a randomized, double-blind, placebo-controlled trial. ( Aegerter, P; Arnoult, F; Attias, D; Barthelet, M; Basquin, A; Boileau, C; Collignon, P; Delorme, G; Detaint, D; Dulac, Y; Dupuis-Girod, S; Edouard, T; Faivre, L; Habib, G; Jondeau, G; Milleron, O; Naudion, S; Odent, S; Pangaud, N; Plauchu, H; Ropers, J; Sassolas, F; Thomas-Chabaneix, J; Tubach, F; Wolf, JE, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| " The risk of new-onset AF was examined in relation to last in-treatment SBP before AF diagnosis or last in-study measurement in the absence of new AF in 8831 hypertensive patients with ECG left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline ECG, randomly assigned to losartan- or atenolol-based treatment." | 5.20 | Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K, 2015) |
| " We aimed to assess the effect of two widely used long-acting drugs: perindopril and losartan in the treatment of hypertension comparing the once-daily (evening) vs." | 5.20 | Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan. ( Csajági, E; Major, Z; Pavlik, G; Szauder, I; Ujhelyi, G, 2015) |
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 5.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "Patients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks." | 5.20 | Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| " This prospective randomized open-label study compared the efficacy and safety of a fixed-dose tablet of losartan (LST)-hydrochlorothiazide (HCTZ) (n = 99) and LST-amlodipine (AML) (n = 77) in Japanese patients whose hypertension was uncontrolled by ARB monotherapy." | 5.19 | Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. ( Hanaoka, K; Hasegawa, T; Kaizu, K; Kamata, K; Kimura, K; Kobayashi, S; Morita, S; Ohtake, T; Oshikawa, J; Sato, T; Taguri, M; Toya, Y; Umemura, S; Yasuda, G, 2014) |
| " In this study, we investigated basal EPC functions in normotensive control subjects and patients with essential hypertension and the effect of losartan on EPC function in hypertensive patients." | 5.19 | Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. ( Fukuda, N; Katakawa, M; Matsumoto, T; Soma, M; Suzuki, R; Tahira, Y; Tsunemi, A; Ueno, T, 2014) |
| "Incident AF was examined in 518 black and 8,313 nonblack hypertensive patients with electrocardiographic left ventricular hypertrophy (LVH) with no history of AF in sinus rhythm on their baseline electrocardiogram, who were randomly assigned to losartan- or atenolol-based treatment." | 5.19 | Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Julius, S; Kjeldsen, SE; Okin, PM; Wachtell, K, 2014) |
| "8 years randomized losartan- or atenolol-based antihypertensive treatment in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study and classified as having ISH (n = 128) if systolic BP ≥ 160 mmHg and diastolic BP < 90 mmHg, or non-ISH divided into two groups by systolic BP ≥ 160 mmHg (non-ISH ≥ 160 mmHg) (n = 645) and systolic BP < 160 mm Hg (n = 100) (non-ISH < 160 mmHg), respectively." | 5.19 | Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). ( Abdelhai, YM; Boman, K; Dahlöf, B; De Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Wachtell, K, 2014) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "Patients with a previous diagnosis of hypertension and type 2 diabetes mellitus were randomly divided into 2 groups and evaluated after 6 weeks of treatment with amlodipine (5 mg/day) or losartan (100 mg/day)." | 5.19 | Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2014) |
| "Male and female patients aged ≥ 18 years with hypertension despite 4-week, stable treatment with losartan 100-mg/d monotherapy were eligible for inclusion in this multicenter, randomized, double-blind study." | 5.19 | Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy. ( Ahn, T; Bae, JH; Han, KR; Hyon, MS; Kim, WH; Kim, YK; Lee, SU; Lim, DS; Park, HK; Suh, SY, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 5.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment." | 5.17 | Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2013) |
| "Baseline low-grade inflammation in patients with hypertension was associated with a poor ambulatory BP response, especially with losartan/HCTZ treatment." | 5.17 | Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study. ( Eguchi, K; Fukutomi, M; Hoshide, S; Kario, K; Watanabe, T, 2013) |
| " The Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/hydrochlorothiazide (HCTZ) combination is superior to high-dose losartan in not only reducing morning systolic blood pressure (SBP) but also ameliorating urinary albumin excretion (UAE) after 3-month treatment." | 5.17 | Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. ( Adachi, H; Imaizumi, T; Kai, H; Kaneyuki, M; Kusaba, K; Mitsutake, Y; Shihara, M; Toyama, Y; Ueda, T; Umei, H, 2013) |
| "The purpose of this trial was to assess the efficacy and tolerability of add-on nebivolol, a vasodilatory β-blocker, in patients with untreated or poorly controlled hypertension, receiving stable therapy with lisinopril (an angiotensin-converting enzyme inhibitor) or losartan (an angiotensin II receptor blocker)." | 5.17 | Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. ( Lin, Y; Stapff, M; Weiss, RJ, 2013) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 5.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| " Patients with type 2 diabetes and hypertension on maximal RAS blockade (n=70) were randomized to nebivolol or metoprolol succinate daily." | 5.17 | Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. ( Bakris, G; Briasoulis, A; Flynn, C; Kalaitzidis, R; Lazich, I; Oliva, R; Schlaffer, C, 2013) |
| "Nine hundred thirty-nine participants in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy had measurable LVM at enrolment." | 5.17 | Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurigemma, GP; Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Køber, L; Roman, MJ; Wachtell, K, 2013) |
| "To observe the effects of Jinshuibao Capsule (JC) combined losartan potassium on some indices of early renal damage of hypertension patients of yin and yang deficiency syndrome (YYDS), such as levels of serum cystatin C (Cys C), beta2-microglobulin (beta2-MG), hypersensitive C-reactive protein (hs-CRP), uric acid (UA), blood pressure, blood lipids, and fasting blood glucose (FBG), and to explore their protective effects on early renal damage of hypertension patients and on the metabolisms of blood lipids and blood glucose." | 5.17 | [Jinshuibao capsule combined losartan potassium intervened early renal damage of hypertension patients of yin and yang deficiency: a clinical research]. ( Ge, ZM; Wang, YQ; Xin, Q; Yin, JQ; Zhang, CQ, 2013) |
| "We conducted a quasi-experimental, validation study in which patients with primary, uncomplicated hypertension received open-label, fixed combination therapy with amlodipine/losartan 5/50 mg or 5/100 mg according to their baseline blood pressure (BP)." | 5.17 | Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). ( Pérez Carreño, JG; Romero, JD; Villar Centeno, JC, 2013) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 5.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "To evaluate the efficiency and safety of two treatment regimens using ramipril or losartan in combination with hydrochlorothiazide (HCT) and amlodipine in grade 1-2 arterial hypertension (AH)." | 5.17 | [Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial]. ( Chazova, IE; Martyniuk, TV, 2013) |
| "To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension." | 5.17 | [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. ( Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013) |
| "8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.17 | Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lund, BP; Nieminen, MS; Okin, PM; Wachtell, K, 2013) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| " In the present study, we examined the effects of ARB (angiotensin receptor blocker) therapy (losartan, 100 mg/day) on insulin sensitivity and endothelial function in 53 subjects with stage I hypertension, abdominal obesity and impaired fasting glucose." | 5.16 | Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. ( Abate, NI; Albu, JB; Creager, MA; Grundy, SM; Henry, RR; Mai, Y; Marks, JB; Mather, KJ; Perlstein, TS; Pool, JL; Rickels, MR, 2012) |
| "In the Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study, a double-blinded, randomized, parallel-group study, 9193 hypertensive patients with electrocardiogram (ECG)-documented left ventricular hypertrophy (LVH), randomized to once-daily losartan- or atenolol-based antihypertensive therapy were followed for a mean of 4." | 5.16 | Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K, 2012) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| "The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension." | 5.16 | Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. ( Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012) |
| "The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension." | 5.16 | Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. ( Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H, 2012) |
| "The goal of this study was to determine the noninferiority of fimasartan to losartan with regard to its efficacy and tolerability in adult Korean patients with mild-to-moderate hypertension." | 5.16 | Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w ( Kim, JJ; Kim, SK; Kim, YJ; Lee, HY; Lee, SE; Oh, BH; Park, CG; Rhee, MY; Yang, HM, 2012) |
| " Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg." | 5.16 | Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. ( Cho, SY; Choi, YJ; Hong, BK; Kim, KS; Park, CG; Yang, JY; Yoon, HJ; Yoon, JH; Yoon, MH, 2012) |
| " We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12." | 5.16 | Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2012) |
| "The Aichi Research on Combination therapy for Hypertension Study was a multicenter, open-label, prospective observational study that investigated the efficacy and safety of 1-year treatment with the losartan-hydrochlorothiazide (HCTZ) combination tablet in patients with hypertension uncontrolled by either ARB monotherapy or combination therapy with a calcium channel blocker (CCB)." | 5.16 | Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. ( Adachi, M; Kinoshita, A; Koh, N; Maeda, K; Miura, Y; Murohara, T, 2012) |
| "An exploratory subgroup analysis of a prospective, randomized, double-blind, forced-titration study comparing the efficacy and safety of once-daily olmesartan medoxomil (OM) and losartan potassium (LOS) in patients with stage 1 or stage 2 hypertension is reported." | 5.16 | Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. ( Chavanu, KJ; Flack, JM; Graff, A; Li, W, 2012) |
| "Data from all patients with at least two echocardiographic examinations in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) echocardiographic substudy (n = 801); high-risk patients on losartan- vs." | 5.16 | Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Greve, AM; Lønnebakken, MT; Nieminen, MS; Okin, PM; Olsen, MH; Omvik, P; Palmieri, V; Wachtell, K, 2012) |
| "A total of 9,027 patients with hypertension and ECG-LVH and without a history of HF were randomized to losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.16 | Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 5.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "A predefined exploratory analysis of a prospective, randomized, double-blind, forced-titration study of olmesartan medoxomil (OM) versus losartan potassium (LOS) in subjects with hypertension not previously or previously treated with antihypertensive medication is reported." | 5.16 | Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. ( Chavanu, KJ; Lewin, A; Li, W; Punzi, HA, 2012) |
| "The objective of this study is to examine the effects of thiazide diuretics, plus medium-dose losartan versus maximal-dose angiotensin II receptor blockers (ARBs) on blood pressure (BP) in Japanese patients with uncontrolled hypertension despite the use of medium-dose ARBs." | 5.16 | Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. ( Emoto, N; Hirata, K; Inoue, Y; Ishida, T; Kitagawa, Y; Miki, T; Nishimura, K; Nonaka, H; Suematsu, M; Toh, R, 2012) |
| "There are limited data on the results of Russia's use of losartan in clinical practice for the treatment of patients with arterial hypertension (AH)." | 5.16 | [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. ( Glezer, MG; Saĭgitov, RT, 2012) |
| "We evaluated ROCK activity in peripheral leukocytes by Western blot analysis in 651 patients with hypertension treated with antihypertensive agents, 28 untreated hypertensive patients and 28 healthy individuals, and the effects of treatment with amlodipine or losartan for 12 weeks on ROCK activity in 28 untreated hypertensive patients who were randomly divided into an amlodipine group (n = 14) and a losartan group (n = 14)." | 5.15 | Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. ( Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2011) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 5.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| "To evaluate the comparative efficacy and safety of once-daily olmesartan medoxomil (OM) and losartan potassium (LOS) in patients with hypertension." | 5.15 | A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. ( Chavanu, KJ; Dubiel, R; Flack, JM; Li, W; Punzi, HA; Stoakes, KA; Weir, MR, 2011) |
| "This is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage I hypertension." | 5.15 | A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, L; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Coelho, EB; Consolim-Colombo, F; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, R; Fuchs, FD; Fuchs, SC; Ghizzoni, F; Gus, M; Irigoyen, MC; Jardim, PC; Mion, D; Moreira, LB; Moreno, H; Mosele, F; Mota, M; Nobre, F; Nóbrega, AC; Pereira e Silva, R; Poli-de-Figueiredo, CE; Ribeiro, AL; Scala, LC; Schlatter, R; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF, 2011) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "The Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial randomised 465 hypertensive overweight subjects with LVH to the direct renin inhibitor aliskiren 300 mg, losartan 100 mg or the combination and followed patients for 9 months." | 5.15 | Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. ( Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H, 2011) |
| "The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension." | 5.15 | Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. ( Hasegawa, H; Kobayashi, Y; Komuro, I; Mizuguchi, T; Namiki, T; Narumi, H; Ohtsuka, M; Takano, H, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 5.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| "The precise relationship of Hyperuricemia found in hypertensive patients is still obscure; this study is a urinary uric acid lowering intervention with Losartan in hypertensive patients induced by Thiazide diuretics." | 5.15 | To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. ( Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J, 2011) |
| "The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36)." | 5.15 | Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. ( Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011) |
| "Losartan, enalapril and amlodipine reduced the number of premature ventricular contractions (PVCs) in patients with essential hypertension as well as blood pressure." | 5.14 | Losartan decreased premature ventricular contractions in patients with hypertension. ( Kuroyanagi, A; Matsubara, H; Sakamoto, T; Shiraishi, H; Shirayama, T, 2009) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 5.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "We randomized 465 patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m(2) to receive aliskiren 300 mg, losartan 100 mg, or their combination daily for 9 months." | 5.14 | Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. ( Appelbaum, E; Berglund, T; Cherif Papst, C; Dahlöf, B; Lukashevich, V; Manning, WJ; Smith, BA; Solomon, SD; Verma, A, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 5.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "A total of 937 hypertensive patients with ECG LVH were studied by echocardiography in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.14 | Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Olofsson, M; Papademetriou, V; Wachtell, K, 2009) |
| "The CORD trials tested ramipril and losartan in patients with hypertension." | 5.14 | CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. ( Dusek, L; Pavlík, T; Soucek, M; Spinar, J; Vítovec, J, 2009) |
| " The primary objective of this randomized, multicenter, comparative, 3-month, open-label study was to evaluate the antihypertensive efficacy of losartan/chlorthalidone versus losartan/hydrochlorothiazide in mild-to-moderate essential hypertension." | 5.14 | A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. ( Basavanagowdappa, H; Chandurkar, N; Kumar, A; Pareek, A; Zawar, S, 2009) |
| "8 years of randomized losartan- or atenolol-based treatment within the echocardiographic substudy of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.14 | Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). ( Dahlöf, B; Devereux, RB; Franklin, S; Gerdts, E; Nieminen, M; Papademetriou, V; Rieck, A; Wachtell, K, 2009) |
| "These data suggest that both bisoprolol and losartan are effective agents for the treatment of patients with recently diagnosed ESH stage 1-2 hypertension." | 5.14 | One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study. ( Caradonna, M; Cardillo, M; Di Pasquale, P; La Rocca, G; Licata, G; Mezzero, M; Parrinello, G; Paterna, S; Torres, D; Trapanese, C, 2009) |
| " A total of 30 patients with type II diabetes, along with hypertension and overt nephropathy, were enrolled in this randomized, two-period, crossover trial of 12 weeks of treatment with losartan (50 mg daily) and telmisartan (40 mg daily)." | 5.14 | Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. ( Azuma, K; Dejima, T; Kanaoka, T; Maeda, A; Masuda, S; Ohsawa, M; Tamura, K; Umemura, S; Wakui, H; Yanagi, M, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 5.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| " Patients with essential hypertension and a blood pressure > 140/90 mmHg on ARB monotherapy (losartan 50 mg/day or candesartan 8 mg/day) were randomly assigned to a nifedipine controlled release (CR) group (n = 15) or amlodipine group (n = 11)." | 5.14 | Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment. ( Ando, C; Inoue, Y; Kodama, S; Mihara, H; Miyoshi, K; Niimura, H; Okamura, K; Sumi, S; Tojyo, H; Tsuchiya, Y; Urata, H; Yamanouchi, Y, 2009) |
| " We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily)." | 5.14 | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. ( Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL, 2009) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 5.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "This pharmacogenetics substudy from the Losartan Intervention for Endpoint reduction in Hypertension study in patients with hypertension and left ventricular hypertrophy (LVH) treated with the angiotensin receptor blocker losartan versus the beta-blocker atenolol for 4." | 5.14 | Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. ( Benn, M; Berg, K; Dahlöf, B; de Faire, U; Edelman, JM; Eliasson, E; Fyhrquist, F; Hille, DA; Ibsen, H; Kontula, K; Lyle, PA; Nordestgaard, BG; Os, I; Sandberg, M; Sethi, AA; Wong, PH, 2010) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35." | 5.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 5.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "We examined risks of cardiovascular death, all-cause death, and stroke following MI or coronary revascularization in hypertensive patients with left ventricular hypertrophy (LVH) enrolled in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)." | 5.14 | Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. ( Cicala, S; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Kjeldsen, SE; Lindholm, LH, 2010) |
| " The present study was designed to investigate the effects of treatment with the angiotensin AT(1) receptor antagonist losartan on monocyte BGN mRNA and protein expression in essential hypertension." | 5.14 | Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients. ( Alibrandi, A; Castaldo, M; Cinquegrani, M; D'Ascola, A; Imbalzano, E; Mandraffino, G; Riggio, S; Saitta, A; Saitta, C; Sardo, MA, 2010) |
| "In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly." | 5.14 | Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). ( Ambrosioni, E; Bombelli, M; Cerasola, G; Cipollone, F; Ferri, C; Grazioli, I; Leprotti, C; Mancia, G; Melzi, G; Mugellini, A; Mulè, G; Palasciano, G; Salvetti, A; Trimarco, B, 2010) |
| "We examined blood pressure (BP) and medication over 5 years in 80 hypertensive patients who participated in the Hypertension Control Based on home systolic pressure (HOSP) study that compares effects of strict and mild control of morning home systolic blood pressure (SBP) as well as amlodipine- and losartan-based regimens." | 5.14 | Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based on Home Systolic Pressure (HOSP) substudy. ( Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Nakamura, S; Yoshihara, F, 2010) |
| "This study investigated the effectiveness and tolerability of barnidipine 10 or 20 mg added to losartan 50 mg versus losartan 100 mg alone in patients with mild to moderate essential hypertension whose BP was uncontrolled by losartan 50-mg monotherapy." | 5.14 | Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-grou ( Cagnoni, F; Destro, M; Giglio, A; Grandi, AM; Lonati, L; Maresca, AM; Monza, M; Omboni, S; Parati, G; Pini, C; Ricci, AR; Venco, A, 2010) |
| "Combined treatment with an angiotensin II receptor blocker and hydrochlorothiazide (HCT) is advocated to control hypertension (HT)." | 5.14 | Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. ( Hu, ZP; Qian, HY; Wang, BN; Wang, Y; Wei, W; Zhou, Q, 2010) |
| "In this study, effective BP control was obtained with losartan and ramipril and LVH was found to be regressed significantly in the hypertensive patients with ADPKD." | 5.14 | A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. ( Kaynar, K; Kiriş, A; Koşucu, P; Orem, C; Ozkan, G; Ulusoy, S, 2010) |
| "The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome." | 5.14 | Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Zoppi, A, 2010) |
| "We think that losartan should be recommended to use for protection against atherosclerosis at the young aged individuals that have multiple risks for atherosclerosis, other than hypertension." | 5.13 | [The effect of losartan on the intima-media thickness of carotid artery]. ( Köseoğlu, K; Sönmez, HM; Turan, FC, 2008) |
| " We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy." | 5.13 | Aliskiren combined with losartan in type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 5.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| " Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria." | 5.13 | Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 5.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS)." | 5.13 | [Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome]. ( Kumova, TA; medvedev, iN; Simonenko, VB, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| " We examined whether 'in-treatment' wall motion abnormalities predicted outcome in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension echocardiographic substudy." | 5.13 | Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Boman, K; Cicala, S; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Nieminen, MS; Wachtell, K, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 5.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 5.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 5.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension used amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order." | 5.13 | Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. ( Donner, K; Hannila-Handelberg, T; Hiltunen, TP; Kontula, K; Miettinen, HE; Paavonen, KJ; Pentikäinen, PJ; Strandberg, T; Suonsyrjä, T; Tikkanen, I; Tilvis, R, 2008) |
| " We tested this proposition in 19 patients with essential hypertension, evaluating whether the angiotensin receptor blockers (ARBs) eprosartan and losartan had identifiable antiadrenergic properties." | 5.12 | Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. ( Campbell, DJ; Esler, M; Krum, H; Lambert, E; Windebank, E, 2006) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with left ventricular hypertrophy (LVH), mainly due to a highly significant 25% reduction in the relative risk of stroke compared with an atenolol-based regimen, for a similar reduction in blood pressure." | 5.12 | Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, G; McInnes, G, 2006) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 5.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 5.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| " The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension." | 5.12 | Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. ( Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "This double-blind, randomised, controlled study compared the efficacy of candesartan cilexetil 8 mg (n = 87) and losartan 50 mg (n = 89), once daily for 6 weeks, relative to placebo (n = 80) in patients with mild-to-moderate essential hypertension (diastolic blood pressure (DBP): 95-115 mmHg)." | 5.12 | A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. ( Asmar, R; Baguet, JP; Mallion, JM; Mouret, S; Nisse-Durgeat, S, 2006) |
| " We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy." | 5.12 | Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. ( Andersen, S; Lajer, M; Parving, HH; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 5.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 5.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2006) |
| "5 mg in Asian patients with essential hypertension whose blood pressure had previously been treated with but not controlled by valsartan 80 mg." | 5.12 | Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. ( Chiang, CE; Coloma, R; Feig, P; Guptha, S; Ke, Y; Kim, D; Massaad, R; Sun, N; Tseng, CD; Vala, M; Watanabe, LA; Wei, M, 2006) |
| "In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study." | 5.12 | Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006) |
| "Patients with essential hypertension (EHT) were randomized to treatment prospectively with losartan (50-100 mg/d) or amlodipine (5-10 mg/d) for 3 months." | 5.12 | The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. ( Fukuoka, T; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Murakami, K; Okura, T; Watanabe, S, 2006) |
| "To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension." | 5.12 | [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. ( Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006) |
| "Losartan is an optimum choice of medication for patients with mild-to-moderate hypertension complicating hyperuricemia." | 5.12 | [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia]. ( Chen, GL; Dang, AM; Liu, GZ; Zhang, YH, 2006) |
| "The short-term and long-term effects of losartan (50 mg) and perindopril (4 mg) on aortic stiffness measured as carotid femoral pulse wave velocity (PWV) were compared in 39 middle-aged Malay subjects with mild-to-moderate hypertension in a 4-month, double-blind, randomized, controlled, parallel-design study." | 5.12 | Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile. ( Ismail, SB; Naing, L; Rahman, AR; Rehman, A; Roshan, TM, 2007) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 5.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "Thus, losartan may have the possibility to inhibit platelet activation in patients with hypertension independent of blood pressure reduction." | 5.12 | Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. ( Andoh, Y; Dong, J; Fujii, S; Furumoto, T; Imagawa, S; Ishimori, N; Ohmura, K; Ohmura, Y; Sato, Y; Tsutsui, H, 2007) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 5.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 5.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 5.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "The present study investigated whether initiating therapy with a combination of losartan (L) and hydrochlorothiazide (HCTZ) allows for faster blood pressure (BP) control and fewer medications than the usual stepped-care approach in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension." | 5.12 | Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. ( Lacourcière, Y; Lefebvre, J; Poirier, L, 2007) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 5.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2007) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicenter observational study that was designed to enroll hypertensive Japanese patients (>30,000 subjects)." | 5.12 | Design and baseline characteristics of an observational study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH). ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that losartan-based treatment reduced risk of the composite endpoint of cardiovascular death, stroke and myocardial infarction compared with atenolol-based treatment in patients with hypertension and left ventricular hypertrophy with similar office blood pressure (BP) reduction." | 5.12 | Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. ( Bang, LE; Hildebrandt, PR; Ibsen, H; Larsen, J; Olsen, MH; Tuxen, C; Wachtell, K; Wiinberg, N, 2007) |
| " This multicenter, randomized, double-blind study was aimed at testing the efficacy and safety of the combination of low-dose nifedipine GITS 20 mg/ losartan 50 mg compared with either monotherapy in patients with grade 1 to 3 hypertension over an eight-week period." | 5.11 | Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. ( Bendersky, M; Grassi, G; Guzman, L; Kuschnir, E; Mancia, G; Pañart, MS; Plotquin, Y; Resk, J; Wagener, G, 2004) |
| "The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. ( Alderman, MH; Beevers, G; Dahlöf, B; Devereux, RB; Douglas, JG; Edelman, JM; Harris, KE; Julius, S; Kjeldsen, SE; Nesbitt, S; Randall, OS; Wright, JT, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| " We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 5.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
| "Losartan prevented more cardiovascular complications than atenolol for the same reduction in blood pressure and have positive additional effects beyond blood pressure control in patients with hypertension and left ventricular hypertrophy." | 5.11 | [Treatment of hypertension in patients with left ventricular hypertrophy]. ( Bratland, B; Gerhardsen, G; Gisholt, K; Kjeldsen, SE; Omvik, P; Risanger, T; Smedsrud, T, 2004) |
| " We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol." | 5.11 | Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. ( Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Koren, MJ; Liu, JE; Nieminen, MS; Palmieri, V; Wachtell, K; Wright, JT; Zabalgoitia, M, 2004) |
| " Baseline and year-1 ECGs and echocardiograms were assessed in 584 hypertensive patients with ECG LVH by Sokolow-Lyon or Cornell voltage-duration product criteria at entry into the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Liu, JE; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 5.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 5.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 5.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 5.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. ( Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H, 2004) |
| "Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001." | 5.11 | Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "A multicentre, randomised, double-blind, double-dummy, parallel-group, dose-titration study was conducted to determine the efficacy and tolerability of telmisartan 40-80 mg once daily compared with losartan 50-100 mg once daily in 180 Taiwanese patients with mild-to-moderate essential hypertension." | 5.11 | A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients. ( Huang, HC; Huang, LC; Kuo, WK; Lee, CM; Lee, YT; Lin, CS; Sheu, SH; Tsai, CW; Tseng, WK; Wang, JS, 2004) |
| "A 12-week (4-week single-blind placebo run-in phase followed by an 8-week double-blind active treatment phase) randomized, parallel-group study reported that the recommended starting dose of the angiotensin II receptor antagonist (angiotensin receptor blocker; ARB) olmesartan medoxomil (Benicar(trade mark)) 20 mg/day was more effective than starting doses of losartan potassium (Cozaar) 50 mg/day, valsartan (Diovan) 80 mg/day, or irbesartan (Avapro) 150 mg/day in reducing cuff DBP in patients with essential hypertension." | 5.11 | Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. ( Dubiel, R; Jones, M; Smith, DH, 2005) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "We measured angiotensin (Ang), bradykinin (BK), and kallidin peptides in subjects with essential hypertension administered placebo, losartan (50 mg OD), and eprosartan (600 mg OD) in randomized order in a double-blind, 3-period, 3-treatment, crossover trial." | 5.11 | Losartan increases bradykinin levels in hypertensive humans. ( Campbell, DJ; Esler, MD; Krum, H, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 5.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 5.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "Treatment with losartan causes an increase in urinary Zn excretion and induces Zn deficiency in patients with hypertension." | 5.11 | The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. ( Berman, S; Dishy, V; Golik, A; Koren-Michowitz, M; Weissgarten, J; Yona, O; Zaidenstein, R, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 5.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "To investigate the relationship between serum asymmetric dimethylarginine (ADMA) and blood pressure as well as target organ damage in essential hypertension, and to evaluate the effects of enalapril and losartan on them." | 5.11 | [Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment]. ( Chen, BM; Tao, LJ; Xiong, Y; Zhang, WR, 2005) |
| "In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens." | 5.11 | Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. ( Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K, 2005) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 5.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "This 16-week, multicenter, double-blind, active-controlled, parallel-group, titration-to-effect trial compared the blood pressure and neurohumoral responses of the selective aldosterone blocker eplerenone (100-200 mg/d; n = 86) with those of the angiotensin receptor blocker losartan (50-100 mg/d; n = 82) in patients with low-renin hypertension (active renin < or = 25 pg/mL [< or = 42." | 5.11 | Effects of eplerenone versus losartan in patients with low-renin hypertension. ( Davidson, RC; Krause, SL; MacDonald, TM; Patrick, JL; Roniker, B; Ruilope, LM; Weinberger, MH; White, WB, 2005) |
| "In a double-blind, randomized, parallel group study 314 patients with hypertension were treated for 12 weeks with 5 mg of nebivolol or 50 mg of losartan once daily." | 5.11 | Quality of life and antihypertensive effect with nebivolol and losartan. ( Bulpitt, CJ; Fici, F; Van Bortel, LM, 2005) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "We studied 17 patients who were similar to those in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? ( Band, M; Carr, E; Davies, J; Morris, A; Struthers, A, 2005) |
| "A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens." | 5.10 | Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002) |
| " Patients > or = 21 years of age with moderate-to-severe essential hypertension, defined as a mean trough sitting diastolic blood pressure (SiDBP) of 105 to 115 mm Hg, were randomly assigned in a 2:2:1 ratio to receive losartan 100 mg/hydrochlorothiazide 25 mg (L100/25), losartan 50 mg/hydrochlorothiazide 12." | 5.10 | A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essent ( Brady, WE; Gazdick, LP; Gradman, AH; Lyle, P; Zeldin, RK, 2002) |
| "The Losartan Vascular Regression Study (LAARS) was a double-blind, parallel-group, randomized, controlled, multicenter study designed to compare the effects of the AII antagonist losartan and the beta-blocker atenolol on ultrasonographically determined intimamedia thickness (IMT) of the common carotid artery (CCA) in patients with mild to moderate essential hypertension." | 5.10 | Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. ( Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U, 2002) |
| "In a randomized, prospective (4 weeks), double blind, parallel study we have compared the influence of losartan (50 mg/day) versus eprosartan (600 mg/day) on uric acid metabolism in 58 patients with mild to moderate essential hypertension." | 5.10 | AT1 blockers and uric acid metabolism: are there relevant differences? ( Puig, JG; Ruilope, LM; Torres, R, 2002) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 5.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 5.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "The goal of this study was to compare myocardial perfusion reserve (MPR) before and after long-term treatment with lisinopril and losartan in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.10 | Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. ( Akinboboye, OO; Bergmann, SR; Chou, RL, 2002) |
| "Both lercanidipine and losartan attenuate LDL oxidation in patients with type 2 diabetes mellitus and hypertension." | 5.10 | Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. ( Levi, Z; Rachmani, R; Ravid, M; Zadok, BS, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "The aim of this study was to investigate blood pressure, renal haemodynamics, hormone secretion and the responses to angiotensin II infusion during candesartan cilexetil (candesartan), losartan potassium (losartan) and valsartan treatment in patients with essential hypertension." | 5.10 | Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. ( Andersson, OK; Elmfeldt, D; Friberg, PR; Fridman, KU; Wysocki, M, 2002) |
| "The present study was conducted among 719 patients enrolled by 109 doctors to evaluate the efficacy and tolerability of the combination of losartan potassium and amlodipine besylate in Indian patients with mild to moderate hypertension." | 5.10 | Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. ( Gokhale, N; Pawar, D; Shahani, S, 2002) |
| "According to a prospective, randomized, cross-over design, 30 hypertensive patients with a previous history of stroke (25 hemorrhage, 5 infarction) were assigned randomly to receive losartan (50 mg) or quinapril (10 mg) once daily for 4 weeks." | 5.10 | Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor. ( Fujiwara, N; Kato, T; Konta, Y; Metoki, N; Okuguchi, T; Okumura, K; Osanai, T, 2002) |
| " Of the 690 patients with mild-to-moderate hypertension completing the preceding 6-week, randomized trial (comparing telmisartan 80 mg with losartan 50 mg/HCTZ 12." | 5.10 | Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. ( Klein, C; Meinicke, TW; Neutel, JM; Schumacher, H, 2002) |
| " The aim of our study was to evaluate the antihypertensive effects of losartan at peak exercise and on cardiac performance during the treadmill test in individuals with essential hypertension." | 5.10 | Can losartan improve cardiac performance during the treadmill exercise test in hypertensive subjects? ( Accardo Palumbo, V; Amato, P; Bascone, F; Bologna, P; Colomba, D; Di Marco, A; Di Pasquale, P; Ducato, G; Follone, G; Fornaciari, E; Licata, G; Parrinello, G; Paterna, S; Sciortino, A; Tarantino, AM, 2002) |
| "To compare the efficacy and safety of losartan with enalapril, in mild to moderate hypertension." | 5.10 | An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. ( Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002) |
| "To evaluate the effect of losartan and amilodipine on the platelet activation and renal function, and to study the relationship between the platelet activation and hypertensive renal damage in patients with mild and moderate hypertension." | 5.10 | [Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension]. ( Xie, XM; Yu, GL; Zhou, P, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 5.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "Black (n = 348) and white (n = 203) patients with mild-to-moderate hypertension were randomized to double-blind treatment with eplerenone 50 mg, the angiotensin II receptor antagonist losartan 50 mg, or placebo once daily." | 5.10 | Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. ( Flack, JM; Garthwaite, S; Kleiman, JH; Krause, SL; Oparil, S; Pratt, JH; Roniker, B; Saunders, E; Workman, D; Yang, Y, 2003) |
| "High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications." | 5.10 | The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003) |
| "Forty-five patients with hypertension were randomly assigned to three groups: 16 patients were treated with perindopril (4 mg/day) for four weeks; 15 were treated with losartan (50 mg/day) for four weeks; and 14 were not treated with either perindopril or losartan (control group)." | 5.10 | Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. ( Horie, H; Horie, M; Kinoshita, M; Matsumoto, T; Matsuo, S; Minai, K; Ohira, N; Ozawa, T; Takashima, H; Tarutani, Y; Yasuda, Y, 2003) |
| "The DASH diet enhances the ABP response to losartan in essential hypertension." | 5.10 | The DASH diet enhances the blood pressure response to losartan in hypertensive patients. ( Appel, LJ; Bohannon, A; Conlin, PR; Erlinger, TP; Miller, ER; Moore, TJ; Svetkey, LP, 2003) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 5.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| "A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest." | 5.10 | Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. ( Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2003) |
| "One hundred eighteen patients with mild-to-moderate essential arterial hypertension were randomized to treatment with 10 mg/d of amlodipine (group 1), 20 mg/d of quinapril (group 2), or 2 x 50 mg/d of losartan (group 3)." | 5.10 | Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. ( Kawecka-Jaszcz, K; Klocek, M; Rajzer, M, 2003) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 5.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "Cardiovascular morbidity and mortality are reduced by treatment with the angiotensin II AT(1)-receptor antagonist losartan compared with conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardiogram-defined left ventricular hypertrophy, many of whom had known vascular disease." | 5.10 | Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2003) |
| "We tested this for the AIIA losartan using a prospective single-blind randomized design in patients with proteinuria (>1 g/24 h) due to non-diabetic chronic renal failure (stable creatinine clearance >20 ml/min) and mild to moderate hypertension (130/80 < blood pressure < 160/110 mmHg)." | 5.10 | The antiproteinuric effect of losartan is systemic blood pressure dependent. ( Crowe, AV; Howse, M; Kemp, GJ; Vinjamuri, S; Williams, PS, 2003) |
| "A prospective, randomised, double-blind, parallel group study was carried out to compare the efficacy, safety and tolerability of telmisartan 40 mg once daily with losartan 50 mg once daily in Indian patients with mild to moderate hypertension." | 5.10 | Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. ( Ballary, C; Desai, A; Dongre, N; Samra, SS, 2003) |
| " We aimed to clarify the effects of losartan and its combination with hydrochlorothiazide on 24-h blood pressures (BPs), central hemodynamics and microcirculation in essential hypertension (EH)." | 5.10 | Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. ( Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003) |
| " Calculated insulin sensitivity index also improved in the enalapril-treated group (p=0." | 5.10 | Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. ( Akalin, S; Akpinar, I; Deyneli, O; Haklar, G; Koç, M; Toprak, A; Velioğlu, A; Yavuz, D, 2003) |
| "The antihypertensive efficacy and tolerability of losartan/hydrochlorothiazide (HCTZ) and losartan monotherapy as initial treatment were compared in a double-blind trial in Chinese patients with mild to moderate essential hypertension." | 5.10 | A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. ( Chen, L; Gao, R; Jiang, B; Li, J; Li, Y; Liu, G; Su, L, 2003) |
| "To observe the relationship between AT1 receptor autoantibodies and clinical features in essential hypertension, and to compare the therapeutic effect of losartan between the positive and the negative group." | 5.10 | [AT1 receptor autoantibodies and essential hypertension]. ( Chen, LL; Liu, H; Yang, Y, 2003) |
| "With a usual antihypertensive dose, both losartan and quinapril had a little suppressive effect on the cardiac sympathetic activity in essential hypertension." | 5.10 | Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. ( Doi, O; Ishikawa, J; Nawada, R; Obayashi, K; Sakata, K; Tamekiyo, H; Yoshida, H, 2002) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 5.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "Both the angiotensin converting enzyme inhibitor enalapril and the AT1 receptor blocking agent losartan acted similarly on pain threshold and tolerance, pain sensitivity being increased during the two anti-hypertensive treatments." | 5.10 | Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade. ( Diolisi, A; Garganico, D; Gaudio, G; Grandi, AM; Guasti, L; Simoni, C; Venco, A; Zanotta, D, 2002) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 5.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Angiotensin II (Ang II) type 1 receptor (AT(1)) antagonists such as losartan (LOS) are widely used for the treatment of hypertension and elicit antiinflammatory and antiaggregatory in vitro and in patients, although the underlying mechanism are unclear." | 5.10 | Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. ( Böger, RH; Drexler, H; Forssmann, WG; Krämer, C; Luchtefeld, M; Schieffer, B; Schmidt, B; Sunkomat, J; Tsikas, D; Walden, M; Witte, J, 2002) |
| "Twenty-one subjects with hypertension and AER between 10 and 200 microg/min were randomized to receive either 50 mg losartan daily (n = 11) or placebo (n = 10)." | 5.10 | Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. ( Akdeniz, A; Cooper, ME; Gilbert, RE; Houlihan, CA; Jerums, G; Tsalamandris, C, 2002) |
| "This study was undertaken to examine whether prostaglandin (PG) inhibition with indomethacin interferes with angiotensin II receptor blockade (losartan) during treatment for arterial hypertension." | 5.09 | Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals. ( Dige-Petersen, H; Hassager, C; Ibsen, H; Olsen, ME; Thomsen, T, 1999) |
| "The article presents data on effects of losartan (Cozaar of the Merck-Sharp-Dohme firm, USA) on neurohumoral indices in patients with mild to moderate forms of hypertension." | 5.09 | [Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan]. ( Belovol, AN; Koval', SN; Masliaeva, LV; Miloslavskiĭ, DK; Mysnichenko, OV, 1999) |
| "The antihypertensive efficacy and tolerability profiles of the selective AT1 receptor antagonists telmisartan and losartan were compared with placebo in a 6-week, multinational, multicentre, randomised, double-blind, double-dummy, parallel-group study of 223 patients with mild-to-moderate hypertension, defined as clinic diastolic blood pressure (DBP) >/=95 and /=140 and /=85 mm Hg." | 5.09 | ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. ( Lacourcière, Y; Mallion, J; Siche, J, 1999) |
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 5.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 5.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 5.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "Losartan is an angiotensin II receptor blocker indicated for treatment of hypertension." | 5.09 | Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial. ( Fitzgerald, D; Kelly, L; Nallen, R; O'Brien, E; Owens, P; Ryan, D, 2000) |
| "Nineteen untreated patients with mild essential hypertension (47+/-2 years, range 30 to 65 years; 57% male) were randomly assigned in double-blind fashion to losartan or atenolol treatment for 1 year." | 5.09 | Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. ( Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM, 2000) |
| " The aim of this study was to evaluate if the efficacy of losartan in hypertension could be enhanced by providing patients with a device for home BP measurement." | 5.09 | Influence of self-measurement of blood pressure on the responder rate in hypertensive patients treated with losartan: results of the SVATCH Study. Standard vs Automatic Treatment Control of COSAAR in Hypertension. ( Brignoli, R; Hess, L; Vetter, W, 2000) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 5.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "To compare the regression of left ventricular hypertrophy in patients with moderate hypertension treated with enalapril, losartan or a combination of the two drugs at lower doses." | 5.09 | Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. ( Avanza, AC; El Aouar, LM; Mill, JG, 2000) |
| "In this case-control study in uncomplicated subjects with essential hypertension, losartan and enalapril, alone or combined with a diuretic, effectively and equally lowered office and ambulatory blood pressure and induced a significant reduction in left ventricular mass during long-term treatment." | 5.09 | Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. ( Benemio, G; Bruni, B; Porcellati, C; Reboldi, GP; Sacchi, N; Schillaci, G; Verdecchia, P, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 5.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, in which hypertensive patients with ECG LV hypertrophy (Cornell voltage-duration product, > 2440 mm x ms and/or SV1 + RV(5-6) > 38 mm) were randomized to > or = 4 years double-blinded treatment with losartan or atenolol." | 5.09 | Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2000) |
| "A combination of 10 mg enalapril daily and 50 mg losartan daily safely induces a supplementary, although modest, fall in clinic DBP in patients with mild-to-moderate essential hypertension." | 5.09 | Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. ( Alexander, J; Azizi, M; Goldberg, A; Linhart, A; Ménard, J; Menten, J; Sweet, C, 2000) |
| "The efficacy, safety and side-effects of treatment with losartan (Ocsaar) was studied for the first time in Israel in a large group of patients with mild to moderate hypertension in several community clinics." | 5.09 | [Israeli experiences of treatment of hypertension with losartan (Ocsaar)--summary of the treatment of 421 patients in community health centers]. ( Zimlichman, R, 1999) |
| "Losartan reduces blood pressure in patients with essential hypertension, but the long-term central hemodynamic effects at rest and during exercise are not known." | 5.09 | Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. ( Gerdts, E; Lund-Johansen, P; Myking, OL; Omvik, P, 2000) |
| "The chronopharmacodynamics of angiotension-converting enzyme (ACE) inhibitors, such as ramipril (R), enalapril (E), acetene (A), caposide-50 (C-50) and the effect of the epiphyseal neurohormone melatonin used alone and in combination with cozaar (Co) and cintome (Ci) in the randomized groups including 124 patients with arterial hypertension (AH)." | 5.09 | [Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension]. ( Biiasilov, N; Komarov, FI; Makarova, LA; Narmanova, OZh; Shakirova, AN; Zaslavskaia, RM, 2000) |
| "We investigated whether a relationship exists between circulating transforming growth factor beta -1 (TGF-beta(1)), collagen type I metabolism, microalbuminuria, and left ventricular hypertrophy in essential hypertension and whether the ability of the angiotensin II type 1 receptor antagonist losartan to correct microalbuminuria and regress left ventricular hypertrophy in hypertensives is related to changes in TGF-beta(1) and collagen type I metabolism." | 5.09 | Transforming growth factor beta in hypertensives with cardiorenal damage. ( Díez, J; Laviades, C; Varo, N, 2000) |
| "After a 4-week placebo run-in period, 268 patients with mild-to-moderate hypertension were allocated randomly to groups to receive placebo, candesartan cilexetil (8 mg once daily) or losartan (50 mg once daily), for 4 weeks." | 5.09 | A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. ( Asmar, R; Lacourcière, Y, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 5.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "In this study the efficacy and safety of long-term losartan administration on renal haemodynamics were evaluated in mild to moderate hypertension." | 5.09 | Effect of long-term losartan administration on renal haemodynamics and function in hypertensive patients. ( Amato, P; Bova, A; Costa, R; Licata, G; Palumbo, VA; Parrinello, G; Paterna, S; Pinto, A; Scaglione, R, 2000) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 5.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 5.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| "To study the effect of losartan potassium in the treatment of mild to moderate hypertension and to compare its efficacy and adverse effect profile with enalaparil maleate." | 5.09 | Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. ( Babu, A; Bhaduri, J; Kamath, S; Kumar, TR; Raju, BS; Rao, M; Shobha, JC, 2000) |
| "We studied 659 participants in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study with both electrocardiographic and echocardiographic LV hypertrophy (68% of the echocardiographic cohort) without previous myocardial infarction." | 5.09 | Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. ( Bella, JN; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Tuxen, C; Wachtell, K, 2001) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 5.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| " This prospective interventional study in men with uncontrolled hypertension (blood pressure > or =140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan." | 5.09 | Sexual dysfunction in hypertensive patients treated with losartan. ( Argaya Roca, M; Aznar Vicente, J; Ferrario, CM; Llisterri, JL; Lozano Vidal, JV; Pol Bravo, C; Sanchez Zamorano, MA, 2001) |
| "To test the hypothesis that the hypercoagulable state in hypertension is significantly altered by anti-hypertensive therapy, we conducted a pilot prospective randomised double-blind trial of 40 untreated hypertensive patients (30 males, mean age 59 years) who were treated with either enalapril (10-20 mg per day) or losartan (50-100 mg per day) for 8 weeks." | 5.09 | Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. ( Beevers, DG; Li-Saw-Hee, FL; Lip, GY, 2001) |
| "625 mg (P/I) compared with the angiotensin II antagonist losartan 50 mg (L50) in the treatment of essential hypertension." | 5.09 | Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. ( Chanudet, X; De Champvallins, M, 2001) |
| "The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial used left ventricular hypertrophy (LVH) on a screening ECG to identify patients at high risk for morbid events." | 5.09 | Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2001) |
| "The objective of this study was to evaluate the long-term effects of enalapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin type 1 receptor antagonist, on the proliferation of peripheral blood mononuclear cells (PBMC) in patients with essential hypertension." | 5.09 | Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral blood mononuclear cells. ( Fagard, RH; Lijnen, PJ; Petrov, VV, 2001) |
| "The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism." | 5.09 | Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. ( Atanassova, I; Natchev, E; Orbetzova, M; Tzingilev, D; Zacharieva, S, 2001) |
| "Twenty-six patients with stable renal function and hypertension, 16 men and 10 women, median age 47 years (range, 25-63 years), were studied in an open randomized crossover trial, comparing a 2-week control period with a 2-week period of once-daily administration of 50 mg of losartan." | 5.09 | Uricosuric effect of losartan in patients with renal transplants. ( Kamper, AL; Nielsen, AH, 2001) |
| "Patients > or = 21 years of age with mild to moderate hypertension, defined as a trough sitting diastolic blood pressure (SiDBP) between 95 and 115 mm Hg, were randomized to receive once-daily losartan (50 mg) or valsartan (80 mg) for 12 weeks." | 5.09 | Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. ( Calhoun, DA; DeLucca, PT; Elliott, WJ; Gazdick, LP; Kerns, DE; Zeldin, RK, 2001) |
| "The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in African American adults with mild to moderate hypertension." | 5.09 | Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. ( Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 5.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| "This study evaluated the long-term effects of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II type 1 receptor antagonist losartan on the angiotensin-converting enzyme activity in T lymphocytes and plasma in patients with essential hypertension." | 5.09 | T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans. ( Fagard, RH; Lijnen, PJ; Petrov, VV, 2001) |
| "The combination of losartan and low-dose diuretics effectively treated hypertension in elderly patients while minimizing the metabolic consequences of diuretic therapy." | 5.09 | Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker. ( Kohno, M; Masugata, H; Ohmori, K; Ohnishi, K; Takagi, Y; Wada, Y; Yukiiri, K, 2001) |
| "625 mg indapamide in essential hypertension." | 5.09 | Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. ( Laurent, S, 2001) |
| "This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function." | 5.09 | [Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan]. ( Badowski, R; Cieślik, P; Haczkiewicz, P; Hefczyc, J; Hrycek, A; Scieszka, J, 2001) |
| "In this multinational, double-blind, randomized, parallel study, the efficacy and tolerability of once-daily losartan (50 mg) versus once-daily ACE inhibitor (captopril; 50 mg) was evaluated in 163 patients with mild to moderate hypertension." | 5.08 | Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. ( Bradstreet, DC; Goldberg, AI; Halasz, S; Lim, NY; Madonna, O; Makris, L; Mallion, JM; Sweet, CS, 1995) |
| "To review the efficacy and safety of losartan and hydrochlorothiazide compared to losartan alone, hydrochlorothiazide alone or placebo in the treatment of mild to moderate hypertension in a clinical trial." | 5.08 | Losartan with hydrochlorothiazide in the treatment of hypertension. ( Schoenberger, JA, 1995) |
| "To compare the incidence of cough with the angiotensin II antagonist losartan, the angiotensin converting enzyme inhibitor lisinopril, and hydrochlorothiazide in hypertensive patients with previous angiotensin converting enzyme inhibitor cough." | 5.08 | Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. ( Ramsay, LE; Yeo, WW, 1995) |
| "The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension." | 5.08 | Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. ( Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS, 1995) |
| "The efficacy and safety of various doses of losartan potassium, a specific and selective angiotensin II receptor antagonist, were compared with those of placebo and enalapril maleate 20 mg in patients with mild to moderate essential hypertension in a randomized, double-blind, parallel study." | 5.08 | A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. ( Arcuri, KE; Goldberg, AI; Gradman, AH; Ikeda, LS; Nelson, EB; Snavely, DB; Sweet, CS, 1995) |
| "This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension." | 5.08 | Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. ( Arcuri, KE; Goldberg, AI; MacKay, JH; Snapinn, SM; Sweet, CS, 1996) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 5.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "One hundred and thirty five non-smoking hypertensive patients with ACE inhibitor cough confirmed by lisinopril rechallenge and placebo dechallenge were recruited into a double-blind random parallel-group comparison of losartan 50 mg, lisinopril 20 mg and hydrochlorothiazide 25 mg each given once daily for a maximum of 8 weeks." | 5.08 | ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. ( Ramsay, LE; Yeo, WW, 1995) |
| "To compare the efficacy and safety of a regimen of losartan potassium (losartan) and a regimen of enalapril maleate (enalapril) in a randomized trial of patients with severe hypertension in which the initial treatments were blinded." | 5.08 | Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. ( Berman, R; Gazdick, LP; Goldberg, AI; Ruff, D; Sweet, CS, 1996) |
| "The pharmacokinetic and pharmacodynamic alterations of multiple doses of losartan, an angiotensin II receptor antagonist, were examined in nine patients with essential hypertension." | 5.08 | Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. ( Ebihara, A; Fujimura, A; Harada, K; Sasaki, M; Sunaga, K, 1996) |
| "To support the use of a combination of losartan, a highly specific and selective AT1 angiotensin II receptor antagonist, and hydrochlorothiazide for treatment of hypertension, a pharmacokinetic drug interaction study was conducted." | 5.08 | Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. ( Capra, NL; Goldberg, MR; Hsieh, JY; Lin, CC; Lo, MW; McCrea, JB; Tomasko, L, 1995) |
| " Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension." | 5.08 | Effects of losartan on insulin sensitivity in hypertensive subjects. ( Karjalainen, L; Laakso, M; Lempiäinen-Kuosa, P, 1996) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 5.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "The antihypertensive activity and safety of losartan, a specific and selective antagonist of angiotensin II (subtype 1) receptors, was evaluated in 100 inpatients with mild to moderate essential hypertension." | 5.08 | An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. ( Bradstreet, TE; Byyny, RL; Merrill, DD; Sweet, CS, 1996) |
| "The antihypertensive efficacy of once- and twice-daily losartan was evaluated in a randomized, double-blind, placebo-controlled, parallel-group trial using ambulatory 24-h blood pressure monitoring in 122 patients with mild to moderate essential hypertension." | 5.08 | Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group. ( Byyny, RL, 1996) |
| "To evaluate the blood pressure lowering efficacy as well as tolerability and safety of the angiotensin II antagonist losartan compared with that of the angiotensin converting enzyme inhibitor enalapril in patients with mild-to-moderate essential hypertension." | 5.08 | Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. ( Jensen, HA; Omvik, P; Tikkanen, I, 1995) |
| "In a 12-week, randomized, double-blind study, 24 patients with essential hypertension were given the angiotensin II antagonist losartan, or the beta-adrenoceptor blocker atenolol." | 5.08 | Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. ( Bergbrant, A; Hansson, L; Himmelmann, A; Svensson, A, 1996) |
| "This study compared the incidence of cough with the angiotensin-converting enzyme (ACE) inhibitor lisinopril and the diuretic metolazone with angiotensin II receptor antagonist losartan in elderly hypertensive patients with previous histories of ACE inhibitor-induced cough." | 5.08 | Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. ( Chan, P; Huang, TY; Ko, JT; Lee, YS; Lin, TS; Tomlinson, B, 1997) |
| "A double-blind, randomized, 12 weeks study of the effects on enalapril 20 mg (n = 46) vs losartan 50 mg daily (n = 47) on blood pressure, albuminuria, fasting blood glucose, and lipids in 57 male and 36 female patients with essential hypertension." | 5.08 | Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. ( Dollerup, J; Jensen, HA; Mogensen, CE; Nielsen, B; Nielsen, S, 1997) |
| "To compare two losartan regimens (with and without hydrochlorothiazide) and amlodipine in treating mild-to-moderate hypertension regarding their blood-pressure-lowering effect, drug tolerability and quality of life." | 5.08 | Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. ( Carney, S; Dahlöf, B; Lindholm, LH; Ostergren, J; Pentikäinen, PJ, 1997) |
| " Twenty patients with essential hypertension were included in a randomized, double-blind, placebo-controlled crossover study of 4 weeks' treatment with losartan, a selective type 1 angiotensin (AT1) receptor antagonist." | 5.08 | Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo. ( Arnesen, H; Aspelin, T; Kjeldsen, SE; Moan, A; Seljeflot, I; Tønnessen, T, 1998) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 5.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| "The antihypertensive efficacy and safety of losartan, a specific and selective angiotensin II (AII) receptor antagonist, was compared to captopril in patients with mild or moderate essential hypertension." | 5.08 | A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. ( Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997) |
| " Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design." | 5.08 | Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. ( Beissner, P; Lerch, M; Schneider, M; Shaw, SG; Teuscher, AU; Weidmann, P, 1998) |
| "The primary objectives of this double-blind study were to compare the antihypertensive efficacy and tolerability of irbesartan and losartan, two angiotensin II (AT1 subtype) receptor antagonists with different pharmacokinetic profiles in patients with mild-to-moderate hypertension." | 5.08 | Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. ( Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 5.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 5.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 5.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| "We compared the hemodynamic, renal, and endocrine effects of captopril alone (25 mg), captopril plus icatibant (100 microg per kilogram of body weight), the angiotensin II subtype 1-receptor antagonist losartan (75 mg), and placebo in 20 subjects with normal blood pressure and 7 subjects with hypertension." | 5.08 | Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. ( Brown, NJ; Gainer, JV; King, DJ; Loveland, A; Morrow, JD, 1998) |
| "The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives." | 5.08 | Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 5.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| "To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic)." | 5.07 | Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. ( Brunner, H; Dobbins, TW; Faison, EP; Irwin, R; Karlberg, BE; Lacourcière, Y; Nelson, EB; Ramsay, LE; Snavely, DB, 1994) |
| "Patients with a history of an ACE inhibitor-associated dry cough confirmed by a second challenge with lisinopril were enrolled into an international, multicenter, randomly allocated, double-blind, parallel-group, controlled trial, to be treated with losartan, lisinopril or hydrochlorothiazide." | 5.07 | Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. ( Faison, EP; Lacourcière, Y; Lefebvre, J; Nakhle, G; Nelson, EB; Snavely, DB, 1994) |
| " The effects of losartan and enalapril were studied in eleven patients with non-diabetic proteinuria and hypertension." | 5.07 | Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1994) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 4.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| "Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases." | 4.87 | Pharmacokinetic evaluation of losartan. ( Burnier, M; Wuerzner, G, 2011) |
| " Several clinical trials have compared candesartan with losartan in the management of essential hypertension." | 4.87 | A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. ( , 2011) |
| "Recently, much attention of medical professionals is directed to correlations between hyperuricemia, arterial hypertension, metabolic syndrome and renal affection because of the evidence that elevated blood level of uric acid raises the risk of cardiovascular complications not only in arterial hypertension and metabolic syndrome but also in diabetes mellitus type 2, coronary heart disease, congestive heart failure and renal dysfunction." | 4.87 | [Lozartan potential in hyperuricemia correction]. ( , 2011) |
| "There is an incremental clinical benefit of irbesartan over losartan in the treatment of hypertension and diabetic nephropathy which can be substantiated by corresponding preclinical study evidence." | 4.86 | Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. ( Bramlage, P; Schindler, C, 2010) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 4.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "Hypertension is a major risk factor for cardiovascular disease, and data regarding the efficacy and tolerability of telmisartan compared with losartan on blood pressure (BP) control in patients with hypertension." | 4.84 | Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. ( Cheng, JW; Lu, GC; Xi, GL, 2008) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 4.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| " We treated patients who had NASH and hypertension with losartan, an angiotensin II receptor antagonist for 48 weeks." | 4.83 | [Clinical utility of angiotensin II receptor antagonist]. ( Haneda, M; Nakamura, K; Yokohama, S, 2006) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 4.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "This is the initial part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin1-receptor antagonist losartan. Part I. Basic clinical pharmacology]. ( Malysheva, NV; Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " AT1 antagonists constitute a new generation of drugs for the treatment of hypertension designed and synthesized to mimic the C-terminal segment of Angiotensin II and to block its binding action on AT1 receptor." | 4.82 | Conformation and bioactivity. Design and discovery of novel antihypertensive drugs. ( Benetis, NP; Giatas, N; Grdadolnik, SG; Kolocouris, A; Kyrikou, I; Matsoukas, J; Mavromoustakos, T; Minakakis, PM; Polevaya, L; Roumelioti, P; Vlahakos, D; Zervou, M; Zoga, A; Zoumpoulakis, P, 2004) |
| " The search terms were stroke, epidemiology, economic impact, disability, quality of life, hypertension, drug therapy, and angiotensin II-receptor antagonists." | 4.82 | Prevention and treatment of stroke in patients with hypertension. ( Mancia, G, 2004) |
| "In the first study, olmesartan 10 mg/d was compared with losartan 50 mg/d in 316 patients with mild to moderate hypertension (mean baseline diastolic blood pressure [DBP], 95-114 mm Hg)." | 4.82 | Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. ( Stumpe, KO, 2004) |
| " Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility." | 4.82 | Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. ( Volpe, M, 2005) |
| "In a 16-week study, eplerenone was more effective than placebo or losartan in lowering systolic blood pressure (BP) and diastolic BP in black patients with mild to moderate hypertension." | 4.81 | Clinical implications of aldosterone blockade. ( Weber, MA, 2002) |
| "comparative data have shown losartan to be as effective as other antihypertensive agents in the treatment of elderly patients with hypertension." | 4.80 | Losartan: a review of its use, with special focus on elderly patients. ( McClellan, KJ; Simpson, KL, 2000) |
| "Losartan, the first potent and specific AT1 receptor antagonist, is orally active with a long duration of action and therefore has potential for treatment of chronic diseases, such as hypertension and heart failure." | 4.79 | The preclinical basis of the therapeutic evaluation of losartan. ( Chiu, AT; Smith, RD; Timmermans, PB; Wong, PC, 1995) |
| "Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve haemodynamics in some patients with congestive heart failure." | 4.79 | Angiotensin II antagonists DuP 753 and TCV 116. ( Brunner, HR; Burnier, M; Delacrétaz, E; Nussberger, J; Waeber, B, 1994) |
| " Experimentally, losartan, a novel selective angiotensin II receptor type 1 antagonist has been shown to decrease cardiac hypertrophic response in models of both hypertension and volume cardiac hypertrophy as well as reverse hypertrophy in spontaneously hypertensive rats." | 4.79 | Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. ( Dahlöf, B, 1995) |
| "Angiotensin II (AII) receptor antagonists, a new class of antihypertensive agents, recently became available for the treatment of clinical hypertension." | 4.79 | Angiotensin II receptor blockers. A new class of antihypertensive drugs. ( Velasquez, MT, 1996) |
| "The clinical efficacy and tolerability of losartan were studied in clinical trials in Japanese patients with essential hypertension." | 4.79 | The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. ( Ogihara, T; Yoshinaga, K, 1996) |
| "Losartan is the first drug of a new therapeutic class, the angiotensin II (A II)-receptor antagonists, to be clinically studied and become available for the management of hypertension." | 4.79 | Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. ( Goldberg, AI; Mallion, JM, 1996) |
| " Experience with losartan, the first of the selective AII receptor antagonists to be approved for clinical use, indicates that this approach is efficacious in all grades of hypertension and offers a more attractive and acceptable tolerability profile than other forms of antihypertensive medications." | 4.79 | Angiotensin II antagonism: a new avenue of hypertension management. ( Gavras, H, 1997) |
| "Losartan potassium, an angiotensin II receptor antagonist, is the first of a new class of agents to be introduced for the treatment of hypertension." | 4.79 | Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. ( Caffe, SE; McIntyre, M; Michalak, RA; Reid, JL, 1997) |
| " The angiotensin II receptors antagonists, of which Losartan will be the first representative on the Belgian market, constitute a new therapeutic class in the treatment of hypertension and even heart failure." | 4.79 | [The advent of a new class of antihypertensive agents: angiotensin II receptor antagonists]. ( Lefebvre, P, 1997) |
| "Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve hemodynamics in some patients with congestive heart failure." | 4.78 | Angiotensin II antagonists. ( Brunner, HR; Burnier, M; Nussberger, J; Waeber, B, 1993) |
| "The co-administration of losartan and puerarin in hypertension rat models was investigated aiming to evaluate their interaction and potential mechanism." | 4.31 | Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan. ( Huang, Y; Xue, M, 2023) |
| " Hypertension is mainly regulated by the renin-angiotensin-aldosterone system (RAAS), with its main mediator being angiotensin II (ANG II)." | 4.31 | Unveiling Angiotensin II and Losartan-Induced Gene Regulatory Networks Using Human Urine-Derived Podocytes. ( Adjaye, J; Erichsen, L; Thimm, C; Wruck, W, 2023) |
| "Using a large, South African private health insurance claims database, we identified patients with a hypertension diagnosis in January 2015 receiving standard doses of perindopril, enalapril or losartan, alone or in combination with other agents." | 4.31 | Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis. ( Alaba, OA; Gumedze, F; Jones, ESW; Ntusi, NAB; Snyman, JR; Tsabedze, N; Vira, A, 2023) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "To describe a case of angioedema associated with increasing the dose of HMG-CoA reductase inhibitor (atorvastatin) from 20 to 40 mg daily in a patient previously stable on angiotensin II receptor blocker (losartan) and calcium channel blocker (amlodipine) as antihypertensive agents." | 4.12 | Dose-dependent atorvastatin associated with angioedema. ( Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA, 2022) |
| " We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension." | 4.12 | Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022) |
| " Losartan, which functions as a typical angiotensin receptor blocker, controls the average arterial pressure of patients with essential hypertension and protects against hypertension-related secondary diseases, including proteinuria and cardiovascular injury." | 4.12 | Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib. ( Chen, X; Fu, Y; Ridwan, KA; Saxu, R; Teng, Y; Xu, X; Yao, J; Yu, P; Zheng, W, 2022) |
| "Losartan prescription in some conditions such as hypertension or ERT could worsen RBF and RVR responses to Ang II." | 4.12 | Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats. ( Choopani, S; Nematbakhsh, M, 2022) |
| "A MassARRAY approach was used to detect single nucleotide polymorphism (SNP) loci in the URAT1 and CYP2C9 genes (16 and 2 loci, respectively) in 111 patients with hypertension and hyperuricemia taking losartan and in 121 healthy controls." | 4.02 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. ( Fan, Y; Li, Z; Mao, D; Wang, Y; Wu, L; Zhuang, W, 2021) |
| " The present study aims to examine whether COX-1 and COX-2 were implicated in endothelial dysfunction in hypertension and calcitriol, an active form of vitamin D preserved endothelial function through regulating COX expression." | 4.02 | Calcitriol inhibits COX-1 and COX-2 expressions of renal vasculature in hypertension: Reactive oxygen species involved? ( Dong, J; Gao, M; Li, Y; Liu, Y; Suo, Z; Xu, C, 2021) |
| "We investigated the therapeutic effects of losartan, an angiotensin II type 1 receptor blocker, on prostatic hyperplasia in spontaneously hypertensive rats (SHRs)." | 4.02 | Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats. ( Higashi, Y; Karashima, T; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2021) |
| "In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)." | 4.02 | Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021) |
| "In this pilot study we demonstrate that losartan was well-tolerated among hospitalized patients with COVID-19 and hypertension." | 3.96 | Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study. ( Ahmad, S; Bolotova, O; Chaudhri, I; Koraishy, FM; Mallipattu, SK; Marcos, LA; Sahib, H; Skopicki, H; Yoo, J, 2020) |
| "Losartan can improve bone mineralization parameters under normal physiological conditions, but the same anabolic effect does not occur under hypertension." | 3.91 | Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats. ( Antoniali, C; Faverani, LP; Mulinari-Santos, G; Okamoto, R; Palin, LP; Santos, JSD; Silva, ACED, 2019) |
| " Blocking angiotensin II (Ang II) type 1 receptor signaling alleviates hypertension and improves outcomes in patients with heart failure." | 3.91 | Angiotensin II inhibits DDAH1-nNOS signaling via AT1R and μOR dimerization to modulate blood pressure control in the central nervous system. ( Chen, HH; Cheng, PW; Ho, CY; Ho, WY; Sun, GC; Tseng, CJ; Wong, TY; Yeh, TC, 2019) |
| " Considering the causal relationship between hypertension and AD and that targeting cerebrovascular pathology with ARBs does not necessarily require their systemic effects, we tested intranasal losartan in the rat model of chronic hypertension (spontaneously hypertensive stroke-prone rats, SHRSP)." | 3.91 | Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats. ( Beer-Hammer, S; Buadze, M; Danielyan, L; Davtyan, T; Drews, HJ; Frey, WH; Gleiter, CH; Kabisch, D; Lourhmati, A; Petschak, S; Schwab, M; Verleysdonk, S; Yenkoyan, K, 2019) |
| "Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy." | 3.88 | Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. ( Busby, J; Cardwell, CR; Hughes, C; Johnston, BT; McMenamin, Ú; Spence, A, 2018) |
| " Hypertension-induced marked elevation of renal malondialdehyde (MDA) and nitrite levels and reduction of reduced glutathione (GSH) level were inhibited by EGb761." | 3.88 | Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats. ( Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM, 2018) |
| " Therefore, the aim of this study was to test whether avocado oil counteracts, to a similar degree as the Ang-II blocker losartan, the deleterious effects of hypertension on blood pressure, renal vascular performance, kidney mitochondrial function, and oxidative stress." | 3.88 | Comparative effects of avocado oil and losartan on blood pressure, renal vascular function, and mitochondrial oxidative stress in hypertensive rats. ( Cortés-Rojo, C; Godínez-Hernández, D; González-Hernández, JC; Hernández de la Paz, JL; Márquez-Ramírez, CA; Ortiz-Avila, O; Raya-Farias, A; Rodríguez-Orozco, AR; Saavedra-Molina, A; Salgado-Garciglia, R, 2018) |
| "Angiotensin II (Ang II) is an octapeptide hormone that plays a significant role in mediating hypertension." | 3.88 | Cathepsin B-Mediated NLRP3 Inflammasome Formation and Activation in Angiotensin II -Induced Hypertensive Mice: Role of Macrophage Digestion Dysfunction. ( Boini, KM; Chen, Y; Huang, Y; Lai, J; Lian, D; Wang, L; Wu, Y; Zhang, Y, 2018) |
| " We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation." | 3.85 | Aliskiren reduces albuminuria after kidney transplantation. ( Biedunkiewicz, B; Chamienia, AL; Debska-Slizien, AM; Heleniak, Z; Lizakowski, S; Małgorzewicz, S; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2017) |
| "Lead is considered a causative factor for hypertension and other cardiovascular diseases." | 3.85 | Sub-chronic lead exposure produces β ( Alonso, MJ; Fioresi, M; Salaices, M; Simões, MR; Toscano, CM; Vassallo, DV, 2017) |
| "Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis." | 3.85 | Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017) |
| "Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)." | 3.85 | Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017) |
| "The high-fat diet elicited overweight, insulin resistance and adipocyte hypertrophy in the high-fat group, all of which losartan rescued in the high-fat-losartan group." | 3.85 | AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice. ( Barbosa-da-Silva, S; de Oliveira Santos, F; Graus-Nunes, F; Rachid, TL; Souza-Mello, V, 2017) |
| "Stroke-prone spontaneously hypertensive (SHRSP) rats were administered losartan, amlodipine or saline for 6 or 16weeks at the onset of prehypertension." | 3.85 | Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model. ( He, DH; Lin, JX; Xie, Q; Xu, CS; Zhang, LM, 2017) |
| "We have previously shown that an association of losartan and hydrochlorothiazide, initiated 1 mo after 5/6 nephrectomy (Nx), reversed hypertension and albuminuria and promoted lasting renoprotection." | 3.83 | An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. ( Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 3.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "We surveyed consecutive newly diagnosed, untreated patients with hypertension who started the treatment with a mid-level dose of one of seven ARBs (losartan 50 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, valsartan 80 mg, irbesartan 100 mg, or azilsartan 20 mg)." | 3.83 | The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements. ( Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M, 2016) |
| " The proportion of patients remaining on any hypertension treatment at 12 months and the adherence rate were similar between the losartan cohort (66." | 3.83 | Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study. ( Ah, YM; Choi, KH; Choi, YJ; Han, N; Kim, B; Kong, J; Lee, HY; Lee, JY; Oh, JM; Shin, WG; Yu, YM, 2016) |
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 3.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| "Risk of incident stroke was examined in relation to abnormal PTFV1 on a baseline ECG in 7778 hypertensive patients with ECG left ventricular hypertrophy, no history of atrial fibrillation, in sinus rhythm on their baseline ECG with no incident atrial fibrillation during follow-up, who were randomly assigned to losartan-based or atenolol-based treatment." | 3.83 | Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. ( Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM, 2016) |
| "Spontaneous rectus sheath haematomas and cough secondary to losartan are individually rare conditions." | 3.83 | Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy. ( Ahmed, S; Sweigart, J; Talari, G; Talari, P, 2016) |
| "With regard to the medications, Atorvastatin, Losartan and Captopril were administered more in patients (groups 1, 2 and 3) than the patients without hypertension and CAD." | 3.83 | Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. ( Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M, 2016) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is involved in hypertension." | 3.81 | Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. ( Hsu, CN; Huang, LT; Lee, CT; Tain, YL, 2015) |
| "We previously reported that binding of prorenin to the (pro)renin receptor (PRR) plays a major role in brain angiotensin II formation and the development of deoxycorticosterone acetate (DOCA)-salt hypertension." | 3.81 | Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension. ( Feng, Y; Li, W; Speth, RC; Sullivan, MN; Worker, CJ; Xiong, Z; Zhang, S, 2015) |
| " We investigated the expression of RAS components in the heart and kidney during the development of hypertension and its perinatal treatment with losartan in young spontaneously hypertensive rats (SHR)." | 3.81 | Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. ( Cacanyiova, S; Klimas, J; Krenek, P; Kristek, F; Kruzliak, P; Ochodnicka-Mackovicova, K; Ochodnicky, P; Olvedy, M, 2015) |
| "To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensive patients with hyperuricemia and the uricosuric action of losartan therapy among hypertensive patients with hyperuricemia." | 3.81 | URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. ( Lou, XY; Peng, Y; Qu, J; Qu, Q; Sun, H; Wang, G; Zeng, Y, 2015) |
| "We determined whether the blood pressure response to losartan in an older Chinese population with essential hypertension was associated with apelin gene polymorphisms." | 3.81 | Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension. ( Jia, J; Men, C; Tang, KT; Zhan, YY, 2015) |
| "Angiotensin II (Ang II) and aldosterone contribute to hypertension, oxidative stress and cardiovascular damage, but the contributions of aldosterone during Ang II-dependent hypertension are not well defined because of the difficulty to assess each independently." | 3.81 | Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. ( Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015) |
| "Elevated homocysteine (Hcy) is a high risk factor of hypertension due to its function in endothelial dysfunction." | 3.81 | Effect of losartan with folic acid on plasma homocysteine and vascular ultrastructural changes in spontaneously hypertensive rats. ( Hu, L; Jia, B; Lin, F; Tang, M; Yu, J; Zhao, F; Zhu, L, 2015) |
| "We used myocytes from Wistar, SHR, losartan-treated SHR (Los-SHR), and Angiotensin II (Ang II)-induced cardiac hypertrophy." | 3.80 | Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system. ( Aiello, EA; Caldiz, CI; Ciancio, MC; De Giusti, VC; Orlowski, A, 2014) |
| " This study assessed the potential therapeutic benefit of combining the mitochondria-specific antioxidant, MitoQ10, with the low-dose angiotensin receptor blocker (ARB), losartan, on attenuation of hypertension and left ventricular hypertrophy." | 3.80 | Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. ( Beattie, E; Beattie, W; Dominiczak, AF; Graham, D; Koh-Tan, CH; McLachlan, J; Murphy, MP; Nicklin, SA; Olson, E, 2014) |
| " Hydralazine (direct vasodilator) or discontinuation of DOCA-salt treatment was used to assess the roles of systemic hypertension." | 3.80 | Roles of hypertension in the rupture of intracranial aneurysms. ( Hashimoto, T; Kitazato, KT; Kudo, M; Liang, EI; Makino, H; Murakami, S; Nagahiro, S; Shimada, K; Tada, Y; Wada, K, 2014) |
| "Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis." | 3.80 | Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 3.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| "The present study aimed to investigate the molecular pharmacodynamic mechanisms of losartan used in the treatment of hypertension." | 3.80 | Novel mechanism of intra‑renal angiotensin II-induced sodium/proton exchanger 3 expression by losartan in spontaneously hypertensive rats. ( Cui, W; Fan, X; Gao, Y; Huang, J; Liu, K; Wang, W, 2014) |
| "Effects of intravenous LKP infusion and then superimposed losartan (AT1R antagonist) on MAP, total renal (RBF, Transonic probe) and renal medullary blood flows (laser-Doppler), and on renal excretion, were examined in anesthetized (1) Wistar rats with acute norepinephrine-induced hypertension, untreated or pretreated with AT2R antagonist (PD 123319) and (2) spontaneously hypertensive rats (SHR) maintained on standard or high-sodium (HS) diet." | 3.80 | Vascular effects of a tripeptide fragment of novokinine in hypertensive rats: Mechanism of the hypotensive action. ( Bądzyńska, B; Kompanowska-Jezierska, E; Lipkowski, AW; Sadowski, J, 2014) |
| "Baseline and year-3 ECG LVH and left ventricular midwall shortening (MWS) were examined in 725 hypertensive patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 3.80 | Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. ( Dahlöf, B; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2014) |
| " In the present study, we tested the hypothesis that the B1 kinin receptor (B1R) contributes to vascular hypertrophy in angiotensin II (ANG II)-induced hypertension, through a mechanism involving reactive oxygen species (ROS) generation and extracellular signal-regulated kinase (ERK1/2) activation." | 3.80 | An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies. ( Akamine, EH; Barreto-Chaves, ML; Carvalho, MH; Ceravolo, GS; Chopard, RP; Costa, TJ; Fernandes, DC; Fortes, ZB; Jordão, MT; Laurindo, FR; Montezano, AC; Takano, AP; Tostes, RC; Touyz, RM, 2014) |
| " Generic losartan became available and was reimbursed in March 2010 providing further opportunities for the authorities in Sweden to save costs with all ARBs seen as similar in managing hypertension and CHF at appropriate doses." | 3.79 | Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. ( Bennie, M; Godman, B; Malmström, RE; Martin, A; Miranda, J; Wettermark, B, 2013) |
| " Adult patients with essential hypertension showing therapy resistance to angiotensin receptor blocker (ARB) as a monotherapy or in combination with Ca channel blockers (CCB) were enrolled, and their previously administered ARBs were replaced with the combination tablet containing losartan (50 mg per day) and hydrochlorothiazide (12." | 3.79 | Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance. ( Asakura, J; Fukada, H; Hasegawa, H; Kanozawa, K; Kogure, H; Komuro, O; Matsuzawa, M; Mitarai, T; Takayanagi, K; Tokushima, H, 2013) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "To investigate the effects of losartan and amlodipine on cell apoptosis in the cerebral cortex of stroke-prone spontaneously hypertensive rats (SHRSP) from the onset of prehypertension or hypertension." | 3.79 | Differential effects of antihypertensive treatments on apoptosis, oxidative stress, and expression of angiotensin receptors in the cerebral cortex from the onset of prehypertension and hypertension in stroke-prone spontaneous hypertensive rats. ( He, DH; Lin, JX; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2013) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 3.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "Telmisartan and losartan, angiotensin II type 1 (AT1) receptor antagonists, are used to manage hypertension." | 3.79 | Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats. ( Kobara, M; Nakata, T; Ohigashi, M; Toba, H; Wang, J, 2013) |
| "Adult patients with angiotensin receptor blocker (ARB)-resistant essential hypertension (n = 104) were enrolled and switched to combination therapy with losartan (50 mg/day) and hydrochlorothiazide (12." | 3.79 | Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension. ( Asakura, J; Hasegawa, H; Iwashita, T; Kawashima, K; Matsuda, A; Mitarai, T; Nakamura, T; Ogawa, T; Shimizu, T; Takayanagi, K; Tayama, Y, 2013) |
| "These findings show that although losartan and aliskiren exerted similar antihypertensive effects, only losartan prevented the activation of vascular profibrotic mechanisms and MMP upregulation associated with vascular remodeling in 2K1C hypertension." | 3.79 | Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. ( Casarini, DE; Castro, MM; Ceron, CS; Costa-Neto, CM; Gerlach, RF; Guimaraes, D; Martins-Oliveira, A; Oliveira, DM; Reis, RI; Ribeiro, AA; Rizzi, E; Tanus-Santos, JE, 2013) |
| " Methods Baseline and follow-up clinical and echocardiographic parameters were assessed in 939 hypertensive patients with electrocardiogram (ECG) LVH participating in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy (66±7 years; 42% women; 11% with diabetes) who did not have aortic or mitral valve stenosis or prosthesis." | 3.79 | Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. ( Boman, K; Casalnuovo, G; Dahlöf, B; De Marco, M; de Simone, G; Devereux, RB; Gerdts, E; Kizer, JR; Migliore, T; Olsen, MH; Wachtell, K, 2013) |
| "Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension." | 3.78 | Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. ( Inoue, A; Mitsutake, R; Miura, S; Saku, K; Shiga, Y; Uehara, Y, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 3.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 3.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "67 Mb heterozygous deletion including the Eln gene, presented with a generalized arteriopathy, hypertension, and cardiac hypertrophy, associated with elevated angiotensin II (angII), oxidative stress parameters, and Ncf1 expression." | 3.78 | Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome. ( Bustelo, XR; Campuzano, V; Coustets, M; Francke, U; Menacho-Márquez, M; Nevado, J; Pérez-Jurado, LA; Sánchez-Rodríguez, C; Segura-Puimedon, M; Terrado, V, 2012) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 3.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "8 years study treatment were assessed in 922 hypertensive patients in the Losartan Intervention For Endpoint reduction in hypertension echocardiography substudy." | 3.78 | Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Wachtell, K, 2012) |
| " Losartan abolished hypertension, suggesting that AT(1a)R plays a primary role in arterial pressure elevation." | 3.78 | Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams. ( Balakrishnan, M; Chinnathambi, V; Gao, H; Sathishkumar, K; Yallampalli, C, 2012) |
| " This subanalysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study included 7629 patients, in whom the serum creatinine level was measured at least twice." | 3.78 | Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. ( Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2012) |
| "To investigate the effect of losartan on prostatic hyperplasia in spontaneous hypertension rats (SHRs) and its pathophysiological mechanism." | 3.78 | [Inhibitory effect of losartan on prostatic hyperplasia in spontaneous hypertension rats and its pathophysiological mechanism]. ( Dong, LN; Qu, XB; Shen, F; Zeng, XF; Zhang, XY; Zhao, XK, 2012) |
| " We investigated the effect of switching from an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) to a combination of losartan and hydrochlorothiazide on left ventricular (LV) relaxation in patients with hypertension and diastolic dysfunction." | 3.78 | Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Shimada, K; Takami, T; Watanabe, H; Yoshikawa, J, 2012) |
| " In other pharmacokinetic studies, it has been reported that bioavailability of losartan is about 33%, and its absorption is excellent." | 3.78 | The clinical pharmacology of losartan in Japanese subjects and patients. ( Nakashima, M; Umemura, K, 1996) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 3.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 3.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| "The clinical course of losartan potassium/hydrochlorothiazide (Preminent(®))-induced hyponatremia has not been described." | 3.77 | Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients. ( Fujiki, K; Kinoshita, H; Kobayashi, K; Koga, N; Tomiyama, J; Yaguramaki, T; Yakushiji, F; Yasuda, M, 2011) |
| " The complex demonstrated efficiency in hypertension control, presenting antagonist action on the pressure effect of angiotensin II within 30 h, as compared to Los alone, 6h, indicating that inclusion of Los in HPβCD enhanced the extent and duration of its antagonistic action." | 3.77 | Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. ( Braga, AN; de Paula, WX; Denadai, AM; Santoro, MM; Santos, RA; Sinisterra, RD, 2011) |
| " Diminished PAME release and its vasorelaxing activity and increased release of angiotensin II in the PVAT suggest a noble role of PVAT in pathogenesis of hypertension." | 3.77 | Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. ( Chang, HH; Chen, MF; Chen, PY; Chiang, CL; Kuo, JS; Lee, TJ; Lee, YC; Liu, CH; Yeh, JI, 2011) |
| "The hypotensive actions of losartan suggest that although the RAS provides an important contribution to BP, it contributes little, if at all, to the hypertension-induced or the greater stress-induced pressor responses in Schlager mice." | 3.77 | Renin-angiotensin and sympathetic nervous system contribution to high blood pressure in Schlager mice. ( Davern, PJ; Elghozi, JL; Head, GA; Jackson, KL; Nguyen-Huu, TP; Palma-Rigo, K, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "Hypertension caused by chronic infusion of angiotensin II (Ang II) in experimental animals is likely to be mediated, at least in part, by an elevation of ongoing sympathetic nerve activity (SNA)." | 3.76 | Does enhanced respiratory-sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II-salt hypertension? ( Fink, GD; Osborn, JW; Pedrino, GR; Toney, GM, 2010) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 3.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.76 | Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010) |
| " The aim of the current study was to evaluate the effects of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'(1H-tetrazol-5-yl)-biphenil-4-yl)methyl]imidazole) and telmisartan (49-[(1,49-dimethyl-29-propyl[2,69-bi-1H-benzimidazo]-19-yl)methyl]-[1,19-biphenyl]-2-carboxylic acid), the angiotensin AT1 receptor antagonists which are widely used in clinical practice, on the protective action of conventional antiepileptic drugs (carbamazepine, phenytoin, valproate and phenobarbital) against maximal electroshock-induced seizures in mice." | 3.76 | Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. ( Czuczwar, SJ; Jakubus, T; Janowska, A; Tochman-Gawda, A; Łukawski, K, 2010) |
| "Baseline and third year ECG LVH and left atrial systolic diameter were examined in 663 patients in the Losartan Intervention For Endpoint reduction in hypertension echocardiographic substudy who were in sinus rhythm at baseline and had no history of atrial fibrillation." | 3.76 | Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2010) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 3.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 3.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "In this salt-sensitive genetic hypertension model, losartan protects from hypertension- and high dietary salt-related vascular oxidative stress, exceeding the benefits of BP reduction." | 3.76 | Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol. ( de Cavanagh, EM; Ferder, LF; Ferder, MD; Inserra, F; Stella, IY; Toblli, JE, 2010) |
| "A case of anaphylaxis and angioedema induced by angiotensin II receptor blocker (ARB), losartan is reported." | 3.76 | Losartan associated anaphylaxis and angioneurotic oedema. ( Kazim, SF; Shahid, M, 2010) |
| " In the present study, we tested the hypothesis that the OVLT mediates the hypertension or the hypotension produced by chronic infusion of ANG II or losartan (AT1 antagonist), respectively." | 3.76 | Role of the organum vasculosum of the lamina terminalis for the chronic cardiovascular effects produced by endogenous and exogenous ANG II in conscious rats. ( Collister, JP; Nahey, DB; Vieira, AA, 2010) |
| "To evaluate 24-hour efficacy of losartan in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index." | 3.76 | [The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome]. ( Frána, P; Plachý, M; Rihácek, I; Schwarz, D; Soucek, M, 2010) |
| "We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke." | 3.75 | Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| " This investigation sought to determine whether hypertension exacerbates the oxidative stress, neurodegeneration, and mitochondrial dysfunction that exists in diabetic retinopathy and whether these changes could be minimized by the angiotensin II type 1 (AT(1)) receptor blocker (ARB) losartan." | 3.75 | Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. ( Biswas, SK; Lopes de Faria, JB; Lopes de Faria, JM; Rosales, MA; Silva, KC, 2009) |
| "To investigate the effects of losartan on left ventricular hypertrophy (LVH) and plasma transforming growth factor-beta1 (TGF-beta1) in elderly patients with essential hypertension (EH)." | 3.75 | [Effects of losartan on left ventricular hypertrophy and plasma transforming growth factor-beta1 in elderly patients with hypertension]. ( Bai, SC; Huang, P; Lai, WY; Li, Y; Su, L; Wu, ZL; Xu, DL, 2009) |
| "The present study was performed to characterize the autoregulatory efficiency of renal blood flow and glomerular filtration rate and the pressure-natriuresis relationship in transgenic rats with inducible angiotensin II (ANG II)-dependent hypertension (Cyp1a1-Ren-2 rats)." | 3.75 | Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. ( Bürgelová, M; Cervenka, L; Erbanová, M; Husková, Z; Kramer, HJ; Mullins, JJ; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z, 2009) |
| "The effects of endogenous angiotensin II (Ang II) and neuronal nitric oxide synthase (nNOS) on tonic sympathetic activity were studied in salt-sensitive hypertension-induced heart failure." | 3.75 | Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure. ( Kato, K; Kemuriyama, T; Maruyama, S; Nishida, Y; Ohta, H; Sato, Y; Tandai-Hiruma, M, 2009) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| " We evaluated 770 hypertensive patients with electrocardiogram findings of left ventricular hypertrophy (age 66 +/- 7 years; 42% women) enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 3.75 | Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). ( Aurigemma, GP; Boman, K; Chinali, M; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Mishra, RK; Wachtell, K, 2009) |
| "A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12." | 3.75 | [Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program]. ( Bubnova, MG; Oganov, RG, 2009) |
| " Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs)." | 3.75 | Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. ( Grujić-Milanović, J; Ivanov, M; Jovović, D; Mihailović-Stanojević, N; Miloradović, Z, 2009) |
| " We prospectively compared MWS derived from linear echocardiographic dimensions with MR strain(in) in septal and posterior locations in 27 subjects with ECG LV hypertrophy in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 3.74 | Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. ( Bella, JN; Biederman, RW; Calhoun, D; Dell'Italia, LJ; Devereux, RB; Doyle, M; Kortright, E; Oparil, S; Perry, G; Pohost, GM; Young, AA, 2008) |
| " We investigated long-term effects of losartan on serum concentrations of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS) by serial measurements over 6 months." | 3.74 | Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. ( Aso, Y; Hara, K; Inoue, T; Inukai, T; Nakano, T; Node, K; Sakai, Y; Shimizu, M; Takayanagi, K; Takebayashi, K; Uchida, T, 2008) |
| " We report a chronic hypertensive pregnant woman treated with losartan before and throughout pregnancy." | 3.74 | [Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case]. ( Catalán M, J; Hasbún H, J; Parra C, M; Salinas Q, S; San Martín O, A; Valdés R, E, 2008) |
| " Losartan improved both the diabetes-related abnormalities and the diabetic hypertension." | 3.74 | Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nogami, T; Taguchi, K, 2008) |
| "The different protein spots expression may play important roles in Losartan's effective protection to hypertension rats renal tissue." | 3.74 | [Losartan's effects on the protein expression of the kidney of spontaneous hypertension rat]. ( Chen, JZ; Du, YX; Li, SP; Wang, XX; Yu, M, 2008) |
| "Our previous studies demonstrated that peripheral overexpression of angiotensin II (ANG II) type 2 receptors (AT(2)R) prevents hypertension-induced cardiac hypertrophy and remodeling without altering high blood pressure." | 3.74 | Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. ( Gao, Y; Grobe, JL; Katovich, MJ; Li, H; Raizada, MK; Sumners, C, 2007) |
| "The mechanisms by which chronic infusion of an initially subpressor low dose of angiotensin II (ANG II) causes a progressive and sustained hypertension remain unclear." | 3.74 | Investigation of the mechanisms by which chronic infusion of an acutely subpressor dose of angiotensin II induces hypertension. ( Cochrane, T; Hood, SG; May, CN; McKinley, MJ, 2007) |
| "Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
| " We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study." | 3.74 | Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. ( Dahlöf, B; de Simone, G; Devereux, RB; Hille, DA; Ibsen, H; Kjeldsen, SE; Lyle, PA; Olsen, MH; Wachtell, K, 2007) |
| "To investigate the effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand on angiotensin II (AngII)-induced endothelin-1 (ET-1) and NO secretion by endothelial cells in comparison with AngII type I receptor (AT1R) antagonist losartan, so as to reveal the relationship between PPAR gamma and essential hypertension." | 3.74 | [Peroxisome proliferator-activated receptor activator troglitazone inhibits angiotensin II-stimulated secretion of vasoactive factors by endothelial cells]. ( Li, YQ; Niu, XL; Wang, CX; Wang, SJ; Wei, J; Zhou, J, 2007) |
| "Losartan reduced significantly the systolic blood pressure as well as the aorta and left ventricular hypertrophy." | 3.74 | Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats. ( Tinel, H, 2007) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 3.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "Despite discontinuation of losartan over the subsequent six months, ARB pre-treatment completely prevented proteinuria and hypertension in these slow renal ablation rats." | 3.74 | Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats. ( Jeong, HJ; Kim, KH; Kim, Y; Mauer, M; Park, HW; Rozen, S; Shin, MH, 2007) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 3.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicentered, observational study that was designed to enroll 30,000 hypertensive Japanese patients from more than 3,000 private practitioners." | 3.74 | Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| " A total of 50 patients with hypertension were divided into 3 groups: a control group receiving neither an ARB nor an ACE inhibitor (n = 14), a losartan group (n = 22) receiving 50 mg/day of losartan, and an ACE inhibitor group (n = 14) receiving either 5 mg/day of enalapril or 5 mg/day of imidapril." | 3.74 | A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. ( Aoyagi, T; Nagai, R; Sonoda, M; Takenaka, K; Uno, K, 2008) |
| " The patient experienced cough 3 days following the initiation of losartan treatment." | 3.74 | Cough induced by losartan with resolution after substitution with enalapril. ( Ahmadi, F; Dashti-Khavidaki, S; Faghihi, T; Khalili, H, 2008) |
| " Ischemia was induced by right femoral artery ligature in Wistar Kyoto rats (WKY) or spontaneously hypertensive rats (SHR) treated with or without angiotensin-converting enzyme inhibitor (Perindopril, 0." | 3.74 | Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. ( Cochain, C; Duriez, M; Lévy, BI; Loinard, C; Mees, B; Silvestre, JS; Vilar, J; You, D, 2008) |
| "In the Losartan Intervention For End-point reduction in hypertension (LIFE) study, we evaluated the impact of antihypertensive treatment on change of PP/SVi as raw indicator of systemic arterial stiffness, and further explored the impact of the change in PP/SVi on the change in LV mass and RWT." | 3.74 | Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. ( Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2008) |
| "8 years losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 3.74 | Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). ( Cramariuc, D; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Wachtell, K, 2008) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 3.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In Lyon genetically hypertensive (LH) rats, an early and long-term angiotensin-converting enzyme (ACE) inhibition with perindopril prevents their hypertension and renal alterations." | 3.73 | Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. ( Chapuis, B; Liu, KL; Lo, M; Naelten, G, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 3.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 3.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 3.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "Our objective was to compare the efficacy and duration of action of 4 angiotensin II receptor blockers (ARBs)--losartan (25-100 mg), candesartan (2-12 mg), valsartan (40-80 mg), and telmisartan (10-40 mg)-in patients with essential hypertension using self-measurement of blood pressure at home (home BP) and to examine the differential effect of the four ARBs on home pulse pressure (home PP)." | 3.73 | Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. ( Asayama, K; Hashimoto, J; Imai, Y; Kikuya, M; Metoki, H; Nishimura, T; Ohkubo, T; Totsune, K, 2005) |
| "These results suggest that reversal of high fructose-induced hypertension and insulin resistance by chronic losartan treatment is not dependent on AT2R activation and that functional activation of AT1R plays a major role in the pathogenesis of high fructose-induced hypertension and insulin resistance." | 3.73 | Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. ( Hsieh, PS, 2005) |
| "In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.73 | Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006) |
| " The mother suffered from essential hypertension and was treated with Cozaar (losartan 50 mg)." | 3.73 | Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. ( Daïkha-Dahmane, F; Jugie, M; Lenclen, R; Levy-Beff, E, 2006) |
| " To assess the relations of LV mass and function with Hgb delivery (ie, the physiological carrier of oxygen), we calculated the product of Hgb concentration and Doppler-derived cardiac output in 864 hypertensive participants with electrocardiographic LVH (359 women) in the Losartan Intervention for End Point Reduction in Hypertension echocardiography substudy." | 3.73 | Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Fyhrquist, F; Gerdts, E; Hoieggen, A; Narayan, P; Nieminen, MS; Papademetriou, V; Wachtell, K, 2006) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| " report increased expression of connective tissue growth factor and transforming growth factor-beta and worsening of remodeling in subcutaneous arterioles of patients with essential hypertension during amlodipine treatment." | 3.73 | Arteriolar remodeling in essential hypertension: are connective tissue growth factor and transforming growth factor involved? ( Rodriguez-Iturbe, B, 2006) |
| "Angiotensin II receptor density in the brain is elevated when dietary salt intake is raised or in the state of hypertension." | 3.73 | The contribution of brain angiotensin II to the baroreflex regulation of renal sympathetic nerve activity in conscious normotensive and hypertensive rats. ( Huang, C; Johns, EJ; Miki, K; Yoshimoto, M, 2006) |
| " Here we asked whether this defect represents a prime determinant in genetic hypertension or whether it is secondary to angiotensin II (Ang II) and/or the mechanical forces exerted on the vascular wall." | 3.73 | Abnormal renovascular parathyroid hormone-1 receptor in hypertension: Primary defect or secondary to angiotensin ii type 1 receptor activation? ( Barthelmebs, M; Coquard, C; Fiaschi-Taesch, N; Helwig, JJ; Massfelder, T; Schordan, E; Welsch, S, 2006) |
| " We report a premature infant born to a 41-year-old mother with a long history of infertility who had received losartan therapy for hypertension throughout an undetected pregnancy." | 3.73 | Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. ( Bass, JK; Faix, RG, 2006) |
| "Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production." | 3.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 3.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "The purpose of this analysis was to evaluate the cost-effectiveness of losartan compared with atenolol for the treatment of hypertension, both from the point of view of society and from that of the health care sector, based on data from the LIFE study." | 3.73 | [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark]. ( Burke, T; Carides, GW; Hildebrandt, P; Keiding, H, 2006) |
| " The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases." | 3.72 | New strategies for prevention of ischemic stroke: the LIFE study. ( Adams, HP, 2003) |
| "Hypertension was induced in Sprague-Dawley rats by infusing angiotensin II (200 ng/kg per min) through osmotic pumps for 12 days." | 3.72 | NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. ( de Champlain, J; El Midaoui, A; Laplante, MA; Wu, R, 2003) |
| "Losartan attenuates BSO-induced hypertension, which appears to be mediated, in part, by angiotensin II and the prostanoid endothelium-derived factors." | 3.72 | Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Silvestrov, N; Socci, RR, 2003) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "The present study evaluates the participation of oxidative stress, tissue angiotensin II (Ang II) and endothelin (ET) in the effects of losartan on blood pressure (BP), ventricular hypertrophy and renal injury in spontaneously hypertensive rats (SHRs), and explores how these effects are modified when spontaneous hypertension is transformed in a low-renin model by the administration of deoxycorticosterone acetate (DOCA)." | 3.72 | Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats. ( Chamorro, V; Duarte, J; O'Valle, F; Osuna, A; Sainz, J; Vargas, F; Wangensteen, R, 2004) |
| "Our previous publication has stressed the benefits of losartan, an angiotensin II receptor blocker, on the permeability of blood-brain barrier (BBB) and blood pressure during L-NAME-induced hypertension." | 3.72 | Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats. ( Arican, N; Elmas, I; Kalayci, R; Kaya, M; Korkut, F; Küçük, M; Kudat, H, 2003) |
| "We investigate whether combined treatment with losartan, an angiotensin II receptor blocker, and exercise training (ET) in spontaneously hypertensive rats (SHR) would have an additive effect in reducing hypertension and improving baroreflex sensitivity when compared with losartan alone." | 3.72 | Effects of losartan combined with exercise training in spontaneously hypertensive rats. ( Azevedo, LF; Barretto, AC; Brum, PC; Junqueira, CM; Mattos, KC; Negrão, CE; Rondon, MU, 2003) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 3.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "Arterial hypertension significantly decreased after the introduction of losartan (p = 0." | 3.72 | Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003) |
| "In the coarctation hypertension model, we showed both dissociation of plasma renin activity from cardiovascular-induced effects and the reversal of hypertension-induced responses by losartan." | 3.72 | Endogenous angiotensin and pressure modulate brain angiotensinogen and AT1A mRNA expression. ( Crescenzi, A; Michelini, LC; Sangaleti, CT, 2004) |
| "The aim of this study was to investigate the effect of long-term treatment with losartan, an angiotensin II (AT1) receptor antagonist, on endothelial dysfunction in an animal model of hypertension in relation to the nitric oxide system." | 3.72 | Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system. ( Bogdanska, J; Jovanoska, E; Korneti, P; Kostova, E; Petrov, S; Slaninka-Miceska, M, 2003) |
| " Since, losartan, an AT1 receptor antagonist, has been shown to attenuate the L-NAME-induced increase in blood pressure, we undertook the present studies to evaluate whether losartan-induced decreased blood pressure in this model of hypertension is associated with attenuation of enhanced expression of Gi proteins and adenylyl cyclase signalling." | 3.72 | Losartan-induced attenuation of blood pressure in L-NAME hypertensive rats is associated with reversal of the enhanced expression of Gi alpha proteins. ( Anand-Srivastava, MB; Hashim, S, 2004) |
| "Hypertension caused by angiotensin II (Ang II) infusion is associated with oxidative stress in the peripheral vasculature and kidney." | 3.72 | Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. ( Davisson, RL; Lazartigues, E; Sharma, RV; Zimmerman, MC, 2004) |
| " Daily he took Losartan potassium, an AIIA, due to hypertension and ate preoperatively dried persimmons, a potassium-rich food." | 3.72 | [A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons]. ( Masuda, N; Miyahara, Y; Miyazaki, T; Tamura, T; Tanaka, Y; Uchida, K; Yamashita, S; Yonei, A, 2004) |
| "Losartan treatment prevents the development of hypertension but not all vascular changes observed after ouabain treatment." | 3.72 | Ouabain-induced hypertension alters the participation of endothelial factors in alpha-adrenergic responses differently in rat resistance and conductance mesenteric arteries. ( Alonso, MJ; Balfagón, G; Rossoni, LV; Salaices, M; Vassallo, DV; Xavier, FE, 2004) |
| "The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH)." | 3.72 | Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. ( Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tokusashi, Y; Yokohama, S; Yoneda, M, 2004) |
| " This study was designed to determine whether our newly developed technique of color-coded TDI may be a useful means of quantifying the improvement in regional left ventricular (LV) myocardial contractility and relaxation after treatment with losartan in patients with hypertension." | 3.72 | Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique. ( Harada, K; Ishimoto, T; Ito, S; Kimura, E; Oishi, Y; Oki, T; Tabata, T; Tanaka, H; Yamada, H, 2004) |
| "To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system." | 3.72 | Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective. ( Burnier, M; Erne, P; Szucs, TD, 2004) |
| "Losartan, an angiotensin II type-1 receptor (AT1) antagonist, was used to investigate whether it can offer protection against the sustained hypertension, cardiac hypertrophy, and renal damage induced by chronic inhibition of nitric oxide (NO) by Nomega-nitro-L-arginine methyl ester (L-NAME)." | 3.72 | Effects of losartan on blood pressure, oxidative stress, and nitrate/nitrite levels in the nitric oxide deficient hypertensive rats. ( Ahmad, M; Al-Shabanah, OA; Khattab, M; Raza, M, 2004) |
| "The study sought to determine whether treatment with the angiotensin II type 1 receptor antagonist losartan would restore the normal dilation of the left main coronary artery (LMCA) by cold pressor test in patients with essential hypertension, as shown by echocardiography." | 3.71 | Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension. ( Chang, Q; Deng, YB; Li, CL; Yang, HY, 2002) |
| "Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II." | 3.71 | Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002) |
| " This study was designed to determine the effects of aging and AT-1 receptor blockade (losartan 30 mg/kg/day beginning at 8 weeks of age) on NO system in this model." | 3.71 | Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. ( Kivlighn, S; Ni, ZN; Shahinfar, S; Vaziri, ND; Wang, XQ, 2002) |
| "To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)." | 3.71 | Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002) |
| "To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)." | 3.71 | [Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001) |
| "The effects of angiotensin II receptor antagonist losartan on elastic properties of aorta in patients with mild to moderate essential hypertension were assessed." | 3.71 | Assessment of effect of angiotensin II receptor antagonist losartan on aortic distensibility in patients with essential hypertension by echocardiography. ( Bi, X; Chang, Q; Deng, Y; Li, C; Pan, M; Yang, H, 2002) |
| "Sympathetic hyperactivity and hypertension caused by chronic treatment with ouabain or sodium-rich artificial cerebrospinal fluid (aCSF) can be prevented by central administration of an angiotensin type 1 (AT(1)) receptor blocker." | 3.71 | AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. ( Leenen, FH; Zhang, J, 2001) |
| "The purpose of this study was to estimate, in current clinical practice, the 3-month cumulative incidence of side effects among first-time users of losartan, ACEIs, and CCBs for hypertension." | 3.71 | Tolerability of antihypertensive drugs in a community-based setting. ( Ciampi, A; Côté, I; Gaudet, M; Grégoire, JP; Guibert, R; Milot, A; Moisan, J, 2001) |
| " To evaluate this effect in vivo, apolipoprotein E(-/-) mice were randomly assigned to receive standard chow, a high-cholesterol diet, or a high-cholesterol diet with hypertension induced by angiotensin II infusion for 8 weeks." | 3.71 | Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. ( Aikawa, M; Hill, CC; Lee, RT; Libby, P; Sakamoto, H; Taylor, WR; Weiss, D, 2001) |
| "In the coarctation hypertension model, we have shown that chronic treatment with losartan causes both normalization of impaired reflex control of heart rate and partial correction of the depressed aortic nerve activity/pressure relationship, even with the persistence of hypertension." | 3.71 | Chronic AT(1) receptor blockade alters autonomic balance and sympathetic responses in hypertension. ( Bezerra, SM; dos Santos, CM; Krieger, EM; Michelini, LC; Moreira, ED, 2001) |
| "To investigate whether brain AT1 receptor stimulation contributes as a hypertensive mechanism to deoxycorticosterone acetate (DOCA)-salt hypertension, losartan (1 mg/4 microL) or artificial cerebrospinal fluid (aCSF) was injected into the lateral cerebral ventricle in conscious control uninephrectomized Wistar rats or rats with DOCA-salt for 2 or 4 weeks, and mean arterial pressure (MAP) and heart rates (HR) were recorded." | 3.71 | Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. ( Leenen, FH; Park, CG, 2001) |
| "Three patients taking the AT2 blocker losartan presented with mucosal swelling in the head and neck clinically consistent with angioedema." | 3.71 | Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. ( Chiu, AG; Deeb, ZE; Krowiak, EJ, 2001) |
| "(1) Salt sensitive hypertension, which occurs as a result of treatment with nitric oxide synthase inhibitors, is associated with a loss of the usual down-regulatory effect of dietary sodium on angiotensin II (Ang II) synthesis." | 3.71 | Dysregulation of angiotensin II synthesis is associated with salt sensitivity in the spontaneous hypertensive rat. ( Duggan, KA; Hodge, G; Ye, VZ, 2002) |
| "We examined the effect and safety of combination therapy with low-dose diuretics (hydrochlorothiazide: HCTZ) and angiotensin II receptor antagonist (losartan) in elderly cases of hypertension, using ambulatory blood pressure monitoring (ABPM)." | 3.71 | [Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension]. ( Abe, I; Eto, K; Iida, M; Tsuchihashi, T, 2002) |
| "To test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist losartan would restore the normal dilation of the left main coronary artery to the cold pressor test in patients with essential hypertension, as assessed by echocardiography." | 3.71 | Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography. ( Deng, YB; Li, CL; Wang, DW; Yang, HY, 2002) |
| "The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in untreated patients with moderate-to-severe essential hypertension or patients with uncontrolled hypertension despite treatment with monotherapy or low-dose combination." | 3.71 | Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. ( Coca, A; de la Sierra, A; Felip, A; Mínguez, A; Pelegrí, A; Plana, J; Sobrino, J; Soler, J; Vila, J, 2002) |
| "This study investigated the comparative effects of losartan and amlodipine on the activation of the sympathetic nervous system, renin-angiotensin-aldosterone system (R-A-A system) and brain natriuretic peptide (BNP) in patients with essential hypertension." | 3.71 | [Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients]. ( Kinoshita, M; Mabuchi, N; Maeda, K; Ohnishi, M; Tsutamoto, T; Tsutsui, T, 2002) |
| " At similar blood pressure control, losartan, as compared to atenolol, reduced the relative risk of primary cardiovascular event (death, myocardial infarction, or stroke) by 13% (p = 0." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| "The three treatments regressed cardiac hypertrophy and normalized sodium/hydrogen ion exchange exchange activity in SHR, and losartan was the most effective treatment for reversing cardiac hypertrophy, despite producing effects on blood pressure and sodium/hydrogen exchange activity similar to that of other antihypertensive drugs." | 3.71 | Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats. ( Alvarez, BV; Cingolani, HE; De Hurtado, MC; Ennis, IL, 2002) |
| "The study was conducted to examine the effects of the angiotensin subtype 1 and 2 receptor antagonists (losartan and PD123319, respectively) on blood pressure (BP) and renal excretory function in chronic hyperinsulinemia-induced hypertension in rats." | 3.70 | Angiotensin receptor blockade blunts hyperinsulinemia-induced hypertension in rats. ( Fang, TC; Huang, WC, 1998) |
| "Angiotensin II type 1 receptor-mediated constrictor effects may be modulated by hypertension-related vascular changes, changes in receptor function and in neurohumoral activity." | 3.70 | Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. ( Baan, J; Chang, PC; Pfaffendorf, M; van Zwieten, PA; Vermeij, P, 1998) |
| "The influence of losartan and the endothelin A and B receptor antagonist, bosentan was assessed on the alterations in renal hemodynamic and function as well as urinary albumin excretion (taken as an index of renal lesions) associated with L-NAME hypertension." | 3.70 | [Renal alterations in L-NAME hypertension: influence of losartan and bosentan]. ( Demeilliers, B; Herizi, A; Jover, B; Mimran, A, 1998) |
| "CNS angiotensin II (AII) hypertension is induced by chronic, low dose intracerebroventricular (ICV) AII infusion only in rats raised on a relatively high sodium chloride diet (250 meq kg(-1)food) from weaning." | 3.70 | AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning. ( Camara, AK; Osborn, JL, 1998) |
| "The consequences of aging for endothelium-dependent and endothelium-independent relaxations of rings from spontaneously hypertensive rats are ameliorated by losartan treatment, suggesting that angiotensin II plays a role via type 1 receptors." | 3.70 | Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998) |
| "To investigate the role of angiotensin II in the pathogenesis of hyperinsulinemia-induced hypertension in rats." | 3.70 | Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. ( Fang, TC; Huang, WC, 1998) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 3.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "This study was designed to investigate the effects of chronic inhibition of NO synthesis as well as chronic angiotensin receptor blockade with losartan in the development of hypertension, on mesenteric arterial bed reactivity as well as on the development of cardiac and kidney hypertrophy in deoxycorticosterone-salt (DOCA) hypertension." | 3.70 | Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. ( Cardinal, R; de Champlain, J; K-Laflamme, A; Oster, L, 1998) |
| "Adult Ren-2 gene transgenic rats, TGR(mRen-2)27, exhibit elevated circulating and kidney angiotensin II (Ang II) levels in the presence of severe hypertension." | 3.70 | Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. ( Mendelsohn, FA; Ohishi, M; Zhuo, J, 1999) |
| "A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure." | 3.70 | Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999) |
| ") was compared to that of Cozaar combination with melatonin (3 mg before sleep) in 21 patients with hypertension stage II (mean age 62 years)." | 3.70 | [Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension]. ( Goncharov, LF; Goncharova, ZF; Komarov, FI; Makarova, LA; Zaslavskaia, RM, 1998) |
| " Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated in patients with essential hypertension." | 3.70 | Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. ( Sever, PS, 1999) |
| "Losartan is the first recently approved drug against hypertension disease that competes with the biological action of angiotensin II (AII) at the AT1 receptor." | 3.70 | An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. ( Kolocouris, A; Matsoukas, J; Mavromoustakos, T; Roumelioti, P; Weisemann, R; Zervou, M, 1999) |
| "To report a case of angioedema associated with losartan administration." | 3.70 | Losartan-induced angioedema. ( Rivera, JO, 1999) |
| "Since the effects of angiotensin II receptor antagonism on arterial function in nitric oxide (NO)-deficient hypertension are unknown, we investigated the influence of losartan therapy (20 mg kg-1 day-1) on the control of arterial tone in NG-nitro-L-arginine methyl ester (L-NAME; 20 mg kg-1 day-1)-induced hypertension." | 3.70 | Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. ( Holm, P; Hutri-Kähönen, N; Jolma, P; Kähönen, M; Kalliovalkama, J; Pörsti, I; Tolvanen, JP; Wu, X, 1999) |
| " This report emphasizes the importance of angiotensin II in vascular function alterations induced by aging in SHR." | 3.70 | Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1999) |
| " ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study." | 3.70 | Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. ( Dahlöf, B; Devereux, RB; Jern, S; Kjeldsen, SE; Okin, PM, 2000) |
| "To compare the efficacy of increasing doses of losartan or the addition of hydrochlorothiazide to achieve adequate blood pressure levels in patients with hypertension." | 3.70 | [Antihypertensive efficacy of monotherapy in increasing doses versus therapy associated in low doses]. ( Fasce, E; Wagemann, H, 1999) |
| " We investigated the role of angiotensin II and endothelin-1 in FD and MT in resistance arteries and their potential change in hypertension." | 3.70 | Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats. ( Henrion, D; Lévy, BI; Matrougui, K, 2000) |
| "We tested the hypothesis that hypertension in atrial natriuretic peptide (ANP) knockout mice is caused in part by disinhibition of angiotensin II-mediated vasopressin release." | 3.70 | Increased central AT(1)-receptor activation, not systemic vasopressin, sustains hypertension in ANP knockout mice. ( Ackermann, U; Azizi, N, 2000) |
| "We assessed the role of angiotensin (Ang) II type 1 receptor (AT1) and endothelin type A and B (ETA & ETB) receptor in cardiovascular hypertrophy associated with angiotensin II-induced hypertension (200 ng/kg." | 3.70 | [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan]. ( Belabbas, H; Herizi, A; Jover, B; Mimran, A, 2000) |
| "Although NAD(P)H oxidase-derived superoxide (O(2)(-)) is increased during the development of angiotensin II (ANG II)-dependent hypertension, vascular regulation at the protein level has not been reported." | 3.70 | Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. ( Carretero, OA; Cifuentes, ME; Pagano, PJ; Rey, FE, 2000) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 3.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| " To further explore the mechanisms underlying fructose-induced hypertension, the effects of the AT1 receptor antagonist losartan on blood pressure, insulin resistance, renal function, and vascular reactivity in mesenteric vascular beds were studied." | 3.69 | Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Perez-Vizcaino, F; Ruilope, LM; Tamargo, J, 1995) |
| "To assess the role of angiotensin (ANG) II in both the increased heart rate (HR) and the impaired baroreceptor reflex control of HR that characterize the chronic phase of coarctation hypertension (CH), we compared basal HR, mean arterial pressure (MAP), and baroreflex sensitivity of coarcted hypertensive rats treated chronically with losartan, captopril, or vehicle." | 3.69 | Losartan improves baroreflex control of heart rate of coarcted hypertensive rats. ( Leomil Neto, M; Michelini, LC; Pontieri, V; Santos, CM, 1995) |
| "This small open study in elderly patients with essential hypertension investigated the effects of the angiotensin II AT1 receptor antagonist on red blood cell haematology and haemorheology." | 3.69 | Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. ( Bailey, RR; Gilchrist, NL; Nicholls, MG; Shand, BI, 1995) |
| "As the AT1 receptor is the primary angiotensin II receptor in the myocardium and vasculature, we assessed the acute myocardial and vascular response to the AT1 angiotensin II antagonist losartan in the spontaneously hypertensive rat (SHR) to determine the contribution of angiotensin II in this genetic form of hypertension." | 3.69 | Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat. ( Binkley, PF; Brown, DM; Cody, RJ; Haas, GJ, 1995) |
| " Angiotensin-converting enzyme (ACE) inhibitors appear to be the drugs of choice since they not only lower blood pressure but also reduce some important risk factors that may cause progressive loss of renal function, such as intraglomerular hypertension, angiotensin II (Ang II)-induced glomerular growth, proteinuria and hyperlipidemia." | 3.69 | Losartan in patients with renal insufficiency. ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1995) |
| " Both captopril treatment and losartan treatment completely blocked the development of hypertension in diabetic SHR." | 3.69 | Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. ( Abe, K; Fu, LP; Kanazawa, M; Kohzuki, M; Obara, K; Saito, T; Yasujima, M; Yoshida, K, 1995) |
| "To clarify the role of endogenous angiotensin II (AngII) in the hypertension of spontaneously hypertensive rats (SHR), we examined the chronic effects of central and systemic administration of losartan, an angiotensin AT1 receptor antagonist, on blood pressure and arterial baroreceptor reflex." | 3.69 | Chronic effects of central and systemic administration of losartan on blood pressure and baroreceptor reflex in spontaneously hypertensive rats. ( Kawano, Y; Matsuoka, H; Omae, T; Yoshida, K, 1994) |
| "This study investigated the ability of the selective angiotensin II (AII)-type (AT)1 receptor antagonist losartan to reverse the fast (< 30 sec) pressor effect of AII, and the hypertension produced by chronic (2 weeks) i." | 3.69 | Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. ( Fink, GD; Gorbea-Oppliger, VJ; Melaragno, MG; Petit, RL; Potter, GS, 1994) |
| "The objective of this study was to investigate the effect of Losartan (NK-954, DuP-753), a new selective angiotensin II receptor antagonist, on insulin sensitivity and sympathetic nervous system activity in patients with severe primary hypertension." | 3.69 | The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. ( Eide, I; Kjeldsen, SE; Moan, A; Risanger, T, 1994) |
| " To test the hypothesis that endogenous angiotensin II (Ang II) in the AHA also plays a role in blood pressure regulation and in NaCl sensitive hypertension in the SHR-S, Type 1 Ang II (AT1) receptors in the AHA were blocked by local microinjection of losartan, a selective nonpeptide AT1 receptor antagonist, and the effects of the intervention on blood pressure were observed." | 3.69 | Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. ( Berecek, KH; Chen, SJ; Jin, HG; Meng, QC; Oparil, S; Wyss, JM; Yang, RH, 1994) |
| " In these studies, we produced chronic NO blockade by oral administration of the NO synthesis inhibitor nitro-L-arginine methyl ester (L-NAME), which produced sustained hypertension and increased renal vascular resistance (RVR) in conscious rats." | 3.69 | Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. ( Baylis, C; Engels, K; Qiu, C, 1994) |
| " NG-Nitro-L-arginine methyl ester (L-NAME) (3 x 10(-4) mol/L) increased tension (82 +/- 11% of the response to 120 mmol/L potassium chloride) in rings of thoracic aorta taken from hypertensive rats 7 to 14 days after aortic coarctation, whereas rings of abdominal aorta from below the coarctation were unresponsive, as were rings of thoracic aorta from rats with deoxycorticosterone-salt-induced hypertension and from the corresponding normotensive controls of either model of hypertension." | 3.69 | Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats. ( Dick, LB; Guan, H; Lin, L; Miller, KB; Nasjletti, A; Pucci, ML, 1994) |
| "We explored the role of angiotensin II and vasopressin in the maintenance of blood pressure during the nephrotic syndrome of adriamycin-induced nephropathy in rats." | 3.69 | Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. ( Ferrari-Spadotto, A; Franco, R; Gavras, H; Gavras, I; Georgette, J; Gut, A, 1994) |
| "We studied the mechanisms responsible for vascular and cardiac hypertrophy in hypertension (pressure load and humoral and genetic factors) in two experimental approaches: (1) We carried out a cosegregation analysis to correlate cardiac and vascular hypertrophy with subphenotypes of blood pressure in an F2 generation of a cross between stroke-prone spontaneously hypertensive rats (SHRSP) and normotensive Wistar-Kyoto rats; (2) we treated 8-week-old SHRSP with perindopril, an angiotensin-converting enzyme inhibitor; losartan, an angiotensin type 1 receptor antagonist; or perindopril combined with a nitric oxide synthase inhibitor to investigate the relative contributions of blood pressure and angiotensin II to the pathogenesis of cardiac hypertrophy and vascular smooth muscle polyploidy." | 3.69 | Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension. ( Anderson, NH; Bohr, DF; Devlin, AM; Dominiczak, AF; Lee, WK; Reid, JL, 1996) |
| "We tested the hypothesis that angiotensin II-induced hypertension is associated with an increase in vascular ." | 3.69 | Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. ( Freeman, BA; Griendling, KK; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Tarpey, M, 1996) |
| " Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD123319 on the vascular hypertrophy in rats with Ang II-induced hypertension." | 3.69 | Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. ( Benessiano, J; Caputo, L; Duriez, M; Henrion, D; Heymes, C; Levy, BI; Poitevin, P; Samuel, JL, 1996) |
| "To investigate the role of angiotensin II (ANG II) in the development of hypertension induced by reduced renal mass (RRM) and the gene expression of ANG II type 1 (AT1) receptors in the remnant renal tissue, four groups of rats were given 1% NaCl in water and subjected to RRM, RRM+ ramipril, RRM+ losartan, or sham surgery (control)." | 3.69 | Regulation of ANG II receptor in hypertension: role of ANG II. ( DiPette, DJ; Wang, DH; Yao, A; Zhao, H, 1996) |
| "We examined the mechanisms mediating hypertension in conscious rats during acute and chronic infusion of angiotensin II (ANG II) at pressor doses (50, 100, and 200 ng." | 3.69 | Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. ( Blaine, EH; Dale, WE; Hasser, EM; Li, Q, 1996) |
| "These experiments tested the hypothesis that hypertension caused by chronic inhibition of nitiric oxide synthase (NOS) is associated with augmented pressor responsiveness to angiotensin II (ANG II)." | 3.69 | Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats. ( Fink, GD; Melaragno, MG, 1996) |
| "Chronic low-dose angiotensin II (Ang II) infusion for 13 days mimics two-kidney, one clip Goldblatt hypertension and increase intrarenal Ang II levels." | 3.69 | Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. ( Hymel, A; Imig, JD; Navar, LG; Ono, H; von Thun, AM; Zou, LX, 1996) |
| "We compared the consequences of chronic angiotensin-converting enzyme (ACE) inhibition with quinapril and of specific AT1 blockade with losartan in a renin-dependent model of hypertension, the (mRen2)27 transgenic rats (TG)." | 3.69 | Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats. ( Bizollon, CA; Gharib, C; Lantelme, P; Lo, M; Mullins, JJ; Sassard, J, 1996) |
| "Hypertension, low-density lipoprotein (LDL), and fibrinogen are risk factors for atherosclerosis." | 3.69 | Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats. ( Born, GV; Brown, MJ; Cardona-Sanclemente, LE; Medina, R, 1997) |
| "Angioedema has not been associated with losartan therapy in hemodialysis patients, as it has been with angiotensin converting enzyme (ACE) inhibitors." | 3.69 | Angioedema associated with angiotensin II receptor antagonist losartan. ( Sharma, PK; Yium, JJ, 1997) |
| "As interactions between the renin-angiotensin and sympathetic nervous systems have been suggested in the pathogenesis of hypertension, we wanted to investigate the effect of chronic renin-angiotensin blockade with losartan and enalaprilat on the sympathetic reactivity to hypotension and on the cardiac beta-adrenergic-coupled adenylyl cyclase pathway in 12-week-old Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR)." | 3.69 | Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. ( Cardinal, R; de Champlain, J; K-Laflamme, A; Oster, L, 1997) |
| "Role of renin-angiotensin system in hypertension induced by cadmium chloride (CdCl2) in rats has been investigated." | 3.69 | Involvement of renin-angiotensin system in hypertensive effect of cadmium in rats. ( Das, N; Gulati, K; Khattar, S; Lall, SB; Peshin, SS; Seth, SD, 1997) |
| "To examine the role played by angiotensin II (AII) in the development of prehypertensive vascular hypertrophy in the spontaneously hypertensive rat (SHR) and to determine whether normalization of prehypertensive vascular hypertrophy attenuates the development of hypertension." | 3.69 | Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats. ( Black, MJ; Bobik, A; Kanellakis, P, 1997) |
| " Treatment with either losartan (25 mg x kg(-1) x d(-1)) or hydralazine (15 mg x kg(-1) x d(-1)), both of which prevented the Ang II-induced hypertension, blocked HO-1 mRNA upregulation." | 3.69 | Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. ( Alexander, RW; De Keulenaer, G; de León, H; Fukui, T; Griendling, KK; Ishizaka, N; Laursen, JB; Wilcox, JN, 1997) |
| " Afterward is considered the importance of the administration of the inhibiting of the receptors AT-1 (Losartan) in the control of the hypertension and of the atherosclerosis." | 3.69 | [Physiopathology of angiotensin II and vascular lesion]. ( Marci, M; Raffa, S; Russo, F, 1997) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 3.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| "Oral losartan at 30 mg/kg per day delayed the development of severe hypertension and prevented stroke in saline-drinking SHRSP." | 3.68 | Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. ( Adler, LA; Chander, PN; Levine, S; Stier, CT, 1993) |
| "To study the effects of renin-angiotensin system blockade by a novel non-peptide angiotensin II receptor antagonist, losartan, on development of hypertension and acceleration of end-organ damage in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.68 | Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. ( Camargo, MJ; Campbell, WG; James, GD; Laragh, JH; Pecker, MS; Timmermans, PB; von Lutterotti, N, 1993) |
| "We examined the chronic effects of losartan (DuP 753), a novel orally active angiotensin II receptor antagonist, on blood pressure and renal function in eight hospitalized patients with essential hypertension." | 3.68 | Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. ( Abe, K; Hagino, T; Imai, Y; Misawa, S; Omata, K; Tsunoda, K; Yoshinaga, K, 1993) |
| "The influence of dietary sodium restriction and angiotensin II blockade on hypertension induced by a 25-day period of administration of the inhibitor of nitric oxide synthesis NG-nitro-L-arginine-methyl ester (10 mg/kg twice daily by gavage) was assessed in Wistar rats fed a normal or low sodium diet." | 3.68 | Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. ( Dupont, M; Herizi, A; Jover, B; Mimran, A; Ventre, F, 1993) |
| "To study the effects of blockade of the renin-angiotensin system upon the development of hypertension, end-organ damage and mortality in Dahl salt-sensitive (DSS) rats using an angiotensin II receptor antagonist, losartan." | 3.68 | Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. ( Camargo, MJ; Campbell, WG; Laragh, JH; Mueller, FB; Sealey, JE; Timmermans, PB; von Lutterotti, N, 1992) |
| " The angiotensin II type 1 receptor antagonist, losartan, prevented the development of hypertension in spontaneously hypertensive rats (SHR)." | 3.68 | Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. ( Bobik, A; Dilley, RJ; Oddie, CJ, 1992) |
| "We examined the chronic effects of MK954, a novel orally active angiotensin II receptor antagonist, on blood pressure and renal function in 8 patients with essential hypertension for 2-4 weeks." | 3.68 | [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension]. ( Abe, K; Hagino, T; Tsunoda, K; Yoshinaga, K, 1992) |
| "Inhibitors of angiotensin converting enzyme, renin, and the angiotensin II (Ang II) receptor lower the blood pressure of spontaneously hypertensive rats (SHR) used as a model of essential hypertension." | 3.68 | Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy. ( Higuchi, K; Inagami, T; Murakami, T; Nakajo, S, 1991) |
| " Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension." | 3.30 | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. ( Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023) |
| "Reversal of left ventricular hypertrophy (LVH) in hypertensive patients appears to be a desirable goal to the reduction cardiac risk." | 2.84 | Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment. ( Affricano, C; Bossini, A; Cassone, R; Gaudio, C; Lopreiato, F; Moroni, C; Scrofani, AR; Tolone, S, 2017) |
| "The aim of current study was to assess the effectiveness of losartan 50 mg in reducing blood pressure among post-dialysis euvolemic hypertensive patients, observing their survival trends and adverse events during the course of study." | 2.84 | Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial. ( Adnan, AS; Aftab, RA; Khan, AH; Khan, TM; Sulaiman, SAS, 2017) |
| "Amlodipine was more effective than losartan in reducing patients' 24-h ambulatory blood pressure at the steady-state sampling time." | 2.84 | The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients. ( de Leeuw, PW; Fagard, R; Kroon, AA, 2017) |
| " Adverse drug reactions (ADRs) were monitored." | 2.82 | Comparison of Effect of Enalapril and Losartan Monotherapy on Quality of Life and Safety of Stage 1 Hypertensive Patients. ( Gupta, LK; Maharshi, V; Rehan, HS; Yadav, M, 2016) |
| "Ninety-one patients with untreated hypertension underwent a home sleep study (55 were found to have OSA; 36 were not)." | 2.82 | Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. ( Manhem, K; Peker, Y; Rosengren, A; Thunström, E, 2016) |
| "Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks." | 2.82 | Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. ( Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 2.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "Morning hypertension is an established risk factor for cardiovascular events." | 2.80 | Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study. ( Anegawa, T; Aoki, Y; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Uchiwa, H; Ueda, T, 2015) |
| "Proteinuric diabetic kidney disease frequently progresses to ESRD." | 2.80 | BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. ( Emanuele, NV; Fried, LF; Guarino, P; Leehey, DJ; Palevsky, PM; Reilly, RF; Whaley-Connell, A; Zhang, JH, 2015) |
| " Besides, its cholesterol-lowering effect, the ability of simvastatin to ameliorate endothelial dysfunction through increasing NO bioavailability and through suppression of oxidative stress and vascular inflammation may play an important role in these effects." | 2.79 | Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. ( Abdel-Zaher, AO; Abudahab, LH; Elbakry, MH; Elkoussi, AE; Elsayed, EA, 2014) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 2.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| "Losartan was titrated to the next dose level (to a 1." | 2.79 | A randomized, open-label, dose-response study of losartan in hypertensive children. ( Blaustein, RO; Dankner, WM; Lam, C; Massaad, R; McCrary Sisk, C; Santoro, EP; Shahinfar, S; Webb, NJ; Wells, TG, 2014) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 2.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| "5 mg) (ARB+D; n = 72) or a combination of amlodipine (5 mg) and the typical dosage of ARBs (ARB+C; n = 68) to evaluate the change in the BP, laboratory values and cognitive function." | 2.78 | Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. ( Hasebe, N; Kikuchi, K; Koyama, S; Maruyama, J; Morimoto, H; Morita, K; Saijo, Y; Sano, H; Sasagawa, Y; Sato, N; Sumitomo, K; Takehara, N; Takeuchi, T, 2013) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 2.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "A significant white coat hypertension was noticed in both the arms." | 2.78 | A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension. ( Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J, 2013) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 2.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| "To assess antihypertensive duration of action of Losartán Cronos in patients with essential hypertension throughout a 24-h dosing interval, using ABPM and response rates, AASI and Smoothness Index." | 2.77 | [Abpm and duration of the antihypertensive effect: a study with a new formulation of sustained release losartan (CRONOS)]. ( Bendersky, M; Caruso, G; Gomez, R; Juncos, L; Kotetzky, M; Lopez-Santi, R; Montaña, O; Penna, M; Piskorz, D; Waisman, GD, 2012) |
| "Hypertension is associated with an increased risk of diastolic dysfunction." | 2.77 | Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Kasayuki, N; Kihara, H; Nakamura, F; Shimada, K; Yoshikawa, J, 2012) |
| "Hypertension is associated with endothelial dysfunction and activated Rho-associated kinases (ROCKs)." | 2.77 | Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. ( Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2012) |
| "Many patients with hypertension have difficulty achieving their target blood pressure (BP)." | 2.77 | Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study. ( Inou, T; Kobayashi, K; Kubara, I; Meno, H; Nakamura, Y; Ota, T; Shiga, Y; Tanaka, M; Tsuchiya, Y, 2012) |
| " This study examined the practical efficacy of a combination therapy of ARB with thiazide diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy in patients with morning hypertension administered an ordinal dosage of ARB." | 2.77 | Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension. ( Hanayama, Y; Makino, H; Nakamura, Y; Uchida, HA, 2012) |
| " This study included 15 subjects whose therapy was changed from a usual dosage of ARB to losartan 50mg/HCTZ 12." | 2.76 | Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. ( Hirose, H; Kawabe, H; Saito, I, 2011) |
| " There were 38 adverse events in 20 patients (21." | 2.76 | Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind ( Chae, SC; Cho, SY; Hong, TJ; Jeong, JW; Jung, JW; Kang, SM; Kim, CH; Kim, JJ; Kim, MH; Kwon, J; Park, CG; Park, SH; Shin, DG; Yang, JY; Yoon, JH; Youn, JC, 2011) |
| " Serious adverse events were more frequent in E (2." | 2.76 | Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study. ( Aoun, J; Girerd, X; Rosenbaum, D, 2011) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 2.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| " Clinical and laboratory adverse events were reported for 29 patients (11%), but serious abnormalities were not observed." | 2.75 | One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2010) |
| "As arterial hypertension is the most important risk factor for ischemic stroke, the relevant guidelines recommend rigorous treatment to normalize blood pressure." | 2.73 | [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)]. ( Bestehorn, K; Diener, HC; Haller, H; Jung, C; Lüders, S; Schmieder, RE; Schrader, J; Smolka, W; Wahle, K, 2008) |
| " Adverse effects related to the treatment during the study were reported in a total of 9 patients (0." | 2.73 | [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study]. ( Ceypová, K; Hauser, T; Kristenová, P; Krupicka, J, 2008) |
| "The prevalence of baseline left ventricular hypertrophy (LVH) was not significantly different among three groups." | 2.73 | Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. ( Argano, C; Avellone, G; Colomba, D; Corrao, S; Di Chiara, T; Donatelli, M; Licata, G; Parrinello, G; Scaglione, R, 2007) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 2.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Amiloride 40 mg was as effective as the other diuretics." | 2.73 | The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. ( Ashby, MJ; Brown, MJ; Hood, SJ; Taylor, KP, 2007) |
| " There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group." | 2.73 | Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. ( Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 2.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| " During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12." | 2.71 | Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. ( Byrne, M; Gil-Extremera, B; Lacourcière, Y; Mueller, O; Williams, L, 2003) |
| " Safety was assessed in both studies by the incidence of adverse experiences." | 2.71 | Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. ( Dickson, TZ; Lin, CC; Lo, MW; Ramjit, D; Ritter, MA; Shahinfar, S; Snavely, D; Zagrobelny, J, 2003) |
| " Both drugs provided effective control over the 24-h dosing interval." | 2.71 | Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. ( Kolloch, RE; Meinicke, TW; Neutel, JM; Plouin, PF; Schumacher, H, 2003) |
| "Atenolol treatment did not induce significant changes in any test score, whereas losartan significantly increased the score of both the word list memory (+2." | 2.71 | Influence of losartan and atenolol on memory function in very elderly hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Zoppi, A, 2003) |
| "Aliskiren was well tolerated at all doses studied." | 2.71 | Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. ( Jensen, C; Nussberger, J; O'Brien, E; Stanton, A, 2003) |
| "001) and the other periods of the 24-h interval compared with the levels achieved by the previous treatment, indicating a clear dose-response relationship." | 2.71 | Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. ( Lacourcière, Y; Poirier, L, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 2.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "Patients with the metabolic syndrome have three or more of five cardiovascular risk factors and increased oxidative stress, arterial stiffness and pressor responses to exercise, which may contribute to their threefold greater risk for coronary heart disease." | 2.71 | Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. ( Egan, BM; Jesri, A; Morrow, JD; Nashar, K; Nguyen, JP, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 2.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system predisposing to a procoagulant state." | 2.71 | Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. ( Hatzizacharias, A; Krespi, P; Makris, TK; Papadopoulos, DP; Stavroulakis, G; Tsoukala, C; Votteas, VE; Zilidis, A, 2004) |
| "Losartan was used in 45 consecutive hypertensive children with chronic renal parenchymal disorders and mean glomerular filtration rate (GFR) 99." | 2.71 | Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. ( Ellis, D; Janosky, JE; Moritz, ML; Vats, A, 2004) |
| "Simvastatin combined with losartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy with either drug in hypercholesterolemic, hypertensive patients." | 2.71 | Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. ( Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK, 2004) |
| " Adverse events with the two treatments were comparable (telmisartan vs." | 2.71 | Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. ( Bai, J; Cai, NS; Cheng, NN; Fan, WH; Guo, JX; Guo, JZ; Ke, YN; Lu, ZY; Sheng, LH; Tang, B; Zhu, JR, 2004) |
| "Obesity has been shown to be associated with increased left ventricular mass (LVM) and heart sympathetic activity even in nonhypertensive subjects." | 2.71 | Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. ( Amador, N; Encarnación, JJ; Guízar, JM; López, M; Rodríguez, L, 2005) |
| "The aim of this study was to determine the dose-response relationship for losartan, 2." | 2.71 | A double-blind, dose-response study of losartan in hypertensive children. ( Ahmed, T; Blumer, J; Briazgounov, I; Cano, F; Gleim, G; Miller, K; Santoro, EP; Shahinfar, S; Soffer, BA; Vogt, B; Zhang, Z, 2005) |
| "Losartan was administered to all of the patients at a dose of 50 mg/day for 24 weeks." | 2.71 | Losartan and simvastatin inhibit platelet activation in hypertensive patients. ( Fukuhara, S; Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A, 2004) |
| "We studied the effects of a chronotherapeutic delivery system of verapamil (controlled-onset extended release [COER]-24 system) dosed at bedtime versus conventional morning administration of both enalapril and losartan on the blood pressure (BP), heart rate, and the heart rate systolic BP product during the first 4 hours after awakening in a placebo-controlled, forced-titration trial." | 2.70 | Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. ( Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 2.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "and enalapril 20 mg o." | 2.70 | A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. ( Fagard, R; Lijnen, P; Pardaens, K; Thijs, L; Vinck, W, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "In losartan-treated patients, CVF decreased from 5." | 2.70 | Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. ( Díez, J; González, A; Larman, M; López, B; Martínez Ubago, JL; Querejeta, R; Varo, N, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "In losartan-treated patients, both cardiomyocyte and noncardiomyocyte apoptosis decreased (P<0." | 2.70 | Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. ( Díez, J; Fortuño, MA; González, A; Larman, M; López, B; Querejeta, R; Ravassa, S, 2002) |
| "Losartan was given in maximal tolerance dose (25-100 mg/day)." | 2.70 | [Effects of long-term therapy with losartan on baroreflex regulation of cardiovascular system]. ( Brodskaia, IS; Gordeeva, MV; Iakovlev, AN; Mamontov, OV; Pushkarev, AA, 2002) |
| "Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase." | 2.70 | A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. ( Abellan, J; Cucalón, JM; Fernández-Vega, F; Gómez de la Cámara, A; Maceira, B; Sanz de Castro, S, 2001) |
| "Hypertension is associated with impaired fibrinolysis." | 2.70 | The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. ( Appel, LJ; Bohannon, AD; Conlin, PR; Erlinger, TP; Macko, RF; Miller, ER; Moore, TJ; Svetkey, LP, 2002) |
| "Losartan was withdrawn in only 6 patients because ofa clinical or laboratory adverse experience." | 2.69 | Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. ( Mitchell, H; Raij, L; Ramjit, D; Shahinfar, S; Shaw, W; Shultz, P; Toh, J; Toto, R, 1998) |
| "Candesartan cilexetil was similarly well tolerated as placebo." | 2.69 | The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. ( Andersson, OK; Neldam, S, 1998) |
| "Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity." | 2.69 | Losartan in Cushing's syndrome. ( Andrewa, M; Angelova-Gateva, P; Natchev, E; Orbetzova, M; Torbova, S; Tzingilev, D; Vergilova, J; Wipperrnann, M; Zacharieva, S, 1998) |
| "Losartan potassium is a recently marketed angiotensin II receptor antagonist." | 2.69 | The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. ( Barnes, CC; Lacourcière, Y; Wilson, TW, 1998) |
| " Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary." | 2.69 | Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. ( Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999) |
| "Treatment with losartan for 3 mo had no effect on LV mass measured by echo (141+/-5 vs." | 2.69 | Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction. ( Ayoub, JC; Costa, OM; de Parma, AH; Delgado, AS; Parro, A; Takakura, IT; Vitola, JV, 1999) |
| "Losartan decreased serum uric acid and increased uric acid excretion without increasing urinary dihydrogen urate, the primary risk factor for acute urate nephropathy, during 21 days of dosing in hypertensive patients with thiazide-induced hyperuricemia." | 2.69 | Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. ( Carides, AD; Coe, FL; Nakagawa, Y; Parks, JH; Shahinfar, S; Simpson, RL; Thiyagarajan, B; Umans, JG, 1999) |
| "The purpose of this double-blind, forced titration study was to compare the antihypertensive effect duration of candesartan cilexetil, which has a longlasting binding to the human AT1-receptor, to that of losartan on ambulatory BP (ABP) not only during the 24-h dosing interval but also during the day of a missed dose intake." | 2.69 | A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo ( Asmar, R; Lacourcière, Y, 1999) |
| "Losartan is a selective, competitive antagonist of the thromboxane A2 receptor in experiments performed in isolated vascular strips and in human and rat platelet-enriched plasma." | 2.69 | Inhibition of platelet aggregability by losartan in essential hypertension. ( Brosnihan, KB; Ferrario, CM; Levy, PJ; Owen, J; Smith, R; Yunis, C, 2000) |
| "Losartan appears to be an effective anti-hypertensive agent in patients with mild to moderate hypertension." | 2.68 | Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. ( Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995) |
| " A dose-response relationship to losartan was observed in this patient population." | 2.68 | Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. ( Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995) |
| "Losartan was shown to have a smooth antihypertensive profile throughout the 24 h period following dosing, which mirrors the diurnal variability of blood pressure." | 2.68 | Efficacy and safety of losartan. ( Goldberg, A; Sweet, C, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " Although plasma inactive renin concentrations did not change acutely after losartan dosing on day 1 or 42 they did increase from 27." | 2.68 | Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. ( Goldberg, MR; Katz, SA; Opsahl, JA, 1995) |
| " Efficacy should be demonstrated not only in the conventional clinical setting, but also throughout the full 24 h day, including the important early morning hours near the end of dosing intervals." | 2.68 | Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent. ( Neutel, JM; Smith, DH; Weber, MA, 1995) |
| "During both models of hyperinsulinemia, plasminogen activator inhibitor activity and antigen decreased significantly (both P<." | 2.68 | Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. ( Arnesen, H; Kjeldsen, S; Moan, A; Sandvik, E; Seljeflot, I, 1996) |
| " for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg)." | 2.68 | Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. ( Bradstreet, TE; Goldberg, MR; Höglund, P; Lo, MW; Ritter, MA, 1995) |
| " The acute pharmacodynamic actions of intravenous (i." | 2.67 | Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. ( Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 2.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| " Losartan's long duration of action is documented by ratios of trough (end of 24-h dosing interval) to peak antihypertensive effects, which are consistently above 50%." | 2.67 | Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. ( Weber, MA, 1992) |
| "Losartan was the ninth most prescribed drug in the United States in 2016, and several other angiotensin-II receptor blockers (ARBs) are widely prescribed." | 2.61 | Current Status of Angiotensin Receptor Blocker Recalls. ( Bhalla, V; Byrd, JB; Chertow, GM; Gunasekaran, PM, 2019) |
| "Losartan generated a lower incidence than angiotensin-converting enzyme inhibitors of reported dry cough (risk ratio 0." | 2.52 | Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. ( Fan, Y; Lang, Y; Wang, S; Wei, F, 2015) |
| "Losartan (Cozaar™) is an angiotensin II receptor antagonist with antihypertensive activity." | 2.52 | Losartan: Comprehensive Profile. ( Abdel-Aziz, HA; Al-Majed, AR; Assiri, E; Khalil, NY, 2015) |
| "Losartan has been widely evaluated for the management of hypertension." | 2.50 | Managing blood pressure control in Asian patients: safety and efficacy of losartan. ( Cheung, BM; Cheung, TT, 2014) |
| "Gout is increasing worldwide." | 2.49 | Hypertension, its treatment, hyperuricaemia and gout. ( Gibson, TJ, 2013) |
| "Incident cancer cases were compared in patients randomized to ARBs versus controls." | 2.47 | Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011) |
| " However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness." | 2.46 | Comparing angiotensin II receptor blockers on benefits beyond blood pressure. ( Siragy, HM, 2010) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 2.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 2.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Losartan is a competitive antagonist that causes a parallel rightward shift of the concentration-contractile response curve to angiotensin-II, while E 3174 is a noncompetitive "insurmountable" antagonist of angiotensin-II." | 2.43 | Clinical pharmacokinetics of losartan. ( Gehr, TW; Ghosh, S; Sica, DA, 2005) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| " The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval." | 2.43 | Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros ( Lacourcière, Y; Neutel, JM; Schumacher, H, 2005) |
| "Losartan (Cozaar) is an angiotensin AT1 receptor antagonist." | 2.43 | Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Moen, MD; Wagstaff, AJ, 2005) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "The major goal of treating high blood pressure in this population is to prevent or reduce the likelihood of target-organ damage." | 2.42 | Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? ( Lakkis, J; Lu, WX; Weir, MR, 2003) |
| "Both telmisartan and losartan were found to be safe and well tolerated." | 2.42 | Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. ( Cramer, MJ; Hettiarachchi, R; Koval, S; Neutel, JM; Smith, DH, 2003) |
| "As stroke is characterised by vascular remodelling and dysfunction and by effects on the cerebral circulation, selecting an agent that has a direct vascular protective effect beyond blood pressure control may be desirable." | 2.42 | Stroke prevention: is it possible? If so, which antihypertensive agent should be used? ( Kim, S, 2003) |
| "Losartan 50-100 mg/day was compared with atenolol 50-100 mg/day in patients with essential hypertension and left ventricular hypertrophy (LVH) [n = 9,193] in the randomized, double-blind Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 2.42 | Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy. ( Keating, GM; Waugh, J, 2003) |
| "For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used." | 2.42 | Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) studied the effect of the angiotensin receptor blocker (ARB) irbesartan on the reduction of BP, urinary protein excretion, and progression to DN." | 2.42 | Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. ( Hunsicker, LG, 2004) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| " The selected studies were included in a meta-analysis of the dose-response relationship for each drug." | 2.41 | The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. ( Elmfeldt, D; Meredith, P; Olofsson, B, 2002) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| " Each drug effectively lowers blood pressure during once daily administration to patients with mild to moderate hypertension, with candesartan cilexetil requiring the lowest dosage and providing dose-dependent efficacy." | 2.41 | Newly emerging pharmacologic differences in angiotensin II receptor blockers. ( Oparil, S, 2000) |
| " Sustained efficacy of blood pressure control, without any evidence of tachyphylaxis, has been demonstrated after long-term administration (3 years) of some of the ARBs." | 2.41 | Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. ( Israili, ZH, 2000) |
| "Hypertension is highly prevalent after renal transplantation and has been associated with lower graft survival." | 2.41 | Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. ( Anaya, F; Del Castillo, D; Holgado, R, 2001) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 2.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| " Further data are needed on the use of losartan potassium in patients with renal impairment before accepting the recommendation that dosage adjustment is not necessary." | 2.40 | A risk-benefit assessment of losartan potassium in the treatment of hypertension. ( Burrell, LM, 1997) |
| "Losartan was the first drug in this class to become commercially available." | 2.40 | Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997) |
| "The consequences of untreated hypertension include myocardial infarction, stroke, congestive heart failure, peripheral vascular disease and renal disease." | 2.40 | Losartan: a new antihypertensive drug. ( Dubois, M; Wilson, TW, 1997) |
| "Losartan has proven antihypertensive effects and its safety profile in the initial controlled trials (approximately 2900 patients) and in general practice (more than 14,000 patients in Sweden) has been very good." | 2.40 | Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan. ( Hansson, L, 1997) |
| " Furthermore, dose-response relationships have not always been clearly defined: for example, in one study diastolic BP reductions (trough) fell in the range 4." | 2.40 | Angiotensin II antagonists: efficacy, duration of action, comparison with other drugs. ( Elliott, HL, 1998) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| "Their use in congestive heart failure and renal disease is under investigation." | 2.40 | Angiotensin-II receptor antagonists: their place in therapy. ( Kirk, JK, 1999) |
| "Valsartan does not cause cough or adverse metabolic effects; first dose hypotension and rebound hypertension on abrupt withdrawal have not been encountered." | 2.40 | Clinical advantage of valsartan. ( McInnes, GT, 1999) |
| "1%) were the most commonly reported clinical adverse experiences in patients treated with losartan." | 2.39 | Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Losartan was selected for its affinity for Ang II receptors, functional antagonism of Ang II, lack of agonist properties, and oral anti-hypertensive effects." | 2.39 | Discovery of losartan, the first angiotensin II receptor antagonist. ( Carini, DJ; Chiu, AT; Duncia, JV; Smith, RD; Timmermans, PB; Wexler, RR; Wong, PC, 1995) |
| "Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist." | 2.39 | Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. ( Goa, KL; Wagstaff, AJ, 1996) |
| " Once-daily dosing with losartan has been documented to be safe." | 2.39 | Losartan: first of a new class of angiotensin antagonists for the management of hypertension. ( Carr, AA; Prisant, LM, 1996) |
| " Previous receptor antagonists for angiotensin II are angiotensin-like peptides with limitations of short duration, lack of oral bioavailability and partial agonistic activity." | 2.39 | Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. ( Timmermans, PB; Wong, PC, 1996) |
| "Losartan was demonstrated to be an effective antagonist of many AII-induced actions and an effective antihypertensive agent in many animal models of hypertension (HTN)." | 2.38 | Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. ( Eberhardt, RT; Frishman, WH; Kang, PM; Kevak, RM, 1993) |
| "Dry cough is the most common and annoying, although harmless, side effect associated with the use of ACE inhibitors." | 2.38 | Cough and inhibition of the renin-angiotensin system. ( Karlberg, BE, 1993) |
| " Although these compounds are absorbed after oral dosing, their bioavailability was less than desired." | 2.38 | Rationale for the chemical development of angiotensin II receptor antagonists. ( Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Timmermans, PB; Wells, GJ; Wexler, RR; Wong, PC, 1992) |
| " This study aimed to evaluate the effects of long-term administration of losartan, aspirin, and atorvastatin on vascular remodeling in juvenile spontaneously hypertensive rats (SHRs)." | 1.91 | Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats. ( Dong, B; Dong, S; Li, L; Liu, Q; Shen, J; Yang, K; Zhao, Y; Zhou, X; Zhu, D, 2023) |
| "Albuminuria was defined as urine albumin/creatinine ratio ≥30 mg/g." | 1.91 | Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy. ( Ahmad, MI; Chen, LY; Kazibwe, R; Singh, S; Soliman, EZ; Soliman, MZ, 2023) |
| "Inhibition of SGLT2 in combination with an angiotensin II receptor blocker effectively improved BP salt sensitivity by reducing renal expression levels of sodium transporters including NHE3 and NKCC2, which eventually led to improvement of BP salt sensitivity and cardiorenal protection." | 1.72 | Cardiorenal protective effects of sodium-glucose cotransporter 2 inhibition in combination with angiotensin II type 1 receptor blockade in salt-sensitive Dahl rats. ( Ali, Y; Dohi, K; Ito, H; Ito, M; Katayama, K; Okamoto, R; Zhe, Y, 2022) |
| " The results demonstrate that the codrug approach is a plausible strategy to develop a single molecular entity with combined AT1 and NEP activities, aiming at achieving improved pharmacokinetics, efficacy and dosage convenience, as well as reduced drug-drug interaction for hypertension patients." | 1.62 | Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition. ( Azevedo, H; Ferreira Junior, MA; Guimarães, CRW; Ishikawa, EE; Mascarello, A, 2021) |
| "Hypertension is a very common cardiovascular disease." | 1.62 | Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients. ( Al-Darraji, AH; Jabbar, AS; Neamah, NF, 2021) |
| "Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear." | 1.62 | Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. ( Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC, 2021) |
| "Hypertension is associated with gut dysbiosis." | 1.56 | Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. ( Algieri, F; de la Visitación, N; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Jiménez, R; Muñoz, R; Redondo, JM; Robles-Vera, I; Romero, M; Sánchez, M; Toral, M; Vezza, T, 2020) |
| " Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models." | 1.56 | Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. ( Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020) |
| "Losartan treatment, however, inhibited BP elevation in both rat strains, doing so to a greater extent in the treatment group SHRs." | 1.56 | Reduction of blood pressure elevation by losartan in spontaneously hypertensive rats through suppression of LARG expression in vascular smooth muscle cells. ( Chiang, FT; Chiang, JY; Chiu, WC; Juang, JM; Su, MJ; Tsai, CT; Tseng, YZ; Wu, CK, 2020) |
| " Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect." | 1.51 | [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients]. ( Jalil Milad, R; Lagos Lucero, M; Pedreros-Rosales, C; Solari Gajardo, S, 2019) |
| "The aim is to explore the treatment effect of coronary artery disease (CAD) and hypertension on plasma levels of renalase activity and also the possible association of renalase rs10887800 gene polymorphism with CAD and hypertension." | 1.51 | Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. ( Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S, 2019) |
| "Losartan treatment prevented these SAD-induced changes." | 1.48 | Effects of losartan on vasomotor function and canonical transient receptor potential channels in the aortas of sinoaortic denervation rats. ( Liang, M; Liu, Y; Miao, F; Wu, H; Zhong, W, 2018) |
| " High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies." | 1.48 | Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. ( Anegawa, T; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Kajimoto, H; Uchiwa, H, 2018) |
| "Hypertension is frequently associated with metabolic disorders." | 1.48 | Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats. ( Cai, X; Lian, G; Lin, Z; Wang, T; Xie, L, 2018) |
| "High blood pressure is a major risk factor for chronic kidney disease." | 1.48 | Danhong Injection Protects Against Hypertension-Induced Renal Injury Via Down-Regulation of Myoglobin Expression in Spontaneously Hypertensive Rats. ( Fan, G; Gao, X; Han, J; Owoicho Orgah, J; Qin, G; Wang, D; Wang, M; Wang, Z; Yang, X; Zhang, Q; Zhu, Y, 2018) |
| "Losartan treatment for three weeks lowered systolic blood pressure in both Control and Restricted groups but this difference was not sustained after the cessation of treatment." | 1.48 | Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. ( Gallo, LA; Mazzuca, MQ; Moritz, KM; Parkington, HC; Tare, M; Walton, SL; Wlodek, ME, 2018) |
| "Treatment with losartan (0." | 1.46 | miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. ( Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J, 2017) |
| "Treatment with losartan suppressed both blood pressure elevation and augmentation of systolic blood pressure variability in rats infused with angiotensin II at 7 and 14 days." | 1.46 | Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats. ( Jiang, D; Kato, J; Kawagoe, Y; Kitamura, K; Kuwasako, K, 2017) |
| "Uric acid plays an important role in CVD pathogenesis by inducing inflammatory COX-2 and ROS pathways." | 1.46 | Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells. ( Çetin, A; Kırça, M; Oğuz, N; Yeşilkaya, A, 2017) |
| "Hypertension was induced by L-N(G)-nitroarginine methyl ester (L-NAME) and hypercholesterolemia was induced by feeding rats with a diet containing 1% cholesterol." | 1.46 | Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms. ( Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM, 2017) |
| " We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on adverse events: hospitalizations or emergency room consultations." | 1.46 | Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. ( Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017) |
| "Losartan treatment decreased wall thickness, wall-to-lumen ratio, and coronary arteriole cell number in db/db mice." | 1.43 | The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice. ( Cismowski, MJ; Galantowicz, ML; Husarek, KE; Katz, PS; Lucchesi, PA; Trask, AJ, 2016) |
| "Spontaneous seizures were video- and EEG-monitored in spontaneously hypertensive rats (SHRs) for a 16-week period after SE." | 1.43 | Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy. ( Atanasova, D; Ivanova, N; Kortenska, L; Lazarov, N; Lozanov, V; Mitreva, R; Pechlivanova, DM; Stoynev, A; Tchekalarova, JD, 2016) |
| "Aldosterone effects were prevented by the AGTR1 antagonist losartan in WT mice." | 1.43 | Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. ( Barhoumi, T; Briet, M; Coelho, SC; Coffman, TM; Mian, MOR; Ouerd, S; Paradis, P; Rautureau, Y; Schiffrin, EL, 2016) |
| "The hypertension is reversible by a low-sodium diet and by the CYP4A inhibitor HET0016." | 1.43 | 20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR. ( Capdevila, JH; Falck, JR; Guengerich, FP; Hsu, MH; Johnson, EF; Savas, Ü; Wei, S, 2016) |
| "Losartan is a selective angiotensin II receptor type 1 blocker and a substrate of drug efflux transporter MDR1 (ABCB1)." | 1.43 | Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. ( Babaoglu, MO; Bozkurt, A; Cevik, L; Göktaş, MT; Gumus, E; Guven, GS; Kalkışım, S; Karaca, Ö; Pepedil, F; Yasar, U, 2016) |
| "The diagnosis of primary aldosteronism (PA) among the older-aged population has posed a crucial challenge." | 1.42 | The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old. ( Balakrishnan, P; Chen, YM; Chueh, SC; Hsein, YC; Kuo, CC; Wang, MJ; Wu, KD; Wu, VC, 2015) |
| "Hypertension is a powerful risk factor of atrial fibrillation (AF)." | 1.42 | Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats. ( Chishaki, A; Hirooka, Y; Inoue, S; Kishi, T; Mukai, Y; Nagayama, T; Sunagawa, K; Takase, S; Takemoto, M, 2015) |
| "Losartan treatment abolished the renal expression of gp91, p22, p47, oxidative stress and reduced NF-κB activation and IL-6 expression." | 1.42 | Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. ( Arcaya, JL; Chávez, M; Correia, D; Fernández, A; Finol, E; Pérez, M; Rincón, J; Romero, F; Summer, R; Talavera, E; Yaguas, K, 2015) |
| "Our study provides novel evidence that chronic ethanol intake increases blood pressure, induces vascular oxidative stress and decreases nitric oxide (NO) bioavailability through AT1-dependent mechanisms." | 1.42 | Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress. ( Antunes-Rodrigues, J; Ceron, CS; Coelho, EB; Mecawi, AS; Passaglia, P; Tirapelli, CR, 2015) |
| "Pretreatment with Losartan (an AT1 receptor blocker) attenuated the AngII-induced expression of TLR4 and inflammatory cytokines." | 1.42 | Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells. ( Ebenezer, PJ; Francis, J; Nair, AR; Saini, Y, 2015) |
| " Downward dosage adjustment appeared essential and may have prevented hypotension-related pathology." | 1.42 | Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker. ( Forsdyke, DR, 2015) |
| "Losartan (LOS) treatment (10 mg/kg body weight/day) for 2 months (Ren-2 TGR+LOS) did not change NADPH oxidase-dependent O(2)(-) production in the kidney." | 1.42 | NADPH oxidase activity and reactive oxygen species production in brain and kidney of adult male hypertensive Ren-2 transgenic rats. ( Rauchová, H; Řezáčová, L; Vaněčková, I; Vokurková, M; Zicha, J, 2015) |
| "Losartan inhibited the increase of these inflammatory markers." | 1.40 | Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. ( Heijnen, BF; Janssen, BJ; Schalkwijk, CG; Struijker-Boudier, HA; Van Essen, H, 2014) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 1.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Rats treated with losartan present memory deficits and decreases in spine-density." | 1.40 | Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit. ( Gong, CX; Hu, J; Liu, X; Luo, H; Wang, JZ; Wang, XC; Wang, Z; Xia, Y; Yu, G; Zeng, K; Zhou, XW, 2014) |
| "Treatment with losartan lowered systolic arterial pressure in S-P467L (132." | 1.40 | Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension. ( Carrillo-Sepulveda, MA; Davis, DR; Grobe, JL; Keen, HL; Sigmund, CD, 2014) |
| "Hypertension is a major risk factor for cardiovascular diseases, which has been related to such changes as gradual bone loss and a decrease in bone mass index." | 1.40 | Healing process of autogenous bone graft in spontaneously hypertensive rats treated with losartan: an immunohistochemical and histomorphometric study. ( Antoniali, C; Garcia-Júnior, IR; Gealh, WC; Luvizuto, ER; Okamoto, R; Pereira, CC, 2014) |
| "Enalapril was found to be more reno-protective compared to losartan." | 1.40 | COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. ( Mugendi, GA; Mwangi, M; Ndwiga, S; Nyamu, DG; Nyamweya, NN; Okalebo, FA, 2014) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 1.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Hypertension is the most frequent condition associated with atrial fibrillation (AF) and stroke, the most terrible complication of AF." | 1.39 | Can dabigatran improve blood pressure control? ( Barrios, V; Escobar, C, 2013) |
| "Arterial hypertension is an important risk factor for cerebrovascular diseases, such as transient ischemic attacks or stroke, and represents a major global health issue." | 1.39 | Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. ( Buck, A; Calcinaghi, N; Fritschy, JM; Jolivet, R; Keller, AL; Matter, CM; Singh, A; Weber, B; Winnik, S; Wyss, MT, 2013) |
| "Treatment with losartan significantly blocked TAC-induced vascular inflammation and macrophage accumulation." | 1.39 | Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. ( Brasier, AR; Cao, JM; Geng, L; Guo, S; Kuang, SQ; Kwartler, CS; Milewicz, DM; Peters, AM; Prakash, SK; Villamizar, C, 2013) |
| "Compound 4 can also inhibit the prostate cancer in vitro and in vivo." | 1.38 | Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects. ( Chen, ZL; Da, YJ; Liang, LS; Nie, YY; Xin, T; Yan, YJ; Ye, Y; Yuan, WD, 2012) |
| "Losartan acts as an immunomodulator that prevents the development of CD14+CD16+ pro-inflammatory monocytes in HD patients." | 1.38 | Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. ( Aljama, P; Alvarez-Lara, MA; Carracedo, J; Martin-Malo, A; Merino, A; Ramirez, R, 2012) |
| "Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase." | 1.38 | An economic evaluation of antihypertensive therapies based on clinical trials. ( Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL, 2012) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Treatment with losartan for 2weeks produced depressor effect, restored the reduced anandamide transporter activity, decreased the plasma anandamide level and increased the plasma level and mRNA expression of CGRP in SHRs." | 1.38 | Decreased anandamide transporter activity and calcitonin gene-related peptide production in spontaneously hypertensive rats: role of angiotensin II. ( Hu, CP; Li, D; Li, SX; Li, YJ; Luo, D; Pan, W; Shi, RZ; Yang, TL; Zhang, GG, 2012) |
| "Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice." | 1.38 | Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. ( Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012) |
| "Hypertension was evident by the second day of treatment, being preceded by reduced renal sodium excretion due to activation of the thiazide-sensitive sodium-chloride co-transporter." | 1.38 | Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. ( Ashek, A; Bailey, MA; Bellamy, CO; Flatman, PW; Harmar, AJ; Kenyon, CJ; Menzies, RI; Mullins, JJ; Mullins, LJ, 2012) |
| "Captopril and losartan were equally effective as mitigators, with DMFs of 1." | 1.37 | Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. ( Cohen, EP; Fish, BL; Moulder, JE, 2011) |
| "Losartan is known to inhibit transforming growth factor β signaling and may be a specific modulator of disease expression in this syndrome." | 1.37 | Arterial tortuosity syndrome with multiple intracranial aneurysms: a case report. ( Levinson, JR; MacRae, CA; Nahed, BV; Naunheim, MR; Ogilvy, CS; Walcott, BP, 2011) |
| " Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)." | 1.37 | Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). ( Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011) |
| "Treatment with Losartan and PD123319 in controls reduced MKP-1 and elevated ERK1/2 phosphorylation to the level observed in BS/GS patients treated with PD123319." | 1.36 | Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. ( Calò, LA; D'Angelo, A; Davis, PA; Mormino, P; Pagnin, E; Pessina, AC; Schiavo, S, 2010) |
| "Losartan treatment for 4-8 weeks reduced blood pressure of SHR to the normal levels seen in WKY." | 1.36 | Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. ( Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010) |
| " The medicated films were evaluated for physical properties, in vitro drug release studies, in vitro skin permeation studies, and pharmacodynamic studies." | 1.36 | Pharmacodynamics of a losartan transdermal system for the treatment of hypertension. ( Alam, MI; Ali, A; Aqil, M; Shams, MS; Sultana, Y, 2010) |
| " These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2." | 1.36 | Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. ( Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010) |
| "When losartan was administered in a single bolus dose, efficacy was evident until the 7th min (p=0." | 1.36 | Hypertension study in anaesthetized rabbits: protocol proposal for AT1 antagonists screening. ( Iliodromitis, EK; Kokotos, G; Kremastinos, DT; Mavromoustakos, TM; Moutevelis-Minakakis, P; Politi, AP; Triantafyllidi, H; Zervou, MV; Zoga, AA; Zoumpoulakis, PG, 2010) |
| "We obtained dose-response curve for the administration of complete extract and extract fractions." | 1.36 | Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. ( Badillo, FH; González-Cortazar, M; Herrera-Ruiz, M; Jiménez-Ferrer, E; Tortoriello, J, 2010) |
| "Hypertension is a lifestyle-related disease which often leads to serious conditions such as heart disease and cerebral hemorrhage." | 1.35 | Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension. ( Fukamizu, A; Ichino, T; Ishida, J; Koyama, T; Matsumoto, H; Mura, E; Nakamura, K; Ohno, O; Ohno, T; Uemura, D; Yamada, K; Yamaguchi, K; Yazawa, K; Ye, M, 2008) |
| "Preeclampsia is a serious pathologic complication during pregnancy, and its pathogenesis remains poorly understood." | 1.35 | Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. ( Chang, H; Cheng, X; Liu, H; Ma, XL; Wang, F; Wang, X; Yang, L; Yang, X; Zhang, M; Zhang, S, 2008) |
| "Losartan was administered (20 mg/kg/day) in drinking water by gavage for 5 weeks." | 1.35 | Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. ( Cebova, M; Koprdova, R; Kristek, F, 2009) |
| " Dose-response curves were constructed for dopamine and isoprenaline that induced falls or increases in renal blood flow, respectively." | 1.35 | Inhibition of Ang II and renal sympathetic nerve influence dopamine-and isoprenaline-induced renal haemodynamic changes in normal Wistar-Kyoto and spontaneously hypertensive rats. ( Abdulla, MH; Abdullah, NA; Anand Swarup, KR; Hazim, AI; Johns, EJ; Khan, MA; Rathore, HA; Sattar, MA, 2008) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 1.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Co-treatment with losartan and carvedilol reduced the renal vasoconstrictor responses to exogenously administered vasoactive agents but to a lesser extent than losartan or carvedilol alone." | 1.35 | Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats. ( Abdulla, MH; Abdullah, NA; Johns, EJ; Khan, MA; Sattar, MA, 2009) |
| "Losartan is an antihypertensive drug with all these capabilities and placebo-like side-effect profile." | 1.35 | [The pleiotropic effects of losartan--the importance of decreasing uric acid level]. ( Cseh, J; Csiky, B; Markó, L; Mikolás, E; Mohás, M; Szíjártó, I; Wittmann, I, 2008) |
| "Hypertension is associated with cerebrovascular remodeling and endothelial dysfunction, which may reduce cerebral vasomotor reactivity to CO2." | 1.35 | Cerebral vasomotor reactivity before and after blood pressure reduction in hypertensive patients. ( Claassen, JA; Levine, BD; Zhang, R, 2009) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 1.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "Chlorthalidone has been used sparingly in clinical practice in large measure because it is not readily available in many fixed-dose combination products." | 1.35 | Chlorthalidone - a renaissance in use? ( Sica, DA, 2009) |
| "Hypertension is strongly associated with increased risk of subsequent heart failure." | 1.35 | [Hypertension and the heart]. ( Andersen, NH; Svendsen, TL; Wachtell, K, 2009) |
| "Spironolactone treatment decreased collagen content in the media of thoracic aortas from prehypertensive SHR, whereas losartan decreased collagen content in the media of aortas from hypertensive SHR." | 1.35 | Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone. ( Che, ZQ; Gao, PJ; Han, WQ; Liu, JJ; Wu, LY; Wu, YJ; Zhang, J; Zhou, HY; Zhu, DL, 2009) |
| "Losartan prevented an increase in BP and SGLT2 expression in diabetic rats." | 1.35 | Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. ( Bautista, R; Escalante, B; Franco, M; Osorio, H; Rios, A; Santamaría, J, 2009) |
| "Losartan-treated (LOS group, n = 10) and untreated rats served as controls (n = 11)." | 1.35 | Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. ( Alexanderson, C; Andersson, IJ; Bergström, G; Holmäng, A; Johansson, ME; Skøtt, O, 2008) |
| "RV hypertrophy was also prevented, but LV hypertrophy only partially, and kidney hypertrophy not at all." | 1.35 | Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. ( Leenen, FH; Liang, B, 2008) |
| "Arterial hypertension is the most frequent chronic disease and it is an important cause of morbidity and mortality in the developed world." | 1.34 | Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach. ( Egido, J; Gállego-Delgado, J; Lázaro, A; Osende, JI; Vivanco, F, 2007) |
| "Hypertension is related to an increased wall tension in the atria, resulting in increased stretch of the individual myocyte, which is one of the major stimuli for the remodeling process." | 1.34 | Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. ( Frank, K; Müller-Ehmsen, J; Rana, OR; Reuter, H; Saygili, E; Schwinger, RH; Zobel, C, 2007) |
| "Hypertension is an important risk factor associated with development and progression of diabetic retinopathy (DR)." | 1.34 | Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. ( Biswas, SK; de Faria, JB; de Faria, JM; Pinto, CC; Silva, KC; Souza, DS, 2007) |
| "Treatment with losartan (30 mg/kg) for 14 days significantly lowered blood pressure, elevated the plasma level of NO, and decreased the plasma concentration of ADMA in SHR." | 1.34 | Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. ( Deng, HW; Jiang, DJ; Li, D; Li, NS; Li, YJ; Luo, D; Wang, S; Xia, K, 2007) |
| "Malignant hypertension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had seizures." | 1.33 | Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. ( Bräsen, JH; Budde, K; Dechend, R; Dragun, D; Eckert, D; Fritsche, L; Hoebeke, J; Kintscher, U; Luft, FC; Mazak, I; Müller, DN; Neumayer, HH; Nieminen-Kelhä, M; Plehm, R; Rudolph, B; Schönemann, C; Unger, T; Wallukat, G, 2005) |
| "Losartan has an antimigratory effect, reducing leukocyte migration by reducing ICAM-1 and P-selectin expression." | 1.33 | Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. ( Carvalho, MH; Cruz, JW; Fortes, ZB; Martinez, LL; Miguel, AS; Nigro, D; Oliveira, MA; Rastelli, VM; Tostes, RC, 2005) |
| "Hyperkalemia is a complications of the use of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and aldosterone antagonists." | 1.33 | [Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. ( Kauffmann, R; Orozco, R; Venegas, JC, 2005) |
| "Losartan was the only treatment that induced alpha1 subunit expression." | 1.33 | Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. ( Amiri, F; Brassard, P; Schiffrin, EL; Thibault, G, 2006) |
| "Losartan potassium is an orally active, non-peptide angiotensin II receptor antagonist." | 1.33 | Study of efficacy and safety of losartan (losar) in Asian Indian hypertensives. ( Chopra, D; Joshi, RM; Joshi, SR; Kale, S; Oomman, A, 2005) |
| "Although cardiac hypertrophy in hypertension has been well recognized, the molecular mechanisms for the development of hypertrophy are still largely unknown." | 1.33 | Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. ( Chen, GQ; Chen, WL; Fang, NY; Jin, X; Liu, ZG; Shi, JZ; Wang, LS; Xia, L; Zhang, L; Zheng, Y, 2006) |
| "Atenolol presented lower LF and higher HF of PI." | 1.33 | Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. ( Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC, 2006) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "Fonsartan and losartan treatment totally abolished these effects." | 1.32 | Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. ( Grötsch, H; Hropot, M; Langer, KH; Linz, W; Wiemer, G, 2003) |
| "Exercise-induced acute renal failure (ARF) developed in a 45-year-old man during antihypertensive therapy with losartan and trichlormethiazide." | 1.32 | A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. ( Hasegawa, Y; Ito, O; Ito, S; Kudo, K; Mitsui, H; Sato, H; Sato, K; Yuda, F, 2003) |
| "Treatment with atenolol did not change PIP and KLV in either subgroup of hypertensives." | 1.32 | The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. ( Beloqui, O; Díez, J; González, A; Laviades, C; López, B; Mayor, G; Orbe, J; Páramo, JA; Zalba, G, 2003) |
| " Since the participation of the renin-angiotensin system (RAS) in this pathology is still unclear, the present study examined the effect of chronic administration of an angiotensin AT1 receptor antagonist, losartan (L), on endothelial nitric oxide synthase (eNOS) activity in aortic endothelium and cardiac tissue, and on the proliferation of primary cultured aortic smooth muscle cells (SMC), obtained from fructose-fed rats (FFR), an experimental model of syndrome X Male Wistar rats were used: Control, FFR and FFR+L (n = 8 in each group)." | 1.32 | Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats. ( Castro, C; Cruzado, M; González, S; Miatello, R; Risler, N; Zumino, AP, 2003) |
| "Hypertension is commonly associated with Wilms tumor, but hypertension secondary to renin-secreting Wilms tumor is uncommon." | 1.32 | Treatment of Wilms tumor-related hypertension with losartan and captopril. ( Mauger, D; Wong, W, 2004) |
| "Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1." | 1.31 | Optimal dose of losartan for renoprotection in diabetic nephropathy. ( Andersen, S; Deinum, J; Juhl, TR; Parving, HH; Rossing, P, 2002) |
| "Losartan treatment significantly decreased the development of hypertension induced by >L-NAME and decreased left ventricular hypertrophy in untreated rats." | 1.31 | N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism. ( Jolma, P; Kalliovalkama, J; Pörsti, I; Ruskoaho, H; Suo, M; Tolvanen, JP; Vuolteenaho, O, 2002) |
| "Losartan therapy was associated with more benefits in stroke risk reduction and in the development of new cases of diabetes." | 1.31 | [Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study]. ( González-Juanatey, JR, 2002) |
| "Losartan can inhibit those deteriorations besides blood pressure lowering." | 1.31 | [Relationship of hypertensive microalbuminuria and endothelial and glomerular impairment]. ( Sun, M; Wu, J; Zhou, HY, 2002) |
| "Losartan was administered for a period of 14." | 1.31 | Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. ( Calviño, J; Lens, XM; Romero, R; Sánchez-Guisande, D, 2000) |
| "In essential hypertensive subjects, acute and chronic administration of losartan was followed by favorable neurohormonal (norepinephrine, endothelin-1) and metabolic changes (microalbuminuria)." | 1.31 | Changes in plasma norepinephrine and endothelin levels and metabolic profile after AT1-receptor blockade in human hypertension. ( Dominguez, J; Garcia-Escribano, JR; Paule, A; Rodriguez-Garcia, JL; Vazquez, M, 2000) |
| "Compared with WKY, SHR exhibited left ventricular hypertrophy, increased (P<0." | 1.31 | Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. ( Díez, J; Etayo, JC; Iraburu, MJ; López, B; Varela, M; Varo, N, 2000) |
| " With this background, this study was undertaken to evaluate how the chronic administration of deoxycortisone acetate (DOCA) modifies the effects of losartan on BP, renal injury, and other variables in L-NAME hypertensive rats." | 1.31 | Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats. ( DE Gracia, MC; Del Moral, RG; Del Rio, CG; O'Valle, F; Osuna, A; Vargas, F; Wangensteen, R, 2000) |
| "Thirty-two patients with untreated hypertension (BP 168/96) had significantly lower levels of both MMP-9 and TIMP-1 when compared to 24 matched normotensive controls (BP 123/80) (P<0." | 1.31 | Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. ( Beevers, DG; Blann, AD; Edmunds, E; Li-Saw-Hee, FL; Lip, GY, 2000) |
| "Because left ventricular hypertrophy is very common in renal transplant recipients, we examined the cardiovascular effects and the safety profile of the AT1 receptor antagonist losartan in hypertensive renal transplant recipients." | 1.31 | Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. ( Delles, C; Fleischmann, E; Klingbeil, AU; Müller, HJ; Schmieder, RE, 2000) |
| "Apparently, when hypertension is sustained, reappearance of target organ damage may not be entirely dependent on angiotensin." | 1.31 | Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 1.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "In losartan treatment TPR for systolic and diastolic AP were 61." | 1.31 | [Evaluation of the evenness of the antihypertensive effect of losartan and captopril by using a 24-hour monitoring of arterial pressure]. ( Deev, AD; Gorbunov, VM; Metelitsa, VI; Savina, LV, 2001) |
| "Patients with chronic renal failure are restricted to mild physical activity and tend to a lack of exercise." | 1.31 | Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. ( Kamimoto, M; Kanazawa, M; Kawamura, T; Kohzuki, M; Kurosawa, H; Minami, N; Mori, N; Nagasaka, M; Saito, T; Wu, XM; Xu, HL; Yoshida, K, 2001) |
| "Treatment with losartan significantly prevented the raise in cholesterol, creatinine, urea and blood urea nitrogen levels." | 1.31 | Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. ( Goyal, RK; Murali, B, 2001) |
| " Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan." | 1.31 | Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. ( Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002) |
| "Losartan-treated ANG II-infused rats exhibited normalized apoptosis, bax, caspase 3 activity, and AT(1) receptors." | 1.31 | Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. ( Diep, QN; El Mabrouk, M; Schiffrin, EL; Yue, P, 2002) |
| "Hydrochlorothiazide treatment did not prevent the hyperuricemia or arteriolopathy despite controlling blood pressure." | 1.31 | Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. ( Chen, Q; Feng, L; Gordon, KL; Han, L; Johnson, RJ; Kanellis, J; Kang, DH; Lan, HY; Mazzali, M; Nakagawa, T; Watanabe, S; Xia, YY, 2002) |
| "But losartan potassium has been found to be more effective with fewer side effects when compared to enalapril maleate." | 1.31 | A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension. ( Arora, P; Neki, NS, 2001) |
| "Losartan (3 mg/kg) was given to the animal for five days." | 1.31 | Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats. ( Arican, N; Cimen, V; Elmas, I; Kalayci, R; Kaya, M; Korkut, F; Kucuk, M; Kudat, H, 2002) |
| "The development of hypertension and left ventricular hypertrophy was prevented by high- but not low-dose ramipril and was not affected by chronic bradykinin B2-receptor blockade." | 1.30 | Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. ( Amann, K; Gohlke, P; Kuwer, I; Mall, G; Schnell, A; Unger, T, 1997) |
| "Hypertension is associated with endothelial dysfunction characterized by decreased endothelium-dependent relaxations and increased endothelium-dependent contractions." | 1.30 | Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. ( Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1997) |
| " The pharmacodynamic activities of losartan and EXP3174 were determined during constant intravenous infusion as the degree of inhibition of angiotensin II-induced increase in the diastolic pressure." | 1.30 | Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ( Bai, SA; Christ, DD; Hellyer, P; Lankford, SM; Plummer, D, 1997) |
| " In isolated rabbit aorta, KRH-594 caused nonparallel shifts to the right of the dose-response curve to AII and decreased the maximal response with a pK(B) of 10." | 1.30 | Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. ( Amano, H; Hashimoto, K; Hirata, T; Inokuma, K; Mikoshiba, I; Okuhira, M; Tamura, K, 1997) |
| "Losartan-treated rats showed reduced tail pressure (104+/-3 versus 117+/-3 mm Hg in the vehicle group)." | 1.30 | Chronic AT1 receptor blockade alters aortic nerve activity in hypertension. ( dos Santos, CM; Krieger, EM; Michelini, LC; Moreira, ED, 1998) |
| " Dose-response curves to angiotensin II of blood pressure show a tenfold higher potency for HR 720 to compete for angiotensin II, thereby decreasing the maximum effects when compared with losartan." | 1.30 | Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats. ( Dendorfer, A; Dominiak, P; Häuser, W; Nguyen, T, 1998) |
| " The chronic administration of losartan was associated with the normalization of apoptosis, Bax expression, and the Bcl-2/Bax ratio in treated SHR." | 1.30 | Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. ( Díez, J; Etayo, JC; Fortuño, MA; Ravassa, S, 1998) |
| "We evaluated the effects on cardiovascular structure of the angiotensin-converting enzyme (ACE) inhibitor enalapril and of the angiotensin II receptor blocker losartan, administered either at hypotensive or nonhypotensive dosage in spontaneously hypertensive rats (SHR)." | 1.30 | Effects of losartan and enalapril on small artery structure in hypertensive rats. ( Agabiti Rosei, E; Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Mulvany, MJ; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D, 1998) |
| "By contrast, neither the concentric left ventricular hypertrophy or depressed myocardial function nor the increased beta-MHC expression were significantly altered." | 1.30 | Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. ( Rupp, H; Turcani, M, 1998) |
| "Vascular and cardiac hypertrophy were significantly attenuated with losartan or perindopril, but were unchanged with other treatments." | 1.30 | Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. ( Anderson, NH; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; Morton, JJ; Reid, JL; Schork, NJ, 1999) |
| "When losartan was administered to another group of PHR not only at weeks 5-9 but once more at weeks of 15-19 of age, the values of their SBP at week 30 were 156." | 1.30 | Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the prague hypertensive rat. ( Heller, J; Hellerová, S, 1998) |
| "In furosemide-treated dogs, orally given SK-1080 produced a dose-dependent and long-lasting (>8 h) antihypertensive effect with a rapid onset of action (time to Emax, 1-1." | 1.30 | In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. ( Kwon, KJ; Lee, BH; Seo, HW; Shin, HS; Yoo, SE, 1999) |
| "Pretreatment with losartan (40 mg/kg/d) did not improve insulin action in the SHR." | 1.30 | Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. ( Caldiz, CI; de Cingolani, GE, 1999) |
| "Losartan and enalapril treatments completely inhibited the increase of systolic blood pressure occurring with ageing in SHR." | 1.30 | Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. ( Kähönen, M; Kalliovalkama, J; Magga, J; Pörsti, I; Romppanen, H; Ruskoaho, H; Tolvanen, JP; Vuolteenaho, O, 1999) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| " A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure." | 1.30 | The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. ( Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J, 1999) |
| " Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability." | 1.29 | Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability. ( Dowle, MD; Hobson, JE; Jack, TI; Judd, DB; Middlemiss, D; Panchal, TA; Pass, M; Ross, BC; Scopes, DI; Tranquillini, E, 1994) |
| " Losartan is as effective as other commonly used antihypertensive agents, but it permits convenient dosing and is better tolerated." | 1.29 | The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension. ( Lacourcière, Y, 1995) |
| "Losartan (10 mg/kg) was administered orally, either as a single dose or for 8 successive days." | 1.29 | Sympathoinhibitory effects of losartan in spontaneously hypertensive rats. ( Giudicelli, JF; Moreau, N; Richer, C; Vincent, MP, 1993) |
| "Losartan was administered for 6 weeks to 14-week-old SHR (60 mg/kg per day orally)." | 1.29 | Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. ( Bobik, A; Dilley, RJ; Kanellakis, P; Oddie, CJ, 1993) |
| "The losartan effect was dose dependent." | 1.29 | Nonpeptide angiotensin AT1 and AT2 receptor ligands modulate the upper limit of cerebral blood flow autoregulation in rats. ( Näveri, L; Saavedra, JM; Strömberg, C, 1993) |
| "Treatment with losartan tended to decrease each of these toward the level of controls." | 1.29 | Effect of chronic treatment with losartan potassium (DuP 753) on the elevation of blood pressure during chronic exposure of rats to cold. ( Brummermann, M; Cade, JR; Fregly, MJ; Rossi, F; Van Bergen, P, 1993) |
| "PD 123319 alone was without effect." | 1.29 | Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats. ( Porter, JP; Toney, GM, 1993) |
| " Pretreatment with NG-nitro-L-arginine methyl ester did not interfere with the vasodepressor effect of sodium nitroprusside or prazosin in rats with aortic coarctation-induced hypertension or with the blood pressure reduction caused by discontinuation of an infusion of phenylephrine in rats made hypertensive by long-term administration of this drug." | 1.29 | Nitric oxide and the depressor response to angiotensin blockade in hypertension. ( Cachofeiro, V; Guan, H; Kaminski, PM; Nasjletti, A; Pucci, ML; Wolin, MS, 1996) |
| "Proteinuria was markedly reduced in both strains by L." | 1.29 | Losartan protects the rat kidney from ischemic injury. ( Cervenka, L; Heller, J; Hellerová, S; Kramer, HJ, 1996) |
| "Losartan (DuP-753) was infused into the renal artery to antagonize angiotensin AT1 receptors in the experimental period." | 1.29 | Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors. ( Arendshorst, WJ; Brännström, K; Morsing, P, 1996) |
| "To investigate in young salt-loaded stroke-prone spontaneously hypertensive rats (SHR-SP) the effects of a long-term administration of the angiotensin II AT1 receptor antagonist losartan [1 mg/kg (L1) and 10 mg/kg (L10) per day, from 5 to 20 weeks of age] on the structural and functional characteristics of the middle cerebral artery." | 1.29 | Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. ( Giudicelli, JF; Richer, C; Vacher, E, 1996) |
| "Treatment with Losartan (10 mg/kg per day) lowered blood pressure markedly." | 1.28 | Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. ( Fukuchi, S; Hashimoto, S; Mizuno, K; Niimura, S; Ohtsuki, M; Sanada, H; Tani, M; Watanabe, H, 1992) |
| "Treatment with Losartan normalized glomerular filtration rate, but not filtration fraction or renal vascular resistance." | 1.28 | Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. ( Antunes, E; de Nucci, G; Lovisolo, SM; Ribeiro, MO; Zatz, R, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 406 (22.47) | 18.2507 |
| 2000's | 842 (46.60) | 29.6817 |
| 2010's | 483 (26.73) | 24.3611 |
| 2020's | 76 (4.21) | 2.80 |
| Authors | Studies |
|---|---|
| Carini, DJ | 6 |
| Duncia, JV | 5 |
| Aldrich, PE | 1 |
| Chiu, AT | 8 |
| Johnson, AL | 4 |
| Pierce, ME | 1 |
| Price, WA | 3 |
| Santella, JB | 1 |
| Wells, GJ | 2 |
| Wexler, RR | 6 |
| Salimbeni, A | 1 |
| Canevotti, R | 1 |
| Paleari, F | 1 |
| Poma, D | 1 |
| Caliari, S | 1 |
| Fici, F | 3 |
| Cirillo, R | 1 |
| Renzetti, AR | 1 |
| Subissi, A | 1 |
| Belvisi, L | 1 |
| Judd, DB | 1 |
| Dowle, MD | 1 |
| Middlemiss, D | 1 |
| Scopes, DI | 1 |
| Ross, BC | 1 |
| Jack, TI | 1 |
| Pass, M | 1 |
| Tranquillini, E | 1 |
| Hobson, JE | 1 |
| Panchal, TA | 1 |
| Nicolaï, E | 1 |
| Curé, G | 1 |
| Goyard, J | 1 |
| Kirchner, M | 1 |
| Teulon, JM | 1 |
| Versigny, A | 1 |
| Cazes, M | 1 |
| Caussade, F | 1 |
| Virone-Oddos, A | 1 |
| Cloarec, A | 1 |
| Timmermans, PB | 15 |
| Wong, PC | 10 |
| Herblin, WF | 2 |
| Benfield, P | 2 |
| Lee, RJ | 3 |
| Saye, JA | 1 |
| Smith, RD | 13 |
| Ismail, MA | 1 |
| Barker, S | 1 |
| Abou el-Ella, DA | 1 |
| Abouzid, KA | 1 |
| Toubar, RA | 1 |
| Todd, MH | 1 |
| Breschi, MC | 1 |
| Calderone, V | 1 |
| Digiacomo, M | 1 |
| Macchia, M | 1 |
| Martelli, A | 1 |
| Martinotti, E | 1 |
| Minutolo, F | 1 |
| Rapposelli, S | 1 |
| Rossello, A | 1 |
| Testai, L | 1 |
| Balsamo, A | 1 |
| Shah, DI | 1 |
| Sharma, M | 1 |
| Bansal, Y | 1 |
| Bansal, G | 1 |
| Singh, M | 2 |
| Ohno, O | 1 |
| Ye, M | 1 |
| Koyama, T | 1 |
| Yazawa, K | 1 |
| Mura, E | 1 |
| Matsumoto, H | 1 |
| Ichino, T | 1 |
| Yamada, K | 3 |
| Nakamura, K | 3 |
| Ohno, T | 1 |
| Yamaguchi, K | 1 |
| Ishida, J | 1 |
| Fukamizu, A | 1 |
| Uemura, D | 1 |
| García, G | 2 |
| Rodríguez-Puyol, M | 2 |
| Alajarín, R | 2 |
| Serrano, I | 2 |
| Sánchez-Alonso, P | 2 |
| Griera, M | 2 |
| Vaquero, JJ | 2 |
| Rodríguez-Puyol, D | 2 |
| Alvarez-Builla, J | 2 |
| Díez-Marqués, ML | 2 |
| Da, YJ | 1 |
| Yuan, WD | 1 |
| Xin, T | 1 |
| Nie, YY | 1 |
| Ye, Y | 1 |
| Yan, YJ | 1 |
| Liang, LS | 1 |
| Chen, ZL | 1 |
| Zhu, W | 4 |
| Da, Y | 2 |
| Wu, D | 5 |
| Zheng, H | 1 |
| Zhu, L | 3 |
| Wang, L | 8 |
| Yan, Y | 3 |
| Chen, Z | 3 |
| Bao, X | 2 |
| Zhang, R | 6 |
| Wen, C | 1 |
| Tang, H | 2 |
| Ren, H | 1 |
| Li, F | 2 |
| Wu, L | 1 |
| Fan, Y | 2 |
| Wang, Y | 6 |
| Li, Z | 5 |
| Mao, D | 1 |
| Zhuang, W | 1 |
| Masajtis-Zagajewska, A | 1 |
| Majer, J | 1 |
| Nowicki, M | 1 |
| Mowry, FE | 1 |
| Peaden, SC | 1 |
| Stern, JE | 1 |
| Biancardi, VC | 2 |
| Řezáčová, L | 2 |
| Vaněčková, I | 6 |
| Hojná, S | 1 |
| Vavřínová, A | 1 |
| Valovič, P | 1 |
| Rauchová, H | 2 |
| Behuliak, M | 1 |
| Zicha, J | 6 |
| Lee, J | 1 |
| Choi, J | 1 |
| Yum, Y | 1 |
| Joo, HJ | 1 |
| Kim, YH | 3 |
| An, H | 1 |
| Kim, EJ | 2 |
| Al-Qaaneh, AM | 2 |
| Obaid, WT | 1 |
| Al-Mohammadi, OS | 1 |
| Rabaan, AA | 1 |
| Mustafa, SM | 1 |
| Toba, H | 2 |
| Ikemoto, MJ | 1 |
| Kobara, M | 2 |
| Nakata, T | 3 |
| Castoldi, G | 1 |
| Carletti, R | 1 |
| Ippolito, S | 1 |
| Stella, A | 1 |
| Zerbini, G | 1 |
| Pelucchi, S | 1 |
| Zatti, G | 1 |
| di Gioia, CRT | 1 |
| Loas, G | 1 |
| Le Corre, P | 1 |
| Lai, X | 1 |
| Dong, Z | 1 |
| Wu, S | 4 |
| Zhou, X | 5 |
| Zhang, G | 4 |
| Xiong, S | 1 |
| Wu, W | 1 |
| Cao, R | 1 |
| Wang, X | 7 |
| Hua, Q | 1 |
| Du, J | 1 |
| Fan, J | 1 |
| Mao, J | 1 |
| Jiang, W | 2 |
| Yuan, H | 1 |
| Chen, Y | 7 |
| Xu, Y | 2 |
| Zhang, J | 6 |
| Dong, G | 1 |
| Zhen, H | 1 |
| Ding, R | 1 |
| Wu, Z | 2 |
| Gao, Y | 4 |
| Vos, MB | 1 |
| Van Natta, ML | 1 |
| Blondet, NM | 1 |
| Dasarathy, S | 1 |
| Fishbein, M | 1 |
| Hertel, P | 1 |
| Jain, AK | 1 |
| Karpen, SJ | 1 |
| Lavine, JE | 1 |
| Mohammad, S | 1 |
| Miriel, LA | 1 |
| Molleston, JP | 1 |
| Mouzaki, M | 1 |
| Sanyal, A | 1 |
| Sharkey, EP | 1 |
| Schwimmer, JB | 1 |
| Tonascia, J | 1 |
| Wilson, LA | 1 |
| Xanthakos, SA | 1 |
| Ito, H | 4 |
| Okamoto, R | 3 |
| Ali, Y | 1 |
| Zhe, Y | 1 |
| Katayama, K | 1 |
| Ito, M | 1 |
| Dohi, K | 1 |
| Mirjalili, M | 1 |
| Soodejani, MT | 1 |
| Raadabadi, M | 1 |
| Dehghani, A | 1 |
| Salemi, F | 1 |
| Shimizu, S | 2 |
| Nagao, Y | 2 |
| Kurabayashi, A | 1 |
| Shimizu, T | 3 |
| Higashi, Y | 4 |
| Karashima, T | 2 |
| Saito, M | 3 |
| de Paula Facioli, T | 3 |
| Vieira Philbois, S | 1 |
| Augusto Aguilar, B | 1 |
| Catarine Veiga, A | 1 |
| Celso Dutra de Souza, H | 1 |
| Mińczuk, K | 1 |
| Schlicker, E | 1 |
| Malinowska, B | 1 |
| Fu, Y | 1 |
| Saxu, R | 1 |
| Ridwan, KA | 1 |
| Yao, J | 1 |
| Chen, X | 4 |
| Xu, X | 3 |
| Zheng, W | 1 |
| Yu, P | 1 |
| Teng, Y | 1 |
| Choopani, S | 1 |
| Nematbakhsh, M | 1 |
| Tian, F | 2 |
| Jia, Y | 3 |
| Yuan, FL | 1 |
| Yuan, ZD | 1 |
| Wu, JJ | 1 |
| Li, YY | 1 |
| Zhang, KW | 1 |
| Guo, DY | 1 |
| Chen, WW | 1 |
| Chen, MN | 1 |
| Chen, ZH | 1 |
| Li, X | 8 |
| Hollingworth, SA | 1 |
| Ankrah, D | 1 |
| Uzochukwu, BSC | 1 |
| Okeke, CC | 1 |
| Ruiz, F | 1 |
| Thacher, E | 1 |
| Khodaei, B | 1 |
| Nasimi, M | 1 |
| Seyedpour, S | 1 |
| Motavalli Khiavi, F | 1 |
| Yoo, TH | 1 |
| Hong, SJ | 7 |
| Kim, S | 2 |
| Shin, S | 2 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 2 |
| Lee, S | 4 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 4 |
| Park, S | 5 |
| Slomski, A | 2 |
| Sinitsina, II | 1 |
| Boyarko, AV | 1 |
| Temirbulatov, II | 1 |
| Sychev, DA | 1 |
| Akmalova, KA | 1 |
| Sozaeva, ZA | 1 |
| Grishina, EA | 1 |
| Mirzaev, KB | 1 |
| Asoskova, AV | 1 |
| Fisenko, VP | 1 |
| Moke, EG | 1 |
| Omogbai, EKI | 1 |
| Osagie-Eweka, SDE | 1 |
| Uchendu, AP | 1 |
| Omogbiya, AI | 1 |
| Ben-Azu, B | 1 |
| Eduviere, AT | 1 |
| Edje, KE | 1 |
| Umukoro, EK | 1 |
| Anachuna, KK | 1 |
| Asiwe, JN | 1 |
| Ahante, E | 1 |
| Oghoghovwe, IJ | 1 |
| Corrêa, BSG | 1 |
| de Barros, S | 1 |
| Vaz, JB | 1 |
| Peres, MA | 1 |
| Uchiyama, MK | 1 |
| da Silva, AA | 2 |
| Furukawa, LNS | 1 |
| Liu, Q | 2 |
| Dong, S | 1 |
| Zhao, Y | 7 |
| Dong, B | 1 |
| Shen, J | 2 |
| Yang, K | 3 |
| Li, L | 4 |
| Zhu, D | 1 |
| Luo, L | 1 |
| Ning, SS | 1 |
| Yang, SZ | 1 |
| Jin, JH | 1 |
| Wang, WT | 1 |
| Zhong, YF | 1 |
| Li, Y | 10 |
| Kozyreva, TV | 1 |
| Voronova, IP | 1 |
| Lamptey, RNL | 1 |
| Sun, C | 2 |
| Singh, J | 1 |
| Rothlin, RP | 1 |
| Pelorosso, FG | 1 |
| Duarte, M | 1 |
| Nicolosi, L | 1 |
| Ignacio, FC | 1 |
| Salgado, MV | 1 |
| Vetulli, H | 1 |
| Eworuke, E | 2 |
| Shinde, M | 1 |
| Hou, L | 1 |
| Paterson, MJ | 1 |
| Jensen, PB | 1 |
| Maro, JC | 1 |
| Rai, A | 1 |
| Scarnecchia, D | 1 |
| Pennap, D | 1 |
| Woronow, D | 1 |
| Ghosh, RE | 1 |
| Welburn, S | 1 |
| Pottegard, A | 1 |
| Platt, RW | 1 |
| Lee, H | 2 |
| Bradley, MC | 1 |
| Hedenmalm, K | 1 |
| Quinten, C | 1 |
| Kurz, X | 1 |
| Bradley, M | 1 |
| Sung, KC | 4 |
| Rhee, MY | 4 |
| Jeong, MH | 2 |
| Kim, DH | 1 |
| Lim, SW | 2 |
| Park, K | 1 |
| Lee, JB | 1 |
| Kim, SY | 3 |
| Cho, JM | 2 |
| Cho, GY | 1 |
| Heo, JH | 2 |
| Kim, SH | 4 |
| Lee, HY | 6 |
| Kim, W | 4 |
| Cho, DK | 1 |
| Shin, J | 4 |
| Pyun, WB | 1 |
| Kwon, K | 1 |
| Rha, SW | 1 |
| Jung, JA | 1 |
| Huang, Y | 3 |
| Xue, M | 1 |
| Philbois, SV | 1 |
| Tank, J | 1 |
| Gastaldi, AC | 2 |
| Aguilar, BA | 1 |
| da Veiga Oliveira, AC | 1 |
| Ferreira, LD | 1 |
| de Souza, HCD | 1 |
| Danilenko, AV | 1 |
| Volov, AN | 1 |
| Volov, NA | 1 |
| Platonova, YB | 1 |
| Savilov, SV | 1 |
| Bassiri, S | 1 |
| Bakhtiari, E | 1 |
| Ghaffarian, N | 1 |
| Moazzen, N | 1 |
| Ravanshad, Y | 1 |
| Azarfar, A | 1 |
| Santos, ISR | 1 |
| Martin-Pastor, M | 1 |
| Tavares Júnior, AG | 1 |
| Queiroz, KA | 1 |
| da Silva Sólon, LG | 1 |
| Sousa, FFO | 1 |
| Kim, MC | 1 |
| Ahn, Y | 1 |
| Kim, MH | 3 |
| Hong, TJ | 5 |
| Kim, H | 1 |
| Chae, IH | 1 |
| Kang, DH | 2 |
| Kim, BK | 1 |
| Kim, HS | 3 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Thimm, C | 1 |
| Erichsen, L | 1 |
| Wruck, W | 1 |
| Adjaye, J | 1 |
| do Carmo, JM | 1 |
| Dai, X | 1 |
| Aitken, N | 1 |
| Larson, KM | 1 |
| Omoto, ACM | 1 |
| Gulke, RR | 1 |
| Wang, Z | 5 |
| Mouton, AJ | 1 |
| Hall, JE | 1 |
| Castilla-Ojo, N | 1 |
| Turkson-Ocran, RA | 1 |
| Conlin, PR | 5 |
| Appel, LJ | 3 |
| Miller, ER | 3 |
| Juraschek, SP | 1 |
| Snyman, JR | 1 |
| Gumedze, F | 1 |
| Jones, ESW | 1 |
| Alaba, OA | 1 |
| Tsabedze, N | 1 |
| Vira, A | 1 |
| Ntusi, NAB | 1 |
| Ahmad, MI | 1 |
| Kazibwe, R | 1 |
| Soliman, MZ | 1 |
| Singh, S | 2 |
| Chen, LY | 1 |
| Soliman, EZ | 1 |
| Sykora, M | 1 |
| Kratky, V | 1 |
| Cervenka, L | 6 |
| Kopkan, L | 2 |
| Tribulova, N | 1 |
| Szeiffova Bacova, B | 1 |
| Sutton Burke, EM | 1 |
| Kelly, TC | 1 |
| Shoales, LA | 1 |
| Nagel, AK | 1 |
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 2 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 2 |
| Mulinari-Santos, G | 1 |
| Santos, JSD | 1 |
| Palin, LP | 1 |
| Silva, ACED | 1 |
| Antoniali, C | 2 |
| Faverani, LP | 1 |
| Gunasekaran, PM | 1 |
| Chertow, GM | 2 |
| Bhalla, V | 2 |
| Byrd, JB | 2 |
| Sun, GC | 1 |
| Wong, TY | 1 |
| Chen, HH | 1 |
| Ho, CY | 1 |
| Yeh, TC | 1 |
| Ho, WY | 2 |
| Tseng, CJ | 2 |
| Cheng, PW | 2 |
| Robles-Vera, I | 1 |
| Toral, M | 1 |
| de la Visitación, N | 1 |
| Sánchez, M | 1 |
| Gómez-Guzmán, M | 1 |
| Muñoz, R | 1 |
| Algieri, F | 1 |
| Vezza, T | 1 |
| Jiménez, R | 1 |
| Gálvez, J | 1 |
| Romero, M | 1 |
| Redondo, JM | 1 |
| Duarte, J | 2 |
| Shi, H | 2 |
| Yang, D | 2 |
| Qiao, J | 1 |
| Sun, R | 1 |
| Li, R | 2 |
| Zhu, C | 2 |
| Jing, R | 1 |
| Liu, L | 4 |
| Huang, L | 2 |
| Jafari, R | 1 |
| Rostami, Z | 1 |
| Nikpoor, M | 1 |
| Javanbakht, M | 1 |
| Ghahroudi, MS | 1 |
| Hosseini, MS | 1 |
| Einollahi, B | 1 |
| Agbaraolorunpo, FM | 1 |
| Sofola, OA | 1 |
| Anigbogu, CN | 1 |
| Azinge, EC | 1 |
| Pedreros-Rosales, C | 1 |
| Jalil Milad, R | 1 |
| Lagos Lucero, M | 1 |
| Solari Gajardo, S | 1 |
| Marin, GH | 1 |
| Messerli, FH | 9 |
| Siontis, GCM | 1 |
| Rexhaj, E | 1 |
| Umair, M | 1 |
| Ahmad, M | 2 |
| Saeed, H | 1 |
| Saleem, Z | 1 |
| Tauqeer, F | 1 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 8 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Wang, J | 8 |
| Xue, L | 1 |
| Yan, X | 2 |
| Huang, S | 1 |
| Xu, T | 1 |
| Li, C | 3 |
| Ji, F | 1 |
| Ming, F | 1 |
| Cheng, J | 2 |
| Zhao, H | 2 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Wei, J | 2 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 3 |
| Dong, Y | 1 |
| Wu, Y | 2 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 2 |
| Davis, DR | 2 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 3 |
| Yang, Y | 7 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Yan, D | 1 |
| Cui, L | 1 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 7 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 4 |
| Xun, J | 1 |
| Hu, Z | 2 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 2 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 3 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 2 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 2 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 2 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 3 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 2 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 2 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 2 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 4 |
| Cai, C | 1 |
| Zhang, Y | 10 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 2 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 3 |
| Choi, ES | 1 |
| Zhao, X | 4 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 3 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Barger, PM | 1 |
| Mann, DL | 2 |
| Liu, J | 2 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 2 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 7 |
| Zhang, Q | 2 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 3 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 2 |
| Ou, X | 1 |
| Zhao, S | 2 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 3 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 2 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 4 |
| Sun, M | 4 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 2 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 2 |
| Pan, K | 1 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 5 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 4 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 2 |
| Chen, C | 2 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 2 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 2 |
| Arinsoy, T | 2 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 4 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 5 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Wan, Y | 5 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 2 |
| Lin, CC | 3 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 3 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 2 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 2 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 2 |
| Jiang, WD | 1 |
| Wu, P | 2 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 2 |
| Zhou, XQ | 1 |
| Feng, L | 2 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 2 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 4 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 4 |
| Zhang, X | 3 |
| Qian, H | 1 |
| Yang, X | 3 |
| Sun, Y | 2 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 2 |
| Yang, E | 1 |
| Yang, W | 1 |
| Hanson, AE | 1 |
| Perusquia, M | 1 |
| Stallone, JN | 1 |
| Suo, Z | 1 |
| Xu, C | 1 |
| Dong, J | 2 |
| Fuchs, FD | 6 |
| Scala, LCN | 1 |
| Vilela-Martin, JF | 3 |
| Whelton, PK | 2 |
| Poli-de-Figueiredo, CE | 3 |
| Pereira E Silva, R | 2 |
| Gus, M | 3 |
| Bortolotto, LA | 3 |
| Consolim-Colombo, FM | 2 |
| Schlatter, RP | 1 |
| Cesarino, JE | 1 |
| Castro, I | 3 |
| Figueiredo Neto, JA | 2 |
| Chaves, H | 3 |
| Steffens, AA | 3 |
| Alves, JG | 3 |
| Brandão, AA | 3 |
| de Sousa, MR | 3 |
| Jardim, PC | 3 |
| Moreira, LB | 3 |
| Franco, RS | 2 |
| Gomes, MM | 2 |
| Afiune Neto, A | 2 |
| Fuchs, FC | 2 |
| Sobral Filho, DC | 2 |
| Nóbrega, AC | 3 |
| Nobre, F | 4 |
| Berwanger, O | 4 |
| Fuchs, SC | 5 |
| Barros, MAV | 1 |
| de Brito Alves, JL | 1 |
| Barros, RGN | 1 |
| Santana E Silva, M | 1 |
| Nasser, S | 1 |
| Tourneur, Y | 1 |
| Leandro, CVG | 1 |
| Vidal, H | 1 |
| Pirola, L | 1 |
| Costa-Silva, JH | 1 |
| Mohebbati, R | 1 |
| Kamkar-Del, Y | 1 |
| Shafei, MN | 1 |
| Zanaty, M | 1 |
| Seara, FAC | 1 |
| Nakagawa, P | 1 |
| Deng, G | 1 |
| Mathieu, NM | 1 |
| Balapattabi, K | 1 |
| Karnik, SS | 1 |
| Grobe, JL | 3 |
| Sigmund, CD | 8 |
| Derington, CG | 1 |
| King, JB | 1 |
| Delate, T | 1 |
| Botts, SR | 1 |
| Kroehl, M | 1 |
| Kao, DP | 1 |
| Trinkley, KE | 1 |
| Bolotova, O | 1 |
| Yoo, J | 1 |
| Chaudhri, I | 1 |
| Marcos, LA | 1 |
| Sahib, H | 1 |
| Koraishy, FM | 1 |
| Skopicki, H | 1 |
| Ahmad, S | 2 |
| Mallipattu, SK | 1 |
| Kim, HY | 2 |
| Mascarello, A | 1 |
| Azevedo, H | 2 |
| Ferreira Junior, MA | 1 |
| Ishikawa, EE | 1 |
| Guimarães, CRW | 1 |
| Fu, Z | 1 |
| Wang, F | 2 |
| Hu, J | 2 |
| Su, J | 1 |
| Lu, X | 1 |
| Lu, A | 1 |
| Symons, JD | 1 |
| Zou, CJ | 1 |
| Yang, T | 3 |
| Nouri-Vaskeh, M | 1 |
| Kalami, N | 1 |
| Zand, R | 1 |
| Soroureddin, Z | 1 |
| Varshochi, M | 1 |
| Ansarin, K | 1 |
| Rezaee, H | 1 |
| Taghizadieh, A | 1 |
| Sadeghi, A | 1 |
| Ahangari Maleki, M | 1 |
| Esmailnajad, A | 1 |
| Saleh, P | 1 |
| Haghdoost, M | 1 |
| Maleki, M | 1 |
| Sharifi, A | 1 |
| Jabbar, AS | 1 |
| Neamah, NF | 1 |
| Al-Darraji, AH | 1 |
| Bryant, CE | 1 |
| Rajai, A | 1 |
| Webb, NJA | 1 |
| Hogg, RJ | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Peña, ME | 1 |
| Angeramo, CA | 1 |
| Schlottmann, F | 1 |
| Sadava, EE | 1 |
| Leite, APO | 1 |
| Li, XC | 4 |
| Hassan, R | 1 |
| Zheng, X | 1 |
| Alexander, B | 1 |
| Casarini, DE | 3 |
| Zhuo, JL | 2 |
| Koide, M | 2 |
| Harraz, OF | 1 |
| Dabertrand, F | 1 |
| Longden, TA | 1 |
| Ferris, HR | 1 |
| Wellman, GC | 1 |
| Hill-Eubanks, DC | 1 |
| Greenstein, AS | 1 |
| Ragab, TIM | 1 |
| Ali, NA | 1 |
| El Gendy, ANG | 1 |
| Mohamed, SH | 1 |
| Shalby, AB | 1 |
| Farrag, AH | 1 |
| Shalaby, ASG | 1 |
| Hori, D | 1 |
| Dunkerly-Eyring, B | 1 |
| Nomura, Y | 1 |
| Biswas, D | 1 |
| Steppan, J | 1 |
| Henao-Mejia, J | 1 |
| Adachi, H | 2 |
| Santhanam, L | 1 |
| Berkowitz, DE | 1 |
| Steenbergen, C | 1 |
| Flavell, RA | 1 |
| Das, S | 1 |
| Moroni, C | 1 |
| Tolone, S | 1 |
| Lopreiato, F | 1 |
| Scrofani, AR | 1 |
| Bossini, A | 1 |
| Affricano, C | 1 |
| Cassone, R | 1 |
| Gaudio, C | 1 |
| Jiang, D | 1 |
| Kawagoe, Y | 1 |
| Kuwasako, K | 1 |
| Kitamura, K | 3 |
| Kato, J | 3 |
| Jenner, R | 1 |
| Fatureto-Borges, F | 1 |
| Costa-Hong, V | 1 |
| Lopes, HF | 1 |
| Teixeira, SH | 1 |
| Marum, E | 1 |
| Giorgi, DAM | 1 |
| Lorenzi-Filho, G | 1 |
| Krieger, EM | 4 |
| Drager, LF | 1 |
| Skrzypecki, J | 1 |
| Gawlak, M | 1 |
| Huc, T | 1 |
| Szulczyk, P | 1 |
| Ufnal, M | 1 |
| Tylicki, L | 2 |
| Debska-Slizien, AM | 1 |
| Lizakowski, S | 1 |
| Przybylska, M | 1 |
| Heleniak, Z | 1 |
| Renke, M | 2 |
| Chamienia, AL | 1 |
| Biedunkiewicz, B | 1 |
| Rutkowski, P | 2 |
| Małgorzewicz, S | 1 |
| Rutkowski, B | 2 |
| Toscano, CM | 1 |
| Simões, MR | 1 |
| Alonso, MJ | 4 |
| Salaices, M | 4 |
| Vassallo, DV | 2 |
| Fioresi, M | 1 |
| Wu, J | 3 |
| Zhang, M | 5 |
| Zhou, M | 1 |
| Xu, F | 1 |
| Zhu, X | 1 |
| Lang, Y | 2 |
| Yang, F | 1 |
| Yun, S | 1 |
| Shi, S | 1 |
| Liu, Z | 2 |
| Aghaei, I | 1 |
| Arjmand, S | 1 |
| Yousefzadeh Chabok, S | 1 |
| Tondar, M | 1 |
| Shabani, M | 1 |
| Fanelli, C | 3 |
| Arias, SCA | 1 |
| Machado, FG | 3 |
| Okuma, JK | 1 |
| Malheiros, DMAC | 1 |
| Moreira-Filho, CA | 1 |
| Camara, NOS | 1 |
| Fujihara, CK | 4 |
| Zatz, R | 5 |
| Ge, L | 1 |
| You, B | 1 |
| Shi, R | 3 |
| Liu, K | 2 |
| Meng, Q | 1 |
| Shi, D | 1 |
| Gomes, PM | 1 |
| Sá, RWM | 1 |
| Aguiar, GL | 1 |
| Paes, MHS | 1 |
| Alzamora, AC | 2 |
| Lima, WG | 1 |
| de Oliveira, LB | 1 |
| Stocker, SD | 1 |
| Antunes, VR | 1 |
| Cardoso, LM | 1 |
| Oğuz, N | 2 |
| Kırça, M | 2 |
| Çetin, A | 2 |
| Yeşilkaya, A | 2 |
| Silva, RMD | 1 |
| Chaves, GC | 1 |
| Chaves, LA | 1 |
| Campos, MR | 1 |
| Luiza, VL | 1 |
| Bertoldi, AD | 1 |
| Ross-Degnan, D | 1 |
| Emmerick, ICM | 1 |
| Smeda, JS | 1 |
| Daneshtalab, N | 1 |
| Abdel-Zaher, AO | 3 |
| Farghaly, HSM | 2 |
| El-Refaiy, AEM | 2 |
| Abd-Eldayem, AM | 2 |
| Jeong, HS | 1 |
| Han, SH | 5 |
| Chang, KY | 1 |
| Hong, BK | 3 |
| Lee, BK | 1 |
| Chae, SC | 6 |
| Kim, WS | 1 |
| Park, CG | 9 |
| Lee, SU | 2 |
| Kim, YD | 2 |
| Kim, KS | 4 |
| Choi, JH | 2 |
| Kang, HJ | 1 |
| Kim, JJ | 4 |
| Kang, SM | 2 |
| Choi, YJ | 5 |
| Shin, JH | 1 |
| Chun, KJ | 1 |
| Shin, DG | 2 |
| Park, SH | 5 |
| Kwan, J | 2 |
| Chae, JK | 1 |
| Kim, DW | 1 |
| Cho, JR | 1 |
| Han, KR | 2 |
| Won, KH | 1 |
| Lee, SK | 1 |
| Jung, J | 1 |
| Kim, CH | 3 |
| Leclerc, J | 1 |
| Blais, C | 1 |
| Rochette, L | 1 |
| Hamel, D | 1 |
| Guénette, L | 1 |
| Poirier, P | 1 |
| Bertoluci, C | 2 |
| Foppa, M | 2 |
| Santos, ABS | 2 |
| Branchi, TV | 1 |
| Liang, M | 1 |
| Zhong, W | 1 |
| Miao, F | 1 |
| Wu, H | 1 |
| Uchiwa, H | 2 |
| Kai, H | 5 |
| Iwamoto, Y | 3 |
| Anegawa, T | 2 |
| Kajimoto, H | 1 |
| Fukuda, K | 2 |
| Imaizumi, T | 5 |
| Fukumoto, Y | 2 |
| Busby, J | 1 |
| McMenamin, Ú | 1 |
| Spence, A | 1 |
| Johnston, BT | 1 |
| Hughes, C | 1 |
| Cardwell, CR | 1 |
| van Gils, T | 1 |
| Robijn, RJ | 1 |
| Bouma, G | 1 |
| Neefjes-Borst, EA | 1 |
| Mulder, CJJ | 1 |
| MacDonald, TM | 4 |
| Williams, B | 3 |
| Webb, DJ | 3 |
| Morant, S | 2 |
| Caulfield, M | 2 |
| Cruickshank, JK | 2 |
| Ford, I | 2 |
| Sever, P | 2 |
| Mackenzie, IS | 2 |
| Padmanabhan, S | 2 |
| McCann, GP | 1 |
| Salsbury, J | 2 |
| McInnes, G | 3 |
| Brown, MJ | 6 |
| Okin, PM | 54 |
| Hille, DA | 22 |
| Kjeldsen, SE | 90 |
| Devereux, RB | 126 |
| Nelson, JW | 1 |
| Ferdaus, MZ | 2 |
| McCormick, JA | 1 |
| Minnier, J | 1 |
| Kaul, S | 1 |
| Ellison, DH | 1 |
| Barnes, AP | 1 |
| Atanasova, D | 2 |
| Tchekalarova, J | 1 |
| Ivanova, N | 2 |
| Nenchovska, Z | 1 |
| Pavlova, E | 1 |
| Atanassova, N | 1 |
| Lazarov, N | 2 |
| Aftab, RA | 3 |
| Khan, AH | 3 |
| Adnan, AS | 3 |
| Sulaiman, SAS | 3 |
| Khan, TM | 3 |
| Yun, L | 1 |
| Dai, Y | 1 |
| Xu, R | 3 |
| Li, G | 1 |
| Zheng, F | 1 |
| Wang, T | 1 |
| Lian, G | 1 |
| Cai, X | 1 |
| Lin, Z | 1 |
| Xie, L | 1 |
| Owoicho Orgah, J | 1 |
| Wang, D | 1 |
| Fan, G | 1 |
| Han, J | 1 |
| Qin, G | 1 |
| Soler, A | 1 |
| Hunter, I | 1 |
| Joseph, G | 1 |
| Hutcheson, R | 1 |
| Hutcheson, B | 1 |
| Zhang, FF | 1 |
| Joshi, SR | 3 |
| Bradford, C | 1 |
| Gotlinger, KH | 1 |
| Maniyar, R | 1 |
| Falck, JR | 3 |
| Proctor, S | 1 |
| Schwartzman, ML | 2 |
| Gupte, SA | 1 |
| Rocic, P | 1 |
| Shevelev, OB | 1 |
| Seryapina, AA | 1 |
| Zavjalov, EL | 1 |
| Gerlinskaya, LA | 1 |
| Goryachkovskaya, TN | 1 |
| Slynko, NM | 1 |
| Kuibida, LV | 1 |
| Peltek, SE | 1 |
| Markel, AL | 1 |
| Moshkin, MP | 1 |
| Chen, P | 1 |
| Qiao, D | 1 |
| Tahara, A | 1 |
| Takasu, T | 1 |
| Márquez-Ramírez, CA | 1 |
| Hernández de la Paz, JL | 1 |
| Ortiz-Avila, O | 1 |
| Raya-Farias, A | 1 |
| González-Hernández, JC | 1 |
| Rodríguez-Orozco, AR | 1 |
| Salgado-Garciglia, R | 1 |
| Saavedra-Molina, A | 1 |
| Godínez-Hernández, D | 1 |
| Cortés-Rojo, C | 1 |
| Maharshi, V | 1 |
| Rehan, HS | 1 |
| Gupta, LK | 1 |
| Yadav, M | 2 |
| Walton, SL | 1 |
| Mazzuca, MQ | 1 |
| Tare, M | 1 |
| Parkington, HC | 1 |
| Wlodek, ME | 1 |
| Moritz, KM | 1 |
| Gallo, LA | 1 |
| Akbari, H | 2 |
| Asadikaram, G | 3 |
| Jafari, A | 1 |
| Nazari-Robati, M | 1 |
| Ebrahimi, G | 1 |
| Ebrahimi, N | 2 |
| Masoumi, M | 3 |
| de Moura Leão, MF | 1 |
| Duarte, JA | 1 |
| Sauzen, PD | 1 |
| Piccoli, JDCE | 1 |
| de Oliveira, LFS | 1 |
| Machado, MM | 1 |
| Tong, Y | 1 |
| Ye, C | 1 |
| Ren, XS | 1 |
| Zang, YH | 1 |
| Xiong, XQ | 1 |
| Wang, JJ | 1 |
| Li, YH | 1 |
| Kang, YM | 2 |
| Zhu, GQ | 3 |
| Lian, D | 1 |
| Lai, J | 1 |
| Boini, KM | 1 |
| Lezama-Martinez, D | 1 |
| Flores-Monroy, J | 1 |
| Fonseca-Coronado, S | 1 |
| Hernandez-Campos, ME | 1 |
| Valencia-Hernandez, I | 1 |
| Martinez-Aguilar, L | 1 |
| Vakili, S | 1 |
| Guan, Y | 1 |
| Kobori, H | 1 |
| Morishita, A | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Nakano, D | 1 |
| Nishiyama, A | 5 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Shahraki, E | 1 |
| Peters, AM | 2 |
| Janda, A | 1 |
| Zhou, P | 3 |
| Arthur, E | 1 |
| Kwartler, CS | 2 |
| Milewicz, DM | 2 |
| Kamal, MSA | 2 |
| Ismail, NH | 2 |
| Satar, NA | 1 |
| Azis, NA | 2 |
| Radjeni, Z | 2 |
| Mohammad Noor, HS | 1 |
| Kasim, N | 1 |
| Singh, H | 1 |
| Drews, HJ | 1 |
| Yenkoyan, K | 1 |
| Lourhmati, A | 1 |
| Buadze, M | 1 |
| Kabisch, D | 1 |
| Verleysdonk, S | 1 |
| Petschak, S | 1 |
| Beer-Hammer, S | 1 |
| Davtyan, T | 1 |
| Frey, WH | 1 |
| Gleiter, CH | 1 |
| Schwab, M | 1 |
| Danielyan, L | 1 |
| Chiu, WC | 1 |
| Chiang, JY | 1 |
| Juang, JM | 1 |
| Wu, CK | 1 |
| Tsai, CT | 1 |
| Tseng, YZ | 1 |
| Su, MJ | 1 |
| Chiang, FT | 1 |
| Agarwal, R | 2 |
| Ismail, NM | 1 |
| Singh, HJ | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Cho, EJ | 2 |
| Sohn, IS | 2 |
| Choi, DJ | 3 |
| Ha, JW | 3 |
| Ahn, YK | 2 |
| Kim, SK | 3 |
| Chung, WJ | 4 |
| Yoo, BS | 2 |
| Youn, HJ | 3 |
| Cho, MC | 3 |
| Kim, CJ | 2 |
| Reyes-Pardo, H | 1 |
| Bautista, R | 2 |
| Vargas-Robles, H | 1 |
| Rios, A | 2 |
| Sánchez, D | 1 |
| Escalante, B | 2 |
| Okura, T | 2 |
| Miyoshi, K | 3 |
| Irita, J | 2 |
| Enomoto, D | 1 |
| Jotoku, M | 1 |
| Nagao, T | 2 |
| Watanabe, K | 1 |
| Matsuoka, H | 7 |
| Ashihara, T | 1 |
| Higaki, J | 4 |
| Bang, CN | 6 |
| Wachtell, K | 82 |
| Dahlöf, B | 125 |
| Arias, SC | 2 |
| Valente, CP | 1 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Malheiros, DM | 3 |
| Fukutomi, M | 2 |
| Hoshide, S | 2 |
| Eguchi, K | 3 |
| Watanabe, T | 4 |
| Kario, K | 3 |
| Kaneyuki, M | 1 |
| Shihara, M | 1 |
| Toyama, Y | 1 |
| Mitsutake, Y | 1 |
| Umei, H | 1 |
| Kusaba, K | 1 |
| Ueda, T | 3 |
| Heijnen, BF | 2 |
| Nelissen, J | 2 |
| van Essen, H | 2 |
| Fazzi, GE | 1 |
| Cohen Tervaert, JW | 1 |
| Peutz-Kootstra, CJ | 1 |
| Mullins, JJ | 7 |
| Schalkwijk, CG | 2 |
| Janssen, BJ | 6 |
| Struijker-Boudier, HA | 3 |
| Elkoussi, AE | 1 |
| Abudahab, LH | 1 |
| Elbakry, MH | 1 |
| Elsayed, EA | 1 |
| Sato, N | 2 |
| Saijo, Y | 2 |
| Sasagawa, Y | 2 |
| Morimoto, H | 2 |
| Takeuchi, T | 2 |
| Sano, H | 2 |
| Koyama, S | 2 |
| Takehara, N | 2 |
| Morita, K | 2 |
| Sumitomo, K | 2 |
| Maruyama, J | 2 |
| Kikuchi, K | 3 |
| Hasebe, N | 2 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 3 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Weiss, RJ | 1 |
| Stapff, M | 3 |
| Jian, DY | 1 |
| Chao, YW | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Chang, CF | 1 |
| Juan, CC | 1 |
| Chen, JY | 1 |
| Ohta, Y | 4 |
| Kawano, Y | 6 |
| Iwashima, Y | 2 |
| Hayashi, S | 1 |
| Yoshihara, F | 2 |
| Matayoshi, T | 1 |
| Takiuchi, S | 3 |
| Kamide, K | 5 |
| Nakamura, S | 2 |
| Horio, T | 4 |
| Watanabe, Y | 1 |
| Halberg, F | 2 |
| Otsuka, K | 2 |
| Cornelissen, G | 2 |
| Godman, B | 4 |
| Wettermark, B | 1 |
| Miranda, J | 3 |
| Bennie, M | 3 |
| Martin, A | 3 |
| Malmström, RE | 2 |
| Wiik, BP | 2 |
| Lindholm, LH | 46 |
| Kusunoki, H | 1 |
| Taniyama, Y | 1 |
| Rakugi, H | 5 |
| Morishita, R | 2 |
| Hasegawa, H | 4 |
| Kanozawa, K | 1 |
| Asakura, J | 2 |
| Takayanagi, K | 3 |
| Komuro, O | 1 |
| Fukada, H | 1 |
| Tokushima, H | 1 |
| Kogure, H | 1 |
| Matsuzawa, M | 1 |
| Mitarai, T | 2 |
| Schwieler, JH | 1 |
| Kahan, T | 2 |
| Wallén, NH | 1 |
| Nussberger, J | 9 |
| Hjemdahl, P | 1 |
| Barrios, V | 2 |
| Escobar, C | 1 |
| Kristek, F | 3 |
| Malekova, M | 1 |
| Cacanyiova, S | 2 |
| Matsumura, K | 4 |
| Arima, H | 3 |
| Tominaga, M | 4 |
| Ohtsubo, T | 3 |
| Sasaguri, T | 3 |
| Fujii, K | 3 |
| Fukuhara, M | 4 |
| Uezono, K | 3 |
| Morinaga, Y | 3 |
| Otonari, T | 3 |
| Kawasaki, J | 3 |
| Kato, I | 3 |
| Tsuchihashi, T | 8 |
| Bishop, I | 1 |
| Campbell, S | 1 |
| Finlayson, AE | 1 |
| Gustafsson, LL | 1 |
| Calcinaghi, N | 1 |
| Wyss, MT | 1 |
| Jolivet, R | 1 |
| Singh, A | 1 |
| Keller, AL | 1 |
| Winnik, S | 1 |
| Fritschy, JM | 1 |
| Buck, A | 1 |
| Matter, CM | 1 |
| Weber, B | 1 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Bendersky, M | 2 |
| Juncos, L | 1 |
| Waisman, GD | 1 |
| Piskorz, D | 1 |
| Lopez-Santi, R | 1 |
| Montaña, O | 1 |
| Caruso, G | 2 |
| Kotetzky, M | 1 |
| Penna, M | 1 |
| Gomez, R | 1 |
| Ihm, SH | 1 |
| Jeon, HK | 1 |
| Lim, DS | 2 |
| Kim, DS | 1 |
| Kim, KH | 3 |
| Baek, SH | 1 |
| Nedogoda, SV | 1 |
| Ledyaeva, AA | 1 |
| Chumachok, EV | 1 |
| Tsoma, VV | 1 |
| Mazina, G | 1 |
| Salasyuk, AS | 1 |
| Barykina, IN | 1 |
| Briasoulis, A | 1 |
| Oliva, R | 1 |
| Kalaitzidis, R | 2 |
| Flynn, C | 1 |
| Lazich, I | 1 |
| Schlaffer, C | 1 |
| Bakris, G | 4 |
| Gerdts, E | 43 |
| Aurigemma, GP | 7 |
| Boman, K | 27 |
| Roman, MJ | 4 |
| Køber, L | 3 |
| Friedberg, MK | 1 |
| Cho, MY | 1 |
| Assad, RS | 1 |
| Rohailla, S | 1 |
| Honjo, O | 1 |
| Apitz, C | 1 |
| Redington, AN | 1 |
| Oshikawa, J | 1 |
| Toya, Y | 3 |
| Morita, S | 1 |
| Taguri, M | 1 |
| Hanaoka, K | 2 |
| Hasegawa, T | 4 |
| Kaizu, K | 1 |
| Kamata, K | 2 |
| Kobayashi, S | 1 |
| Ohtake, T | 1 |
| Sato, T | 2 |
| Yasuda, G | 2 |
| Kimura, K | 1 |
| Umemura, S | 8 |
| Hamada, T | 3 |
| Kuwabara, M | 1 |
| Watanabe, A | 1 |
| Mizuta, E | 3 |
| Ohtahara, A | 2 |
| Omodani, H | 1 |
| Watanabe, M | 1 |
| Nakamura, H | 1 |
| Hirota, Y | 1 |
| Miyazaki, S | 1 |
| Kato, M | 2 |
| Ogino, K | 2 |
| Kosaka, H | 1 |
| Haruaki, N | 1 |
| Taniguchi, S | 1 |
| Yamamoto, K | 4 |
| Kotake, H | 1 |
| Hisatome, I | 4 |
| Kuang, SQ | 1 |
| Geng, L | 1 |
| Prakash, SK | 1 |
| Cao, JM | 1 |
| Guo, S | 1 |
| Villamizar, C | 1 |
| Brasier, AR | 1 |
| Zhang, YF | 1 |
| Qin, L | 1 |
| Kwok, TC | 1 |
| Yeung, BH | 1 |
| Li, GD | 1 |
| Liu, F | 4 |
| Takagi, H | 1 |
| Niwa, M | 1 |
| Mizuno, Y | 1 |
| Goto, SN | 1 |
| Umemoto, T | 1 |
| Zhang, CQ | 1 |
| Yin, JQ | 1 |
| Xin, Q | 1 |
| Wang, YQ | 1 |
| Ge, ZM | 3 |
| Wier, WG | 1 |
| He, DH | 3 |
| Zhang, LM | 3 |
| Ning, RB | 2 |
| Wang, HJ | 4 |
| Xu, CS | 4 |
| Lin, JX | 3 |
| Song, WH | 1 |
| Lee, JU | 1 |
| Shin, MS | 1 |
| Kim, BO | 1 |
| Hong, KS | 2 |
| Han, SW | 1 |
| Seo, HS | 1 |
| Knight, WD | 1 |
| Saxena, A | 1 |
| Shell, B | 1 |
| Nedungadi, TP | 1 |
| Mifflin, SW | 1 |
| Cunningham, JT | 1 |
| Salvi, P | 1 |
| Pucci, G | 1 |
| Battista, F | 1 |
| Schillaci, G | 3 |
| Pérez Carreño, JG | 1 |
| Romero, JD | 1 |
| Villar Centeno, JC | 1 |
| Saseen, JJ | 1 |
| Ghushchyan, V | 1 |
| Kaila, S | 1 |
| Allen, RR | 1 |
| Nair, KV | 1 |
| Hesse, U | 1 |
| Petzold, M | 1 |
| Radchenko, GD | 1 |
| Sirenko, YM | 1 |
| Kushnir, SM | 1 |
| Torbas, OO | 1 |
| Dobrokhod, AS | 1 |
| Nishida, Y | 2 |
| Takahashi, Y | 2 |
| Susa, N | 1 |
| Kanou, N | 1 |
| Nakayama, T | 1 |
| Asai, S | 1 |
| Suzuki, R | 2 |
| Fukuda, N | 2 |
| Katakawa, M | 2 |
| Tsunemi, A | 2 |
| Tahira, Y | 1 |
| Matsumoto, T | 4 |
| Ueno, T | 4 |
| Soma, M | 1 |
| Orlowski, A | 1 |
| Ciancio, MC | 1 |
| Caldiz, CI | 2 |
| De Giusti, VC | 1 |
| Aiello, EA | 1 |
| Ohigashi, M | 1 |
| Tayama, Y | 1 |
| Nakamura, T | 2 |
| Kawashima, K | 1 |
| Iwashita, T | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Stamatelopoulos, K | 1 |
| Bramos, D | 1 |
| Manios, E | 1 |
| Alexaki, E | 1 |
| Kaladaridou, A | 1 |
| Georgiopoulos, G | 1 |
| Koroboki, E | 1 |
| Kolyviras, A | 1 |
| Stellos, K | 1 |
| Zakopoulos, N | 1 |
| Toumanidis, S | 1 |
| Kwon, HM | 1 |
| Shin, JW | 1 |
| Lim, JS | 2 |
| Hong, YH | 1 |
| Lee, YS | 3 |
| Nam, H | 1 |
| McLachlan, J | 1 |
| Beattie, E | 1 |
| Murphy, MP | 1 |
| Koh-Tan, CH | 1 |
| Olson, E | 1 |
| Beattie, W | 1 |
| Dominiczak, AF | 6 |
| Nicklin, SA | 1 |
| Graham, D | 3 |
| Lin, LM | 1 |
| Zhang, DM | 1 |
| Yu, XJ | 1 |
| Qi, J | 1 |
| Su, Q | 1 |
| Suo, YP | 1 |
| Yue, LY | 1 |
| Qin, DN | 1 |
| Tilstone, J | 1 |
| Saleem, N | 1 |
| Olsson, E | 1 |
| Acosta, A | 1 |
| Restrepo, L | 1 |
| Tada, Y | 1 |
| Wada, K | 1 |
| Shimada, K | 13 |
| Makino, H | 2 |
| Liang, EI | 1 |
| Murakami, S | 1 |
| Kudo, M | 1 |
| Kitazato, KT | 1 |
| Nagahiro, S | 1 |
| Hashimoto, T | 2 |
| Gottlieb, AB | 1 |
| Chazova, IE | 2 |
| Martyniuk, TV | 1 |
| Sakallı, H | 1 |
| Baskın, E | 1 |
| Bayrakcı, US | 1 |
| Moray, G | 1 |
| Haberal, M | 1 |
| Xia, Y | 1 |
| Yu, G | 2 |
| Zeng, K | 1 |
| Luo, H | 1 |
| Gong, CX | 1 |
| Wang, JZ | 1 |
| Zhou, XW | 1 |
| Wang, XC | 1 |
| Lawrence Gould, A | 1 |
| Unniachan, S | 2 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 2 |
| Lin, JW | 1 |
| Chang, CH | 1 |
| Caffrey, JL | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Stevanović, J | 1 |
| O'Prinsen, AC | 1 |
| Verheggen, BG | 1 |
| Schuiling-Veninga, N | 1 |
| Postma, MJ | 2 |
| Pechlivanoglou, P | 1 |
| Julius, S | 40 |
| Mancusi, C | 2 |
| De Simone, G | 16 |
| Abdelhai, YM | 1 |
| Lønnebakken, MT | 4 |
| Sakamoto, T | 2 |
| Kudoh, T | 1 |
| Sakamoto, K | 1 |
| Matsui, K | 1 |
| Ogawa, H | 2 |
| Fervenza, FC | 1 |
| Perazella, MA | 1 |
| Zhang, H | 2 |
| Takeshita, K | 1 |
| Murohara, T | 4 |
| Cheung, TT | 1 |
| Cheung, BM | 2 |
| Wang, JG | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Kanda, S | 1 |
| Yoshioka, K | 1 |
| Amino, M | 1 |
| Deguchi, Y | 1 |
| Aizawa, T | 2 |
| Tanabe, T | 1 |
| Ikari, Y | 1 |
| Hsu, CN | 1 |
| Lee, CT | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Webb, NJ | 3 |
| Wells, TG | 3 |
| Shahinfar, S | 14 |
| Massaad, R | 3 |
| Dankner, WM | 1 |
| Lam, C | 3 |
| Santoro, EP | 2 |
| McCrary Sisk, C | 1 |
| Blaustein, RO | 1 |
| Li, LD | 1 |
| Tian, M | 1 |
| Liao, YH | 2 |
| Zhou, ZH | 2 |
| Wei, F | 2 |
| Zhu, F | 2 |
| Wang, B | 2 |
| Wei, YM | 2 |
| Okada, Y | 1 |
| Mori, H | 1 |
| Nishida, K | 1 |
| Uriu, K | 1 |
| Tanaka, Y | 3 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 2 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 2 |
| Numaguchi, H | 3 |
| Nishida, C | 3 |
| Yamaguchi, H | 5 |
| Fujimoto, G | 1 |
| Azuma, K | 6 |
| Shirakawa, M | 3 |
| Hanson, ME | 2 |
| Fujita, KP | 4 |
| Pozzobon, CR | 3 |
| Gismondi, RA | 3 |
| Bedirian, R | 3 |
| Ladeira, MC | 3 |
| Neves, MF | 3 |
| Oigman, W | 5 |
| Kuo, CC | 1 |
| Balakrishnan, P | 1 |
| Hsein, YC | 1 |
| Wu, VC | 1 |
| Chueh, SC | 1 |
| Chen, YM | 1 |
| Wu, KD | 1 |
| Wang, MJ | 1 |
| Rosendahl, A | 1 |
| Niemann, G | 1 |
| Lange, S | 1 |
| Ahadzadeh, E | 1 |
| Krebs, C | 1 |
| Contrepas, A | 1 |
| van Goor, H | 1 |
| Wiech, T | 1 |
| Bader, M | 2 |
| Schwake, M | 1 |
| Peters, J | 2 |
| Stahl, R | 1 |
| Nguyen, G | 1 |
| Wenzel, UO | 1 |
| Navarro Suay, R | 1 |
| de Tena Gómez, MD | 1 |
| García Aroca, MÁ | 1 |
| López Soberón, E | 1 |
| Imbalzano, E | 2 |
| Scarpelli, M | 1 |
| Mandraffino, G | 2 |
| Creazzo, M | 1 |
| Lizio, G | 1 |
| Trapani, G | 1 |
| Dattilo, G | 1 |
| Dalbeni, A | 1 |
| Tomasello, C | 1 |
| Sardo, MA | 2 |
| Saitta, A | 2 |
| Volkova, NI | 1 |
| Lazoryshynets, VV | 1 |
| Rajagopalan, S | 3 |
| Fan, X | 1 |
| Cui, W | 1 |
| Huang, J | 2 |
| Wang, W | 2 |
| Carrillo-Sepulveda, MA | 1 |
| Keen, HL | 1 |
| Shiga, Y | 5 |
| Miura, S | 4 |
| Norimatsu, K | 1 |
| Hitaka, Y | 1 |
| Nagata, I | 1 |
| Koyoshi, R | 1 |
| Morii, J | 2 |
| Kuwano, T | 2 |
| Uehara, Y | 3 |
| Inoue, A | 3 |
| Shirotani, T | 1 |
| Fujisawa, K | 1 |
| Matsunaga, E | 1 |
| Saku, K | 4 |
| Suh, SY | 1 |
| Ahn, T | 1 |
| Bae, JH | 1 |
| Kim, YK | 2 |
| Hyon, MS | 1 |
| Kim, WH | 1 |
| Park, HK | 1 |
| Bądzyńska, B | 1 |
| Lipkowski, AW | 1 |
| Sadowski, J | 2 |
| Kompanowska-Jezierska, E | 2 |
| Guha, S | 1 |
| Avasthi, R | 1 |
| Narain, VS | 1 |
| Rajendiran, C | 1 |
| Mitra, M | 1 |
| Ray, S | 1 |
| Majumdar, D | 1 |
| Mondal, MM | 1 |
| Mani, S | 1 |
| Mookerjee, S | 1 |
| Saha, J | 1 |
| Dastidaro, DG | 1 |
| Tamura, K | 7 |
| Ohki, K | 1 |
| Kobayashi, R | 1 |
| Uneda, K | 1 |
| Azushima, K | 1 |
| Ohsawa, M | 3 |
| Wakui, H | 3 |
| Sakai, M | 1 |
| Tokita, Y | 2 |
| Gealh, WC | 1 |
| Pereira, CC | 1 |
| Luvizuto, ER | 1 |
| Garcia-Júnior, IR | 1 |
| López, RM | 1 |
| Castillo, MC | 1 |
| López, JS | 1 |
| Guevara, G | 1 |
| López, P | 1 |
| Castillo, EF | 1 |
| Metoki, H | 4 |
| Obara, T | 3 |
| Asayama, K | 4 |
| Satoh, M | 2 |
| Hosaka, M | 2 |
| Elnagar, N | 1 |
| Miyawaki, Y | 1 |
| Kojima, I | 1 |
| Ohkubo, T | 4 |
| Imai, Y | 5 |
| Venci, JV | 1 |
| Shamaskin, JA | 1 |
| Takase, B | 1 |
| Nagata, M | 1 |
| Nagayama, T | 1 |
| Hirooka, Y | 2 |
| Kishi, T | 2 |
| Mukai, Y | 1 |
| Inoue, S | 1 |
| Takase, S | 1 |
| Takemoto, M | 1 |
| Chishaki, A | 1 |
| Sunagawa, K | 2 |
| Suzuki, H | 5 |
| Fujiwara, K | 2 |
| Ceravolo, GS | 2 |
| Montezano, AC | 1 |
| Jordão, MT | 1 |
| Akamine, EH | 1 |
| Costa, TJ | 1 |
| Takano, AP | 1 |
| Fernandes, DC | 1 |
| Barreto-Chaves, ML | 1 |
| Laurindo, FR | 1 |
| Tostes, RC | 2 |
| Fortes, ZB | 5 |
| Chopard, RP | 1 |
| Touyz, RM | 5 |
| Carvalho, MH | 4 |
| Frau, F | 4 |
| Zaninello, R | 4 |
| Salvi, E | 4 |
| Ortu, MF | 2 |
| Braga, D | 2 |
| Velayutham, D | 2 |
| Argiolas, G | 4 |
| Fresu, G | 2 |
| Troffa, C | 3 |
| Bulla, E | 2 |
| Bulla, P | 2 |
| Pitzoi, S | 2 |
| Piras, DA | 2 |
| Glorioso, V | 3 |
| Chittani, M | 2 |
| Bernini, G | 2 |
| Bardini, M | 2 |
| Fallo, F | 2 |
| Malatino, L | 2 |
| Stancanelli, B | 2 |
| Regolisti, G | 2 |
| Ferri, C | 4 |
| Desideri, G | 2 |
| Scioli, GA | 1 |
| Galletti, F | 1 |
| Sciacqua, A | 2 |
| Perticone, F | 2 |
| Degli Esposti, E | 2 |
| Sturani, A | 1 |
| Semplicini, A | 1 |
| Veglio, F | 3 |
| Mulatero, P | 3 |
| Williams, TA | 2 |
| Lanzani, C | 3 |
| Hiltunen, TP | 7 |
| Kontula, K | 7 |
| Boerwinkle, E | 3 |
| Turner, ST | 3 |
| Manunta, P | 3 |
| Barlassina, C | 2 |
| Cusi, D | 4 |
| Glorioso, N | 5 |
| Li, W | 4 |
| Sullivan, MN | 1 |
| Zhang, S | 2 |
| Worker, CJ | 1 |
| Xiong, Z | 1 |
| Speth, RC | 1 |
| Feng, Y | 2 |
| Flavahan, S | 1 |
| Leung, SW | 1 |
| Xu, A | 1 |
| Vanhoutte, PM | 1 |
| Flavahan, NA | 1 |
| Vatseba, MO | 1 |
| Maksimov, VF | 2 |
| Korostyshevskaya, IM | 1 |
| Markel', AL | 4 |
| Yakobson, GS | 2 |
| Rudenko, NS | 2 |
| Donner, KM | 3 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Chapman, AB | 2 |
| Gums, JG | 1 |
| Gong, Y | 2 |
| Cooper-DeHoff, RM | 2 |
| Johnson, JA | 2 |
| Kontula, KK | 2 |
| Rincón, J | 1 |
| Correia, D | 1 |
| Arcaya, JL | 1 |
| Finol, E | 1 |
| Fernández, A | 1 |
| Pérez, M | 1 |
| Yaguas, K | 1 |
| Talavera, E | 1 |
| Chávez, M | 1 |
| Summer, R | 1 |
| Romero, F | 1 |
| Citterio, L | 2 |
| Carpini, SD | 2 |
| Simonini, M | 1 |
| Pozzoli, S | 1 |
| Melander, O | 1 |
| Rivera, NV | 1 |
| Condorelli, G | 1 |
| Trimarco, B | 3 |
| Boitsov, SA | 1 |
| Bazaeva, EV | 1 |
| Luk'ianov, MM | 1 |
| Drapkina, OM | 1 |
| Panov, AV | 1 |
| Terent'ev, BP | 1 |
| Tiurin, VP | 1 |
| Shchukina, GN | 1 |
| Korostyshevskaia, IM | 1 |
| Kurganov, SA | 1 |
| Iakobson, GS | 1 |
| Klimas, J | 1 |
| Olvedy, M | 1 |
| Ochodnicka-Mackovicova, K | 1 |
| Kruzliak, P | 1 |
| Krenek, P | 1 |
| Ochodnicky, P | 1 |
| Nakane, H | 1 |
| Kamouchi, M | 1 |
| Hata, J | 1 |
| Ibayashi, S | 1 |
| Kusuda, K | 1 |
| Omae, T | 2 |
| Ago, T | 1 |
| Aoki, Y | 1 |
| Passaglia, P | 1 |
| Ceron, CS | 2 |
| Mecawi, AS | 1 |
| Antunes-Rodrigues, J | 2 |
| Coelho, EB | 3 |
| Tirapelli, CR | 1 |
| Katsuki, M | 1 |
| Milleron, O | 1 |
| Arnoult, F | 1 |
| Ropers, J | 1 |
| Aegerter, P | 1 |
| Detaint, D | 1 |
| Delorme, G | 1 |
| Attias, D | 1 |
| Tubach, F | 1 |
| Dupuis-Girod, S | 1 |
| Plauchu, H | 1 |
| Barthelet, M | 1 |
| Sassolas, F | 1 |
| Pangaud, N | 1 |
| Naudion, S | 1 |
| Thomas-Chabaneix, J | 1 |
| Dulac, Y | 1 |
| Edouard, T | 1 |
| Wolf, JE | 1 |
| Faivre, L | 1 |
| Odent, S | 1 |
| Basquin, A | 1 |
| Habib, G | 1 |
| Collignon, P | 1 |
| Boileau, C | 1 |
| Jondeau, G | 1 |
| Derosa, G | 10 |
| Querci, F | 2 |
| Franzetti, I | 2 |
| Dario Ragonesi, P | 1 |
| D'Angelo, A | 5 |
| Maffioli, P | 5 |
| Nair, AR | 1 |
| Ebenezer, PJ | 1 |
| Saini, Y | 1 |
| Francis, J | 1 |
| Al-Majed, AR | 1 |
| Assiri, E | 1 |
| Khalil, NY | 1 |
| Abdel-Aziz, HA | 1 |
| Qiu, B | 1 |
| Du, JL | 1 |
| Deng, SB | 1 |
| Liu, YJ | 1 |
| She, Q | 1 |
| Forsdyke, DR | 1 |
| Larstorp, AC | 5 |
| Sun, H | 2 |
| Qu, Q | 1 |
| Qu, J | 2 |
| Lou, XY | 1 |
| Peng, Y | 1 |
| Zeng, Y | 1 |
| Wang, G | 1 |
| Mohapatra, A | 1 |
| Matthai, SM | 1 |
| Vijayakumar, K | 1 |
| Basu, G | 1 |
| Jia, J | 1 |
| Men, C | 1 |
| Tang, KT | 1 |
| Zhan, YY | 1 |
| Husarek, KE | 1 |
| Katz, PS | 1 |
| Trask, AJ | 1 |
| Galantowicz, ML | 1 |
| Cismowski, MJ | 1 |
| Lucchesi, PA | 1 |
| Szauder, I | 1 |
| Csajági, E | 1 |
| Major, Z | 1 |
| Pavlik, G | 1 |
| Ujhelyi, G | 1 |
| Minas, JN | 1 |
| Thorwald, MA | 1 |
| Conte, D | 1 |
| Vázquez-Medina, JP | 1 |
| Ortiz, RM | 1 |
| Mugellini, A | 14 |
| Pesce, RM | 2 |
| Bouwer, GT | 1 |
| Seymour, AJ | 1 |
| Korpal, AK | 1 |
| Schwenke, DO | 1 |
| Brown, CH | 1 |
| Vishram, JK | 1 |
| Ibsen, H | 54 |
| Mancia, G | 6 |
| Rothwell, PM | 1 |
| Olsen, MH | 39 |
| Thunström, E | 2 |
| Manhem, K | 3 |
| Rosengren, A | 2 |
| Peker, Y | 3 |
| Palmieri, V | 17 |
| Nieminen, MS | 61 |
| Papademetriou, V | 19 |
| Cicero, AF | 2 |
| Tocci, G | 1 |
| Tchekalarova, JD | 1 |
| Pechlivanova, DM | 1 |
| Kortenska, L | 1 |
| Mitreva, R | 1 |
| Lozanov, V | 1 |
| Stoynev, A | 1 |
| Kelloniemi, A | 1 |
| Aro, J | 2 |
| Näpänkangas, J | 1 |
| Koivisto, E | 1 |
| Mustonen, E | 1 |
| Ruskoaho, H | 5 |
| Rysä, J | 2 |
| Leehey, DJ | 1 |
| Zhang, JH | 1 |
| Emanuele, NV | 1 |
| Whaley-Connell, A | 1 |
| Reilly, RF | 1 |
| Guarino, P | 1 |
| Fried, LF | 1 |
| Souza, RA | 1 |
| Walsh, KR | 1 |
| Kuwabara, JT | 1 |
| Shim, JW | 1 |
| Wainford, RD | 1 |
| Hsing, SC | 1 |
| Lu, KC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Chung, CH | 1 |
| Kao, SY | 1 |
| Zhang, L | 2 |
| He, D | 1 |
| Lin, J | 2 |
| Vokurková, M | 1 |
| Yu, J | 1 |
| Jia, B | 1 |
| Zhao, F | 1 |
| Tang, M | 1 |
| Hu, L | 2 |
| Lin, F | 1 |
| Cifuentes, F | 1 |
| Paredes, A | 1 |
| Palacios, J | 1 |
| Muñoz, F | 1 |
| Carvajal, L | 1 |
| Nwokocha, CR | 1 |
| Morales, G | 1 |
| Toh, N | 1 |
| Ishii, K | 3 |
| Kihara, H | 2 |
| Iwakura, K | 3 |
| Watanabe, H | 3 |
| Yoshikawa, J | 3 |
| Xiao, WY | 1 |
| Ning, N | 1 |
| Tan, MH | 1 |
| Jiang, XS | 1 |
| Zhou, L | 1 |
| Yi, D | 1 |
| Wei, P | 1 |
| Maranon, RO | 2 |
| Reckelhoff, JF | 2 |
| White, DP | 1 |
| Mugendi, GA | 1 |
| Nyamu, DG | 1 |
| Okalebo, FA | 1 |
| Nyamweya, NN | 1 |
| Ndwiga, S | 1 |
| Mwangi, M | 1 |
| Scala, LC | 2 |
| de Mello, RB | 2 |
| Mosele, F | 2 |
| de Alencastro, PR | 1 |
| E Silva, RP | 1 |
| Schlatter, R | 2 |
| Cesarino, EJ | 2 |
| Neto, JA | 1 |
| Neto, AA | 1 |
| Filho, DC | 1 |
| Haga, T | 1 |
| Murakami, T | 2 |
| Kikuya, M | 3 |
| Inoue, R | 2 |
| Mano, N | 1 |
| Ah, YM | 1 |
| Lee, JY | 1 |
| Kong, J | 1 |
| Kim, B | 1 |
| Choi, KH | 2 |
| Han, N | 1 |
| Yu, YM | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Briet, M | 1 |
| Barhoumi, T | 1 |
| Mian, MOR | 1 |
| Coelho, SC | 1 |
| Ouerd, S | 1 |
| Rautureau, Y | 2 |
| Coffman, TM | 1 |
| Paradis, P | 2 |
| Schiffrin, EL | 8 |
| Peotta, V | 1 |
| Rahmouni, K | 1 |
| Segar, JL | 1 |
| Morgan, DA | 1 |
| Pitz, KM | 1 |
| Rice, OM | 1 |
| Roghair, RD | 1 |
| Tanoue, MT | 1 |
| Kopaliani, I | 1 |
| Martin, M | 1 |
| Zatschler, B | 1 |
| Müller, B | 1 |
| Deussen, A | 1 |
| Kamel, H | 1 |
| Savas, Ü | 1 |
| Wei, S | 1 |
| Hsu, MH | 1 |
| Guengerich, FP | 1 |
| Capdevila, JH | 1 |
| Johnson, EF | 1 |
| Göktaş, MT | 1 |
| Pepedil, F | 1 |
| Karaca, Ö | 1 |
| Kalkışım, S | 1 |
| Cevik, L | 1 |
| Gumus, E | 1 |
| Guven, GS | 1 |
| Babaoglu, MO | 1 |
| Bozkurt, A | 1 |
| Yasar, U | 1 |
| Gandhi, H | 1 |
| Naik, P | 1 |
| Agrawal, N | 1 |
| Uzuner, F | 1 |
| Miloradović, Z | 4 |
| Ivanov, M | 3 |
| Jovović, Đ | 1 |
| Karanović, D | 1 |
| Vajić, UJ | 1 |
| Marković-Lipkovski, J | 1 |
| Mihailović-Stanojević, N | 4 |
| Milanović, JG | 2 |
| Yucel-Lindberg, T | 1 |
| Lindberg, C | 1 |
| Nasser, SA | 1 |
| Sabra, R | 1 |
| Elmallah, AI | 1 |
| El-Din, MM | 1 |
| Khedr, MM | 1 |
| El-Mas, MM | 1 |
| Midtbø, H | 1 |
| Zahid, HM | 1 |
| Ohara, H | 1 |
| Isomura, M | 1 |
| Nabika, T | 1 |
| Olson, NJ | 1 |
| Cervinski, MA | 1 |
| Ornstein, DL | 1 |
| Rubio-Guerra, AF | 1 |
| Garro-Almendaro, AK | 1 |
| Elizalde-Barrera, CI | 1 |
| Suarez-Cuenca, JA | 1 |
| Duran-Salgado, MB | 1 |
| Muñoz, MC | 1 |
| Burghi, V | 1 |
| Miquet, JG | 1 |
| Cervino, IA | 1 |
| Quiroga, DT | 1 |
| Mazziotta, L | 1 |
| Dominici, FP | 1 |
| Lian, GL | 1 |
| Lin, X | 1 |
| Zhong, HB | 1 |
| Xie, LD | 1 |
| Talari, G | 1 |
| Talari, P | 1 |
| Sweigart, J | 1 |
| Ahmed, S | 1 |
| Graus-Nunes, F | 1 |
| Rachid, TL | 1 |
| de Oliveira Santos, F | 1 |
| Barbosa-da-Silva, S | 1 |
| Souza-Mello, V | 1 |
| Sepehri, Z | 1 |
| Kiani, Z | 1 |
| Nasiri, AA | 1 |
| Kohan, F | 1 |
| Sheikh Fathollahi, M | 1 |
| Kazemi Arababadi, M | 1 |
| Yadav, VR | 1 |
| Teng, B | 1 |
| Mustafa, JS | 1 |
| Maida, KD | 1 |
| de Araújo, JE | 1 |
| de Souza, HC | 1 |
| Ferket, BS | 1 |
| Hunink, MG | 1 |
| Khanji, M | 1 |
| Agarwal, I | 1 |
| Fleischmann, KE | 1 |
| Petersen, SE | 1 |
| de Leeuw, PW | 4 |
| Fagard, R | 2 |
| Kroon, AA | 2 |
| Xie, Q | 1 |
| Matsushima, T | 1 |
| Nakajima, H | 1 |
| Ohko, K | 1 |
| Nakajima, K | 1 |
| Sano, S | 1 |
| Skibitsky, VV | 1 |
| Fendrikova, AV | 1 |
| Pyhalova, NE | 1 |
| Sirotenko, DV | 1 |
| Lemkens, P | 1 |
| Spijkers, LJ | 1 |
| Meens, MJ | 1 |
| Janssen, B | 1 |
| Peters, SL | 1 |
| Schiffers, PM | 1 |
| De Mey, JG | 1 |
| Sönmez, HM | 1 |
| Turan, FC | 1 |
| Köseoğlu, K | 1 |
| Parving, HH | 11 |
| Persson, F | 1 |
| Lewis, JB | 2 |
| Lewis, EJ | 1 |
| Hollenberg, NK | 1 |
| Zhao, LL | 1 |
| Chen, HJ | 1 |
| Chen, JZ | 2 |
| Yu, M | 4 |
| Ni, YL | 1 |
| Zhang, WF | 1 |
| Wang, Q | 1 |
| Guo, J | 1 |
| Yin, Z | 1 |
| Xu, J | 1 |
| Wu, X | 4 |
| Sun, YX | 1 |
| Chen, M | 1 |
| Schrader, J | 1 |
| Lüders, S | 1 |
| Diener, HC | 3 |
| Haller, H | 1 |
| Schmieder, RE | 5 |
| Wahle, K | 2 |
| Smolka, W | 4 |
| Jung, C | 4 |
| Bestehorn, K | 5 |
| Teschemacher, AG | 1 |
| Raizada, MK | 4 |
| Paton, JF | 3 |
| Kasparov, S | 3 |
| Biederman, RW | 1 |
| Doyle, M | 1 |
| Young, AA | 1 |
| Kortright, E | 1 |
| Perry, G | 1 |
| Bella, JN | 11 |
| Oparil, S | 35 |
| Calhoun, D | 2 |
| Pohost, GM | 1 |
| Dell'Italia, LJ | 2 |
| Porthan, K | 1 |
| Viitasalo, M | 8 |
| Vaananen, H | 1 |
| Dabek, J | 1 |
| Suonsyrja, T | 4 |
| Hannila-Handelberg, T | 4 |
| Virolainen, J | 2 |
| Toivonen, L | 8 |
| Oikarinen, L | 12 |
| Aksnes, TA | 2 |
| Flaa, A | 2 |
| Sevre, K | 1 |
| Mundal, HH | 1 |
| Rostrup, M | 1 |
| Chang, H | 1 |
| Yang, L | 1 |
| Cheng, X | 1 |
| Ma, XL | 1 |
| Waeber, B | 8 |
| Mourad, JJ | 1 |
| Du, Y | 1 |
| Chen, H | 2 |
| Koprdova, R | 1 |
| Cebova, M | 1 |
| Ichida, K | 2 |
| Hosoyamada, M | 1 |
| Yanagihara, K | 1 |
| Sonoyama, K | 1 |
| Sugihara, S | 1 |
| Igawa, O | 3 |
| Hosoya, T | 3 |
| Shigamasa, C | 1 |
| Yamamoto, Y | 2 |
| Ninomiya, H | 2 |
| Uchida, T | 1 |
| Shimizu, M | 1 |
| Sakai, Y | 1 |
| Hara, K | 1 |
| Takebayashi, K | 1 |
| Inoue, T | 2 |
| Node, K | 2 |
| Inukai, T | 1 |
| Aso, Y | 1 |
| Hasbún H, J | 1 |
| Valdés R, E | 1 |
| San Martín O, A | 1 |
| Catalán M, J | 1 |
| Salinas Q, S | 1 |
| Parra C, M | 1 |
| Abdulla, MH | 2 |
| Sattar, MA | 2 |
| Abdullah, NA | 2 |
| Hazim, AI | 1 |
| Anand Swarup, KR | 1 |
| Rathore, HA | 1 |
| Khan, MA | 3 |
| Johns, EJ | 4 |
| Siegl, PK | 2 |
| Kivlighn, SD | 2 |
| Broten, TP | 1 |
| Mallion, JM | 4 |
| Bradstreet, DC | 2 |
| Makris, L | 2 |
| Goldberg, AI | 12 |
| Halasz, S | 1 |
| Sweet, CS | 13 |
| Lim, NY | 2 |
| Madonna, O | 2 |
| Schoenberger, JA | 1 |
| Ramsay, LE | 3 |
| Yeo, WW | 2 |
| Dunlay, MC | 3 |
| Kloner, RA | 1 |
| Neutel, J | 1 |
| Roth, EM | 1 |
| Weiss, R | 1 |
| Weinberger, MH | 2 |
| Thakker, KM | 1 |
| Schwartz, B | 1 |
| Gregg, AM | 1 |
| Shiraishi, H | 1 |
| Shirayama, T | 2 |
| Kuroyanagi, A | 1 |
| Matsubara, H | 5 |
| Zietkiewicz, M | 1 |
| Larczyński, W | 1 |
| Yin, T | 1 |
| Maekawa, K | 1 |
| Saito, Y | 1 |
| Hanada, H | 1 |
| Miyashita, K | 2 |
| Kokubo, Y | 1 |
| Akaiwa, Y | 1 |
| Otsubo, R | 1 |
| Nagatsuka, K | 1 |
| Otsuki, T | 1 |
| Minematsu, K | 1 |
| Naritomi, H | 7 |
| Tomoike, H | 1 |
| Sawada, J | 1 |
| Miyata, T | 1 |
| Baumann, M | 3 |
| Rob Hermans, JJ | 1 |
| Bartholome, R | 1 |
| Smits, JF | 3 |
| Struijker Boudier, HA | 2 |
| Tang, TF | 2 |
| Zhou, QL | 2 |
| Zhu, LL | 1 |
| Tang, R | 3 |
| Ao, X | 2 |
| Fujita, T | 5 |
| Ito, S | 7 |
| Ogihara, T | 10 |
| Shimamoto, K | 7 |
| Tanaka, H | 8 |
| Yoshiike, N | 5 |
| Kojima, T | 1 |
| Akishita, M | 1 |
| Iijima, K | 1 |
| Eto, M | 1 |
| Ouchi, Y | 1 |
| Kobayashi, T | 2 |
| Nogami, T | 1 |
| Taguchi, K | 1 |
| Ikeda, H | 3 |
| Hamamoto, Y | 2 |
| Honjo, S | 2 |
| Nabe, K | 2 |
| Wada, Y | 3 |
| Koshiyama, H | 2 |
| Krupicka, J | 1 |
| Ceypová, K | 1 |
| Kristenová, P | 1 |
| Hauser, T | 1 |
| Minamikawa, J | 1 |
| Nakamura, Y | 5 |
| Beevers, G | 15 |
| de Faire, U | 23 |
| Fyhrquist, F | 27 |
| Lederballe-Pedersen, O | 21 |
| Narayan, P | 3 |
| Omvik, P | 27 |
| Wedel, H | 19 |
| Anguita, M | 1 |
| Toledano, F | 1 |
| León, C | 1 |
| Castillo, JC | 1 |
| Gabor, A | 1 |
| Leenen, FH | 6 |
| Park, YM | 1 |
| Lim, BH | 1 |
| Park, JB | 3 |
| Xia, H | 1 |
| Obr, TD | 1 |
| Hickman, PJ | 1 |
| Lazartigues, E | 2 |
| Brandish, PE | 1 |
| Forest, TW | 1 |
| Gatto, NT | 1 |
| Molon-Noblot, S | 1 |
| Zwierzynski, I | 1 |
| Szczerba, P | 1 |
| Adamson, GE | 1 |
| Ma, BK | 1 |
| Flores, OA | 1 |
| Hershey, JC | 1 |
| Solomon, SD | 2 |
| Appelbaum, E | 2 |
| Manning, WJ | 1 |
| Verma, A | 1 |
| Berglund, T | 1 |
| Lukashevich, V | 2 |
| Cherif Papst, C | 1 |
| Smith, BA | 2 |
| Susic, D | 2 |
| Frohlich, ED | 2 |
| Senador, D | 1 |
| Kanakamedala, K | 1 |
| Irigoyen, MC | 2 |
| Morris, M | 1 |
| Elased, KM | 1 |
| Csiky, B | 1 |
| Markó, L | 1 |
| Mohás, M | 1 |
| Cseh, J | 1 |
| Mikolás, E | 1 |
| Szíjártó, I | 1 |
| Wittmann, I | 1 |
| Claassen, JA | 2 |
| Levine, BD | 3 |
| Minami, J | 4 |
| Furukata, S | 2 |
| Ishimitsu, T | 4 |
| Bönner, G | 1 |
| Uzu, T | 2 |
| Sakaguchi, M | 1 |
| Yokomaku, Y | 1 |
| Kume, S | 2 |
| Kanasaki, M | 1 |
| Isshiki, K | 2 |
| Araki, SI | 1 |
| Sugiomoto, T | 1 |
| Koya, D | 2 |
| Haneda, M | 4 |
| Kashiwagi, A | 2 |
| Lyle, PA | 16 |
| Silva, KC | 2 |
| Rosales, MA | 1 |
| Biswas, SK | 2 |
| Lopes de Faria, JB | 1 |
| Lopes de Faria, JM | 1 |
| Wu, ZL | 1 |
| Xu, DL | 1 |
| Lai, WY | 1 |
| Huang, P | 1 |
| Bai, SC | 1 |
| Su, L | 2 |
| Gallego-Delgado, J | 2 |
| Connolly, SB | 1 |
| Lázaro, A | 2 |
| Sadlier, D | 1 |
| Kieran, NE | 1 |
| Sugrue, DD | 1 |
| Doran, P | 1 |
| Brady, HR | 1 |
| Osende, J | 1 |
| Egido, J | 3 |
| Kohlmann, O | 3 |
| Roca-Cusachs, A | 3 |
| Laurent, S | 3 |
| Wenzel, RR | 2 |
| Fogari, R | 13 |
| Erbanová, M | 1 |
| Thumová, M | 2 |
| Husková, Z | 4 |
| Vanourková, Z | 4 |
| Kramer, HJ | 5 |
| Bürgelová, M | 1 |
| Rakusan, D | 3 |
| Edelman, JM | 22 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Colombari, E | 1 |
| Menani, JV | 2 |
| Kemuriyama, T | 1 |
| Tandai-Hiruma, M | 1 |
| Kato, K | 1 |
| Ohta, H | 2 |
| Maruyama, S | 1 |
| Sato, Y | 2 |
| Olofsson, M | 2 |
| Hultström, M | 1 |
| Helle, F | 1 |
| Iversen, BM | 2 |
| Choi, SM | 1 |
| Seo, MJ | 1 |
| Kang, KK | 1 |
| Kim, JH | 2 |
| Ahn, BO | 1 |
| Yoo, M | 1 |
| Okano, Y | 4 |
| Kuji, T | 1 |
| Masuda, S | 4 |
| Tochikubo, O | 3 |
| Fan, WH | 3 |
| Ngau, YY | 1 |
| Tong, P | 1 |
| Kim, BS | 1 |
| Santos, M | 1 |
| Lin, WH | 1 |
| Buranakitjaroen, P | 1 |
| Nixon, RM | 1 |
| Müller, E | 1 |
| Lowy, A | 1 |
| Falvey, H | 2 |
| Mitsuhashi, H | 1 |
| Yamauchi, J | 1 |
| Ozawa, M | 2 |
| Yanagi, M | 2 |
| Dejima, T | 2 |
| Kanaoka, T | 2 |
| Maeda, A | 2 |
| Tsurumi-Ikeya, Y | 1 |
| Ishigami, T | 1 |
| Ohnishi, T | 1 |
| Gersak, K | 1 |
| Cvijic, M | 1 |
| Cerar, LK | 1 |
| García-Redondo, AB | 1 |
| Briones, AM | 2 |
| Avendaño, MS | 1 |
| Hernanz, R | 2 |
| Vítovec, J | 1 |
| Soucek, M | 2 |
| Dusek, L | 1 |
| Pavlík, T | 1 |
| Pareek, A | 1 |
| Basavanagowdappa, H | 1 |
| Zawar, S | 1 |
| Kumar, A | 1 |
| Chandurkar, N | 1 |
| Jessup, JA | 1 |
| Westwood, BM | 1 |
| Chappell, MC | 3 |
| Groban, L | 1 |
| Keating, GM | 2 |
| Queiroz-Madeira, EP | 1 |
| Lara, LS | 1 |
| Wengert, M | 2 |
| Landgraf, SS | 2 |
| Líbano-Soares, JD | 1 |
| Zapata-Sudo, G | 2 |
| Sudo, RT | 2 |
| Takiya, CM | 2 |
| Gomes-Quintana, E | 1 |
| Lopes, AG | 1 |
| Caruso-Neves, C | 2 |
| Franklin, S | 1 |
| Rieck, A | 1 |
| Nieminen, M | 1 |
| Cangussu, LM | 1 |
| de Castro, UG | 1 |
| do Pilar Machado, R | 1 |
| Silva, ME | 1 |
| Ferreira, PM | 1 |
| dos Santos, RA | 2 |
| Campagnole-Santos, MJ | 1 |
| Arase, Y | 1 |
| Suzuki, F | 1 |
| Suzuki, Y | 2 |
| Akuta, N | 1 |
| Kobayashi, M | 3 |
| Kawamura, Y | 1 |
| Yatsuji, H | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Hirakawa, M | 1 |
| Saito, S | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Abe, M | 4 |
| Okada, K | 4 |
| Maruyama, T | 2 |
| Matsumoto, K | 5 |
| Park, D | 1 |
| Jeon, JH | 2 |
| Choi, BH | 1 |
| Jang, MJ | 1 |
| Joo, SS | 1 |
| Oh, KW | 1 |
| Hong, JT | 1 |
| Suh, KH | 1 |
| Kim, YB | 1 |
| Parrinello, G | 4 |
| Paterna, S | 4 |
| Torres, D | 1 |
| Di Pasquale, P | 3 |
| Mezzero, M | 1 |
| La Rocca, G | 1 |
| Cardillo, M | 1 |
| Trapanese, C | 1 |
| Caradonna, M | 1 |
| Licata, G | 5 |
| Sica, DA | 3 |
| Harada, N | 1 |
| Shimozawa, N | 1 |
| Okajima, K | 1 |
| Andersen, NH | 1 |
| Svendsen, TL | 1 |
| Han, WQ | 1 |
| Wu, LY | 1 |
| Zhou, HY | 2 |
| Che, ZQ | 1 |
| Wu, YJ | 1 |
| Liu, JJ | 1 |
| Zhu, DL | 2 |
| Gao, PJ | 1 |
| Morin, DP | 1 |
| John, M | 1 |
| Wenzel, P | 1 |
| Schulz, E | 2 |
| Münzel, T | 2 |
| Kappert, K | 1 |
| Tsuprykov, O | 1 |
| Kaufmann, J | 1 |
| Fritzsche, J | 1 |
| Ott, I | 1 |
| Goebel, M | 1 |
| Bähr, IN | 1 |
| Hässle, PL | 1 |
| Gust, R | 1 |
| Fleck, E | 1 |
| Unger, T | 7 |
| Stawowy, P | 1 |
| Kintscher, U | 2 |
| Fortuño, A | 2 |
| Bidegain, J | 1 |
| Robador, PA | 1 |
| Hermida, J | 1 |
| López-Sagaseta, J | 1 |
| Beloqui, O | 3 |
| Díez, J | 15 |
| Zalba, G | 4 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Kinouchi, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Itoh, H | 2 |
| Calò, LA | 1 |
| Schiavo, S | 1 |
| Davis, PA | 1 |
| Pagnin, E | 1 |
| Mormino, P | 1 |
| Pessina, AC | 1 |
| Osorio, H | 1 |
| Franco, M | 1 |
| Santamaría, J | 1 |
| Chinali, M | 1 |
| Mishra, RK | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Kodama, S | 1 |
| Inoue, Y | 2 |
| Sumi, S | 1 |
| Okamura, K | 1 |
| Tojyo, H | 1 |
| Ando, C | 1 |
| Niimura, H | 1 |
| Tsuchiya, Y | 3 |
| Mihara, H | 1 |
| Yamanouchi, Y | 1 |
| Urata, H | 1 |
| Weir, MR | 6 |
| Yeh, F | 1 |
| Silverman, A | 1 |
| Galloway, JM | 1 |
| Henderson, JA | 1 |
| Howard, WJ | 1 |
| Russell, M | 1 |
| Wilson, C | 1 |
| Ratner, R | 1 |
| Sorkin, J | 1 |
| Umans, JG | 2 |
| Fleg, JL | 1 |
| Stylianou, M | 1 |
| Lee, E | 1 |
| Howard, BV | 1 |
| Boman, JH | 1 |
| Andersson, J | 1 |
| Bubnova, MG | 1 |
| Oganov, RG | 1 |
| Stålhammar, J | 3 |
| Hasvold, P | 3 |
| Bodegard, J | 3 |
| Olsson, U | 1 |
| Russell, D | 3 |
| Grujić-Milanović, J | 1 |
| Jovović, D | 3 |
| Kang, DW | 1 |
| Bae, HJ | 1 |
| Han, MK | 1 |
| Park, JM | 1 |
| Rha, JH | 1 |
| Koo, JS | 1 |
| Cho, YJ | 1 |
| Kwon, SU | 1 |
| Kim, SE | 1 |
| Mehdi, UF | 1 |
| Adams-Huet, B | 1 |
| Raskin, P | 1 |
| Vega, GL | 1 |
| Toto, RD | 1 |
| Snapinn, SM | 12 |
| Neldam, S | 4 |
| Hitomi, H | 1 |
| Bocanegra, V | 1 |
| Manucha, W | 1 |
| Peña, MR | 1 |
| Cacciamani, V | 1 |
| Vallés, PG | 1 |
| Meredith, PA | 3 |
| Murray, LS | 1 |
| McInnes, GT | 2 |
| Owens, AP | 1 |
| Subramanian, V | 1 |
| Moorleghen, JJ | 1 |
| Guo, Z | 2 |
| McNamara, CA | 1 |
| Cassis, LA | 2 |
| Daugherty, A | 1 |
| Woo, KT | 1 |
| Wong, KS | 1 |
| Chan, CM | 1 |
| Bramlage, P | 2 |
| Schindler, C | 1 |
| Huang, X | 1 |
| Fang, F | 1 |
| Chen, B | 1 |
| Cai, J | 1 |
| Shi, X | 1 |
| Geng, YJ | 1 |
| Cheng, WH | 1 |
| Lu, PJ | 1 |
| Tung, CS | 1 |
| Hsiao, M | 1 |
| Nordestgaard, BG | 1 |
| Benn, M | 1 |
| Eliasson, E | 1 |
| Berg, K | 1 |
| Sandberg, M | 1 |
| Sethi, AA | 1 |
| Wong, PH | 1 |
| Os, I | 7 |
| Kita, T | 2 |
| Yokota, N | 2 |
| Ichiki, Y | 2 |
| Ayabe, T | 2 |
| Etoh, T | 2 |
| Tamaki, N | 2 |
| Eto, T | 2 |
| Loeys, T | 1 |
| Strehlau, J | 2 |
| Santoro, E | 1 |
| Manas, D | 1 |
| Gleim, GW | 5 |
| Sabharwal, R | 1 |
| Zhang, Z | 6 |
| Abboud, FM | 2 |
| Russo, AF | 1 |
| Chapleau, MW | 2 |
| Racine, N | 1 |
| Hamet, P | 7 |
| Sampalis, JS | 1 |
| Longo, N | 1 |
| Bastien, N | 1 |
| Guo, F | 1 |
| Liu, B | 2 |
| Tang, F | 1 |
| Lane, S | 1 |
| Souslova, EA | 1 |
| Chudakov, DM | 1 |
| Shams, MS | 1 |
| Alam, MI | 1 |
| Ali, A | 1 |
| Sultana, Y | 1 |
| Aqil, M | 1 |
| Weiss, J | 1 |
| Sauer, A | 1 |
| Divac, N | 1 |
| Herzog, M | 1 |
| Schwedhelm, E | 1 |
| Böger, RH | 2 |
| Haefeli, WE | 2 |
| Benndorf, RA | 1 |
| Williams, DE | 1 |
| Prieto, MC | 1 |
| Navar, LG | 2 |
| Mitchell, KD | 1 |
| Toney, GM | 3 |
| Pedrino, GR | 1 |
| Fink, GD | 3 |
| Osborn, JW | 1 |
| Preti, P | 6 |
| Zoppi, A | 10 |
| Kondo, T | 1 |
| Hirai, M | 1 |
| Shigemasa, C | 1 |
| Politi, AP | 1 |
| Zervou, MV | 1 |
| Triantafyllidi, H | 1 |
| Zoumpoulakis, PG | 1 |
| Mavromoustakos, TM | 1 |
| Zoga, AA | 1 |
| Moutevelis-Minakakis, P | 1 |
| Kokotos, G | 1 |
| Iliodromitis, EK | 1 |
| Kremastinos, DT | 1 |
| Huang, F | 1 |
| Lezama, MA | 1 |
| Ontiveros, JA | 1 |
| Bravo, G | 1 |
| Villafaña, S | 1 |
| del-Rio-Navarro, BE | 1 |
| Hong, E | 1 |
| Henriksson, M | 1 |
| Kjeldsen, S | 4 |
| Levin, LÅ | 1 |
| Belous, AS | 1 |
| Pokrovskii, MV | 1 |
| Pokrovskaya, TG | 1 |
| Kochkarov, VI | 1 |
| Artyushkova, EB | 1 |
| Pashin, EN | 1 |
| Zhavbert, ES | 2 |
| Tarasov, SA | 1 |
| Dugina, YL | 2 |
| Kachanova, MV | 2 |
| Sergeeva, SA | 2 |
| Epshtein, OI | 2 |
| Medvedeva, NA | 1 |
| Artem'eva, MM | 1 |
| Kheyfets, IA | 1 |
| Sabanov, LB | 1 |
| Zabolotneva, YA | 1 |
| Escano, CS | 1 |
| Yang, Z | 2 |
| Asico, L | 1 |
| Jones, JE | 2 |
| Armando, I | 1 |
| Lu, Q | 1 |
| Sibley, DR | 1 |
| Eisner, GM | 3 |
| Jose, PA | 3 |
| Rokkedal, JE | 2 |
| Maniadakis, N | 1 |
| Ekman, M | 1 |
| Fragoulakis, V | 1 |
| Papagiannopoulou, V | 1 |
| Yfantopoulos, J | 1 |
| Søraas, CL | 1 |
| Tønnessen, T | 2 |
| Høieggen, A | 7 |
| Lindholm, L | 1 |
| Rybczynska, A | 1 |
| Jurska-Jasko, A | 1 |
| Boblewski, K | 1 |
| Lehmann, A | 1 |
| Orlewska, C | 1 |
| Łukawski, K | 1 |
| Janowska, A | 1 |
| Jakubus, T | 1 |
| Tochman-Gawda, A | 1 |
| Czuczwar, SJ | 1 |
| Cicala, S | 2 |
| Jiménez-Ferrer, E | 1 |
| Badillo, FH | 1 |
| González-Cortazar, M | 1 |
| Tortoriello, J | 1 |
| Herrera-Ruiz, M | 1 |
| Riggio, S | 1 |
| D'Ascola, A | 1 |
| Alibrandi, A | 1 |
| Saitta, C | 1 |
| Castaldo, M | 1 |
| Cinquegrani, M | 1 |
| An, J | 1 |
| Nakajima, T | 1 |
| Kuba, K | 1 |
| Kimura, A | 1 |
| Siragy, HM | 2 |
| Ambrosioni, E | 2 |
| Bombelli, M | 1 |
| Cerasola, G | 2 |
| Cipollone, F | 1 |
| Grazioli, I | 1 |
| Leprotti, C | 1 |
| Melzi, G | 1 |
| Mulè, G | 2 |
| Palasciano, G | 1 |
| Salvetti, A | 1 |
| Agelis, G | 1 |
| Roumelioti, P | 3 |
| Resvani, A | 1 |
| Durdagi, S | 1 |
| Androutsou, ME | 1 |
| Kelaidonis, K | 1 |
| Vlahakos, D | 2 |
| Mavromoustakos, T | 4 |
| Matsoukas, J | 3 |
| Kujal, P | 2 |
| Vernerová, Z | 2 |
| Mrázová, I | 1 |
| Parati, G | 2 |
| Giglio, A | 1 |
| Lonati, L | 1 |
| Destro, M | 3 |
| Ricci, AR | 1 |
| Cagnoni, F | 1 |
| Pini, C | 1 |
| Venco, A | 3 |
| Maresca, AM | 1 |
| Monza, M | 1 |
| Grandi, AM | 3 |
| Omboni, S | 1 |
| Yanes, LL | 1 |
| Romero, DG | 1 |
| Iliescu, R | 2 |
| Davis, D | 1 |
| de Cavanagh, EM | 2 |
| Ferder, LF | 1 |
| Ferder, MD | 1 |
| Stella, IY | 1 |
| Toblli, JE | 3 |
| Inserra, F | 2 |
| Hu, ZP | 1 |
| Wang, BN | 1 |
| Qian, HY | 1 |
| Zhou, Q | 3 |
| Wei, W | 1 |
| Ulusoy, S | 1 |
| Ozkan, G | 1 |
| Orem, C | 1 |
| Kaynar, K | 1 |
| Koşucu, P | 1 |
| Kiriş, A | 1 |
| Ferreira, DN | 1 |
| Katayama, IA | 1 |
| Oliveira, IB | 1 |
| Rosa, KT | 1 |
| Furukawa, LN | 1 |
| Coelho, MS | 1 |
| Heimann, JC | 1 |
| Kazim, SF | 1 |
| Shahid, M | 1 |
| Lazzari, P | 6 |
| Liao, M | 1 |
| Li, S | 2 |
| Pan, W | 2 |
| Sodhi, K | 1 |
| Wu, CC | 1 |
| Gotlinger, K | 1 |
| Inoue, K | 1 |
| Goli, M | 1 |
| Abraham, NG | 1 |
| Vieira, AA | 1 |
| Nahey, DB | 1 |
| Collister, JP | 1 |
| Chábová, VČ | 1 |
| Walkowska, A | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Kinoshita, H | 1 |
| Kobayashi, K | 4 |
| Yaguramaki, T | 1 |
| Yasuda, M | 1 |
| Fujiki, K | 1 |
| Tomiyama, J | 1 |
| Koga, N | 1 |
| Yakushiji, F | 1 |
| da Silva, AQ | 1 |
| Fontes, MA | 1 |
| Kanagy, NL | 1 |
| Ortega, KC | 2 |
| Gusmão, JL | 1 |
| Pierin, AM | 1 |
| Nishiura, JL | 1 |
| Ignez, EC | 1 |
| Segre, CA | 1 |
| Ventura, CG | 1 |
| Mano, GP | 1 |
| Fontes, V | 1 |
| Cunha, FM | 1 |
| Mion, D | 3 |
| Yoshida, C | 1 |
| Goda, A | 1 |
| Naito, Y | 1 |
| Nakaboh, A | 1 |
| Matsumoto, M | 3 |
| Otsuka, M | 1 |
| Ohyanagi, M | 1 |
| Hirotani, S | 1 |
| Lee-Kawabata, M | 1 |
| Tsujino, T | 1 |
| Masuyama, T | 1 |
| Hata, T | 2 |
| Soga, J | 2 |
| Hidaka, T | 2 |
| Idei, N | 2 |
| Fujii, Y | 2 |
| Fujimura, N | 2 |
| Mikami, S | 2 |
| Maruhashi, T | 2 |
| Kihara, Y | 2 |
| Chayama, K | 2 |
| Kato, H | 2 |
| Noma, K | 2 |
| Liao, JK | 2 |
| Yabana, M | 1 |
| Silva, JS | 1 |
| Pinheiro, AA | 1 |
| de Paula, WX | 1 |
| Denadai, AM | 1 |
| Santoro, MM | 1 |
| Braga, AN | 1 |
| Santos, RA | 2 |
| Sinisterra, RD | 1 |
| Tripodi, G | 1 |
| Ferrandi, M | 1 |
| Messaggio, E | 1 |
| Staessen, JA | 1 |
| Macciardi, F | 2 |
| Valentini, G | 1 |
| Ferrari, P | 1 |
| Bianchi, G | 1 |
| Ferrari, I | 1 |
| Palumbo, I | 1 |
| Randazzo, S | 1 |
| Fogari, E | 4 |
| Handler, J | 2 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 3 |
| Rihácek, I | 1 |
| Frána, P | 1 |
| Schwarz, D | 1 |
| Plachý, M | 1 |
| Hirose, H | 1 |
| Kawabe, H | 1 |
| Saito, I | 2 |
| Du, YX | 1 |
| Wang, XX | 1 |
| Li, SP | 1 |
| Moon, JC | 2 |
| Flett, AS | 1 |
| Godman, BB | 1 |
| Grosso, AM | 2 |
| Wierzbicki, AS | 1 |
| Moulder, JE | 1 |
| Cohen, EP | 1 |
| Fish, BL | 1 |
| Bodalia, PN | 1 |
| Macallister, RJ | 1 |
| Hingorani, AD | 1 |
| Scott, MA | 1 |
| Minhas, R | 1 |
| Pitt, B | 1 |
| Le Bailly De Tilleghem, C | 1 |
| Punzi, HA | 2 |
| Flack, JM | 5 |
| Stoakes, KA | 1 |
| Chavanu, KJ | 3 |
| Dubiel, R | 2 |
| Nemati, F | 1 |
| Rahbar-Roshandel, N | 1 |
| Hosseini, F | 1 |
| Mahmoudian, M | 1 |
| Shafiei, M | 1 |
| Xiao, Z | 1 |
| Pouranan, V | 1 |
| Bortolotto, L | 1 |
| Consolim-Colombo, F | 1 |
| Moreno, H | 1 |
| Franco, R | 2 |
| Ribeiro, AL | 1 |
| Mota, M | 1 |
| Ghizzoni, F | 1 |
| Thuresson, M | 1 |
| Grujic Milanovic, J | 1 |
| Nunes, FC | 1 |
| Braga, VA | 1 |
| Naunheim, MR | 1 |
| Walcott, BP | 1 |
| Nahed, BV | 1 |
| MacRae, CA | 1 |
| Levinson, JR | 1 |
| Ogilvy, CS | 1 |
| Desvigne-Nickens, P | 1 |
| Burnier, M | 7 |
| Wuerzner, G | 1 |
| Holtkamp, FA | 2 |
| de Zeeuw, D | 7 |
| de Graeff, PA | 2 |
| Laverman, GD | 2 |
| Berl, T | 1 |
| Remuzzi, G | 3 |
| Packham, D | 1 |
| Lambers Heerspink, HJ | 3 |
| Thomas, MC | 1 |
| Cooper, ME | 5 |
| Hillege, HJ | 1 |
| Brenner, BM | 6 |
| Yamada, Y | 3 |
| Tsuboi, K | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Ohtake, M | 1 |
| Furukawa, M | 1 |
| Ueyama, J | 1 |
| Nagata, K | 1 |
| Huber, DA | 1 |
| Schreihofer, AM | 1 |
| Circelli, M | 1 |
| Cremonesi, G | 1 |
| Miao, Y | 1 |
| Ottenbros, SA | 1 |
| Grobbee, DE | 1 |
| Park, HW | 2 |
| Kim, Y | 2 |
| Rozen, S | 2 |
| Najafian, B | 1 |
| Mauer, M | 2 |
| Peng, WS | 1 |
| Veeraragoo, P | 1 |
| Sakima, A | 2 |
| Ohshiro, K | 2 |
| Nakada, S | 2 |
| Yamazato, M | 2 |
| Kohagura, K | 2 |
| Nakamoto, M | 1 |
| Tana, T | 2 |
| Ohya, Y | 2 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Pouleur, AC | 1 |
| Uno, H | 2 |
| Prescott, MF | 1 |
| Desai, A | 2 |
| Mitsutake, R | 2 |
| Jarvis, SC | 1 |
| Lund, BP | 1 |
| Corradi, L | 5 |
| Takano, H | 2 |
| Narumi, H | 1 |
| Ohtsuka, M | 1 |
| Mizuguchi, T | 1 |
| Namiki, T | 1 |
| Kobayashi, Y | 2 |
| Komuro, I | 2 |
| Ohno, E | 1 |
| Nakano, N | 3 |
| Akashiba, A | 2 |
| Numabe, A | 1 |
| Wright, RF | 1 |
| Duprez, D | 2 |
| Purkayastha, D | 2 |
| Samuel, R | 2 |
| Ferdinand, KC | 1 |
| Kamura, A | 1 |
| Kuroki, S | 1 |
| Ishida, S | 1 |
| Iimori, K | 1 |
| Kato, T | 2 |
| Naitoh, H | 1 |
| Tamesue, S | 1 |
| Lee, YC | 1 |
| Chang, HH | 1 |
| Chiang, CL | 1 |
| Liu, CH | 1 |
| Yeh, JI | 1 |
| Chen, MF | 1 |
| Chen, PY | 1 |
| Kuo, JS | 1 |
| Lee, TJ | 1 |
| Perlstein, TS | 1 |
| Henry, RR | 1 |
| Mather, KJ | 1 |
| Rickels, MR | 1 |
| Abate, NI | 1 |
| Grundy, SM | 1 |
| Mai, Y | 1 |
| Albu, JB | 1 |
| Marks, JB | 1 |
| Pool, JL | 1 |
| Creager, MA | 2 |
| Khan, BV | 1 |
| Venegas-Pont, M | 1 |
| Mathis, KW | 1 |
| Ray, WH | 1 |
| Glover, PH | 1 |
| Ryan, MJ | 1 |
| Grande, MT | 1 |
| Pascual, G | 1 |
| Riolobos, AS | 1 |
| Clemente-Lorenzo, M | 1 |
| Bardaji, B | 1 |
| Barreiro, L | 1 |
| Tornavaca, O | 1 |
| Meseguer, A | 1 |
| López-Novoa, JM | 2 |
| Rajzer, M | 2 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 2 |
| Undas, A | 1 |
| Palma-Rigo, K | 1 |
| Jackson, KL | 1 |
| Davern, PJ | 1 |
| Nguyen-Huu, TP | 1 |
| Elghozi, JL | 4 |
| Head, GA | 2 |
| Khan, M | 1 |
| Khan, RA | 1 |
| Islam, F | 1 |
| Laghari, J | 1 |
| Jamali, SN | 1 |
| Zhang, HG | 1 |
| Cheng, YQ | 1 |
| Zhou, JZ | 1 |
| Wang, XQ | 2 |
| Girndt, M | 1 |
| Kasayuki, N | 1 |
| Nakamura, F | 1 |
| Fukuda, S | 2 |
| Ram, CV | 1 |
| Ramaswamy, K | 1 |
| Qian, C | 1 |
| Biskupiak, J | 1 |
| Ryan, A | 1 |
| Quah, R | 1 |
| Russo, PA | 1 |
| Ariansen, I | 2 |
| Reims, HM | 6 |
| Gjesdal, K | 2 |
| Shimizu, R | 1 |
| Miyazaki, M | 2 |
| Iwanaga, K | 1 |
| Kakemi, M | 1 |
| Baker, TM | 1 |
| Goh, J | 1 |
| Johnston, A | 1 |
| Brede, Y | 1 |
| Brown, RE | 1 |
| Dhaun, N | 1 |
| Kuriyama, S | 2 |
| Ohno, I | 2 |
| Kawamura, T | 2 |
| Ogura, M | 1 |
| Ikeda, M | 1 |
| Ishikawa, M | 1 |
| Hayashi, F | 1 |
| Kanai, T | 1 |
| Tomonari, H | 1 |
| Soejima, M | 1 |
| Akaba, K | 1 |
| Tokudome, G | 1 |
| Endo, S | 2 |
| Fukui, A | 1 |
| Gomi, H | 1 |
| Hamaguchi, A | 1 |
| Hara, Y | 2 |
| Hayakawa, H | 1 |
| Hikida, M | 1 |
| Hirano, K | 1 |
| Horiguchi, M | 1 |
| Hosoya, M | 1 |
| Imai, T | 1 |
| Ishii, T | 2 |
| Ishikawa, H | 1 |
| Kameda, C | 1 |
| Kasai, T | 1 |
| Kobayashi, A | 2 |
| Kobayashi, H | 2 |
| Kurashige, M | 1 |
| Kusama, Y | 1 |
| Maezawa, H | 1 |
| Maezawa, Y | 1 |
| Maruyama, Y | 1 |
| Matsuda, H | 1 |
| Matsuo, N | 1 |
| Matsuo, T | 1 |
| Miura, Y | 2 |
| Miyajima, M | 1 |
| Miyakawa, M | 2 |
| Miyazaki, Y | 1 |
| Mizuguchi, M | 1 |
| Nakao, M | 1 |
| Nokano, H | 1 |
| Ohkido, I | 1 |
| Ohtsuka, Y | 1 |
| Okamoto, H | 2 |
| Okonogi, H | 1 |
| Saikawa, H | 1 |
| Saito, H | 1 |
| Sekiguchi, C | 1 |
| Suetsugu, Y | 1 |
| Sugano, N | 1 |
| Suzuki, T | 3 |
| Takahashi, H | 1 |
| Takamizawa, S | 1 |
| Takane, K | 1 |
| Morita, T | 2 |
| Takazoe, K | 1 |
| Tanaka, S | 1 |
| Terawaki, H | 1 |
| Toyoshima, R | 1 |
| Tsuboi, N | 1 |
| Udagawa, T | 1 |
| Ueda, H | 1 |
| Ueda, Y | 1 |
| Uetake, M | 1 |
| Unemura, S | 1 |
| Utsunomiya, M | 1 |
| Utsunomiya, Y | 1 |
| Yamada, T | 2 |
| Yamaguchi, Y | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Yokoyama, K | 1 |
| Yonezawa, H | 1 |
| Yoshida, H | 2 |
| Yoshida, M | 1 |
| Yoshizawa, T | 2 |
| Fujimori, S | 1 |
| Oka, Y | 1 |
| Ogata, N | 1 |
| Eto, K | 2 |
| Youn, JC | 1 |
| Yang, JY | 3 |
| Jeong, JW | 2 |
| Jung, JW | 1 |
| Yoon, JH | 2 |
| Kwon, J | 1 |
| Cho, SY | 3 |
| Ferdinand, K | 1 |
| Wright, R | 1 |
| Rehman, A | 2 |
| Leibowitz, A | 1 |
| Yamamoto, N | 2 |
| Meno, H | 2 |
| Inou, T | 2 |
| Tanaka, M | 2 |
| Ota, T | 2 |
| Kubara, I | 2 |
| Li, D | 4 |
| Scott, L | 1 |
| Crambert, S | 1 |
| Zelenin, S | 1 |
| Eklöf, AC | 1 |
| Di Ciano, L | 1 |
| Ibarra, F | 1 |
| Aperia, A | 1 |
| Lo, CS | 1 |
| Shi, Y | 1 |
| Maachi, H | 1 |
| Chenier, I | 1 |
| Godin, N | 1 |
| Filep, JG | 2 |
| Ingelfinger, JR | 3 |
| Zhang, SL | 2 |
| Chan, JS | 2 |
| Adam, WR | 1 |
| Merino, A | 1 |
| Alvarez-Lara, MA | 1 |
| Ramirez, R | 1 |
| Carracedo, J | 1 |
| Martin-Malo, A | 1 |
| Aljama, P | 1 |
| Tsuji, RL | 1 |
| Silva, GV | 1 |
| Mion Júnior, D | 1 |
| Kameda, Y | 1 |
| Kubota, A | 1 |
| Garcia-Touza, M | 1 |
| Sowers, JR | 2 |
| Deji, N | 1 |
| Araki, S | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Maegawa, H | 1 |
| Shi, RZ | 1 |
| Hu, CP | 1 |
| Luo, D | 2 |
| Li, SX | 1 |
| Yang, TL | 2 |
| Li, YJ | 2 |
| Zhang, GG | 1 |
| Campuzano, V | 1 |
| Segura-Puimedon, M | 1 |
| Terrado, V | 1 |
| Sánchez-Rodríguez, C | 1 |
| Coustets, M | 1 |
| Menacho-Márquez, M | 1 |
| Nevado, J | 1 |
| Bustelo, XR | 1 |
| Francke, U | 1 |
| Pérez-Jurado, LA | 1 |
| Girerd, X | 1 |
| Rosenbaum, D | 1 |
| Aoun, J | 1 |
| Ring, T | 1 |
| Hirsch, S | 1 |
| Saito, T | 4 |
| Musha, Y | 1 |
| Itoh, S | 1 |
| Ohtsuji, M | 1 |
| Hanson, MA | 1 |
| Takeda, S | 1 |
| Lee, SE | 1 |
| Yang, HM | 1 |
| Oh, BH | 1 |
| Guerrot, D | 1 |
| Dussaule, JC | 1 |
| Mael-Ainin, M | 1 |
| Xu-Dubois, YC | 1 |
| Rondeau, E | 1 |
| Chatziantoniou, C | 2 |
| Placier, S | 1 |
| Cui, Y | 1 |
| Jiang, J | 1 |
| Chen, S | 1 |
| Peng, J | 1 |
| Wu, Q | 1 |
| Saura, H | 1 |
| Ogasawara, K | 1 |
| Kuroda, H | 1 |
| Yamashita, T | 1 |
| Terasaki, K | 1 |
| Ogawa, A | 1 |
| Gupte, M | 1 |
| Thatcher, SE | 1 |
| Boustany-Kari, CM | 1 |
| Shoemaker, R | 1 |
| Yiannikouris, F | 1 |
| Karounos, M | 1 |
| Novotny, SR | 1 |
| Wallace, K | 1 |
| Heath, J | 1 |
| Moseley, J | 1 |
| Dhillon, P | 1 |
| Weimer, A | 1 |
| Wallukat, G | 2 |
| Herse, F | 1 |
| Wenzel, K | 1 |
| Martin, JN | 1 |
| Dechend, R | 3 |
| Lamarca, B | 1 |
| Yoon, MH | 1 |
| Yoon, HJ | 1 |
| Miyagawa, S | 1 |
| Yamada, H | 2 |
| Martins-Oliveira, A | 1 |
| Castro, MM | 1 |
| Oliveira, DM | 1 |
| Rizzi, E | 1 |
| Guimaraes, D | 1 |
| Reis, RI | 1 |
| Costa-Neto, CM | 1 |
| Ribeiro, AA | 1 |
| Gerlach, RF | 1 |
| Tanus-Santos, JE | 1 |
| Cheng, XW | 1 |
| Sathishkumar, K | 1 |
| Balakrishnan, M | 1 |
| Chinnathambi, V | 1 |
| Gao, H | 1 |
| Yallampalli, C | 1 |
| Ashek, A | 1 |
| Menzies, RI | 1 |
| Mullins, LJ | 1 |
| Bellamy, CO | 1 |
| Harmar, AJ | 1 |
| Kenyon, CJ | 1 |
| Flatman, PW | 1 |
| Bailey, MA | 1 |
| Hirose, T | 1 |
| Sato, M | 1 |
| Kabutoya, T | 1 |
| Adachi, M | 1 |
| Kinoshita, A | 1 |
| Koh, N | 1 |
| Graff, A | 1 |
| Greve, AM | 1 |
| Tyagi, S | 1 |
| Budhiraja, RD | 1 |
| Lewin, A | 1 |
| Hong, NJ | 1 |
| Garvin, JL | 1 |
| Toh, R | 1 |
| Ishida, T | 1 |
| Nishimura, K | 1 |
| Nonaka, H | 1 |
| Kitagawa, Y | 1 |
| Suematsu, M | 1 |
| Miki, T | 1 |
| Emoto, N | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Xu, H | 1 |
| Oliveira-Sales, EB | 1 |
| McBride, F | 1 |
| Hewinson, J | 1 |
| Toward, M | 1 |
| Hendy, EB | 1 |
| Giannotta, M | 1 |
| Waki, H | 1 |
| Ascione, R | 1 |
| Otsuka, Y | 2 |
| Shen, F | 1 |
| Dong, LN | 1 |
| Zhang, XY | 1 |
| Zhao, XK | 1 |
| Zeng, XF | 1 |
| Qu, XB | 1 |
| Takami, T | 1 |
| Peng, F | 1 |
| Lin, L | 2 |
| Koba, S | 1 |
| Watanabe, R | 1 |
| Kano, N | 1 |
| Glezer, MG | 1 |
| Saĭgitov, RT | 1 |
| Shimada, Y | 1 |
| Yamamuro, M | 1 |
| Kan, H | 1 |
| Takashio, S | 1 |
| Tayama, S | 1 |
| Kaikita, K | 1 |
| Hokimoto, S | 1 |
| Sumida, H | 1 |
| Sugiyama, S | 1 |
| Hanayama, Y | 1 |
| Uchida, HA | 1 |
| Arnold, AC | 1 |
| Okamoto, LE | 1 |
| Gamboa, A | 1 |
| Shibao, C | 1 |
| Raj, SR | 1 |
| Robertson, D | 1 |
| Biaggioni, I | 1 |
| Minatoguchi, S | 1 |
| Aoyama, T | 1 |
| Kawai, N | 1 |
| Iwasa, M | 1 |
| Oda, M | 1 |
| Kida, K | 1 |
| Kojima, S | 1 |
| Goto, N | 1 |
| Goto, M | 1 |
| Sugishita, F | 1 |
| Takai, K | 1 |
| Tanaka, R | 1 |
| Hiei, K | 1 |
| Minagawa, T | 1 |
| Watanabe, I | 1 |
| Yasue, T | 1 |
| Gibson, TJ | 1 |
| De Marco, M | 1 |
| Casalnuovo, G | 1 |
| Migliore, T | 1 |
| Kizer, JR | 5 |
| Liu, JE | 3 |
| Andersen, S | 4 |
| Rossing, P | 4 |
| Juhl, TR | 3 |
| Deinum, J | 2 |
| Jilma, B | 1 |
| Li-Saw-Hee, FL | 3 |
| Wagner, OF | 1 |
| Beevers, DG | 8 |
| Lip, GY | 8 |
| Hasford, J | 1 |
| Mimran, A | 6 |
| Simons, WR | 1 |
| Borch-Johnsen, K | 7 |
| James, IG | 1 |
| Jones, A | 1 |
| Davies, P | 1 |
| Krum, H | 3 |
| Nolly, H | 1 |
| Workman, D | 2 |
| He, W | 1 |
| Roniker, B | 3 |
| Krause, S | 1 |
| Fakouhi, K | 1 |
| Kavgaci, H | 1 |
| Sahin, A | 1 |
| Onder Ersoz, H | 1 |
| Erem, C | 1 |
| Ozdemir, F | 1 |
| Gradman, AH | 3 |
| Brady, WE | 4 |
| Gazdick, LP | 3 |
| Lyle, P | 1 |
| Zeldin, RK | 2 |
| Ludwig, M | 1 |
| Ribeiro, A | 1 |
| Fritschka, E | 1 |
| Tholl, U | 1 |
| Stumpe, KO | 3 |
| Puig, JG | 1 |
| Torres, R | 2 |
| Ruilope, LM | 13 |
| Brochu, I | 1 |
| Labonté, J | 1 |
| Bkaily, G | 1 |
| D'Orléans-Juste, P | 1 |
| Zanchetti, A | 3 |
| Nicholls, MG | 3 |
| Yu, CM | 1 |
| Aurup, P | 10 |
| Johansson, M | 1 |
| Kristianson, K | 13 |
| Snapinn, S | 7 |
| Suo, M | 1 |
| Kalliovalkama, J | 6 |
| Pörsti, I | 6 |
| Jolma, P | 3 |
| Tolvanen, JP | 6 |
| Vuolteenaho, O | 3 |
| Akinboboye, OO | 1 |
| Chou, RL | 1 |
| Bergmann, SR | 1 |
| Malik, RA | 1 |
| Sugawara, AM | 1 |
| Vendramini, RC | 1 |
| Barbosa, SP | 1 |
| Brunetti, IL | 1 |
| De Luca, LA | 1 |
| Böhm, S | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Zadok, BS | 1 |
| Ravid, M | 1 |
| González-Juanatey, JR | 1 |
| Edelman, J | 2 |
| Deng, YB | 2 |
| Yang, HY | 2 |
| Li, CL | 2 |
| Chang, Q | 2 |
| Ishizaka, N | 3 |
| Saito, K | 1 |
| Mitani, H | 1 |
| Yamazaki, I | 1 |
| Sata, M | 2 |
| Usui, S | 1 |
| Mori, I | 2 |
| Ohno, M | 2 |
| Nagai, R | 3 |
| White, WB | 3 |
| Mansoor, GA | 1 |
| Anders, RJ | 2 |
| Fridman, KU | 1 |
| Elmfeldt, D | 2 |
| Wysocki, M | 1 |
| Friberg, PR | 1 |
| Andersson, OK | 3 |
| Vaziri, ND | 1 |
| Ni, ZN | 1 |
| Kivlighn, S | 1 |
| Kubo, T | 6 |
| Hagiwara, Y | 5 |
| Fukumori, R | 4 |
| Van Brabandt, H | 1 |
| Vandenbroucke, JP | 2 |
| Tedesco, MA | 5 |
| Ratti, G | 4 |
| Di Salvo, G | 2 |
| Natale, F | 2 |
| Dominiak, P | 4 |
| Zidek, W | 2 |
| Massie, BM | 1 |
| Gokhale, N | 1 |
| Shahani, S | 1 |
| Pawar, D | 1 |
| Liang, X | 2 |
| Xie, X | 1 |
| Gurevich, MA | 1 |
| Stergiou, GS | 2 |
| Efstathiou, SP | 1 |
| Skeva, II | 2 |
| Baibas, NM | 2 |
| Kalkana, CB | 2 |
| Mountokalakis, TD | 2 |
| Weber, MA | 5 |
| Mehra, MR | 1 |
| Okuguchi, T | 1 |
| Osanai, T | 1 |
| Fujiwara, N | 1 |
| Metoki, N | 1 |
| Konta, Y | 1 |
| Okumura, K | 1 |
| Morgan, T | 2 |
| Griffiths, C | 2 |
| Delbridge, L | 2 |
| Graham, MR | 1 |
| Allcock, NM | 1 |
| Olofsson, B | 1 |
| Meredith, P | 1 |
| Neutel, JM | 6 |
| Klein, C | 1 |
| Meinicke, TW | 2 |
| Schumacher, H | 3 |
| Mahmud, A | 1 |
| Feely, J | 1 |
| Resnick, LM | 1 |
| Lester, MH | 1 |
| Brown, NJ | 2 |
| Kumar, S | 1 |
| Painter, CA | 1 |
| Vaughan, DE | 1 |
| Rokkedal, J | 9 |
| Smith, G | 4 |
| Kang, SK | 1 |
| Yu, HC | 1 |
| Cho, BH | 1 |
| Park, SK | 1 |
| Karpov, IuA | 1 |
| Adams, HP | 1 |
| Amato, P | 2 |
| Bologna, P | 1 |
| Fornaciari, E | 1 |
| Follone, G | 2 |
| Di Marco, A | 1 |
| Tarantino, AM | 1 |
| Ducato, G | 1 |
| Accardo Palumbo, V | 1 |
| Colomba, D | 2 |
| Sciortino, A | 1 |
| Bascone, F | 1 |
| Mancini, GB | 1 |
| Weder, AB | 1 |
| Donmez, G | 1 |
| Erbas, D | 1 |
| Onk, A | 1 |
| Sindel, S | 1 |
| Hasanoglu, E | 1 |
| Schneider, MP | 1 |
| Trenkwalder, P | 1 |
| Yu, GL | 3 |
| Liang, XQ | 2 |
| Zheng, JQ | 1 |
| He, BX | 1 |
| Fleming, T | 1 |
| Borer, J | 2 |
| Armstrong, PW | 2 |
| Pfeffer, M | 1 |
| Klein, IH | 1 |
| Ligtenberg, G | 1 |
| Oey, PL | 1 |
| Koomans, HA | 2 |
| Blankestijn, PJ | 1 |
| Jacobsen, P | 1 |
| Tarnow, L | 3 |
| Tremblay, J | 2 |
| Kunes, J | 3 |
| Dobesova, Z | 3 |
| Pausova, Z | 2 |
| Deng, AY | 2 |
| Sun, YL | 1 |
| Jacob, HJ | 2 |
| Chowta, KN | 1 |
| Chowta, MN | 1 |
| Bhat, P | 1 |
| Adhikari, PM | 1 |
| van der Linde, NA | 1 |
| van den Meiracker, AH | 1 |
| Boomsma, F | 1 |
| Xie, XM | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 3 |
| Werkö, L | 1 |
| Grossman, E | 4 |
| Fournier, A | 2 |
| Oprisiu, R | 1 |
| Andrejak, M | 1 |
| Fernandez, L | 1 |
| Achard, JM | 1 |
| Ongali, B | 1 |
| Buck, Hde S | 1 |
| Cloutier, F | 1 |
| Legault, F | 1 |
| Regoli, D | 1 |
| Lambert, C | 2 |
| Thibault, G | 2 |
| Couture, R | 1 |
| Pedersen, OL | 2 |
| Marchand, EL | 1 |
| Der Sarkissian, S | 2 |
| deBlois, D | 3 |
| Zukowska-Szczechowska, E | 1 |
| Gosek, K | 1 |
| Grzeszczak, W | 2 |
| Hropot, M | 1 |
| Langer, KH | 1 |
| Wiemer, G | 1 |
| Grötsch, H | 1 |
| Linz, W | 3 |
| Mayorov, DN | 1 |
| Woolard, J | 1 |
| Hale, TM | 2 |
| Bushfield, TL | 1 |
| Adams, MA | 2 |
| Deng, Y | 1 |
| Bi, X | 1 |
| Pan, M | 1 |
| Pratt, JH | 3 |
| Garthwaite, S | 1 |
| Kleiman, JH | 1 |
| Krause, SL | 2 |
| Saunders, E | 2 |
| Ben-Yehuda, O | 1 |
| Odabas, AR | 1 |
| Cetinkaya, R | 1 |
| Selcuk, Y | 1 |
| Keles, S | 1 |
| Bilen, H | 1 |
| Krizanova, O | 1 |
| Sebokova, E | 1 |
| Klimes, I | 1 |
| Berg, T | 1 |
| Jego, C | 1 |
| Michaut, V | 1 |
| Graffin, B | 1 |
| Paris, JF | 1 |
| Carli, P | 1 |
| Minai, K | 1 |
| Horie, H | 1 |
| Ohira, N | 1 |
| Takashima, H | 1 |
| Tarutani, Y | 1 |
| Yasuda, Y | 3 |
| Ozawa, T | 1 |
| Matsuo, S | 2 |
| Kinoshita, M | 2 |
| Horie, M | 1 |
| Laplante, MA | 2 |
| Wu, R | 2 |
| El Midaoui, A | 1 |
| de Champlain, J | 5 |
| Fries, R | 1 |
| Böhm, M | 3 |
| Cambien, F | 1 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lu, WX | 1 |
| Lakkis, J | 1 |
| Schunkert, H | 1 |
| Liebson, PR | 1 |
| Erlinger, TP | 2 |
| Bohannon, A | 1 |
| Svetkey, LP | 2 |
| Moore, TJ | 2 |
| Bayorh, MA | 3 |
| Ganafa, AA | 2 |
| Socci, RR | 1 |
| Eatman, D | 3 |
| Silvestrov, N | 1 |
| Abukhalaf, IK | 1 |
| Park, HC | 1 |
| Xu, ZG | 1 |
| Choi, S | 1 |
| Goo, YS | 1 |
| Kang, SW | 1 |
| Ha, SK | 1 |
| Han, DS | 1 |
| Bardin, T | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 2 |
| Tsutsumi, Z | 1 |
| Ka, T | 1 |
| Fukuchi, M | 1 |
| Jern, S | 13 |
| Schmidt, B | 2 |
| Schieffer, B | 3 |
| Babadzhan, VD | 1 |
| Alföldi, S | 1 |
| Klocek, M | 1 |
| Lacourcière, Y | 11 |
| Gil-Extremera, B | 2 |
| Mueller, O | 1 |
| Byrne, M | 1 |
| Williams, L | 1 |
| Dickson, TZ | 1 |
| Zagrobelny, J | 1 |
| Ritter, MA | 2 |
| Snavely, D | 3 |
| Ramjit, D | 2 |
| Lo, MW | 3 |
| Terra, SG | 1 |
| Martina, B | 3 |
| Dieterle, T | 2 |
| Sigle, JP | 1 |
| Surber, C | 1 |
| Battegay, E | 2 |
| Bakris, GL | 3 |
| Shanifar, S | 1 |
| Douglas, J | 1 |
| van Dijk, DJ | 1 |
| Ito, O | 1 |
| Hasegawa, Y | 1 |
| Sato, K | 1 |
| Mitsui, H | 1 |
| Yuda, F | 1 |
| Sato, H | 2 |
| Kudo, K | 1 |
| Volpe, M | 3 |
| Junren, Z | 1 |
| Maxwell, T | 1 |
| Rodriguez, A | 1 |
| Gamboa, R | 1 |
| Gomez-Fernandez, P | 1 |
| Ortega-Gonzalez, G | 1 |
| Matadamas, N | 2 |
| Rodriguez, F | 1 |
| Dass, B | 1 |
| Kyle, C | 1 |
| Clarysse, L | 1 |
| Bryce, A | 1 |
| Moreno-Heredia, E | 1 |
| Germano, G | 1 |
| Gilles, L | 2 |
| Sanderson, JE | 1 |
| Kolloch, RE | 1 |
| Plouin, PF | 1 |
| Zhang, W | 2 |
| Sidorenko, BA | 4 |
| Preobrazhenskiĭ, DV | 3 |
| Stetsenko, TM | 3 |
| Tarykina, EV | 2 |
| Tsurko, VV | 2 |
| Malysheva, NV | 1 |
| Helle Berg, S | 1 |
| Smith, DH | 3 |
| Cramer, MJ | 1 |
| Hettiarachchi, R | 1 |
| Koval, S | 2 |
| Lapointe, N | 1 |
| Pourdjabbar, A | 1 |
| Rouleau, JL | 1 |
| Qadri, F | 2 |
| Arens, T | 1 |
| Schwarz, EC | 1 |
| Häuser, W | 3 |
| Dendorfer, A | 2 |
| Aronow, WS | 2 |
| Baumgart, P | 3 |
| Yin, P | 1 |
| Rong, YD | 1 |
| Ugriumova, MO | 1 |
| Crowe, AV | 1 |
| Howse, M | 1 |
| Vinjamuri, S | 1 |
| Kemp, GJ | 1 |
| Williams, PS | 1 |
| Morato, M | 1 |
| Sousa, T | 1 |
| Guimarães, S | 1 |
| Moura, D | 1 |
| Albino-Teixeira, A | 1 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Krantz, MJ | 1 |
| Chamorro, V | 1 |
| Wangensteen, R | 2 |
| Sainz, J | 1 |
| O'Valle, F | 2 |
| Osuna, A | 2 |
| Vargas, F | 2 |
| Wargo, KA | 1 |
| Chong, K | 1 |
| Chan, EC | 1 |
| Kaya, M | 2 |
| Kalayci, R | 2 |
| Küçük, M | 2 |
| Arican, N | 2 |
| Elmas, I | 2 |
| Kudat, H | 2 |
| Korkut, F | 2 |
| Lakó-Futó, Z | 1 |
| Szokodi, I | 1 |
| Sármán, B | 1 |
| Földes, G | 1 |
| Tokola, H | 1 |
| Ilves, M | 1 |
| Leskinen, H | 1 |
| Skoumal, R | 1 |
| deChâtel, R | 1 |
| Tóth, M | 1 |
| Samra, SS | 1 |
| Dongre, N | 1 |
| Ballary, C | 1 |
| Azevedo, LF | 1 |
| Brum, PC | 1 |
| Mattos, KC | 1 |
| Junqueira, CM | 1 |
| Rondon, MU | 1 |
| Barretto, AC | 1 |
| Negrão, CE | 1 |
| Kopp, UC | 1 |
| Cicha, MZ | 1 |
| Pasotti, C | 1 |
| Alanko, J | 1 |
| Kööbi, P | 1 |
| Riutta, A | 1 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Ratova, LG | 1 |
| Dmitriev, VV | 1 |
| Sinitsin, VE | 1 |
| Stukalova, OV | 1 |
| Winkler, G | 1 |
| Jermendy, G | 1 |
| Matos, L | 1 |
| Podzolkov, VI | 2 |
| Bulatov, VA | 2 |
| Son, EA | 2 |
| Stanton, A | 1 |
| Jensen, C | 1 |
| O'Brien, E | 2 |
| Laviades, C | 2 |
| Orbe, J | 2 |
| López, B | 7 |
| González, A | 5 |
| Mayor, G | 1 |
| Páramo, JA | 2 |
| Yavuz, D | 2 |
| Koç, M | 1 |
| Toprak, A | 1 |
| Akpinar, I | 1 |
| Velioğlu, A | 2 |
| Deyneli, O | 2 |
| Haklar, G | 2 |
| Akalin, S | 2 |
| Stanton, R | 1 |
| Liu, G | 2 |
| Jiang, B | 1 |
| Gao, R | 1 |
| Poirier, L | 2 |
| Iñigo, P | 2 |
| Campistol, JM | 2 |
| Saracho, R | 1 |
| Del Castillo, D | 2 |
| Anaya, F | 2 |
| Esforzado, N | 1 |
| Navarro, MD | 1 |
| Oppenheimer, F | 1 |
| Chen, LL | 1 |
| Miatello, R | 1 |
| Risler, N | 1 |
| Castro, C | 1 |
| Cruzado, M | 1 |
| González, S | 1 |
| Zumino, AP | 1 |
| Di Garbo, V | 1 |
| Avellone, G | 2 |
| Tuttolomondo, A | 1 |
| Cardinale, A | 1 |
| Maniscalchi, T | 1 |
| Ma, X | 1 |
| Hingtgen, SD | 1 |
| Tian, X | 1 |
| Davisson, RL | 5 |
| Kuschnir, E | 1 |
| Resk, J | 1 |
| Pañart, MS | 1 |
| Guzman, L | 1 |
| Plotquin, Y | 1 |
| Grassi, G | 3 |
| Wagener, G | 1 |
| Kowala, MC | 1 |
| Murugesan, N | 1 |
| Tellew, J | 1 |
| Carlson, K | 1 |
| Monshizadegan, H | 1 |
| Ryan, C | 1 |
| Gu, Z | 1 |
| Kane, B | 1 |
| Fadnis, L | 1 |
| Baska, RA | 1 |
| Beyer, S | 1 |
| Arthur, S | 1 |
| Dickinson, K | 1 |
| Zhang, D | 1 |
| Perrone, M | 1 |
| Ferrer, P | 1 |
| Giancarli, M | 1 |
| Baumann, J | 1 |
| Bird, E | 1 |
| Panchal, B | 1 |
| Trippodo, N | 1 |
| Barrish, J | 1 |
| Macor, JE | 1 |
| Waugh, J | 1 |
| Sangaleti, CT | 1 |
| Crescenzi, A | 1 |
| Michelini, LC | 4 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Onuigbo, MA | 1 |
| Frishman, WH | 2 |
| Zervou, M | 3 |
| Zoumpoulakis, P | 2 |
| Kyrikou, I | 2 |
| Benetis, NP | 1 |
| Polevaya, L | 1 |
| Giatas, N | 1 |
| Zoga, A | 2 |
| Minakakis, PM | 1 |
| Kolocouris, A | 2 |
| Grdadolnik, SG | 1 |
| Siapi, E | 1 |
| Daliani, I | 1 |
| Dimitriou, D | 1 |
| Pitsas, A | 1 |
| Kamoutsis, C | 1 |
| Laggner, P | 1 |
| de la Sierra, A | 2 |
| Calvo, C | 1 |
| Campo, C | 1 |
| García-Puig, J | 3 |
| Márquez, E | 1 |
| Oliván, J | 1 |
| Roca Cusachs, A | 1 |
| Sanz de Castro, S | 2 |
| Pontes, C | 1 |
| Delgadillo, J | 1 |
| Makolkin, VI | 1 |
| Ferrario, C | 1 |
| Abdelhamed, AI | 1 |
| Moore, M | 1 |
| Rayner, B | 1 |
| Alderman, MH | 1 |
| Douglas, JG | 1 |
| Harris, KE | 10 |
| Nesbitt, S | 1 |
| Randall, OS | 1 |
| Wright, JT | 3 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Burke, TA | 3 |
| Krobot, K | 1 |
| Carides, GW | 4 |
| Bratland, B | 1 |
| Gerhardsen, G | 1 |
| Gisholt, K | 1 |
| Risanger, T | 2 |
| Smedsrud, T | 1 |
| Koren, MJ | 1 |
| Zabalgoitia, M | 1 |
| Slaninka-Miceska, M | 1 |
| Bogdanska, J | 1 |
| Korneti, P | 1 |
| Kostova, E | 1 |
| Jovanoska, E | 1 |
| Petrov, S | 1 |
| Fossum, E | 8 |
| Tamaki, S | 2 |
| Uchida, Y | 1 |
| Ohmichi, N | 1 |
| Yamaoka, O | 1 |
| Miyauchi, N | 1 |
| Fukuhara, T | 1 |
| Sayama, H | 1 |
| Nomura, S | 2 |
| Shouzu, A | 2 |
| Omoto, S | 2 |
| Nishikawa, M | 3 |
| Iwasaka, T | 6 |
| Packard, KA | 1 |
| Arouni, AJ | 1 |
| Hilleman, DE | 1 |
| Gannon, JM | 1 |
| Hashim, S | 1 |
| Anand-Srivastava, MB | 1 |
| Hiyoshi, H | 1 |
| Yayama, K | 1 |
| Takano, M | 1 |
| Bobik, A | 4 |
| Moriwaki, H | 1 |
| Nagakane, Y | 1 |
| Hayashida, K | 1 |
| Wong, W | 2 |
| Mauger, D | 1 |
| Koh, KK | 3 |
| Ahn, JY | 2 |
| Jin, DK | 1 |
| Park, GS | 1 |
| Kang, WC | 1 |
| Ahn, TH | 2 |
| Shin, EK | 3 |
| Okigaki, M | 1 |
| Ishikawa, Y | 1 |
| Kohno, M | 2 |
| Tatsuno, I | 1 |
| Kumagai, H | 3 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Saruta, T | 3 |
| Tomiyama, H | 2 |
| Takata, Y | 1 |
| Yamashina, A | 1 |
| Arakawa, K | 1 |
| Nashar, K | 1 |
| Nguyen, JP | 1 |
| Jesri, A | 1 |
| Morrow, JD | 2 |
| Egan, BM | 1 |
| Zimmerman, MC | 1 |
| Sharma, RV | 1 |
| Roncal, C | 1 |
| Rodriguez, JA | 1 |
| Belzunce, M | 1 |
| Miyahara, Y | 1 |
| Miyazaki, T | 1 |
| Uchida, K | 1 |
| Tamura, T | 1 |
| Masuda, N | 1 |
| Yamashita, S | 1 |
| Yonei, A | 1 |
| Chung, NA | 1 |
| Lip, G | 1 |
| Tuxen, C | 5 |
| Bang, LE | 4 |
| Hall, C | 3 |
| Hildebrandt, P | 3 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| Magrini, F | 1 |
| Akdemir, R | 1 |
| Ozhan, H | 1 |
| Yazici, M | 1 |
| Gunduz, H | 1 |
| Duran, S | 1 |
| Gurel, C | 1 |
| Ozdas, S | 1 |
| Uyan, C | 1 |
| Basar, I | 1 |
| Ulutin, T | 1 |
| Xavier, FE | 1 |
| Rossoni, LV | 1 |
| Balfagón, G | 1 |
| Fox, JC | 1 |
| Leight, K | 1 |
| Sutradhar, SC | 1 |
| Demopoulos, LA | 1 |
| Lewin, AJ | 1 |
| Mogensen, CE | 4 |
| Zelveian, PA | 1 |
| Oshchepkova, EV | 1 |
| Buniatian, MS | 1 |
| Rogoza, AN | 1 |
| Willemsen, JM | 1 |
| Rabelink, TJ | 1 |
| Boer, P | 1 |
| Gaillard, CA | 1 |
| Novosel, A | 1 |
| Heger, A | 1 |
| Lohse, P | 1 |
| Schmidt, H | 1 |
| Makris, TK | 1 |
| Stavroulakis, G | 1 |
| Papadopoulos, DP | 1 |
| Krespi, P | 1 |
| Hatzizacharias, A | 1 |
| Zilidis, A | 1 |
| Tsoukala, C | 1 |
| Votteas, VE | 1 |
| Hunsicker, LG | 1 |
| Yokohama, S | 2 |
| Yoneda, M | 1 |
| Okamoto, S | 1 |
| Okada, M | 1 |
| Aso, K | 1 |
| Tokusashi, Y | 1 |
| Miyokawa, N | 1 |
| Nakao, N | 1 |
| Senou, H | 1 |
| Kasuga, H | 1 |
| Toriyama, T | 1 |
| Kawahara, H | 1 |
| Oki, T | 1 |
| Tabata, T | 1 |
| Harada, K | 3 |
| Kimura, E | 1 |
| Oishi, Y | 1 |
| Ishimoto, T | 1 |
| Ellis, D | 1 |
| Moritz, ML | 1 |
| Vats, A | 1 |
| Janosky, JE | 1 |
| Zhu, J | 1 |
| Friesema, J | 1 |
| Huang, T | 1 |
| Roman, RJ | 1 |
| Lombard, JH | 1 |
| Gröholm, T | 1 |
| Finckenberg, P | 1 |
| Palojoki, E | 1 |
| Saraste, A | 1 |
| Bäcklund, T | 1 |
| Eriksson, A | 1 |
| Laine, M | 1 |
| Mervaala, E | 1 |
| Tikkanen, I | 6 |
| Kazama, K | 1 |
| Anrather, J | 1 |
| Girouard, H | 1 |
| Frys, K | 1 |
| Milner, TA | 1 |
| Iadecola, C | 1 |
| Caruso, D | 1 |
| D'Avino, M | 1 |
| Acampora, C | 1 |
| Romano, L | 1 |
| Bevilacqua, N | 1 |
| Esposti, DD | 1 |
| Borghi, C | 1 |
| Gao, XY | 1 |
| Zhang, F | 1 |
| Han, Y | 1 |
| Ferrario, CM | 9 |
| Salerno, CM | 1 |
| Demopoulos, L | 1 |
| Mukherjee, R | 1 |
| Harris, K | 1 |
| Oliveira, RP | 1 |
| Joaquim, LF | 1 |
| Fazan, R | 2 |
| Salgado, MC | 2 |
| Salgado, HC | 3 |
| Quon, MJ | 2 |
| Seo, YH | 1 |
| Kang, MH | 1 |
| Choi, IS | 1 |
| Doumas, MN | 1 |
| Douma, SN | 1 |
| Petidis, KM | 1 |
| Vogiatzis, KV | 1 |
| Bassagiannis, IC | 1 |
| Zamboulis, CX | 1 |
| Lee, YT | 1 |
| Lee, CM | 1 |
| Lin, CS | 1 |
| Sheu, SH | 1 |
| Kuo, WK | 1 |
| Tsai, CW | 1 |
| Huang, LC | 1 |
| Huang, HC | 2 |
| Wang, JS | 1 |
| Tseng, WK | 1 |
| Zhu, JR | 3 |
| Bai, J | 1 |
| Cai, NS | 2 |
| Tang, B | 1 |
| Guo, JZ | 1 |
| Ke, YN | 2 |
| Guo, JX | 2 |
| Sheng, LH | 1 |
| Cheng, NN | 1 |
| Béchir, M | 1 |
| Enseleit, F | 1 |
| Chenevard, R | 2 |
| Lüscher, TF | 3 |
| Noll, G | 2 |
| Jones, M | 1 |
| Yeolekar, ME | 1 |
| Tripathi, KK | 1 |
| Giri, J | 1 |
| Maity, AK | 1 |
| Chopda, M | 1 |
| Gujarathi, S | 1 |
| Maroli, S | 1 |
| Maity, A | 1 |
| Campbell, DJ | 2 |
| Esler, MD | 1 |
| Singh, RB | 1 |
| Amador, N | 1 |
| Encarnación, JJ | 1 |
| Guízar, JM | 1 |
| Rodríguez, L | 1 |
| López, M | 1 |
| Egan, B | 1 |
| Gleim, G | 2 |
| Panish, J | 1 |
| Dragun, D | 1 |
| Müller, DN | 2 |
| Bräsen, JH | 1 |
| Fritsche, L | 1 |
| Nieminen-Kelhä, M | 1 |
| Rudolph, B | 1 |
| Hoebeke, J | 1 |
| Eckert, D | 1 |
| Mazak, I | 1 |
| Plehm, R | 1 |
| Schönemann, C | 1 |
| Budde, K | 1 |
| Neumayer, HH | 1 |
| Luft, FC | 2 |
| Szucs, TD | 1 |
| Erne, P | 2 |
| Hornestam, B | 2 |
| Lehto, M | 2 |
| Slotwiner, DJ | 1 |
| Bourassa, MG | 1 |
| Witkowski, S | 2 |
| Arbab-Zadeh, A | 1 |
| Prasad, A | 1 |
| Okazaki, K | 1 |
| Uchiyama-Tanaka, Y | 1 |
| Mori, Y | 1 |
| Kishimoto, N | 1 |
| Fukui, M | 2 |
| Nose, A | 1 |
| Kijima, Y | 1 |
| Yamahara, H | 1 |
| Kosaki, A | 1 |
| Cano, F | 1 |
| Soffer, BA | 2 |
| Ahmed, T | 1 |
| Miller, K | 1 |
| Vogt, B | 1 |
| Blumer, J | 1 |
| Briazgounov, I | 1 |
| Spiering, W | 1 |
| Fuss-Lejeune, MJ | 1 |
| Hjerkinn, E | 1 |
| Nesbitt, SD | 1 |
| Andersen, UB | 1 |
| Phillips, RA | 1 |
| Gaboury, CL | 1 |
| Yoshida, D | 1 |
| Higashiura, K | 2 |
| Koren-Michowitz, M | 1 |
| Dishy, V | 1 |
| Zaidenstein, R | 2 |
| Yona, O | 1 |
| Berman, S | 1 |
| Weissgarten, J | 2 |
| Golik, A | 2 |
| Fukuhara, S | 1 |
| Doggrell, SA | 1 |
| Cosentino, F | 1 |
| Savoia, C | 1 |
| De Paolis, P | 1 |
| Francia, P | 1 |
| Russo, A | 1 |
| Maffei, A | 1 |
| Venturelli, V | 1 |
| Schiavoni, M | 1 |
| Lembo, G | 1 |
| Hildebrandt, PR | 3 |
| Montanaro, D | 1 |
| Gropuzzo, M | 1 |
| Tulissi, P | 1 |
| Vallone, C | 1 |
| Boscutti, G | 1 |
| Mioni, R | 1 |
| Risaliti, A | 1 |
| Baccarani, U | 1 |
| Adani, GL | 1 |
| Sainz, M | 1 |
| Bresadola, F | 1 |
| Mioni, G | 1 |
| Zhang, WR | 1 |
| Chen, BM | 1 |
| Xiong, Y | 1 |
| Tao, LJ | 1 |
| Naelten, G | 1 |
| Liu, KL | 1 |
| Chapuis, B | 1 |
| Lo, M | 3 |
| Quarti, F | 1 |
| O'Rourke, MF | 2 |
| Safar, ME | 2 |
| Jönsson, B | 1 |
| Dasbach, EJ | 1 |
| Iwai, K | 1 |
| Morimoto, S | 3 |
| De Gennaro Colonna, V | 2 |
| Rigamonti, A | 2 |
| Fioretti, S | 2 |
| Bonomo, S | 2 |
| Manfredi, B | 2 |
| Ferrario, P | 1 |
| Bianchi, M | 1 |
| Berti, F | 2 |
| Muller, EE | 2 |
| Rossoni, G | 2 |
| Ersoy, A | 2 |
| Kahvecioglu, S | 1 |
| Ersoy, C | 1 |
| Cift, A | 1 |
| Dilek, K | 2 |
| Oku, N | 1 |
| Kitagawa, K | 1 |
| Imaizumi, M | 1 |
| Takasawa, M | 1 |
| Piao, R | 1 |
| Kimura, Y | 1 |
| Kajimoto, K | 1 |
| Hatazawa, J | 1 |
| Asai, T | 1 |
| Kushiro, T | 2 |
| Fujita, H | 1 |
| Kanmatsuse, K | 1 |
| Khattab, M | 1 |
| Al-Shabanah, OA | 1 |
| Raza, M | 1 |
| Gehr, TW | 1 |
| Ghosh, S | 1 |
| Neland, K | 1 |
| Dige-Petersen, H | 2 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Martinez, LL | 1 |
| Oliveira, MA | 1 |
| Miguel, AS | 1 |
| Rastelli, VM | 1 |
| Cruz, JW | 1 |
| Nigro, D | 3 |
| Nishimura, T | 1 |
| Hashimoto, J | 1 |
| Totsune, K | 1 |
| Franklin, SS | 1 |
| Malliani, A | 1 |
| Montano, N | 1 |
| Moan, A | 6 |
| Lavoie, P | 1 |
| Robitaille, G | 1 |
| Agharazii, M | 2 |
| Ledbetter, S | 1 |
| Lebel, M | 3 |
| Larivière, R | 3 |
| Hobara, N | 1 |
| Gessei-Tsutsumi, N | 1 |
| Goda, M | 1 |
| Takayama, F | 1 |
| Akiyama, S | 1 |
| Kurosaki, Y | 1 |
| Kawasaki, H | 1 |
| Kauffmann, R | 1 |
| Orozco, R | 1 |
| Venegas, JC | 1 |
| Davidson, RC | 1 |
| Patrick, JL | 1 |
| Nattel, S | 1 |
| Hsieh, PS | 1 |
| Demirci, B | 1 |
| McKeown, PP | 1 |
| Bayraktutan, U | 1 |
| Walton, M | 1 |
| Feuerstein, GZ | 2 |
| Dang, A | 1 |
| Chen, G | 1 |
| Lambert, E | 1 |
| Windebank, E | 1 |
| Esler, M | 1 |
| Van Bortel, LM | 2 |
| Bulpitt, CJ | 1 |
| Carr, AA | 2 |
| Kowey, PR | 1 |
| Ogata, C | 1 |
| Sasaki, O | 1 |
| Kubota, Y | 1 |
| Inenaga, T | 1 |
| Brassard, P | 1 |
| Amiri, F | 1 |
| Zanchi, A | 2 |
| Tuttle, JB | 1 |
| Hannan, JL | 1 |
| Smallegange, C | 1 |
| Heaton, JP | 1 |
| Takai, S | 1 |
| Kirimura, K | 1 |
| Jin, D | 1 |
| Muramatsu, M | 1 |
| Yoshikawa, K | 1 |
| Mino, Y | 1 |
| de P Rodrigues, SF | 1 |
| Silva-Antonialli, MM | 2 |
| Scavone, C | 1 |
| de Cássia Tostes, R | 1 |
| Carides, G | 1 |
| Kale, S | 1 |
| Oomman, A | 1 |
| Joshi, RM | 1 |
| Chopra, D | 1 |
| Bek, MJ | 1 |
| Asico, LD | 2 |
| Zheng, S | 1 |
| Grandy, DK | 2 |
| Carey, RM | 2 |
| Soares-da-Silva, P | 1 |
| Moen, MD | 1 |
| Wagstaff, AJ | 2 |
| Chen, WQ | 1 |
| Ferder, L | 1 |
| Piotrkowski, B | 1 |
| Stella, I | 1 |
| Rinaldi, A | 1 |
| Formica, RN | 1 |
| Friedman, AL | 1 |
| Lorber, MI | 1 |
| Smith, JD | 1 |
| Eisen, T | 1 |
| Bia, MJ | 1 |
| Rayner, BL | 1 |
| Trinder, YA | 1 |
| Baines, D | 1 |
| Isaacs, S | 1 |
| Opie, LH | 1 |
| Dyer, O | 1 |
| Gómez-Garre, D | 1 |
| Martín-Ventura, JL | 1 |
| Granados, R | 1 |
| Sancho, T | 1 |
| Ruano, M | 1 |
| Jin, X | 1 |
| Wang, LS | 1 |
| Shi, JZ | 1 |
| Zheng, Y | 1 |
| Chen, WL | 1 |
| Liu, ZG | 1 |
| Chen, GQ | 1 |
| Fang, NY | 1 |
| Rocha, JC | 1 |
| Gomes, MA | 1 |
| Salgado, N | 1 |
| Feitosa, GS | 1 |
| Dallaverde, E | 1 |
| Ribeiro, AB | 3 |
| Chern, CM | 1 |
| Hsu, HY | 1 |
| Hu, HH | 1 |
| Chen, YY | 1 |
| Hsu, LC | 1 |
| Chao, AC | 1 |
| Lee, Y | 1 |
| Davies, J | 1 |
| Carr, E | 1 |
| Band, M | 1 |
| Morris, A | 1 |
| Struthers, A | 1 |
| Sachetelli, S | 1 |
| Hsieh, TJ | 1 |
| Brezniceanu, ML | 1 |
| Guo, DF | 1 |
| Daïkha-Dahmane, F | 2 |
| Levy-Beff, E | 1 |
| Jugie, M | 1 |
| Lenclen, R | 1 |
| Hoieggen, A | 1 |
| Anis, AH | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Rodriguez-Iturbe, B | 1 |
| Baguet, JP | 1 |
| Nisse-Durgeat, S | 1 |
| Mouret, S | 1 |
| Asmar, R | 3 |
| De Godoy, MA | 1 |
| Rattan, S | 1 |
| Yoshimoto, M | 1 |
| Miki, K | 1 |
| Ruiatkina, LA | 1 |
| Schjoedt, KJ | 1 |
| Lajer, M | 1 |
| Welsch, S | 1 |
| Schordan, E | 1 |
| Coquard, C | 1 |
| Massfelder, T | 1 |
| Fiaschi-Taesch, N | 1 |
| Helwig, JJ | 1 |
| Barthelmebs, M | 1 |
| Cuspidi, C | 1 |
| Meani, S | 1 |
| Valerio, C | 1 |
| Fusi, V | 1 |
| Sala, C | 1 |
| Maisaidi, M | 1 |
| Gavras, H | 4 |
| Bass, JK | 1 |
| Faix, RG | 1 |
| Simonetti, GD | 1 |
| von Vigier, RO | 1 |
| Konrad, M | 1 |
| Rizzi, M | 1 |
| Fossali, E | 1 |
| Bianchetti, MG | 1 |
| Krauser, DG | 1 |
| Fernandes, L | 1 |
| Tostes, R | 1 |
| Santos, JA | 1 |
| Mori, MA | 1 |
| Pesquero, JB | 1 |
| de Carvalho, MH | 1 |
| Gardiner, SM | 4 |
| March, JE | 3 |
| Kemp, PA | 3 |
| Ballard, SA | 1 |
| Bennett, T | 4 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Kadomoto, Y | 1 |
| Park, H | 1 |
| Hasegawa, G | 1 |
| Obayashi, H | 1 |
| Fujinami, A | 1 |
| Ohta, M | 1 |
| Hara, H | 1 |
| Adachi, T | 1 |
| Nakajima, Y | 1 |
| Kimura, F | 1 |
| Ogata, M | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Little, WC | 3 |
| Zile, MR | 2 |
| Appleton, CP | 1 |
| Kitzman, DW | 2 |
| Wesley-Farrington, DJ | 1 |
| Nielsen, OW | 1 |
| Wergeland, R | 1 |
| Calabrò, R | 1 |
| Nagasawa, H | 1 |
| Inoue, H | 1 |
| Hiwada, K | 2 |
| Guptha, S | 2 |
| Bakkum, JN | 1 |
| Brost, BC | 1 |
| Johansen, KL | 1 |
| Johnston, BW | 1 |
| Watson, WJ | 1 |
| Watanabe, LA | 2 |
| Wei, M | 1 |
| Sun, N | 1 |
| Kim, D | 2 |
| Chiang, CE | 1 |
| Ke, Y | 1 |
| Tseng, CD | 1 |
| Coloma, R | 1 |
| Vala, M | 1 |
| Feig, P | 1 |
| da Silva, CA | 1 |
| Reyes, AJ | 1 |
| Leary, WP | 1 |
| Xia, K | 2 |
| Zhao, ZY | 1 |
| Keiding, H | 1 |
| Burke, T | 1 |
| Luchtefeld, M | 2 |
| Bandlow, N | 1 |
| Tietge, UJ | 1 |
| Grote, K | 1 |
| Pfeilschifter, J | 1 |
| Kaszkin, M | 1 |
| Beck, S | 1 |
| Drexler, H | 2 |
| Christensen, MK | 1 |
| Wiinberg, N | 2 |
| Cacina, H | 1 |
| Aksoy, N | 1 |
| Taga, Y | 1 |
| Katovich, MJ | 4 |
| Sumners, C | 1 |
| Zoccal, DB | 1 |
| Bonagamba, LG | 1 |
| Oliveira, FR | 1 |
| Machado, BH | 1 |
| McGrath, JC | 1 |
| Hermans, JJ | 2 |
| Peutz-Kootstra, C | 2 |
| Witzke, O | 2 |
| Watanabe, S | 2 |
| Kurata, M | 1 |
| Manabe, S | 1 |
| Fukuoka, T | 1 |
| Murakami, K | 1 |
| Rodrigue, ME | 1 |
| Osende, JI | 1 |
| Vivanco, F | 1 |
| Otterstad, JE | 1 |
| Varughese, GI | 1 |
| Tahrani, AA | 1 |
| He, B | 1 |
| Wu, ZG | 1 |
| Ma, H | 1 |
| Li, XL | 1 |
| Chen, YZ | 1 |
| Dang, AM | 1 |
| Liu, GZ | 1 |
| Zhang, YH | 1 |
| Chen, GL | 1 |
| Usher-Smith, JA | 1 |
| Ramsbottom, T | 2 |
| Pearmain, H | 2 |
| Kirby, M | 2 |
| Alvarez, Y | 1 |
| Pérez-Girón, JV | 1 |
| García-Redondo, A | 1 |
| Beltrán, A | 1 |
| Hood, SG | 1 |
| Cochrane, T | 1 |
| McKinley, MJ | 1 |
| May, CN | 1 |
| Ismail, SB | 1 |
| Naing, L | 1 |
| Roshan, TM | 1 |
| Rahman, AR | 1 |
| Saygili, E | 2 |
| Rana, OR | 1 |
| Reuter, H | 1 |
| Frank, K | 1 |
| Schwinger, RH | 1 |
| Müller-Ehmsen, J | 1 |
| Zobel, C | 1 |
| Scaglione, R | 2 |
| Argano, C | 1 |
| Di Chiara, T | 1 |
| Donatelli, M | 1 |
| Corrao, S | 1 |
| Paavonen, KJ | 2 |
| Miettinen, HE | 2 |
| Strandberg, T | 2 |
| Tilvis, R | 2 |
| Pentikäinen, PJ | 3 |
| Fujii, S | 1 |
| Imagawa, S | 1 |
| Ohmura, K | 1 |
| Ohmura, Y | 1 |
| Andoh, Y | 1 |
| Ishimori, N | 1 |
| Furumoto, T | 1 |
| Tsutsui, H | 1 |
| Giles, TD | 2 |
| Silfani, TN | 1 |
| Wang, A | 1 |
| Walker, JF | 1 |
| Flammer, AJ | 1 |
| Hermann, F | 1 |
| Wiesli, P | 1 |
| Schwegler, B | 1 |
| Hürlimann, D | 1 |
| Sudano, I | 1 |
| Gay, S | 1 |
| Neidhart, M | 1 |
| Riesen, W | 1 |
| Ruschitzka, F | 1 |
| Lehmann, R | 1 |
| Eijkelkamp, WB | 1 |
| Keane, WF | 2 |
| Abe, C | 1 |
| Takahashi, T | 2 |
| Kameda, T | 1 |
| Fischer, R | 1 |
| Gapelyuk, A | 1 |
| Shagdarsuren, E | 1 |
| Gruner, K | 1 |
| Gruner, A | 1 |
| Gratze, P | 1 |
| Wellner, M | 1 |
| Fiebeler, A | 1 |
| Dietz, R | 2 |
| Schirdewan, A | 1 |
| Sakatani, T | 1 |
| Takamatsu, T | 1 |
| Spitzer, KW | 1 |
| Tarsitano, CA | 1 |
| Paffaro, VA | 1 |
| Pauli, JR | 1 |
| da Silva, GH | 1 |
| Saad, MJ | 1 |
| Salgado, I | 1 |
| da Cruz-Höfling, MA | 1 |
| Hyslop, S | 1 |
| Lefebvre, J | 2 |
| Bahadir, O | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Bahadir, MA | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Zhu, WW | 1 |
| Liu, XP | 1 |
| Wu, N | 1 |
| Zhao, TT | 1 |
| Shao, JH | 1 |
| Pinto, CC | 1 |
| Souza, DS | 1 |
| de Faria, JB | 1 |
| de Faria, JM | 1 |
| Moore, N | 1 |
| Dicker, P | 1 |
| O'Brien, JK | 1 |
| Stojanovic, M | 1 |
| Conroy, RM | 1 |
| Treumann, A | 1 |
| O'Brien, ET | 1 |
| Fitzgerald, D | 2 |
| Shields, D | 1 |
| Stanton, AV | 1 |
| Mitsuyama, S | 1 |
| Maeda, C | 1 |
| Schaan, B | 1 |
| Oliveira, E | 1 |
| Oliveira, V | 1 |
| De Angelis, K | 1 |
| Irigoyen, M | 1 |
| Prabhakar, H | 1 |
| Rath, GP | 1 |
| Arora, R | 1 |
| Hood, SJ | 1 |
| Taylor, KP | 1 |
| Ashby, MJ | 1 |
| Layas, MF | 1 |
| Mann, G | 1 |
| Thygesen, K | 1 |
| Li, YQ | 1 |
| Niu, XL | 1 |
| Wang, CX | 1 |
| Wang, SJ | 1 |
| Tinel, H | 1 |
| Aulakh, GK | 1 |
| Sodhi, RK | 1 |
| Boersma, C | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Chattopadhyay, A | 1 |
| Petkow-Dimitrow, P | 1 |
| Cao, G | 1 |
| Lombraña, A | 1 |
| Rivero, M | 1 |
| Castellano, JM | 1 |
| Barba, J | 1 |
| Pirro, M | 1 |
| Mannarino, E | 1 |
| Li, NS | 1 |
| Jiang, DJ | 1 |
| Deng, HW | 1 |
| Jeong, HJ | 1 |
| Shin, MH | 1 |
| Toki, M | 1 |
| Hirayama, Y | 1 |
| Nonaka, K | 1 |
| Takahashi, K | 1 |
| Dai, Q | 1 |
| Xu, M | 1 |
| Yao, M | 1 |
| Sun, B | 1 |
| Förster, A | 2 |
| Victor, RG | 1 |
| Heemann, U | 1 |
| Boudier, HA | 1 |
| Filigheddu, F | 1 |
| Cocco, F | 1 |
| Degortes, S | 1 |
| Fadda, S | 1 |
| Pinna Parpaglia, P | 1 |
| Baraccani, C | 1 |
| Shimosawa, T | 1 |
| Gohchi, K | 1 |
| Yatomi, Y | 1 |
| Narkiewicz, K | 2 |
| Hedner, T | 5 |
| Larsen, J | 1 |
| Kim, KY | 1 |
| Baek, A | 1 |
| Cho, H | 1 |
| Lee, YH | 1 |
| Kim, JW | 1 |
| Kim, KI | 1 |
| Yoon, DY | 1 |
| Oh, GT | 1 |
| Kim, E | 1 |
| Belsey, JD | 1 |
| Usher-Smith, J | 1 |
| Mattar, AL | 1 |
| Johansson, ME | 1 |
| Andersson, IJ | 1 |
| Alexanderson, C | 1 |
| Skøtt, O | 1 |
| Holmäng, A | 1 |
| Bergström, G | 2 |
| Filyushina, EE | 1 |
| Shmerling, MD | 1 |
| Lazarev, VA | 1 |
| Buzuyeva, II | 1 |
| Milan, A | 1 |
| Fukuda, D | 1 |
| Yao, EH | 1 |
| Kobayashi, N | 1 |
| Yamamoto, C | 1 |
| Cramariuc, D | 2 |
| Franco, V | 1 |
| Sendra, J | 1 |
| Llorente-Cortés, V | 1 |
| Costales, P | 1 |
| Huesca-Gómez, C | 1 |
| Badimon, L | 1 |
| Mascagni, F | 1 |
| Simonenko, VB | 1 |
| medvedev, iN | 1 |
| Kumova, TA | 1 |
| Molitch, M | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Triposkiadis, F | 1 |
| Abate, N | 1 |
| Chen, E | 1 |
| Galet, V | 1 |
| Jia, G | 1 |
| Lerman, A | 1 |
| Pool, J | 1 |
| Tershakovec, AM | 1 |
| Sonoda, M | 1 |
| Aoyagi, T | 1 |
| Takenaka, K | 1 |
| Uno, K | 1 |
| Zhou, C | 1 |
| Lu, F | 1 |
| Cao, K | 1 |
| Xu, D | 1 |
| Goltzman, D | 1 |
| Miao, D | 1 |
| Matsuhisa, S | 1 |
| Otani, H | 1 |
| Okazaki, T | 3 |
| Yamashita, K | 1 |
| Akita, Y | 1 |
| Sato, D | 1 |
| Moriguchi, A | 4 |
| Imamura, H | 1 |
| Sarma, GRK | 1 |
| Kamath, V | 1 |
| Mathew, T | 1 |
| Roy, AK | 1 |
| Dashti-Khavidaki, S | 1 |
| Faghihi, T | 1 |
| Ahmadi, F | 1 |
| Khalili, H | 1 |
| Liang, B | 1 |
| Milanović, S | 1 |
| Kageyama, S | 1 |
| You, D | 1 |
| Cochain, C | 1 |
| Loinard, C | 1 |
| Vilar, J | 1 |
| Mees, B | 1 |
| Duriez, M | 2 |
| Lévy, BI | 7 |
| Silvestre, JS | 1 |
| Sabino, B | 1 |
| Lessa, MA | 1 |
| Nascimento, AR | 1 |
| Rodrigues, CA | 1 |
| Henriques, Md | 1 |
| Garzoni, LR | 1 |
| Tibiriçá, E | 1 |
| Xi, GL | 1 |
| Cheng, JW | 1 |
| Lu, GC | 1 |
| Yildiz, A | 1 |
| Yigit, Z | 1 |
| Okcun, B | 1 |
| Baskurt, M | 1 |
| Ortak, K | 1 |
| Kaya, A | 1 |
| Kucukoglu, S | 1 |
| Donner, K | 1 |
| Burgess, E | 1 |
| Weir, M | 1 |
| Davidai, G | 1 |
| Kang, YJ | 1 |
| Song, IH | 1 |
| Choi, HC | 1 |
| Devlin, AM | 3 |
| Davidson, AO | 1 |
| Gordon, JF | 1 |
| Campbell, AM | 1 |
| Morton, JJ | 2 |
| Reid, JL | 6 |
| Schnecko, A | 1 |
| Witte, K | 1 |
| Lemmer, B | 1 |
| Johnston, CI | 2 |
| McCoy, R | 1 |
| Navarro-Cid, J | 5 |
| Maeso, R | 7 |
| Perez-Vizcaino, F | 1 |
| Cachofeiro, V | 9 |
| Tamargo, J | 1 |
| Lahera, V | 7 |
| Schaad, NC | 1 |
| Osterheld, MC | 1 |
| Grouzmann, E | 1 |
| Brunner, HR | 12 |
| Nishimura, N | 1 |
| Takase, H | 1 |
| Morita, O | 1 |
| Kushida, H | 1 |
| Kunihara, M | 1 |
| Santos, CM | 1 |
| Pontieri, V | 1 |
| Leomil Neto, M | 1 |
| Gabel, RA | 1 |
| Zingaro, GJ | 1 |
| Schorn, TW | 1 |
| Schaffer, LW | 1 |
| Ashton, WT | 1 |
| Chang, LL | 1 |
| Flanagan, K | 1 |
| Greenlee, WJ | 1 |
| Shand, BI | 3 |
| Gilchrist, NL | 1 |
| Bailey, RR | 1 |
| Bauer, IH | 1 |
| Reams, GP | 1 |
| Lau-Sieckman, A | 1 |
| Wiens, B | 1 |
| Bornkessel, B | 1 |
| Caputo, L | 2 |
| Tedgui, A | 1 |
| Bartholomeusz, B | 1 |
| Widdop, RE | 1 |
| Itskovitz, HD | 1 |
| Guthrie, GP | 1 |
| Rodrigo, E | 6 |
| Navarro, J | 2 |
| Lark, LA | 1 |
| Wappel, SM | 1 |
| Weyhenmeyer, JA | 1 |
| Cody, RJ | 1 |
| Binkley, PF | 1 |
| Haas, GJ | 1 |
| Brown, DM | 1 |
| Keller, SE | 1 |
| Goldberg, A | 4 |
| Sweet, C | 2 |
| de Jong, PE | 2 |
| van Zwieten, PA | 2 |
| Lie, KI | 1 |
| Moreau, N | 1 |
| Richer, C | 5 |
| Vincent, MP | 2 |
| Giudicelli, JF | 5 |
| Fornes, P | 1 |
| Vacher, E | 2 |
| Bruneval, P | 1 |
| Provencher, PH | 1 |
| Saltis, J | 1 |
| Funder, JW | 1 |
| Berman, RS | 1 |
| Jallard, N | 1 |
| Saenz, A | 1 |
| Weidler, DJ | 1 |
| Peleg, E | 1 |
| Carroll, J | 1 |
| Shamiss, A | 1 |
| Rosenthal, T | 2 |
| MacFadyen, RJ | 1 |
| Brunner, H | 2 |
| Irwin, R | 1 |
| Karlberg, BE | 2 |
| Snavely, DB | 3 |
| Dobbins, TW | 1 |
| Faison, EP | 2 |
| Nelson, EB | 3 |
| Barber, DA | 1 |
| Barber, CH | 1 |
| Bivins, CL | 1 |
| Tackett, RL | 1 |
| Gahnem, F | 1 |
| Camargo, MJ | 6 |
| von Lutterotti, N | 5 |
| Laragh, JH | 7 |
| Sealey, JE | 4 |
| Kohzuki, M | 3 |
| Yasujima, M | 2 |
| Kanazawa, M | 3 |
| Yoshida, K | 4 |
| Fu, LP | 1 |
| Obara, K | 2 |
| Abe, K | 4 |
| Arcuri, KE | 3 |
| Ikeda, LS | 1 |
| Goldberg, MR | 4 |
| Bradstreet, TE | 3 |
| McWilliams, EJ | 1 |
| Tanaka, WK | 1 |
| Lipert, S | 1 |
| Bjornsson, TD | 1 |
| Waldman, SA | 1 |
| Osborne, B | 1 |
| Pivadori, L | 1 |
| Lewis, G | 1 |
| Delacrétaz, E | 1 |
| Jover, B | 6 |
| Wright, JW | 1 |
| Hamilton, TA | 1 |
| Harding, JW | 1 |
| Haws, RM | 1 |
| Shaul, PW | 1 |
| Arant, BS | 1 |
| Atiyeh, BA | 1 |
| Seikaly, MG | 1 |
| Radhakrishnan, R | 1 |
| Sim, MK | 2 |
| Nakhle, G | 1 |
| Gorbea-Oppliger, VJ | 1 |
| Melaragno, MG | 2 |
| Potter, GS | 1 |
| Petit, RL | 1 |
| Rockman, HA | 1 |
| Wachhorst, SP | 1 |
| Mao, L | 1 |
| Ross, J | 1 |
| Iyer, SN | 3 |
| Eide, I | 1 |
| Qiu, HY | 1 |
| Henrion, D | 3 |
| Kline, RL | 2 |
| Yang, RH | 2 |
| Jin, HG | 1 |
| Chen, SJ | 1 |
| Meng, QC | 1 |
| Berecek, KH | 2 |
| Wyss, JM | 3 |
| Abeta, H | 1 |
| Takahashi, A | 1 |
| Furukawa, L | 1 |
| Asagami, T | 1 |
| Hino, T | 1 |
| Saito, F | 1 |
| Crabos, M | 1 |
| Bertschin, S | 1 |
| Bühler, FR | 1 |
| Rogg, H | 1 |
| Evéquoz, D | 1 |
| Eberhard, M | 1 |
| van der Mark, J | 1 |
| Brosnihan, KB | 3 |
| Ganten, D | 6 |
| Qiu, C | 1 |
| Engels, K | 1 |
| Baylis, C | 1 |
| Pucci, ML | 2 |
| Miller, KB | 1 |
| Dick, LB | 1 |
| Guan, H | 2 |
| Nasjletti, A | 3 |
| Himeno, H | 1 |
| Crawford, DC | 1 |
| Hosoi, M | 1 |
| Chobanian, AV | 1 |
| Brecher, P | 1 |
| Paré, MC | 1 |
| Maltais, S | 1 |
| Escher, E | 1 |
| Oddie, CJ | 2 |
| Dilley, RJ | 2 |
| Kanellakis, P | 2 |
| Pollock, DM | 1 |
| Divish, BJ | 1 |
| Polakowski, JS | 1 |
| Opgenorth, TJ | 1 |
| Gut, A | 1 |
| Ferrari-Spadotto, A | 1 |
| Georgette, J | 1 |
| Gavras, I | 1 |
| Moreira, ED | 3 |
| Ida, F | 1 |
| Pires, MD | 1 |
| da Silva, VJ | 1 |
| da Silva, SV | 1 |
| Arendshorst, WJ | 3 |
| Eberhardt, RT | 1 |
| Kevak, RM | 1 |
| Kang, PM | 1 |
| Foote, EF | 1 |
| Halstenson, CE | 1 |
| Stier, CT | 1 |
| Adler, LA | 1 |
| Levine, S | 1 |
| Chander, PN | 1 |
| Porter, JP | 2 |
| Soltis, EE | 1 |
| Campbell, WG | 2 |
| Pecker, MS | 2 |
| James, GD | 2 |
| Olins, GM | 1 |
| Smits, GJ | 1 |
| Koepke, JP | 1 |
| Reitz, DB | 1 |
| Manning, RE | 1 |
| Blaine, EH | 2 |
| Tsunoda, K | 2 |
| Hagino, T | 2 |
| Omata, K | 1 |
| Misawa, S | 1 |
| Yoshinaga, K | 4 |
| Strömberg, C | 1 |
| Näveri, L | 1 |
| Saavedra, JM | 1 |
| Fregly, MJ | 1 |
| Rossi, F | 1 |
| Van Bergen, P | 1 |
| Brummermann, M | 1 |
| Cade, JR | 1 |
| Herizi, A | 3 |
| Ventre, F | 1 |
| Dupont, M | 1 |
| Sasaki, M | 2 |
| Fujimura, A | 2 |
| Sunaga, K | 2 |
| Ebihara, A | 2 |
| Chan, JC | 2 |
| Critchley, JA | 2 |
| Lappe, JT | 1 |
| Raskin, SJ | 1 |
| Awan, NA | 1 |
| Mason, DT | 1 |
| Opsahl, JA | 1 |
| Katz, SA | 1 |
| Chauvin, B | 1 |
| MacKay, JH | 1 |
| Fitzpatrick, V | 1 |
| Chrysant, S | 1 |
| Francischetti, EA | 1 |
| Metsärinne, K | 1 |
| Nordby, G | 1 |
| Eide, IK | 1 |
| Hansson, L | 3 |
| Kaminski, PM | 1 |
| Wolin, MS | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Lee, WK | 1 |
| Anderson, NH | 2 |
| Bohr, DF | 1 |
| Schlienger, RG | 1 |
| Saxer, M | 1 |
| Mann, J | 1 |
| Kurz, S | 2 |
| Tarpey, M | 1 |
| Freeman, BA | 1 |
| Griendling, KK | 2 |
| Harrison, DG | 2 |
| Goodfriend, TL | 1 |
| Elliott, ME | 1 |
| Catt, KJ | 1 |
| Velasquez, MT | 1 |
| Seljeflot, I | 2 |
| Sandvik, E | 1 |
| Arnesen, H | 2 |
| Brink, M | 1 |
| Wellen, J | 1 |
| Delafontaine, P | 1 |
| Glasgow, NJ | 1 |
| Murdoch, JC | 1 |
| Baynouna, L | 1 |
| al Sabosy, MM | 1 |
| al Jabiri, ON | 1 |
| Harron, DW | 2 |
| Wallerson, DC | 1 |
| Ruff, D | 1 |
| Berman, R | 1 |
| Heller, J | 2 |
| Hellerová, S | 2 |
| McCrea, JB | 1 |
| Tomasko, L | 1 |
| Hsieh, JY | 1 |
| Capra, NL | 1 |
| Höglund, P | 1 |
| Benessiano, J | 1 |
| Heymes, C | 1 |
| Poitevin, P | 2 |
| Samuel, JL | 2 |
| Wang, DH | 2 |
| Yao, A | 1 |
| DiPette, DJ | 1 |
| Li, Q | 1 |
| Dale, WE | 1 |
| Hasser, EM | 1 |
| Kaneko, K | 1 |
| Nunez, E | 1 |
| Ruan, X | 1 |
| Scholze, J | 2 |
| Simpson, RL | 3 |
| Toh, J | 2 |
| Karasek, D | 1 |
| Adamski, M | 1 |
| Domergue, V | 1 |
| Nagura, J | 2 |
| Hui, C | 2 |
| Yamamoto, M | 2 |
| Yasuda, S | 2 |
| Hachisu, M | 2 |
| Konno, F | 2 |
| Laakso, M | 1 |
| Karjalainen, L | 1 |
| Lempiäinen-Kuosa, P | 1 |
| Zou, LX | 1 |
| Imig, JD | 1 |
| von Thun, AM | 1 |
| Hymel, A | 1 |
| Ono, H | 1 |
| Pfaffendorf, M | 2 |
| Lantelme, P | 2 |
| Gharib, C | 1 |
| Bizollon, CA | 1 |
| Sassard, J | 1 |
| Zimlichman, R | 2 |
| Fauvel, JP | 1 |
| Velon, S | 1 |
| Berra, N | 1 |
| Pozet, N | 1 |
| Zech, P | 1 |
| Laville, M | 1 |
| Goa, KL | 1 |
| Byyny, RL | 2 |
| Merrill, DD | 1 |
| Junggren, IL | 1 |
| Sun, X | 1 |
| Demeilliers, B | 2 |
| Munoz-Garcia, R | 4 |
| Casal, MC | 1 |
| Nakashima, M | 1 |
| Umemura, K | 1 |
| Krasnikova, TL | 1 |
| Pichler, M | 1 |
| Klein, W | 1 |
| Huber, K | 1 |
| Pachinger, O | 1 |
| Brännström, K | 1 |
| Morsing, P | 2 |
| Prisant, LM | 1 |
| Bertolino, S | 1 |
| Julien, C | 1 |
| Medeiros, IA | 1 |
| Cuisinaud, G | 1 |
| Vincent, M | 1 |
| Barrès, C | 1 |
| Gouédard, O | 1 |
| Gaudet, E | 1 |
| Blanc, J | 2 |
| Ponchon, P | 2 |
| Huang, BS | 1 |
| Aukland, K | 1 |
| Jensen, HA | 2 |
| Smith, MC | 1 |
| Barrows, S | 1 |
| Meibohm, A | 1 |
| Weigel, K | 1 |
| Dunn, MJ | 1 |
| Baldinger, S | 1 |
| Irvine, RJ | 1 |
| White, JM | 1 |
| Head, RJ | 1 |
| Himmelmann, A | 1 |
| Svensson, A | 1 |
| Bergbrant, A | 1 |
| Medina, R | 1 |
| Cardona-Sanclemente, LE | 1 |
| Born, GV | 1 |
| Burrell, LM | 2 |
| Metelitsa, VI | 2 |
| Gohlke, P | 2 |
| Kuwer, I | 1 |
| Schnell, A | 1 |
| Amann, K | 2 |
| Mall, G | 1 |
| Blume, A | 1 |
| Lebrun, CJ | 1 |
| Herdegen, T | 1 |
| Bravo, R | 2 |
| Möllenhoff, E | 1 |
| Tomlinson, B | 2 |
| Chan, TY | 1 |
| Cockram, CS | 1 |
| Liu, PF | 1 |
| Randall, MD | 1 |
| Chan, P | 1 |
| Huang, TY | 1 |
| Ko, JT | 1 |
| Lin, TS | 1 |
| Ichikawa, M | 1 |
| Nishizawa, M | 1 |
| Oshima, N | 1 |
| Goldsmith, DJ | 1 |
| Sharma, PK | 1 |
| Yium, JJ | 1 |
| Erlich, Y | 1 |
| Rosenmann, E | 1 |
| Cohen, A | 1 |
| Cheung, B | 1 |
| Paolisso, G | 1 |
| Tagliamonte, MR | 1 |
| Gambardella, A | 1 |
| Manzella, D | 1 |
| Gualdiero, P | 1 |
| Varricchio, G | 1 |
| Verza, M | 1 |
| Varricchio, M | 1 |
| Laursen, JB | 2 |
| Borthayre, A | 1 |
| Keiser, J | 1 |
| Haleen, S | 1 |
| Giaid, A | 1 |
| Dubois, M | 1 |
| Wilson, TW | 2 |
| Devereux, R | 1 |
| Grekin, RJ | 1 |
| Dumont, CJ | 1 |
| Vollmer, AP | 1 |
| Watts, SW | 1 |
| Webb, RC | 1 |
| Peiró, C | 1 |
| Llergo, JL | 1 |
| Angulo, J | 1 |
| Rodríguez-López, A | 1 |
| Rodríguez-Mañas, L | 1 |
| Sánchez-Ferrer, CF | 1 |
| K-Laflamme, A | 3 |
| Oster, L | 2 |
| Cardinal, R | 3 |
| Nielsen, S | 1 |
| Dollerup, J | 1 |
| Nielsen, B | 1 |
| Scheen, AJ | 2 |
| Yo, Y | 1 |
| Nagano, M | 1 |
| Yu, H | 1 |
| Mikami, H | 1 |
| Lu, D | 2 |
| Iyer, S | 1 |
| Reaves, P | 1 |
| Lall, SB | 1 |
| Peshin, SS | 1 |
| Gulati, K | 1 |
| Khattar, S | 1 |
| Das, N | 1 |
| Seth, SD | 1 |
| Black, MJ | 1 |
| de León, H | 1 |
| Fukui, T | 1 |
| Wilcox, JN | 1 |
| De Keulenaer, G | 1 |
| Alexander, RW | 1 |
| McIntyre, M | 1 |
| Caffe, SE | 1 |
| Michalak, RA | 1 |
| Tikkanen, T | 1 |
| Blanche, P | 1 |
| Raynaud, E | 1 |
| Kerob, D | 1 |
| Galezowski, N | 1 |
| Albrecht, D | 1 |
| Henklein, P | 1 |
| Gifford, RW | 1 |
| Shibasaki, M | 2 |
| Fujimori, A | 2 |
| Kusayama, T | 1 |
| Tokioka, T | 1 |
| Satoh, Y | 1 |
| Uchida, W | 1 |
| Inagaki, O | 2 |
| Yanagisawa, I | 2 |
| Carney, S | 1 |
| Ostergren, J | 1 |
| Lankford, SM | 1 |
| Plummer, D | 1 |
| Hellyer, P | 1 |
| Christ, DD | 1 |
| Bai, SA | 1 |
| Okuhira, M | 1 |
| Amano, H | 1 |
| Inokuma, K | 1 |
| Hirata, T | 1 |
| Mikoshiba, I | 1 |
| Hashimoto, K | 1 |
| Jiang, YC | 1 |
| Markind, JE | 1 |
| Kida, I | 1 |
| Tomita, N | 1 |
| Hunyady, L | 1 |
| Nagy, L | 1 |
| Peczkowska, M | 1 |
| Kabat, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Lefebvre, P | 1 |
| Horn, S | 1 |
| Holzer, H | 1 |
| Horina, J | 1 |
| Degaute, JP | 1 |
| Sternon, J | 1 |
| Pees, C | 1 |
| Toto, R | 1 |
| Shultz, P | 1 |
| Raij, L | 1 |
| Mitchell, H | 1 |
| Shaw, W | 1 |
| Russo, F | 1 |
| Marci, M | 1 |
| Raffa, S | 1 |
| Aspelin, T | 1 |
| Foucart, S | 1 |
| Moreau, P | 1 |
| Wagner, J | 1 |
| Drab, M | 1 |
| Bohlender, J | 2 |
| Wienen, W | 1 |
| Aquino, D | 2 |
| Caccavale, A | 1 |
| Acitorio, M | 1 |
| Rocereto, A | 1 |
| Cosimi, R | 1 |
| Coppolino, P | 1 |
| Iarussi, D | 3 |
| Iacono, A | 4 |
| dos Santos, CM | 2 |
| Lepe, L | 1 |
| Cifkova, R | 1 |
| Karpov, YA | 1 |
| Lerch, M | 1 |
| Teuscher, AU | 1 |
| Beissner, P | 1 |
| Schneider, M | 1 |
| Shaw, SG | 1 |
| Weidmann, P | 1 |
| Zacharieva, S | 2 |
| Orbetzova, M | 2 |
| Natchev, E | 2 |
| Vergilova, J | 1 |
| Andrewa, M | 1 |
| Wipperrnann, M | 1 |
| Torbova, S | 1 |
| Tzingilev, D | 2 |
| Angelova-Gateva, P | 1 |
| Kassler-Taub, K | 1 |
| Littlejohn, T | 1 |
| Elliott, W | 1 |
| Ruddy, T | 1 |
| Adler, E | 1 |
| d'Uscio, LV | 1 |
| Shaw, S | 1 |
| Barton, M | 1 |
| Cottone, S | 1 |
| Vadalà, A | 1 |
| Vella, MC | 1 |
| Nardi, E | 1 |
| Contorno, A | 1 |
| Riccobene, R | 1 |
| Elliott, HL | 1 |
| Nishikawa, K | 1 |
| Suga, A | 1 |
| Nguyen, T | 1 |
| Han, NL | 1 |
| Weinbacher, M | 2 |
| Drewe, J | 1 |
| Gasser, P | 1 |
| Bunt, T | 5 |
| Dumaswala, A | 1 |
| Onuigbo, M | 1 |
| Fang, TC | 2 |
| Huang, WC | 2 |
| Fortuño, MA | 3 |
| Ravassa, S | 3 |
| Etayo, JC | 3 |
| Rizzoni, D | 2 |
| Porteri, E | 1 |
| Piccoli, A | 1 |
| Castellano, M | 1 |
| Bettoni, G | 1 |
| Muiesan, ML | 1 |
| Pasini, G | 1 |
| Guelfi, D | 1 |
| Mulvany, MJ | 1 |
| Agabiti Rosei, E | 1 |
| Sabri, A | 1 |
| Marotte, F | 1 |
| Rappaport, L | 1 |
| Cerutti, C | 1 |
| Paultre, CZ | 1 |
| Ducher, M | 1 |
| Baan, J | 1 |
| Chang, PC | 1 |
| Vermeij, P | 1 |
| Barnes, CC | 1 |
| Limongelli, G | 1 |
| Mennella, S | 2 |
| Galzerano, D | 1 |
| Camara, AK | 1 |
| Osborn, JL | 1 |
| Goffin, E | 1 |
| Pochet, JM | 1 |
| Lejuste, P | 1 |
| De Plaen, JF | 1 |
| Anderson, OK | 1 |
| Lusardi, P | 2 |
| Gainer, JV | 1 |
| Loveland, A | 1 |
| King, DJ | 1 |
| Szczepańska-Sadowska, E | 1 |
| Paczwa, P | 1 |
| Loń, S | 1 |
| Yang, G | 1 |
| Beltz, TG | 2 |
| Cassell, MD | 3 |
| Johnson, AK | 2 |
| Elkins, M | 1 |
| Liss, C | 1 |
| Vrecenak, AJ | 1 |
| Barr, E | 1 |
| Didenko, VA | 1 |
| Simonov, DV | 1 |
| Turcani, M | 1 |
| Rupp, H | 1 |
| Lang, SM | 1 |
| Schiffl, H | 1 |
| Teisman, AC | 1 |
| Pinto, YM | 2 |
| Buikema, H | 1 |
| Flesch, M | 1 |
| Paul, M | 2 |
| van Gilst, WH | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Yoneda, H | 1 |
| Toriumi, W | 1 |
| Ohmachi, Y | 1 |
| Okumura, F | 1 |
| Fujimura, H | 1 |
| Nishiyama, S | 1 |
| Ledingham, JM | 1 |
| Laverty, R | 1 |
| Cicco, G | 1 |
| van der Kleij, AJ | 1 |
| Manicone, A | 1 |
| Vicenti, P | 1 |
| Dolce, E | 1 |
| Pirelli, A | 1 |
| Hamilton, CA | 1 |
| Schork, NJ | 1 |
| Zhuo, J | 1 |
| Ohishi, M | 1 |
| Mendelsohn, FA | 1 |
| Endemann, D | 1 |
| He, G | 1 |
| Li, JS | 1 |
| Carabello, BA | 1 |
| Conrad, CC | 1 |
| Buckley, JM | 1 |
| DeFreyte, G | 1 |
| Barnes, M | 1 |
| Tomanek, RJ | 1 |
| Wei, CC | 1 |
| Cooper, G | 1 |
| Zaslavskaia, RM | 2 |
| Komarov, FI | 2 |
| Goncharov, LF | 1 |
| Goncharova, ZF | 1 |
| Makarova, LA | 2 |
| Strawn, WB | 1 |
| Gallagher, PE | 1 |
| Tallant, EA | 1 |
| Lee, BH | 1 |
| Seo, HW | 1 |
| Kwon, KJ | 1 |
| Yoo, SE | 1 |
| Shin, HS | 1 |
| Chung, O | 1 |
| Csikós, T | 1 |
| Sever, PS | 1 |
| Olsen, ME | 1 |
| Thomsen, T | 1 |
| Hassager, C | 1 |
| Azizi, M | 2 |
| Venkata, C | 1 |
| Ram, S | 1 |
| Fierro, G | 1 |
| Varo, N | 4 |
| Beaumont, J | 1 |
| Iraburu, MJ | 2 |
| Montiel, C | 1 |
| Gil, MJ | 1 |
| Monreal, I | 1 |
| Kähönen, M | 4 |
| Karjala, K | 1 |
| Mäkynen, H | 1 |
| Dimitrova, A | 1 |
| Todorova, M | 1 |
| Bianov, K | 1 |
| Halachev, N | 1 |
| Dineva, S | 1 |
| Elenkova, A | 1 |
| Rasmussen, K | 1 |
| Rapelli, A | 1 |
| Gatlin, M | 1 |
| Kobi, P | 1 |
| Sullivan, J | 1 |
| Oddou-Stock, P | 1 |
| Warner, JG | 1 |
| Metzger, DC | 1 |
| Wesley, DJ | 1 |
| Weisemann, R | 1 |
| D'Elom, E | 1 |
| Beaumont, FJ | 1 |
| Jones, RE | 1 |
| Ball, EV | 1 |
| Kirk, JK | 1 |
| Ibusuki, T | 3 |
| Saito, E | 2 |
| Kambe, T | 3 |
| Nakagawa, H | 1 |
| Daihara, M | 1 |
| Tamakawa, H | 1 |
| Nozue, T | 1 |
| Kawahara, K | 1 |
| Elisaf, M | 3 |
| Tsimichodimos, V | 1 |
| Bairaktari, E | 2 |
| Siamopoulos, KC | 1 |
| Birkenhäger, WH | 2 |
| van der Meulen, J | 1 |
| Cleophas, TJ | 1 |
| Zwinderman, AH | 1 |
| Koval', SN | 1 |
| Belovol, AN | 1 |
| Miloslavskiĭ, DK | 1 |
| Masliaeva, LV | 1 |
| Mysnichenko, OV | 1 |
| Hung, MJ | 1 |
| Lin, FC | 1 |
| Cherng, WJ | 1 |
| Wang, CH | 1 |
| Hung, KC | 1 |
| Hsieh, IC | 1 |
| Wen, MS | 1 |
| Ruzicka, M | 1 |
| Yuan, B | 1 |
| Kawasaki, S | 1 |
| Hashiba, T | 1 |
| Chen, CJ | 1 |
| Hatakeyama, H | 1 |
| Asakura, H | 1 |
| Kikuchi, M | 1 |
| Matsuda, T | 1 |
| Fletcher, EC | 1 |
| Bao, G | 1 |
| de Cingolani, GE | 1 |
| Bech, JN | 1 |
| Pedersen, EB | 1 |
| Müller, GA | 1 |
| Nawarskas, JJ | 1 |
| Townsend, RR | 1 |
| Cirigliano, MD | 1 |
| Spinler, SA | 1 |
| Melo, LG | 1 |
| Veress, AT | 1 |
| Chong, CK | 1 |
| Ackermann, U | 2 |
| Sonnenberg, H | 1 |
| Ayoub, JC | 1 |
| Vitola, JV | 1 |
| Parro, A | 1 |
| Costa, OM | 1 |
| Delgado, AS | 1 |
| de Parma, AH | 1 |
| Takakura, IT | 1 |
| Rivera, JO | 1 |
| Kaplan, NM | 1 |
| Mallion, J | 1 |
| Siche, J | 1 |
| Pastore, L | 1 |
| Tessitore, A | 1 |
| Martinotti, S | 1 |
| Toniato, E | 1 |
| Alesse, E | 1 |
| Bravi, MC | 1 |
| Gulino, A | 1 |
| Santucci, A | 1 |
| Satomi, T | 1 |
| Suzuki, J | 1 |
| Ikemoto, F | 1 |
| Nishikibe, M | 1 |
| Catanzaro, DF | 1 |
| Hutri-Kähönen, N | 1 |
| Holm, P | 1 |
| Reaves, PY | 1 |
| Gelband, CH | 1 |
| Carides, AD | 1 |
| Thiyagarajan, B | 1 |
| Nakagawa, Y | 1 |
| Parks, JH | 1 |
| Coe, FL | 1 |
| Plante, GE | 1 |
| Alderman, M | 2 |
| Spence, JD | 2 |
| Dell'Oro, R | 1 |
| Turri, C | 1 |
| Erdem, Y | 1 |
| Usalan, C | 1 |
| Haznedaroğlu, IC | 1 |
| Altun, B | 1 |
| Arici, M | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Cağlar, S | 1 |
| Oosting, J | 1 |
| Manzo, G | 1 |
| Grieco, M | 1 |
| Rainone, AC | 1 |
| Calviño, J | 1 |
| Lens, XM | 1 |
| Romero, R | 1 |
| Sánchez-Guisande, D | 1 |
| Laude, D | 2 |
| Magga, J | 1 |
| Romppanen, H | 1 |
| Anguita Sánchez, M | 1 |
| Coca, A | 2 |
| Giner, V | 1 |
| Hadjigavriel, M | 1 |
| Kyriakides, G | 1 |
| Maillard, MP | 1 |
| Mazzolai, L | 1 |
| Daven, V | 1 |
| Centeno, C | 1 |
| Leary, AC | 1 |
| Kamenskaia, EP | 1 |
| Carlson, SH | 1 |
| Shelton, J | 1 |
| White, CR | 1 |
| Petkun, W | 1 |
| Vidt, DG | 2 |
| Cice, G | 1 |
| Ferrara, L | 1 |
| Tagliamonte, E | 1 |
| Russo, PE | 1 |
| Di Benedetto, A | 1 |
| Hayek, T | 1 |
| Attias, J | 1 |
| Coleman, R | 1 |
| Brodsky, S | 1 |
| Smith, J | 1 |
| Breslow, JL | 1 |
| Keidar, S | 1 |
| Voipio, J | 1 |
| Pekki, A | 1 |
| Doris, PA | 1 |
| Ylitalo, P | 1 |
| Taguchi, Ji | 1 |
| Tang, SS | 1 |
| Owens, P | 1 |
| Kelly, L | 1 |
| Nallen, R | 1 |
| Ryan, D | 1 |
| Cerbai, E | 1 |
| Crucitti, A | 1 |
| Sartiani, L | 1 |
| De Paoli, P | 1 |
| Pino, R | 1 |
| Rodriguez, ML | 1 |
| Gensini, G | 1 |
| Mugelli, A | 1 |
| Fasce, E | 1 |
| Wagemann, H | 1 |
| Intengan, HD | 2 |
| Tsujimura, M | 2 |
| Hasegawa, S | 1 |
| Iesato, K | 1 |
| Tsukahara, T | 1 |
| Kondou, Y | 1 |
| Ogawa, M | 1 |
| Ueda, S | 1 |
| Gerbaulet, S | 1 |
| Krämer, J | 1 |
| Gross, M | 1 |
| Kirchengast, M | 1 |
| Rodriguez-Garcia, JL | 1 |
| Paule, A | 1 |
| Dominguez, J | 1 |
| Garcia-Escribano, JR | 1 |
| Vazquez, M | 1 |
| Simpson, KL | 1 |
| McClellan, KJ | 1 |
| Vetter, W | 1 |
| Hess, L | 1 |
| Brignoli, R | 1 |
| Kraiczi, H | 1 |
| Hedner, J | 1 |
| Grote, L | 1 |
| Redon, J | 2 |
| Tea, BS | 1 |
| Benedict, C | 1 |
| Bunt, AM | 1 |
| Matrougui, K | 1 |
| Azizi, N | 1 |
| Sosa-Canache, B | 1 |
| Cierco, M | 1 |
| Gutierrez, CI | 1 |
| Israel, A | 1 |
| Hernández-Hernández, R | 1 |
| Velasco, M | 1 |
| Armas-Hernández, MJ | 1 |
| Armas-Padilla, MC | 1 |
| Israili, ZH | 1 |
| Varela, M | 1 |
| Arai, T | 2 |
| Takaya, T | 2 |
| Toshima, S | 2 |
| Kashiki, Y | 2 |
| Yoshimii, N | 1 |
| Fujiwara, H | 2 |
| Lee, YJ | 1 |
| Chiang, YF | 1 |
| Tsai, JC | 1 |
| Farsang, C | 1 |
| Niegowska, J | 1 |
| Baiz, AQ | 1 |
| Vrijens, F | 1 |
| Bortman, G | 1 |
| Eliseeva, LN | 1 |
| Blednova, AIu | 1 |
| Avakimian, ZA | 1 |
| Tkachenko, AM | 1 |
| Orlova, TA | 1 |
| Avanza, AC | 1 |
| El Aouar, LM | 1 |
| Mill, JG | 1 |
| Feldman, R | 1 |
| Ragot, S | 1 |
| Genès, N | 1 |
| Vaur, L | 1 |
| Herpin, D | 1 |
| Howes, L | 1 |
| Reboldi, GP | 1 |
| Sacchi, N | 1 |
| Bruni, B | 1 |
| Benemio, G | 1 |
| Porcellati, C | 1 |
| Costagliola, C | 1 |
| Verolino, M | 1 |
| De Rosa, ML | 2 |
| Iaccarino, G | 1 |
| Ciancaglini, M | 1 |
| Mastropasqua, L | 1 |
| Linhart, A | 1 |
| Alexander, J | 2 |
| Menten, J | 1 |
| Ménard, J | 1 |
| Reaux, A | 1 |
| Iturrioz, X | 1 |
| Vazeux, G | 1 |
| Fournie-Zaluski, MC | 1 |
| David, C | 1 |
| Roques, BP | 1 |
| Corvol, P | 1 |
| Llorens-Cortes, C | 1 |
| Elliott, WJ | 2 |
| Belabbas, H | 1 |
| Myking, OL | 1 |
| Lund-Johansen, P | 1 |
| Yeung, PK | 1 |
| Jamieson, A | 1 |
| Smith, GJ | 1 |
| Fice, D | 1 |
| Pollak, PT | 1 |
| Ding, Y | 1 |
| Stec, DE | 1 |
| Catterall, JF | 1 |
| Shakirova, AN | 1 |
| Narmanova, OZh | 1 |
| Biiasilov, N | 1 |
| Cifuentes, ME | 1 |
| Rey, FE | 1 |
| Carretero, OA | 1 |
| Pagano, PJ | 1 |
| DE Gracia, MC | 1 |
| Del Moral, RG | 1 |
| Del Rio, CG | 1 |
| Edmunds, E | 1 |
| Blann, AD | 1 |
| Pinto-Sietsma, SJ | 1 |
| Philipp, T | 1 |
| Engler, S | 1 |
| Kossamehl, P | 1 |
| Hocher, B | 1 |
| Marquardt, H | 1 |
| Sethmann, S | 1 |
| Lauster, R | 1 |
| Merker, HJ | 1 |
| Stevenson, KM | 1 |
| Edgley, AJ | 1 |
| Worthy, K | 1 |
| Kett, MM | 1 |
| Anderson, WP | 1 |
| Badguet, JP | 1 |
| Levy, PJ | 1 |
| Yunis, C | 1 |
| Owen, J | 1 |
| Smith, R | 1 |
| Costa, R | 1 |
| Bova, A | 1 |
| Palumbo, VA | 1 |
| Pinto, A | 1 |
| Lynn, KL | 1 |
| Manolis, AJ | 1 |
| Jelakovic, B | 1 |
| Jacovides, A | 1 |
| Bernhardi, DC | 1 |
| Cabrera, WJ | 1 |
| Barragan, J | 1 |
| Mendiola, A | 1 |
| Woo, KS | 1 |
| Mejia, AD | 1 |
| Dumortier, T | 1 |
| Yoshimi, N | 1 |
| Klingbeil, AU | 1 |
| Müller, HJ | 1 |
| Delles, C | 1 |
| Fleischmann, E | 1 |
| Girard, A | 1 |
| Holand, S | 1 |
| Milionis, HJ | 2 |
| Elisaf, MS | 2 |
| Blezer, EL | 1 |
| Nicolay, K | 1 |
| Joles, JA | 1 |
| Takeda, K | 1 |
| Harada, S | 1 |
| Oguni, A | 1 |
| Hatta, T | 1 |
| Kawa, T | 1 |
| Sasaki, S | 1 |
| Nakagawa, M | 1 |
| Matsumura, M | 1 |
| Shobha, JC | 1 |
| Kumar, TR | 1 |
| Raju, BS | 1 |
| Kamath, S | 1 |
| Rao, M | 1 |
| Babu, A | 1 |
| Bhaduri, J | 1 |
| Paul, B | 1 |
| Sapra, B | 1 |
| Maheshwari, S | 1 |
| Goyal, RK | 2 |
| Jiménez, AM | 1 |
| Montón, M | 1 |
| García, R | 2 |
| Núñez, A | 1 |
| Gómez, J | 1 |
| Rico, L | 1 |
| García-Colis, E | 1 |
| de Miguel, LS | 1 |
| Arriero, MM | 1 |
| Cabestrero, F | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Pathansali, R | 1 |
| Smith, NM | 1 |
| Bath, PM | 1 |
| Lijnen, P | 1 |
| Pardaens, K | 1 |
| Thijs, L | 1 |
| Vinck, W | 1 |
| Weinberg, EO | 1 |
| Herzig, JW | 1 |
| Kagiyama, S | 1 |
| Abe, I | 2 |
| Schmidt, A | 1 |
| Gruber, U | 1 |
| Böhmig, G | 1 |
| Köller, E | 1 |
| Mayer, G | 1 |
| Gorbunov, VM | 1 |
| Savina, LV | 1 |
| Deev, AD | 1 |
| Somoza, B | 1 |
| Ruiz-Gayo, M | 1 |
| González, C | 1 |
| Fernández-Alfonso, MS | 1 |
| Gupta, S | 1 |
| Dash, SC | 1 |
| Bhowmik, D | 1 |
| Mohanty, NK | 1 |
| Agarwal, SK | 1 |
| Tiwari, SC | 1 |
| Scivoletto, R | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 2 |
| Aznar, J | 1 |
| Esmatjes, E | 1 |
| Flores, L | 1 |
| Lario, S | 1 |
| Holgado, R | 1 |
| Lozano Vidal, JV | 1 |
| Aznar Vicente, J | 1 |
| Argaya Roca, M | 1 |
| Pol Bravo, C | 1 |
| Sanchez Zamorano, MA | 1 |
| Khazine, F | 1 |
| Simons, O | 1 |
| Lambot, MA | 1 |
| Vermeylen, D | 1 |
| Noël, JC | 1 |
| Grégoire, JP | 1 |
| Moisan, J | 1 |
| Guibert, R | 1 |
| Ciampi, A | 1 |
| Milot, A | 1 |
| Côté, I | 1 |
| Gaudet, M | 1 |
| Chanudet, X | 1 |
| De Champvallins, M | 1 |
| Miller, AB | 1 |
| Srivastava, P | 1 |
| Sakamoto, H | 1 |
| Aikawa, M | 1 |
| Hill, CC | 1 |
| Weiss, D | 1 |
| Taylor, WR | 1 |
| Libby, P | 1 |
| Lee, RT | 1 |
| Magometschnigg, D | 1 |
| Hauser, AC | 1 |
| Hörl, WH | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Ball, KJ | 1 |
| Williams, PA | 1 |
| Querejeta, R | 3 |
| Larman, M | 3 |
| Martínez Ubago, JL | 2 |
| Coats, AJ | 1 |
| Ridley, E | 1 |
| Rahman, M | 1 |
| Harris, S | 1 |
| Vendetti, J | 1 |
| Michelson, EL | 1 |
| Wang, R | 1 |
| Roussias, LG | 1 |
| De Bruno, MP | 1 |
| Reynoso, HA | 1 |
| Coviello, A | 1 |
| Martinovic, J | 1 |
| Benachi, A | 1 |
| Laurent, N | 1 |
| Gubler, MC | 1 |
| Chrysant, SG | 1 |
| Dumont, Y | 1 |
| D'Amours, M | 1 |
| Petrov, VV | 2 |
| Fagard, RH | 2 |
| Lijnen, PJ | 2 |
| Atanassova, I | 1 |
| Kamper, AL | 1 |
| Nielsen, AH | 1 |
| Ito, A | 1 |
| Egashira, K | 1 |
| Narishige, T | 1 |
| Muramatsu, K | 1 |
| Takeshita, A | 1 |
| Calhoun, DA | 1 |
| DeLucca, PT | 1 |
| Kerns, DE | 1 |
| Gradman, A | 1 |
| Lester, FM | 1 |
| Green, S | 1 |
| Vargas, R | 1 |
| Espenshade, M | 1 |
| Ceesay, P | 1 |
| Mitch, WE | 1 |
| Bek, M | 1 |
| Goldstein, DS | 1 |
| Rubinstein, M | 1 |
| Bezerra, SM | 1 |
| Bloomgarden, ZT | 1 |
| Malamani, G | 1 |
| Würzner, G | 1 |
| Gerster, JC | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Kamimoto, M | 1 |
| Wu, XM | 1 |
| Xu, HL | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Minami, N | 1 |
| Ohnishi, K | 1 |
| Yukiiri, K | 1 |
| Masugata, H | 1 |
| Takagi, Y | 1 |
| Ohmori, K | 1 |
| Nikas, S | 2 |
| Murali, B | 1 |
| Guasti, L | 2 |
| Petrozzino, MR | 1 |
| Mainardi, LT | 1 |
| Grimoldi, P | 1 |
| Zanotta, D | 2 |
| Garganico, D | 2 |
| Diolisi, A | 2 |
| Simoni, C | 2 |
| Gaudio, G | 2 |
| Cerutti, S | 1 |
| Fishman, S | 1 |
| Rapoport, MJ | 1 |
| Dishi, V | 1 |
| Hartzeanu, I | 1 |
| Sakata, K | 1 |
| Obayashi, K | 1 |
| Ishikawa, J | 1 |
| Tamekiyo, H | 1 |
| Nawada, R | 1 |
| Doi, O | 1 |
| Chiu, AG | 1 |
| Krowiak, EJ | 1 |
| Deeb, ZE | 1 |
| Zhong, S | 1 |
| Lai, W | 1 |
| Xiu, J | 1 |
| Agabiti-Rosei, E | 1 |
| Bergamaschi, CT | 1 |
| Lopes, OU | 1 |
| Campos, RR | 1 |
| Liberopoulos, E | 1 |
| Christides, D | 1 |
| Sica, D | 1 |
| Ram, V | 1 |
| Fagan, T | 1 |
| Vaitkus, PT | 1 |
| Sun, Z | 1 |
| Cade, R | 1 |
| Morales, C | 1 |
| Björnstad, H | 1 |
| Cardace, P | 1 |
| Rossi, M | 1 |
| Baiano, A | 1 |
| de Cristofaro, A | 1 |
| Shibasaki, Y | 1 |
| Masaki, H | 1 |
| Nishiue, T | 1 |
| Aalto, T | 1 |
| Siva, S | 1 |
| Dunn, SR | 1 |
| Sharma, K | 1 |
| Rizos, E | 1 |
| Milionis, H | 1 |
| Siamopoulos, K | 1 |
| Sonmez, A | 1 |
| Kisa, U | 1 |
| Uckaya, G | 1 |
| Eyileten, T | 1 |
| Comert, B | 1 |
| Koc, B | 1 |
| Kocabalkan, F | 1 |
| Ozata, M | 1 |
| Shimamura, T | 1 |
| Iwasaki, T | 1 |
| Hayasaki-Kajiwara, Y | 1 |
| Naya, N | 1 |
| Nakajima, M | 1 |
| Hodge, G | 1 |
| Ye, VZ | 1 |
| Duggan, KA | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 2 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Kristiansson, K | 2 |
| Diep, QN | 1 |
| El Mabrouk, M | 1 |
| Yue, P | 1 |
| Krämer, C | 1 |
| Sunkomat, J | 1 |
| Witte, J | 1 |
| Walden, M | 1 |
| Tsikas, D | 1 |
| Forssmann, WG | 1 |
| Baudin, B | 1 |
| Iida, M | 1 |
| Mamontov, OV | 1 |
| Iakovlev, AN | 1 |
| Gordeeva, MV | 1 |
| Pushkarev, AA | 1 |
| Brodskaia, IS | 1 |
| Ohkoshi, N | 1 |
| Shoji, S | 1 |
| Abellan, J | 1 |
| Cucalón, JM | 1 |
| Maceira, B | 1 |
| Gómez de la Cámara, A | 1 |
| Wang, DW | 1 |
| Hrycek, A | 1 |
| Badowski, R | 1 |
| Scieszka, J | 1 |
| Haczkiewicz, P | 1 |
| Hefczyc, J | 1 |
| Cieślik, P | 1 |
| Lindenfeld, J | 1 |
| Mazzali, M | 1 |
| Kanellis, J | 1 |
| Han, L | 1 |
| Xia, YY | 1 |
| Gordon, KL | 1 |
| Nakagawa, T | 1 |
| Lan, HY | 1 |
| Johnson, RJ | 1 |
| Usta, M | 1 |
| Yavuz, M | 1 |
| Güllülü, M | 1 |
| Oktay, B | 1 |
| Yurtkuran, M | 1 |
| Konstam, MA | 1 |
| Bonhomme, MC | 1 |
| Diebold, S | 1 |
| Einecke, D | 1 |
| Morgan, RJ | 1 |
| Mikhailidis, DP | 1 |
| Sobrino, J | 1 |
| Soler, J | 1 |
| Felip, A | 1 |
| Pelegrí, A | 1 |
| Mínguez, A | 1 |
| Vila, J | 1 |
| Plana, J | 1 |
| Neki, NS | 1 |
| Arora, P | 1 |
| Houlihan, CA | 1 |
| Akdeniz, A | 1 |
| Tsalamandris, C | 1 |
| Jerums, G | 1 |
| Gilbert, RE | 1 |
| Macko, RF | 1 |
| Bohannon, AD | 1 |
| Nilsson, P | 1 |
| Heinzl, S | 1 |
| Chiba, S | 1 |
| Rapi, J | 1 |
| Tsutamoto, T | 1 |
| Mabuchi, N | 1 |
| Tsutsui, T | 1 |
| Ohnishi, M | 1 |
| Cimen, V | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| McIntyre, H | 1 |
| Costa, FV | 1 |
| Düsing, R | 1 |
| Gerth, W | 1 |
| Alvarez, BV | 1 |
| Ennis, IL | 1 |
| De Hurtado, MC | 1 |
| Cingolani, HE | 1 |
| Christen, Y | 1 |
| Munafo, A | 1 |
| Mueller, FB | 2 |
| Mizuno, K | 2 |
| Tani, M | 2 |
| Hashimoto, S | 1 |
| Niimura, S | 2 |
| Sanada, H | 2 |
| Ohtsuki, M | 1 |
| Fukuchi, S | 2 |
| Haga, H | 1 |
| Gomibuchi, T | 1 |
| Ribeiro, MO | 1 |
| Antunes, E | 1 |
| de Nucci, G | 1 |
| Lovisolo, SM | 1 |
| Véniant, M | 1 |
| Clozel, JP | 1 |
| Hess, P | 1 |
| Fischli, W | 1 |
| Jin, H | 1 |
| Sander, M | 1 |
| Lee, MA | 1 |
| Bachmann, J | 1 |
| Djavidani, B | 1 |
| Brooks, DP | 1 |
| Fredrickson, TA | 1 |
| Weinstock, J | 1 |
| Ruffolo, RR | 1 |
| Edwards, RM | 1 |
| Gellai, M | 1 |
| Wood, JM | 1 |
| Mah, SC | 1 |
| Schnell, C | 1 |
| Sakakibara, T | 1 |
| Tofovic, SP | 1 |
| Pong, AS | 1 |
| Jackson, EK | 1 |
| Henning, R | 1 |
| Schölkens, BA | 1 |
| Fenoy, FJ | 1 |
| Milicic, I | 1 |
| Roman, R | 1 |
| Bovee, KC | 1 |
| Thoolen, MJ | 1 |
| Inagami, T | 1 |
| Higuchi, K | 1 |
| Nakajo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Losartan and Eprosartan Induce a Similar Effect on Oral Fructose-induced Rise in Serum Uric Acid Concentration in Patients With Metabolic Syndrome[NCT04954560] | 16 participants (Actual) | Interventional | 2008-01-01 | Completed | |||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study[NCT00971165] | Phase 3 | 655 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension[NCT03897868] | Phase 2 | 248 participants (Actual) | Interventional | 2019-03-21 | Completed | ||
| A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605[NCT02916602] | Phase 3 | 340 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension[NCT00994617] | Phase 4 | 600 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controll[NCT02294539] | Phase 4 | 231 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.[NCT00734630] | Phase 4 | 491 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients[NCT01830517] | Phase 4 | 84 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK954/Losartan Potassium in Pediatric Patients With Hypertension[NCT00756938] | Phase 3 | 101 participants (Actual) | Interventional | 2009-03-01 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium[NCT01307046] | Phase 3 | 336 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®][NCT01307033] | Phase 3 | 278 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration[NCT01302691] | Phase 3 | 327 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical [NCT01299376] | Phase 3 | 286 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.[NCT00408512] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893] | Phase 3 | 303 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment[NCT00701428] | Phase 4 | 90 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.[NCT01603940] | Phase 4 | 30 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955] | Phase 2 | 496 participants | Interventional | 2004-10-31 | Completed | ||
| Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure[NCT03371823] | Phase 4 | 8 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to We experienced challenges recruiting unmedicated women with high blood pressure for the intervention.) | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy[NCT00354991] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome[NCT00546052] | Phase 3 | 1,738 participants (Actual) | Interventional | 2005-09-01 | Completed | ||
| A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178] | Phase 3 | 306 participants (Actual) | Interventional | 2007-06-01 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essentia[NCT00219141] | Phase 3 | 460 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose[NCT00675987] | Phase 4 | 53 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy[NCT00940667] | Phase 3 | 185 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension.[NCT00942344] | Phase 2 | 320 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination: A Comparison of Active and Usual Titration Regimen in the Treatment of Hypertensive Patients Insufficiently Controlled by Monotherapy[NCT00708344] | Phase 4 | 832 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension[NCT00922480] | Phase 3 | 506 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension[NCT02466490] | Phase 3 | 272 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy[NCT00940680] | Phase 3 | 142 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects[NCT00949884] | Phase 4 | 941 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure[NCT00223717] | Phase 1 | 152 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease[NCT02373241] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.) | ||
| [NCT00000608] | Phase 2 | 0 participants | Interventional | 1997-02-28 | Completed | ||
| Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension[NCT02653560] | Phase 4 | 30 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Methodological Improvement in Measuring Efficacy Outcome in Antihypertensive Trials in Children[NCT01070342] | 170 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| [NCT00005474] | 1,063 participants (Actual) | Observational | 1996-09-30 | Completed | |||
| HYZAAR Versus Ramipril Diabetic Patients[NCT00480805] | Phase 3 | 312 participants (Actual) | Interventional | 2001-08-08 | Completed | ||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure[NCT02627196] | 1,200 participants (Anticipated) | Interventional | 2016-04-19 | Active, not recruiting | |||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.[NCT00140959] | Phase 4 | 120 participants | Interventional | 2003-02-01 | Completed | ||
| A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertensio[NCT00092209] | Phase 3 | 840 participants | Interventional | 2002-04-30 | Completed | ||
| A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure[NCT00289887] | Phase 3 | 261 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study[NCT06098300] | 30 participants (Anticipated) | Observational | 2023-09-01 | Recruiting | |||
| A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt N[NCT00168857] | Phase 4 | 860 participants (Actual) | Interventional | 2003-07-09 | Completed | ||
| A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)[NCT00882440] | Phase 3 | 576 participants (Actual) | Interventional | 1990-12-31 | Completed | ||
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars[NCT05259137] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)[NCT03310684] | 160 participants (Anticipated) | Observational | 2018-12-03 | Active, not recruiting | |||
| [NCT00005757] | 293 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial[NCT01574248] | Phase 4 | 33 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to DSMC recommended discontinuation for futility and feasibility) | ||
| A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study[NCT00043836] | Phase 2 | 20 participants | Interventional | 2002-07-31 | Completed | ||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries[NCT01480791] | Phase 2 | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn (stopped due to Because of results of Altitude trial, this trial was cancelled.) | ||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Psychosocial Factors and Cardiovascular Disease[NCT00005315] | 0 participants | Observational | 1993-09-30 | Completed | |||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)[NCT03201185] | Phase 4 | 194 participants (Actual) | Interventional | 2018-02-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
Change from Baseline in Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) at Week 12, Last Observation Carried Forward (LOCF). (NCT00734630)
Timeframe: From baseline Visit 5 (Week 0) to Visit 10 (Week 12)
| Intervention | mmHG (Mean) |
|---|---|
| Nebivolol | -7.8 |
| Placebo | -3.5 |
Change from Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12, Last Observation Carried Forward (LOCF). (NCT00734630)
Timeframe: From baseline Visit 5 (Week 0) to Visit 10 (Week 12)
| Intervention | mmHG (Mean) |
|---|---|
| Nebivolol | -10.1 |
| Placebo | -7.3 |
Sitting BP (or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Diastolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart. (NCT00756938)
Timeframe: Baseline and Day 21
| Intervention | mmHg (Mean) |
|---|---|
| Losartan Potassium 0.1 to 1.4 mg/kg | -8.25 |
| Losartan Potassium 0.3 to 1.4 mg/kg | -5.15 |
| Losartan Potassium 0.7 to 1.4 mg/kg | -6.73 |
Sitting blood pressure ([BP] or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Systolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart. (NCT00756938)
Timeframe: Baseline and Day 21
| Intervention | mmHg (Mean) |
|---|---|
| Losartan Potassium 0.1 to 1.4 mg/kg | -7.31 |
| Losartan Potassium 0.3 to 1.4 mg/kg | -7.65 |
| Losartan Potassium 0.7 to 1.4 mg/kg | -6.67 |
(NCT00756938)
Timeframe: up to 12 weeks (Base Study); up to 24 months (Extension)
| Intervention | Participants (Number) | |
|---|---|---|
| Clinical Adverse Event | Laboratory Adverse Event | |
| Base Study-Losartan Potassium 0.1 mg/kg | 21 | 1 |
| Base Study-Losartan Potassium 0.3 mg/kg | 30 | 1 |
| Base Study-Losartan Potassium 0.7 mg/kg | 36 | 0 |
| Base Study-Losartan Potassium 1.4 mg/kg | 22 | 0 |
| Extension-Losartan Potassium | 75 | 5 |
(NCT00756938)
Timeframe: up to 12 weeks (Base Study); up to 24 months (Extension)
| Intervention | Participants (Number) | |
|---|---|---|
| Clinical Adverse Event | Laboratory Adverse Event | |
| Base Study-Losartan Potassium 0.1 mg/kg | 0 | 0 |
| Base Study-Losartan Potassium 0.3 mg/kg | 0 | 0 |
| Base Study-Losartan Potassium 0.7 mg/kg | 0 | 0 |
| Base Study-Losartan Potassium 1.4 mg/kg | 0 | 0 |
| Extension-Losartan Potassium | 1 | 0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -8.7 |
| Losartan | -3.6 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -14.5 |
| Losartan | -5.4 |
(NCT01307046)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MK-0954A | 31.3 |
| Losartan | 26.5 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -5.3 |
| MK-0954A (L100/H12.5) | -5.0 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -6.2 |
| MK-0954A (L100/H12.5) | -8.5 |
(NCT01307033)
Timeframe: Up to 52 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5→L100/H12.5 Open Label (Period 2) | 71.0 |
| L100/H12.5→L100/H12.5 Open Label (Period 2) | 72.4 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -9.1 |
| L50 + A5 | -8.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -13.4 |
| L50 + A5 | -10.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 30.5 |
| L50 + A5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 11.6 |
| L50 + A5 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50 + A5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.6 |
| L50 + A5 | 0.6 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm (NCT01302691)
Timeframe: up to 8 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 1.2 |
| L50 + A5 | 0.0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -12.1 |
| L50/H12.5 | -6.2 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -17.7 |
| L50/H12.5 | -7.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 27.0 |
| L50/H12.5 | 29.7 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants that experienced at least 1 AE during long-term period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 70.9 |
| L50/H12.5→L50/H12.5/A5 | 66.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 12.1 |
| L50/H12.5 | 14.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the long-term reporting period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 27.7 |
| L50/H12.5→L50/H12.5/A5 | 14.3 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. the percentage of participants that experienced an SAE that assessed as possibly, probably, or definitely related to the study drug by the investigator was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 0.0 |
| L50/H12.5→L50/H12.5/A5 | 0.8 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50/H12.5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Those SAEs assessed as possibly, probably, or definitely related to the study drug during the long-term period were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 3.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week double-blind treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug discontinued during the 44 week extension due to an AE regardless of completion status were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 2.3 |
Compare both group effects on diastolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 80 |
| Benazepril | 82 |
Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of maximal vasodilation (Median) |
|---|---|
| Losartan | 9.4 |
| Benazepril | 8.8 |
Compare both groups effects on systolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 134 |
| Benazepril | 139 |
Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril). (NCT01603940)
Timeframe: 12 weeks.
| Intervention | m/s (Median) |
|---|---|
| Losartan | 8.5 |
| Benazepril | 8.5 |
Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of augmentation pressure (Median) |
|---|---|
| Losartan | 28 |
| Benazepril | 35 |
Cutaneous blood flow is measured via laser Doppler flowmetry during cutaneous microdialysis perfusions of ET-A and ET-B receptor antagonists as previously described by Wenner MM in 2017(see reference list). (NCT03371823)
Timeframe: Each participant was assessed at baseline and 2 weeks later.
| Intervention | % change blood flow flux (Mean) | |
|---|---|---|
| ETA blockade | ETB blockade | |
| Normotensive | 437 | 42 |
Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -0.36 |
Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -19.17 |
Absolute change in Body Mass Index Baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Kg/m2 (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -7.3 |
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -9.84 |
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.02 |
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.04 |
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -16.95 |
Absolute change in Waist Circumference between baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | cm (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.28 |
Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.21 |
Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.49 |
Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -2.98 |
Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 1.09 |
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks (NCT00546052)
Timeframe: 52 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Achieved Target Blood Pressure | Did NOT achieve target Blood Pressure | |
| Overall Intend to Treat | 1200 | 514 |
| Overall Per Protocol | 1200 | 311 |
| Overall Total | 1200 | 538 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -3.8 |
| Amlodipine-Hypertensive Participants | 0.8 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -5.5 |
| Amlodipine-Hypertensive Participants | -0.1 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan | -35.80 |
| Amlodipine/Placebo | 1.37 |
"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Change in GFR mL/min1.73m^2 (Least Squares Mean) |
|---|---|
| Losartan Open Label Extension | 3.3 |
| Enalapril Open Label Extension | 7.0 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan Open Label Extension | -30.01 |
| Enalapril Open Label Extension | -40.45 |
Left ventricular mass index (LVMI) was measured by magnetic resonance imaging (MRI). An increase in LVMI indicates hypertrophy of the left ventricle. This could be a normal reversible response to cardiovascular conditioning (athletic heart) or an abnormal irreversible response to chronically increased volume load (preload) or increased pressure load (afterload). Thickening of the ventricular muscle results in increased left ventricular pressure, increased end-systolic volume, and decreased end-diastolic volume, causing an overall reduction in cardiac output. (NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g/m^2 (Least Squares Mean) |
|---|---|
| Aliskiren 300 mg | -5.51 |
| Losartan 100 mg | -4.81 |
| Aliskiren/Losartan 300/100 mg | -5.61 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm * ms (Mean) |
|---|---|
| Aliskiren 300 mg | -104.97 |
| Losartan 100 mg | -150.31 |
| Aliskiren/Losartan 300/100 mg | -130.65 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.71 |
| Losartan 100 mg | -0.64 |
| Aliskiren/Losartan 300/100 mg | -0.86 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.95 |
| Losartan 100 mg | -1.20 |
| Aliskiren/Losartan 300/100 mg | -1.17 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | percent (Mean) |
|---|---|
| Aliskiren 300 mg | 0.62 |
| Losartan 100 mg | 2.02 |
| Aliskiren/Losartan 300/100 mg | 1.92 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g (Mean) |
|---|---|
| Aliskiren 300 mg | -9.81 |
| Losartan 100 mg | -9.92 |
| Aliskiren/Losartan 300/100 mg | -12.29 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -7.05 |
| Losartan 100 mg | -4.52 |
| Aliskiren/Losartan 300/100 mg | -7.03 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -3.20 |
| Losartan 100 mg | -4.73 |
| Aliskiren/Losartan 300/100 mg | -5.14 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.88 |
| Losartan 100 mg | -0.89 |
| Aliskiren/Losartan 300/100 mg | -0.90 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g/m^2 (Mean) |
|---|---|
| Aliskiren 300 mg | -4.87 |
| Losartan 100 mg | -4.79 |
| Aliskiren/Losartan 300/100 mg | -5.81 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -3.89 |
| Losartan 100 mg | 0.24 |
| Aliskiren/Losartan 300/100 mg | -2.24 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -1.07 |
| Losartan 100 mg | -0.97 |
| Aliskiren/Losartan 300/100 mg | -1.43 |
Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. A correlation was made between the ABPM device readings and measurements taken with a mercury sphygmomanometer and stethoscope. Following the correlation procedure, blood pressure was measured at study specified intervals. (NCT00219141)
Timeframe: Baseline the end of study (Week 36)
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Aliskiren 300 mg | -2.67 | -1.31 |
| Aliskiren/Losartan 300/100 mg | -6.97 | -4.11 |
| Losartan 100 mg | -3.81 | -1.92 |
E-selectin is expressed on inflamed endothelial cells in response to treatment with inflammatory cytokines. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | -1.6 |
| Losartan | -0.6 |
F2-isoprostanes is a marker of oxidative stress. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/mg of creatinine (Mean) |
|---|---|
| Placebo | 0.4 |
| Losartan | 0.9 |
hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | percentage change (Mean) |
|---|---|
| Placebo | -10 |
| Losartan | -34 |
MCP-1 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Placebo | -37 |
| Losartan | -24 |
ox-LDL measures protein damage due to the oxidative modification of the ApoB subunit on LDL cholesterol. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | units/l (Mean) |
|---|---|
| Placebo | -2.0 |
| Losartan | -5.5 |
Urine was obtained to assess for the presence of microalbuminuria. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | mg/mmol (Mean) |
|---|---|
| Placebo | 0.4 |
| Losartan | 0.2 |
VCAM-1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | 29 |
| Losartan | -21 |
Endothelial function assessed as the ratio of pulse volume amplitude after compared with before a reactive hyperemia stimulus, measured by peripheral (fingertip) arterial tonometry. Reported values indicate the percentage change from Baseline in the ratio of pulse volume amplitude after compared to before the reactive hyperemia stimulus. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | percentage change (Mean) |
|---|---|
| Placebo | 1.76 |
| Losartan | 2.11 |
Insulin clamp derived insulin sensitivity, as insulin stimulated glucose disposal corrected for steady state insulin level. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | mg/kg/min (Mean) |
|---|---|
| Placebo | 5.3 |
| Losartan | 2.8 |
Value of DBP at 12 Weeks minus value of DBP at Baseline while in a sitting position (NCT00922480)
Timeframe: baseline and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Control: Losartan / Week 12 -ITT | -8.56 |
| Test: Fimasartan / Week 12 -ITT | -11.26 |
"Value of DBP at 4 Weeks minus value of DBP at Baseline while in a sitting position~Value of DBP at 8 Weeks minus value of DBP at Baseline while in a sitting position" (NCT00922480)
Timeframe: baseline and 4 weeks, 8 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Week 4 | Week 8 | |
| Control: Losartan / Week 4,8 -ITT | -5.73 | -8.01 |
| Test: Fimasartan / Week 4,8 -ITT | -8.22 | -11.01 |
The change from baseline in trough SDBP at Week 4 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -9.0 |
| Combined Olmesartan | -8.8 |
| Losartan | -6.2 |
The change from baseline in trough SSBP at Week 4 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -12.3 |
| Combined Olmesartan | -12.0 |
| Losartan | -8.5 |
The change from baseline in trough SDBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -9.8 |
| Combined Olmesartan | -9.7 |
| Losartan | -7.1 |
The change from baseline in trough SSBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -13.6 |
| Combined Olmesartan | -13.6 |
| Losartan | -9.7 |
The change from Week 4 in trough SDBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Week 4, Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -0.8 |
| Combined Olmesartan | -0.9 |
| Losartan | 0.0 |
The change from Week 4 in trough SSBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Week 4, Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Olmesartan | -1.1 |
| Combined Olmesartan | -1.4 |
| Losartan | 0.0 |
In week 4, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. (NCT00949884)
Timeframe: Baseline, Week 4
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Combined Olmesartan | -7.3 | -4.8 |
| Losartan | -5.9 | -3.7 |
| Olmesartan | -7.3 | -4.9 |
In week 8, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. (NCT00949884)
Timeframe: Baseline, Week 8
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Combined Olmesartan | -9.2 | -6.1 |
| Losartan | -5.6 | -3.6 |
| Olmesartan | -9.1 | -6.1 |
In week 4, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Systolic and diastolic blood pressure readings taken in the final 2, 4, and 6 hours of the 24-hour ABPM cycle are summarized. (NCT00949884)
Timeframe: Baseline, Week 4
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| 2 hour systolic blood pressure | 2 hour diastolic blood pressure | 4 hour systolic blood pressure | 4 hour diastolic blood pressure | 6 hour systolic blood pressure | 6 hour diastolic blood pressure | |
| Combined Olmesartan | -8.4 | -5.6 | -8.3 | -5.6 | -8.0 | -5.4 |
| Losartan | -6.8 | -3.8 | -6.5 | -4.1 | -6.2 | -3.9 |
| Olmesartan | -8.7 | -5.8 | -8.4 | -5.8 | -8.0 | -5.5 |
In week 8, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Systolic and diastolic blood pressure readings taken in the final 2, 4, and 6 hours of the 24-hour ABPM cycle are summarized. (NCT00949884)
Timeframe: Baseline, Week 8
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| 2 hour systolic blood pressure | 2 hour diastolic blood pressure | 4 hour systolic blood pressure | 4 hour diastolic blood pressure | 6 hour systolic blood pressure | 6 hour diastolic blood pressure | |
| Combined Olmesartan | -9.5 | -6.0 | -10.1 | -6.7 | -9.7 | -6.5 |
| Losartan | -7.2 | -4.0 | -6.9 | -4.1 | -6.5 | -4.0 |
| Olmesartan | -10.0 | -6.3 | -10.5 | -7.1 | -10.0 | -6.8 |
In week 4, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Daytime (8am to 4pm) and nighttime (10pm to 6am) systolic and diastolic blood pressure readings are summarized. (NCT00949884)
Timeframe: Baseline, Week 4
| Intervention | mmHg (Least Squares Mean) | |||
|---|---|---|---|---|
| Daytime systolic blood pressure | Daytime diastolic blood pressure | Nighttime systolic blood pressure | Nighttime diastolic blood pressure | |
| Combined Olmesartan | -7.5 | -5.2 | -6.8 | -4.3 |
| Losartan | -5.8 | -3.5 | -5.5 | -3.4 |
| Olmesartan | -7.6 | -5.4 | -6.7 | -4.4 |
In week 8, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Daytime (8am to 4pm) and nighttime (10pm to 6am) systolic and diastolic blood pressure readings are summarized. (NCT00949884)
Timeframe: Baseline, Week 8
| Intervention | mmHg (Least Squares Mean) | |||
|---|---|---|---|---|
| Daytime systolic blood pressure | Daytime diastolic blood pressure | Nighttime systolic blood pressure | Nighttime diastolic blood pressure | |
| Combined Olmesartan | -8.7 | -6.1 | -9.3 | -6.1 |
| Losartan | -5.2 | -3.7 | -6.3 | -4.1 |
| Olmesartan | -8.7 | -6.2 | -9.3 | -6.2 |
The change from baseline in trough systolic and diastolic blood pressure at Week 2 as measured by the Omron monitor. Morning doses of study medication were taken after the exam, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Baseline, Week 2
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| Olmesartan | -8.3 | -11.9 |
| Placebo Followed by Olmesartan | -4.0 | -3.3 |
Participants from pre-selected sites had 24-hour ambulatory blood pressure readings collected. Daytime readings were results collected between 8am and 4pm. Nighttime readings were results collected between 10pm and 6am. (NCT00949884)
Timeframe: Week 8
| Intervention | percentage of population (Number) | ||
|---|---|---|---|
| Mean 24-hour | Mean Daytime | Mean Nighttime | |
| Combined Olmesartan | 58.5 | 32.1 | 77.4 |
| Losartan | 40.9 | 21.8 | 66.4 |
| Olmesartan | 59.2 | 32.7 | 76.5 |
"Percentage of participants who achieved the following goals:~Systolic blood pressure: <140 mmHg, <135 mmHg, <130 mmHg, <120 mmHg Diastolic blood pressure: <90 mmHg, <85 mmHg, <80 mmHg Blood pressure: <140/90 mmHg, <135/80 mmHg, <130/80 mmHg" (NCT00949884)
Timeframe: Week 4
| Intervention | percentage of participants analyzed (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Systolic BP <140 mmHg | Systolic BP <135 mmHg | Systolic BP <130 mmHg | Systolic BP <120 mmHg | Diastolic BP <90 mmHg | Diastolic BP <85 mmHg | Diastolic BP <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | |
| Combined Olmesartan | 36.7 | 27.1 | 16.5 | 3.5 | 38.8 | 23.9 | 10.4 | 26.5 | 7.6 | 5.9 |
| Losartan | 25.6 | 14.1 | 7.2 | 2.0 | 24.5 | 13.0 | 4.6 | 14.3 | 2.2 | 1.5 |
| Olmesartan | 37.9 | 28.1 | 16.8 | 3.1 | 39.6 | 24.2 | 10.6 | 27.3 | 7.4 | 5.5 |
"Percentage of participants who achieved the following goals:~Systolic blood pressure: <140 mmHg, <135 mmHg, <130 mmHg, <120 mmHg Diastolic blood pressure: <90 mmHg, <85 mmHg, <80 mmHg Blood pressure: <140/90 mmHg, <135/80 mmHg, <130/80 mmHg, <120/80 mmHg" (NCT00949884)
Timeframe: Week 8
| Intervention | percentage of participants analyzed (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic BP <140 mmHg | Systolic BP <135 mmHg | Systolic BP <130 mmHg | Systolic BP <120 mmHg | Diastolic BP <90 mmHg | Diastolic BP <85 mmHg | Diastolic BP <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Combined Olmesartan | 41.0 | 30.0 | 18.4 | 6.6 | 42.5 | 22.9 | 11.8 | 31.6 | 9.9 | 7.5 | 4.7 |
| Losartan | 28.9 | 20.4 | 13.1 | 3.8 | 30.5 | 15.5 | 6.6 | 19.5 | 4.9 | 4.5 | 2.3 |
| Olmesartan | 41.1 | 29.9 | 18.2 | 6.8 | 43.2 | 22.9 | 12.2 | 32.6 | 10.2 | 7.6 | 4.9 |
"Outcome 1a. Document the rate of acceptance (quantitative) and reasons for acceptance/rejection (qualitative) in a randomized trial of trial of losartan for SCD patients with abnormal nocturnal blood pressures.~Outcome 1b. Identify the adherence rate to losartan during a randomized three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure.~Outcome 1c. Determine the adherence rate to study procedures among participants enrolled in a three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure." (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
As a feasibility trial, the effect of losartan on lowering nocturnal hypertension will be monitored to identify the difference in nocturnal BP improvement between the two treatment arms, and within group standard deviation of BP (NCT02373241)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Blood Pressure Management | 1 |
We will prospectively evaluate the incidence of hypertension (Clinic BP in pts >5yrs and ABPM in pts >10 yrs) and role of blood and urine biomarkers (pts >5ys) among participants with HbSS or SB0 thalassemia (expected cohort n=200) over 5 yrs. We identified 20 participants (34%) with incident hypertension but randomized one to the study. The study was terminated as the eGFR was determined not to be a reliable endpoint in pediatric sickle cell. (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
Systolic blood pressure was measured through an ambulatory blood pressure monitoring device worn by each participant for 24 hours after completing each treatment phase. This devise measures blood pressure intermittently throughout the day and night and provides the average of all readings. (NCT02653560)
Timeframe: 4 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Potassium Magnesium Citrate (KMgCit) Arm | 127 |
| Potassium Citrate Arm | 127 |
| Potassium Chloride Arm | 126 |
| Placebo | 129 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.9 |
| Placebo | -7.1 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -14.1 |
| Placebo | -6.0 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -9.7 |
| Placebo | -6.9 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -16.7 |
| Placebo | -6.8 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -19.1 |
| Placebo | -6.4 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.1 |
| Placebo | -6.8 |
(NCT00882440)
Timeframe: 6 hours post dose at Baseline and 8 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -4.7 |
| Losartan 10 mg | -7.3 |
| Losartan 25 mg | -9.9 |
| Losartan 50 mg | -11.9 |
| Losartan 100 mg | -10.4 |
| Losartan 150 mg | -13.1 |
| Enalapril 20 | -16.2 |
(NCT00882440)
Timeframe: 24 hours post dose at Baseline and Week 8
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -5.6 |
| Losartan 10 mg | -7.9 |
| Losartan 25 mg | -6.8 |
| Losartan 50 mg | -10.1 |
| Losartan 100 mg | -9.9 |
| Losartan 150 mg | -9.7 |
| Enalapril 20 | -11.2 |
"Patients in Category I (defined as excellent in protocol) if SuDBP was <90 mmHg, Category II (defined as good in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as fair or inadequate in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg." (NCT00882440)
Timeframe: 24 hours post dose at Week 8
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Category I | Category II | Category III | |
| Enalapril 20 | 35 | 16 | 31 |
| Losartan 10 mg | 19 | 17 | 44 |
| Losartan 100 mg | 29 | 19 | 41 |
| Losartan 150 mg | 28 | 12 | 44 |
| Losartan 25 mg | 21 | 7 | 54 |
| Losartan 50 mg | 24 | 15 | 39 |
| Placebo | 10 | 14 | 54 |
(NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Icatibant | 0 |
| Placebo | 3 |
(NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Icatibant | 11 |
| Placebo | 16 |
(NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Icatibant | 11 |
| Placebo | 16 |
(NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Icatibant | 6 |
| Placebo | 6 |
(NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Icatibant | 2 |
| Placebo | 1 |
Average of blood pressure measurements from zero to forty-eight hours provided. (NCT01574248)
Timeframe: T0 to T48 hours
| Intervention | mmHg (Mean) |
|---|---|
| Icatibant | 134 |
| Placebo | 133 |
Time interval between initiation of treatment and when there is no symptom, by visual analog scale <1 cm. Data provided are for worst symptom. (NCT01574248)
Timeframe: 48 hours
| Intervention | hours (Median) |
|---|---|
| Icatibant | 36 |
| Placebo | 24 |
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
209 reviews available for losartan and Hypertension
| Article | Year |
|---|---|
Angiotensin II receptors and angiotensin II receptor antagonists.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Age | 1993 |
Efficacy and Safety of Angiotensin Receptor Blockers in Pediatric Patients (Aged 6 to 18) with Hypertension: A Systematic Review.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2023 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2020 |
Current Status of Angiotensin Receptor Blocker Recalls.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Carcinogens; Drug Recalls; Drug Utilizati | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hypertension; Losartan; | 2013 |
Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2014 |
Managing blood pressure control in Asian patients: safety and efficacy of losartan.
Topics: Adult; Antihypertensive Agents; Asia; Asian People; Blood Pressure; Female; Humans; Hypertension; Lo | 2014 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calciu | 2014 |
Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
Losartan: Comprehensive Profile.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Chemistry | 2015 |
Angiotensin 2 type 1 receptor blockade different affects postishemic kidney injury in normotensive and hypertensive rats.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Gene Expression Regulation; G | 2016 |
The preclinical basis of the therapeutic evaluation of losartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease M | 1995 |
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 1995 |
[Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2008 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny | 2009 |
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2009 |
Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2009 |
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2010 |
Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Randomi | 2010 |
Clinical trials of the past decade in the management of chronic kidney disease.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2009 |
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Com | 2010 |
Comparing angiotensin II receptor blockers on benefits beyond blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis | 2010 |
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2011 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro | 2011 |
Pharmacokinetic evaluation of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Heart Failure; H | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; L | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Drug Therapy, Combination; | 2011 |
[Lozartan potential in hyperuricemia correction].
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Losartan; Metabolic Syndrome; Uric Aci | 2011 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
Hypertension, its treatment, hyperuricaemia and gout.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemi | 2013 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
Does the angiotensin II receptor antagonist losartan improve cognitive function?
Topics: Aged; Aged, 80 and over; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2002 |
[Policy of antihypertensive therapy in arterial hypertension in the elderly. II].
Topics: Acrylates; Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor | 2002 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica | 2002 |
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
[Antihypertensive treatment in patients with diabetes mellitus].
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothel | 2002 |
[Therapy for hypertension associated with kidney disease].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2003 |
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 2003 |
[Diurnal blood pressure control in the optimal treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphen | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
[Angiotensin1-receptor antagonist losartan. Part I. Basic clinical pharmacology].
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Humans; Hypertension; Losartan; Pharmacolo | 2003 |
Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Moni | 2003 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Humans; Hypertension; Hypertrophy, Left Ventricular; Losar | 2003 |
Treatment of hypertension and prevention of ischemic stroke.
Topics: Algorithms; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Diltiazem; Humans; Hyperte | 2004 |
Conformation and bioactivity. Design and discovery of novel antihypertensive drugs.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; An | 2004 |
Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Binding Sites; Biphen | 2004 |
AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephro | 2004 |
Advances in the treatment of diabetic renal disease: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
[High blood pressure and cardiac hypertrophy].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
[Hypertension in patients with cardiac hypertrophy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2004 |
[Hyperuricemia in hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Diet, Sodium-Restricte | 2004 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Management of hypertensive patients with cardiovascular damage].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
[Development of combined drugs (ARB and diuretics)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Prevention and treatment of stroke in patients with hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anticoagulants; Antihypertensive Agents; Costs and | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
[Kidney and hypertension--evidence based medicine].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Clinical Trials as | 2005 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan.
Topics: Angiotensin II; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Losartan; S | 2004 |
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Dise | 2005 |
Hypertension, antihypertensive treatment and stroke prevention.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Clinical Trials as Topic; Humans; | 2005 |
[Treatment of hypertension in elderly patients with coronary heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: RA system inhibitor].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2005 |
Clinical pharmacokinetics of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2005 |
Update on the efficacy of angiotensin receptor blockers in treatment of hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Diabetes Complications; Drug E | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2005 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Hypertension; Hypertrophy, Left Ventricular; Losart | 2005 |
[Current views about the role of purin metabolism disorders in patients with arterial hypertension and losartan potentialities].
Topics: Angiotensin-Converting Enzyme Inhibitors; Humans; Hypertension; Losartan; Purines | 2006 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2006 |
[Clinical utility of angiotensin II receptor antagonist].
Topics: Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Humans; Hypertension; Insulin Resistance; Live | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Endothelium, Vascular; Fibrosis; H | 2006 |
[Electrocardiographic findings].
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Clinical Trials as Topic; Electrocardi | 2006 |
[LIFE].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Double-Bl | 2006 |
[HOSP study].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
[J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2007 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cli | 2007 |
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Endot | 2007 |
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Humans; | 2007 |
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2007 |
[Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
Topics: Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Clinical Trials as Topic; Diastole; | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Calcium Channel B | 2008 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Angiotensin receptor antagonists: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1995 |
[Angiotensin II receptor antagonists].
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biph | 1995 |
Angiotensin receptor antagonists as a treatment for hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Heart Failure; Humans | 1994 |
Angiotensin II antagonists DuP 753 and TCV 116.
Topics: Administration, Oral; Angiotensin II; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Respo | 1994 |
Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1994 |
Clinical experience with angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Tolerance | 1993 |
Angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Humans; Hypertension; | 1993 |
Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseas | 1993 |
New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clini | 1993 |
Cough and inhibition of the renin-angiotensin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Coug | 1993 |
Angiotensin antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1993 |
Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1996 |
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular | 1995 |
Discovery of losartan, the first angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clini | 1995 |
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1995 |
The future role of losartan.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Forec | 1995 |
[Angiotensin receptor antagonists. A new class of antihypertensive agents].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Clinical Tri | 1996 |
Angiotensin receptors and their antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; Biphenyl Co | 1996 |
Angiotensin II receptor blockers. A new class of antihypertensive drugs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans | 1996 |
[Angiotensin II receptor antagonists. Clinical relevance].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combina | 1996 |
[Antagonists of angiotensin II receptor].
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Diseases; Humans; Hypertension; Imidazol | 1996 |
Angiotensin II receptor inhibition. A new therapeutic principle.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
[Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1996 |
Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Tetrazoles | 1996 |
The diversified pharmacology of angiotensin II-receptor blockade.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
The clinical pharmacology of losartan in Japanese subjects and patients.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Biphenyl Compounds; Dose-Response Relationship | 1996 |
The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical | 1996 |
Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Female; | 1996 |
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Losartan: first of a new class of angiotensin antagonists for the management of hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Humans; Hype | 1996 |
Pathologic consequences of increased angiotensin II activity.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; History, 20th Century | 1996 |
A risk-benefit assessment of losartan potassium in the treatment of hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; | 1997 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 1997 |
Losartan: a new antihypertensive drug.
Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losar | 1997 |
The medicine of the month. Losartan (Cozaar).
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Human | 1997 |
[Angiotensin receptor antagonist for therapy of patients with hypertension].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 1997 |
Angiotensin II antagonism: a new avenue of hypertension management.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; | 1997 |
Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan.
Topics: Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Humans | 1997 |
Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.
Topics: Age Factors; Angiotensin Receptor Antagonists; Antihypertensive Agents; Drug Interactions; Humans; H | 1997 |
Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1997 |
Losartan versus ACE inhibitors in the treatment of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Clinical Trials a | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
[New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Cardiovascular Diseases; Clinical Tria | 1997 |
[The advent of a new class of antihypertensive agents: angiotensin II receptor antagonists].
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Ben | 1997 |
[Current therapy: losartan].
Topics: Angiotensin II; Antihypertensive Agents; Drug Costs; Humans; Hypertension; Losartan; Renin-Angiotens | 1997 |
Angiotensin II receptor blockers in hypertension and renal disease.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Kidney Diseases; Lo | 1998 |
Angiotensin II antagonists: efficacy, duration of action, comparison with other drugs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Controlled Clinical Trials as Top | 1998 |
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1998 |
Irbesartan treatment in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Ena | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Angiotensin II receptor pharmacology and AT1-receptor blockers.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 1999 |
The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
[Comparison with other antihypertensive drugs, especially with ACEI].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1999 |
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Los | 1999 |
Clinical advantage of valsartan.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Los | 1999 |
Angiotensin II receptor antagonists in the treatment of hypertension.
Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazole | 1999 |
. . . and losartan was no better than placebo.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood | 1999 |
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials | 1999 |
Angiotensin II receptor antagonists: enlarging therapeutic possibilities in arterial hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Humans; Hyperten | 1999 |
Uric acid in hypertension and cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Pressure; Coronary Dise | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Age | 1999 |
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1998 |
Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2000 |
Is there an advantage to combination therapy with ACE inhibitors and angiotensin II-receptor blockers?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2000 |
Losartan: a review of its use, with special focus on elderly patients.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Heart Failure; Humans; Hypertension; Losartan | 2000 |
Angiotensin II antagonists for hypertension: are there differences in efficacy?
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; | 2000 |
Angiotensin II receptor antagonists in arterial hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Hyp | 2000 |
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biological Availabi | 2000 |
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2000 |
[Use of angiotensin-II-antagonists in hypertension].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination | 2000 |
Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure.
Topics: Aminopeptidases; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihyp | 2000 |
Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Los | 2000 |
Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2000 |
[Losartan potassium, an angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Losartan | 2000 |
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
Role of losartan therapy in the management of diabetic hypertension.
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypertension; Losartan; Randomized Controlled Tri | 2000 |
Management of hypertension and heart failure with AT1 receptor blockade.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiac Output, Low; Clinical Trial | 2001 |
Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
[Angiotensin receptor blockers--significance for the therapy of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2001 |
[Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykin | 2001 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
Hypertensive pulmonary oedema is due to diastolic dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Diastole; Echocardiography, Doppler; Heart Fa | 2001 |
Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Genetic Predisposition to Disease; Geneti | 2002 |
[Results from the LIFE study: promising effects of new hypertensive agents].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Humans; Hyper | 2002 |
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benz | 2002 |
The role of losartan in cost-effective hypertension control.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Germany; Humans; Hypertension; Italy; Losartan; Pati | 2002 |
Rationale for the chemical development of angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug | 1992 |
Angiotensin II receptors and functional correlates.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pres | 1992 |
[Renin-angiotensin system blockade. What can be expected from angiotensin II antagonists?].
Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losar | 1992 |
In vivo pharmacology of DuP 753.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Imidazoles; Losartan | 1991 |
595 trials available for losartan and Hypertension
| Article | Year |
|---|---|
Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Topics: Acrylates; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyp | 2021 |
Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drugs, Chinese Herbal; Essential Hyper | 2022 |
Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Topics: Adolescent; Angiotensin Receptor Antagonists; Blood Pressure; Child; Double-Blind Method; Female; Hu | 2022 |
Comments on ''Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial''.
Topics: Abdominoplasty; Cicatrix; Double-Blind Method; Humans; Hypertension; Losartan; Mammaplasty; Treatmen | 2023 |
Invited Response on: Comment: "Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial".
Topics: Abdominoplasty; Cicatrix; Double-Blind Method; Humans; Hypertension; Losartan; Mammaplasty; Treatmen | 2023 |
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Thera | 2023 |
Aerobic Physical Exercise is Essential for Cardiac Autonomic Regulation in Hypertensive Patients Undergoing Chronic Treatment with Renin- Angiotensin System Inhibitors.
Topics: Adult; Angiotensins; Antihypertensive Agents; Blood Pressure; Enalapril; Exercise; Heart Rate; Human | 2023 |
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L | 2023 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Effects of sang-qi granules on blood pressure and endothelial dysfunction in stage I or II hypertension: study protocol for a randomized double-blind double-simulation controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; China; Double-Blind Method; D | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Diabetes Me | 2021 |
Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Dose-Response Relationship, Drug; Double- | 2020 |
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; COVID-19; Double-Blind | 2021 |
Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.
Topics: Adult; Antihypertensive Agents; Child; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; | 2021 |
Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Essential Hypertension; Female; Follow-Up Studies; Hu | 2017 |
Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Humans; Hydrochlorothiazide; Hype | 2017 |
Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; | 2017 |
Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Atrial Function, Left; Atrial Remodeling; Blood Pre | 2018 |
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relation | 2017 |
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Humans; Hypertension; Hypertro | 2017 |
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Losartan; Mal | 2018 |
Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Femal | 2017 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Fil | 2016 |
Comparison of Effect of Enalapril and Losartan Monotherapy on Quality of Life and Safety of Stage 1 Hypertensive Patients.
Topics: Antihypertensive Agents; Blood Pressure; Enalapril; Female; Humans; Hypertension; Kidney Function Te | 2016 |
Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Down-Regulation; Female; Fi | 2018 |
Diuretics are Similar to Losartan on Echocardiographic Target-Organ Damage in Stage I Hypertension. PREVER-Treatment Study.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Ech | 2019 |
Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Do | 2019 |
The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Carotid-Femoral Pulse Wave Velocity; Fema | 2019 |
Assessment of Losartan 50 mg on Survival of Post-Dialysis Euvolemic Hypertensive Patients: Findings from HELD Trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Follow-Up Studies; Humans; Hypertensio | 2019 |
Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Th | 2013 |
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Confidence Intervals; Death, Sudden, C | 2013 |
Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Res | 2013 |
Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2013 |
Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; C-Re | 2014 |
Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calc | 2013 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II T | 2013 |
Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2013 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation | 2013 |
[Abpm and duration of the antihypertensive effect: a study with a new formulation of sustained release losartan (CRONOS)].
Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Blood Pressure Monitoring, Ambulatory; Dela | 2012 |
Benidipine has effects similar to losartan on the central blood pressure and arterial stiffness in mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Bl | 2013 |
Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Enalapril; Female; Humans | 2013 |
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converti | 2013 |
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Dilatation; Doubl | 2013 |
Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diur | 2014 |
A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Blood Pressure; Dose-Response Relationship, Drug; Drug Combi | 2014 |
[Jinshuibao capsule combined losartan potassium intervened early renal damage of hypertension patients of yin and yang deficiency: a clinical research].
Topics: Aged; Aged, 80 and over; beta 2-Microglobulin; C-Reactive Protein; Cystatin C; Drugs, Chinese Herbal | 2013 |
Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; C | 2014 |
Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study).
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2013 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2013 |
Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cell Proliferation | 2014 |
Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2013 |
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Double- | 2014 |
[Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Diu | 2013 |
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Black People; Female; Humans; Hypertension; Hype | 2014 |
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Female; Humans; | 2014 |
Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Dose-Response Relationship, Drug | 2014 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
A randomized, open-label, dose-response study of losartan in hypertensive children.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Child | 2014 |
Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Com | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2014 |
Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Drug Combinations; Drug Mo | 2015 |
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
Topics: Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diastole; Drug The | 2015 |
Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; | 2015 |
Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; | 2014 |
A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Double-Blind Method | 2013 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Differential effects of angiotensin II receptor blocker and losartan/hydrochlorothiazide combination on central blood pressure and augmentation index.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Dose-Respon | 2015 |
Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Brachial Artery; Drug Therapy, Combination; Endothelium, | 2014 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Dioxygenase | 2015 |
[Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; | 2013 |
Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2015 |
Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial.
Topics: Aorta; Benzazepines; Blood Pressure; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; | 2015 |
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrochlo | 2015 |
Visit-to-visit variability and seasonal variation in blood pressure: Combination of Antihypertensive Therapy in the Elderly, Multicenter Investigation (CAMUI) Trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans | 2015 |
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Aorti | 2015 |
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-R | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; E | 2015 |
Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2015 |
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines | 2015 |
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2015 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea.
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Case-Control Studies; Continuous Positive Airway P | 2016 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics.
Topics: Amino Acids; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2015 |
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2015 |
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2016 |
Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; F | 2016 |
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hypertensio | 2016 |
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2016 |
Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Continuous Positive Airw | 2016 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Fem | 2017 |
Efficacy of Losartan in the management of Post-Dialysis Euvolemic Hypertension (HELD-Trial): A Single-Blind Randomized Control Trial.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Middle | 2016 |
Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Dose-Response Relationship, Drug; D | 2017 |
The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; F | 2017 |
[The effect of losartan on the intima-media thickness of carotid artery].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Carot | 2008 |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Amides; Angiotensin II Type 1 Receptor Bloc | 2008 |
[Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; C-Reactive P | 2008 |
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Topics: Action Potentials; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cross-Over Studi | 2009 |
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Doubl | 2008 |
Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 1995 |
Losartan with hydrochlorothiazide in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; | 1995 |
Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cough; Diuretics; | 1995 |
Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2008 |
Losartan decreased premature ventricular contractions in patients with hypertension.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Enalapril; Humans; Hypertension; Losartan; Middle Aged; Ve | 2009 |
The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospectiv
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2008 |
Nocturia in elderly people with hypertension--no influence of low-dose thiazide added to losartan.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Dose-Response Relationship, Drug; Femal | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
[The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2008 |
Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Carotid Arterie | 2009 |
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocard | 2009 |
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug | 2009 |
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzo | 2009 |
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rh | 2009 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Fem | 2009 |
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Exercise; Fe | 2009 |
Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Autonomic Nervous System; Benzimidazoles; Benzoates; | 2009 |
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asia | 2009 |
Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Ankle; Antihypertensive Agents; Biomarke | 2009 |
CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; H | 2009 |
A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Ther | 2009 |
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Echocardiography; Female; Humans; Hypertens | 2009 |
Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2009 |
One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Double-Blind Method; Female; Heart; Heart Function Tests | 2009 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell M | 2009 |
Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Female; Humans; Hypertension; Imidazoles; Losartan; M | 2009 |
Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatinine; Dose-Response Relationsh | 2009 |
Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Benzimidazol | 2009 |
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S | 2009 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2008 |
Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment.
Topics: Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combin | 2009 |
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2009 |
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Double-Blind M | 2010 |
Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Brain; Brain Ischemia; Calcium Channel | 2010 |
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood | 2009 |
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Fem | 2009 |
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Endpoint Determination; Female; Ge | 2010 |
One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors.
Topics: Aged; Antihypertensive Agents; Asian People; Drug Therapy, Combination; Female; Humans; Hydrochlorot | 2010 |
Randomized, double-blind, controlled study of losartan in children with proteinuria.
Topics: Adolescent; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers | 2010 |
A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glu | 2010 |
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.
Topics: Adult; Aged; Amlodipine; Anthracenes; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; D | 2010 |
Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2010 |
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Topics: Aged; Blood Pressure; Cardiovascular System; Echocardiography; Endocardium; Female; Follow-Up Studie | 2010 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; An | 2010 |
Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biglycan; Blood Pressure; C-Reactive | 2010 |
Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Topics: Acrylates; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Age | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based on Home Systolic Pressure (HOSP) substudy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2010 |
Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-grou
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relati | 2010 |
Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2010 |
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2010 |
Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Female; Fibrinolysis; Fuma | 2010 |
How to avoid discontinuation of antihypertensive treatment: The experience in São Paulo, Brazil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Calcium Channel Blockers | 2010 |
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2011 |
Calcium channel blocker and Rho-associated kinase activity in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2011 |
Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Topics: Androstanols; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Female; Genetic | 2010 |
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.
Topics: Adipose Tissue; Adult; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass | 2011 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects.
Topics: Adiponectin; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Glucose; Blood P | 2011 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography | 2011 |
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Preschool; Dou | 2011 |
A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 2011 |
Racial differences in incident heart failure during antihypertensive therapy.
Topics: Aged; Antihypertensive Agents; Asian; Black or African American; Blood Pressure; Electrocardiography | 2011 |
A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.
Topics: Adult; Aged; Amiloride; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pres | 2011 |
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Diab | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2011 |
Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Combina | 2011 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
Topics: Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Demography; Female; Fumarates; Heart V | 2011 |
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Doub | 2013 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Ca | 2011 |
Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA
Topics: Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Dose-Respons | 2011 |
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Double-Blind Method; End | 2012 |
Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Coagulation; Female; Fibrin; Humans; H | 2012 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodiu | 2011 |
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2012 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation | 2012 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hydrochlo | 2011 |
Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
Effect of changing heart rate during treatment of hypertension on incidence of heart failure.
Topics: Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiog | 2012 |
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressur | 2011 |
Antihypertensive efficacy of the losartan/hydrochlorothiazide combination and its effect on plasma B-type natriuretic peptide in hypertensive patients uncontrolled by angiotensin II type 1 receptor antagonist-based therapy: a multicentre prospective obser
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Humans; Hyd | 2012 |
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascu | 2012 |
Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2012 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyd | 2012 |
Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2012 |
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2012 |
Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug-Related Side Effects and Adve | 2011 |
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2012 |
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2012 |
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2012 |
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2012 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2012 |
Does a combination pill of antihypertensive drugs improve medication adherence in Japanese? A randomized controlled trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2012 |
Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Long-term antihypertensive efficacy of losartan/hydrochlorothiazide combination therapy on home blood pressure control.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pre | 2012 |
Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A | 2012 |
The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Drug Combinations; | 2012 |
Change in high-sensitive cardiac troponin T on hypertensive treatment.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2013 |
Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Chan | 2012 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind M | 2012 |
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; | 2012 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertens | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Bl | 2012 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; | 2012 |
Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diure | 2012 |
Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian People; Blood Pressure; Circa | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
[Series: Clinical study from Japan and its reflections morning hypertension and angiotensin receptor blocker/hydrochlorothiazide combination therapy study--MAPPY study].
Topics: Aged; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 2012 |
Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Th | 2012 |
[Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Diur | 2012 |
Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2012 |
Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2013 |
Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Subst | 2013 |
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Disease Progression; Double-Blind | 2002 |
Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cell Adhesion Molecules; Chemokine C | 2002 |
A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Met | 2002 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiot | 2002 |
The effects of losartan and fosinopril in hypertensive type 2 diabetic patients.
Topics: Adult; Alanine Transaminase; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspa | 2002 |
A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essent
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pre | 2002 |
Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Double-Blind Method; Female; | 2002 |
AT1 blockers and uric acid metabolism: are there relevant differences?
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; H | 2002 |
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Fema | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C | 2002 |
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Pr | 2002 |
Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Antioxidants; Cross-Over Studies; Diabet | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-Blind | 2002 |
Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl | 2002 |
What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Endpoint Determination; Heart Fai | 2002 |
Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Dose-Response Relationship, Drug; Drug Admini | 2002 |
Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure De | 2002 |
Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Circadian Rhythm; Cr | 2002 |
Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diastole; Diuretics; Doubl | 2002 |
Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction.
Topics: Aged; Angiotensin II; Antihypertensive Agents; Aorta; Blood Pressure; Brachial Artery; Cross-Over St | 2002 |
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular | 2002 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
Can losartan improve cardiac performance during the treadmill exercise test in hypertensive subjects?
Topics: Adult; Blood Pressure; Cardiovascular System; Exercise Test; Female; Heart Rate; Humans; Hypertensio | 2002 |
Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure Determination; Dose-Response Relationship, Drug; Drug | 2002 |
Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects.
Topics: Angiotensin II; Antihypertensive Agents; Diuresis; Diuretics; Drug Synergism; Drug Therapy, Combinat | 2003 |
[Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension].
Topics: Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Kidney; Kidney Function Tests; Lo | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2003 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Echocardiography; Female; Humans; Hypertension; Hy | 2003 |
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Topics: Adult; Aldosterone; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response | 2003 |
Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Doub | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Disease | 2003 |
The DASH diet enhances the blood pressure response to losartan in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Di | 2003 |
The DASH diet enhances the blood pressure response to losartan in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Di | 2003 |
The DASH diet enhances the blood pressure response to losartan in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Di | 2003 |
The DASH diet enhances the blood pressure response to losartan in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Di | 2003 |
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Glomerulonephritis, IGA; Humans; | 2003 |
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; | 2003 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2003 |
Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension.
Topics: Adult; Aldosterone; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Flow Velocity; Blood Pres | 2003 |
Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 2003 |
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Do | 2003 |
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment.
Topics: Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; | 2003 |
Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Blood Pressure Determination; Dose-Response Relationship, Dr | 2003 |
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2003 |
Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2003 |
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; | 2003 |
[Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].
Topics: Adult; Aged; Coronary Circulation; Echocardiography, Three-Dimensional; Echocardiography, Transesoph | 2003 |
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
[Effect of losartan and Nitrendipine on fibrinolytic system in patient with essential hypertensim].
Topics: Adult; Aged; Fibrinolysis; Humans; Hypertension; Losartan; Male; Middle Aged; Nitrendipine | 2003 |
The antiproteinuric effect of losartan is systemic blood pressure dependent.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Dose-Response Relationship, Drug; Drug | 2003 |
Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2003 |
Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2003 |
Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension.
Topics: Adult; Analysis of Variance; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiac Output; | 2003 |
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Blood Pressure M | 2003 |
Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Blood pressure and diabetic nephropathy.
Topics: Antihypertensive Agents; Blood Pressure; Diabetic Nephropathies; Humans; Hypertension; Losartan; Pla | 2003 |
A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; China; Double-Blind Method; Drug T | 2003 |
Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response | 2003 |
[AT1 receptor autoantibodies and essential hypertension].
Topics: Aged; Antihypertensive Agents; Autoantibodies; Female; Humans; Hypertension; Losartan; Male; Middle | 2003 |
Different effects of losartan and delapril on plasma PAI-1 levels in patients with mild to moderate hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Female; Huma | 2003 |
Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination | 2004 |
Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Do | 2004 |
[Efficacy of losartan potassium and its combination with hydrochlorothiazide in hypertensive disease. Focus on the state of microcirculation].
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Forearm; Hemodynamics; Huma | 2003 |
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Atenolol; Black People; Blood Pressu | 2004 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hyperten | 2004 |
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Elec | 2004 |
[Treatment of hypertension in patients with left ventricular hypertrophy].
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertro | 2004 |
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventric | 2004 |
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Catecholamines; Female; Follow-Up Studie | 2004 |
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2004 |
Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diastole; Female; G | 2004 |
Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Angiotensin Receptor Antagonists; Biomarkers; Blood Pressure; Chemokines; Diabetes Complicatio | 2004 |
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Brachial Ar | 2004 |
Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Pressure; Choles | 2004 |
Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Endotheliu | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2004 |
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chi-Square Distribution; Diabetes | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2004 |
Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Drug Administration Schedule; Female; Fibr | 2004 |
Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Child; | 2004 |
Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cross-Over Studies; Da | 2004 |
Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Diuretics; Drug Therapy, Co | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Catecholamines; Chromatography, | 2004 |
A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2004 |
Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2005 |
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetic Angiopathies; Drug Combi | 2004 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2005 |
Losartan increases bradykinin levels in hypertensive humans.
Topics: Acrylates; Adolescent; Adult; Aged; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Bl | 2005 |
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diuretics; Double-Blind Method; Ech | 2005 |
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Metho | 2004 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Carotid Artery Diseases; Female; Humans; Hypertension | 2005 |
A double-blind, dose-response study of losartan in hypertensive children.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Body Weight; Child; Dose-Response Relationship, | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diet, Sodium-Restr | 2005 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2005 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2005 |
The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.
Topics: Antihypertensive Agents; Creatinine; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; | 2005 |
Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Topics: Aged; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Platelet Activation; Platelet Aggre | 2004 |
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy | 2005 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment].
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Enalapril; Female; Humans; Hypertension; Losartan; M | 2005 |
Hemodynamic influences of losartan on the brain in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Brain; Cerebrovascular Circulation; Female; Heart Rat | 2005 |
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
Topics: Aged; Atenolol; Blood Pressure; Carotid Arteries; Female; Humans; Hypertension; Losartan; Male; Time | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug | 2005 |
Effects of eplerenone versus losartan in patients with low-renin hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Double-Blind Method; Eplerenone; Female; Humans; Hype | 2005 |
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Do | 2006 |
Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.
Topics: Acrylates; Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor An | 2006 |
Quality of life and antihypertensive effect with nebivolol and losartan.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; An | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Cost-Benefit Analysis; Female; Fol | 2006 |
Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; | 2006 |
Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Female; | 2006 |
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relati | 2006 |
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Female; Fibr | 2006 |
Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Conn | 2006 |
[The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square | 2006 |
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Femal | 2006 |
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; CD40 Ligand; Cross-Over Studies; Drug T | 2007 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-O | 2005 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2006 |
A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cytochrome P-450 CYP11B | 2006 |
Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure Determ | 2006 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil | 2006 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2006 |
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Echocardiography, | 2006 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein | 2006 |
Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2006 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiograp | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2006 |
Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood P | 2006 |
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Corona | 2007 |
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Bl | 2006 |
Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients.
Topics: Acetylglucosaminidase; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2006 |
The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; China; Double-Blind Method; Female; Humans; Hypert | 2006 |
[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Female; Fol | 2006 |
Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aorta; Dou | 2007 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Biomarkers; Blood Pressure; Collagen Type I; C | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Angiotensin II Type 1 Rece | 2007 |
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Rela | 2007 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mel | 2007 |
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Aged; Albuminuria; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2007 |
Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administr | 2007 |
Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Com | 2007 |
Impact of losartan on stroke risk in hypertensive patients in primary care.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dr | 2007 |
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Bloo | 2007 |
The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Topics: Aged; Aldosterone; Amiloride; Bendroflumethiazide; Cross-Over Studies; Double-Blind Method; Female; | 2007 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Drug Therapy, Combination; Fema | 2007 |
Design and baseline characteristics of an observational study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Asian People; Blood Pressur | 2007 |
Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Diureti | 2007 |
Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Captopril; Dou | 2007 |
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Fema | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography, Doppler; Female; Human | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
[Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Drug Administration Schedule; Fema | 2008 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Echocardiography; Female; Follow-Up Studies; Human | 2008 |
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Co | 2008 |
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination | 2008 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Electrocardiography | 2008 |
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Calcium; Cross-Over Studies; | 2008 |
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressur | 2008 |
Losartan--a new antihypertensive.
Topics: Antihypertensive Agents; Biphenyl Compounds; Double-Blind Method; Humans; Hypertension; Imidazoles; | 1995 |
Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
Topics: Aldosterone; Angiotensin II; Biphenyl Compounds; Blood Pressure; Creatinine; Drug Combinations; Fema | 1995 |
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diast | 1995 |
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Hum | 1995 |
Efficacy and safety of losartan.
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-R | 1995 |
Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; H | 1994 |
Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Bod | 1994 |
Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cough; Double-Blind Method; Femal | 1994 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Biphenyl Compounds; Blood Pressure; Dose-Response Re | 1995 |
Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Meth | 1995 |
Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cough; Double-Blind Method; Fema | 1994 |
Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Enalapr | 1994 |
Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Dela | 1995 |
Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.
Topics: Antihypertensive Agents; Biphenyl Compounds; Double-Blind Method; Female; Humans; Hydrochlorothiazid | 1995 |
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug | 1996 |
Losartan potassium as initial therapy in patients with severe hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Biphen | 1995 |
Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Cir | 1995 |
ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 1995 |
Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1996 |
[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans | 1996 |
Doing randomized controlled trials in a developing country: some practical realities.
Topics: Antihypertensive Agents; Biphenyl Compounds; Developing Countries; Double-Blind Method; Humans; Hype | 1996 |
Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 1996 |
Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1996 |
Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diuretics; Drug Interactions | 1995 |
Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cimetidine; Cr | 1995 |
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Asthenia; Biphenyl Compounds; Blood Pressure; Controlled Clinical Tr | 1996 |
Effects of losartan on insulin sensitivity in hypertensive subjects.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Fatty Acids, Nones | 1996 |
Effects of losartan on renal function in patients with essential hypertension.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Com | 1996 |
An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 1996 |
The clinical pharmacology of losartan in Japanese subjects and patients.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Biphenyl Compounds; Dose-Response Relationship | 1996 |
Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; B | 1996 |
Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pre | 1995 |
The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphen | 1995 |
[The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 1995 |
Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female; Hea | 1996 |
Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Ca | 1997 |
Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothi | 1997 |
Increased left-ventricular mass after losartan treatment.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Human | 1997 |
Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Female; Glucose; Hemodynamics; Humans; Hypertension; Im | 1997 |
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme | 1997 |
Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 1997 |
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Dose-Response R | 1998 |
Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo.
Topics: Adult; Aged; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Endothelin-1; Fasting | 1998 |
[The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothi | 1998 |
A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Captopril; Double-Blind Method; Drug Administration Schedul | 1997 |
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 1998 |
Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cholesterol, HDL; Cross-Over Studi | 1998 |
Losartan in Cushing's syndrome.
Topics: Administration, Oral; Antihypertensive Agents; Cushing Syndrome; Humans; Hypertension; Kallikrein-Ki | 1998 |
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 1998 |
Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Capillaries; | 1998 |
Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1998 |
The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; | 1998 |
Effects of losartan on hypertension and left ventricular mass: a long-term study.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hype | 1998 |
ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cross-Over | 1998 |
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1998 |
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1998 |
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1998 |
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1998 |
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.
Topics: Aged; Aging; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug | 1998 |
Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Press | 1998 |
Losartan and anaemia of end-stage renal disease.
Topics: Anemia; Antihypertensive Agents; Erythropoietin; Humans; Hypertension; Kidney Failure, Chronic; Losa | 1998 |
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Body Mass Index; Double- | 1998 |
Candesartan cilexetil vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Tetrazo | 1998 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
The effect of Losartan on red blood cell deformability and tissue oxygenation in patients with arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbon Dioxide; Echocardiography; Erythrocyte Deform | 1998 |
Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure Monitoring, | 1999 |
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agent | 1999 |
Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Met | 1999 |
Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 1999 |
[Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan].
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Female; Hemodynam | 1999 |
Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Delayed-Action Preparations; Felodipine; | 1999 |
Effects of losartan, an angiotensin II receptor antagonist, on the fibrinolytic system in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Female; Fibrinolysis; Humans; Hypertension; Losartan; Male; Middle Ag | 1999 |
A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function.
Topics: Antihypertensive Agents; Captopril; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged | 1999 |
Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; C | 1999 |
Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction.
Topics: Adult; Aged; Antihypertensive Agents; Echocardiography; Electrocardiography; Female; Humans; Hyperte | 1999 |
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1999 |
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Benzothiadiazines; Diuretics; Double-Blind Method; Female; Hum | 1999 |
Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive A | 1999 |
Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 1999 |
Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Cognition; Diuretics; Double | 1999 |
Efficacy and safety of losartan in renal transplant recipients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hyp | 1999 |
A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 1999 |
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 1999 |
[The effect of losartan on cardiac rhythm variability in patients with arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Echocardiography; Electrocardiography, Ambulatory; Heart Rate; | 1999 |
[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial.
Topics: Antihypertensive Agents; Blood Platelets; Blood Pressure; Diuretics; Double-Blind Method; Drug Thera | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Influence of self-measurement of blood pressure on the responder rate in hypertensive patients treated with losartan: results of the SVATCH Study. Standard vs Automatic Treatment Control of COSAAR in Hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pre | 2000 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Circulation; B | 2000 |
Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cough; Diabetic Angiopathies; Double-Blind Method; Female; | 2000 |
The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure | 2000 |
Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 2000 |
Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement, and reproducibility of blood pressure response.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure De | 2000 |
Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pres | 2000 |
Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Gla | 2000 |
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyp | 2000 |
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Echocardiography; Electrocardiography; Eu | 2000 |
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Echocardiography; Electrocardiography; Eu | 2000 |
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Echocardiography; Electrocardiography; Eu | 2000 |
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Echocardiography; Electrocardiography; Eu | 2000 |
Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
[Israeli experiences of treatment of hypertension with losartan (Ocsaar)--summary of the treatment of 421 patients in community health centers].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertensio | 1999 |
Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Echocardiog | 2000 |
[Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Blood Pressure; Blo | 2000 |
Transforming growth factor beta in hypertensives with cardiorenal damage.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Collagen; Collagen Type I; Female; Humans; Hyp | 2000 |
A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2000 |
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; F | 2000 |
Inhibition of platelet aggregability by losartan in essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Double-Blind Method; Enzyme-Linked | 2000 |
Effect of long-term losartan administration on renal haemodynamics and function in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Glomerular Filtration Rate; H | 2000 |
A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2000 |
Angiotensin II receptor antagonists cannot prevent symptomless dysphagia in hypertensive bedridden older patients with stroke.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bed Rest; Case-C | 2000 |
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Ther | 2001 |
Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate.
Topics: Adult; Double-Blind Method; Enalapril; Female; Humans; Hypertension; India; Losartan; Male; Middle A | 2000 |
A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over St | 2001 |
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Disease Progression; Echocardiography, Doppler; El | 2001 |
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
Sexual dysfunction in hypertensive patients treated with losartan.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Female; H | 2001 |
Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cross-Sectio | 2001 |
Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Humans; Hyp | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Losartan; | 2001 |
Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism?
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiac Volume; Echocardiography; | 2001 |
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Echocardiography; Female; Heart Ventricles; Humans | 2001 |
Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral blood mononuclear cells.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 2001 |
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Topics: Administration, Oral; Age Factors; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive A | 2001 |
Uricosuric effect of losartan in patients with renal transplants.
Topics: Adult; Angiotensin Receptor Antagonists; Cross-Over Studies; Cyclosporine; Drug Administration Sched | 2001 |
Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; M | 2001 |
Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension.
Topics: Antihypertensive Agents; Black or African American; Double-Blind Method; Drug Therapy, Combination; | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Bl | 2001 |
T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cros | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2001 |
Autonomic function and baroreflex sensitivity during angiotensin-converting enzyme inhibition or angiotensin II AT-1 receptor blockade in essential hypertensive patients.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Auto | 2001 |
Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Doubl | 2002 |
Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Drug Tolera | 2001 |
Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.
Topics: Analysis of Variance; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2002 |
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy | 2002 |
Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; D | 2002 |
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography; Electrocardiogr | 2002 |
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hyp | 2000 |
Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Leptin; Losartan; Male; Middle Aged; T | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arachidonic Acid; Biotransformation; Cells, Cultur | 2002 |
Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Blood Pressure; Buttocks | 2000 |
[Effects of long-term therapy with losartan on baroreflex regulation of cardiovascular system].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Cardiovascular Diseases; Humans; Hypert | 2002 |
A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Humans; Hyp | 2001 |
Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female | 2002 |
[Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Bilirubin; Blood Glucose; Blood Pressu | 2001 |
Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2002 |
Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients.
Topics: Adolescent; Adult; Albuminuria; Angiotensin II; Antihypertensive Agents; Blood Pressure; Female; Hum | 2002 |
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Topics: Angiotensin II; Antihypertensive Agents; Blood Pressure; Diet, Sodium-Restricted; Female; Fibrinolys | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Clinical experience with angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertens | 1992 |
Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose- | 1992 |
1007 other studies available for losartan and Hypertension
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
Topics: Administration, Oral; Adrenal Glands; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1991 |
N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Humans; Hypertension; Male; Models, | 1995 |
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
Topics: Administration, Oral; Amino Acid Sequence; Angiotensin Receptor Antagonists; Animals; Antihypertensi | 1994 |
Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Azoles; Hypertension; Male; Models, | 1994 |
Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Binding, Competitive; Bip | 2006 |
New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Drug Design; Drug Evaluat | 2006 |
Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Drug Desi | 2008 |
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzoates | 2008 |
Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
Topics: Alcohols; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Blood Pres | 2009 |
New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
Topics: Amides; Amines; Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta, Thoracic; Caf | 2012 |
Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Cell Line | 2012 |
Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzimidazoles; Binding Sites; Dose-Response | 2014 |
Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Hypertension; Magnetic Resonance | 2016 |
N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pres | 2016 |
The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Cytochrome P-450 CYP2C9; Female; Humans; Hypertension; Hyperur | 2021 |
TLR4 and AT1R mediate blood-brain barrier disruption, neuroinflammation, and autonomic dysfunction in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Baroreflex; Brain; Heart Rate; | 2021 |
Both central sympathoexcitation and peripheral angiotensin II-dependent vasoconstriction contribute to hypertension development in immature heterozygous Ren-2 transgenic rats.
Topics: Angiotensin II; Animals; Blood Pressure; Hypertension; Losartan; Male; Rats; Rats, Transgenic; Renin | 2022 |
Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: Findings from real-world, multicenter observational databases.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Losartan; Treatment Outcome; Uric Acid | 2021 |
Dose-dependent atorvastatin associated with angioedema.
Topics: Aged; Amlodipine; Angioedema; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Femal | 2022 |
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext | 2022 |
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Hypertension | 2021 |
Comment on 'Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial'.
Topics: Amlodipine; Antihypertensive Agents; COVID-19; Humans; Hypertension; Losartan; SARS-CoV-2 | 2021 |
Cardiorenal protective effects of sodium-glucose cotransporter 2 inhibition in combination with angiotensin II type 1 receptor blockade in salt-sensitive Dahl rats.
Topics: Angiotensin II; Animals; Blood Pressure; Glucose; Humans; Hypertension; Losartan; Rats; Rats, Inbred | 2022 |
Does Losartan reduce the severity of COVID-19 in hypertensive patients?
Topics: Antihypertensive Agents; COVID-19; Humans; Hypertension; Losartan; SARS-CoV-2 | 2022 |
Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2022 |
Combined effects of angiotensin receptor blocker use and physical training in hypertensive men.
Topics: Angiotensin Receptor Antagonists; Baroreflex; Blood Pressure; Exercise; Heart Rate; Humans; Hyperten | 2022 |
Cross-Talk between CB
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Losartan; Paraventricular H | 2022 |
Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Blood Pressure; Humans; Hypertension; Losartan; Mice; Qu | 2022 |
Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Estradiol; Female; | 2022 |
Antihypertensive medicine use differs between Ghana and Nigeria.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Humans; Hypertensio | 2023 |
Co-administration of metformin and/or glibenclamide with losartan reverse N
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Esters; Glyburide | 2023 |
COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Blood Pressure; C | 2023 |
Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Collagen; Hypertension; Int | 2023 |
[Effect of electroacupuncture on transforming growth factor-β1 and renal tubular epithelial mesenchymal transformation in renal tissue of spontaneously hypertensive rats].
Topics: Animals; Cadherins; Electroacupuncture; Epithelial-Mesenchymal Transition; Hypertension; Losartan; M | 2023 |
Expression of Trpa1 and Trpv1 Genes in the Hypothalamus and Blood Pressure in Normotensive and Hypertensive Rats. Effect of Losartan and Captopril.
Topics: Angiotensin II; Animals; Blood Pressure; Captopril; Hypertension; Hypothalamus; Losartan; Rats; TRPA | 2023 |
Brain-targeted delivery of losartan through functionalized liposomal nanoparticles for management of neurogenic hypertension.
Topics: Animals; Brain; Hypertension; Liposomes; Losartan; Nanoparticles; Rats; Rats, Inbred SHR; Rats, Inbr | 2023 |
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19.
Topics: Antihypertensive Agents; COVID-19; Humans; Hypertension; Losartan; Telmisartan | 2023 |
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cana | 2023 |
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Germany; Humans; Hyperte | 2023 |
Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan.
Topics: Animals; Antihypertensive Agents; Cytochrome P-450 CYP2C9; Humans; Hypertension; Losartan; Rats | 2023 |
Design, synthesis and biological evaluation of novel indole-3-carboxylic acid derivatives with antihypertensive activity.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 2023 |
Metabolomic Profile and Its Correlation with the Plasmatic Levels of Losartan, EXP3174 and Blood Pressure Control in Hypertensive and Chronic Kidney Disease Patients.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Losartan; Renal Insufficiency, Chroni | 2023 |
Unveiling Angiotensin II and Losartan-Induced Gene Regulatory Networks Using Human Urine-Derived Podocytes.
Topics: Angiotensin II; Gene Regulatory Networks; Humans; Hypertension; Losartan; Podocytes; Receptor, Angio | 2023 |
Sex differences in weight gain, blood pressure control, and responses to melanocortin-4 receptor antagonism in offspring from lean and obese parents.
Topics: Adrenergic Agents; Adult; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Obesity; Rec | 2023 |
Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Enalapril; Humans | 2023 |
Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Electrocardiography; Heart Failure; Hum | 2023 |
The treatment with trandolapril and losartan attenuates pressure and volume overload alternations of cardiac connexin-43 and extracellular matrix in Ren-2 transgenic rats.
Topics: Animals; Blood Pressure; Connexin 43; Extracellular Matrix; Fistula; Heart Failure; Hypertension; Lo | 2023 |
Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats.
Topics: Alveolar Process; Animals; Antihypertensive Agents; Blood Pressure; Bone Regeneration; Calcification | 2019 |
Angiotensin II inhibits DDAH1-nNOS signaling via AT1R and μOR dimerization to modulate blood pressure control in the central nervous system.
Topics: Amidohydrolases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; D | 2019 |
Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Gastrointestinal Microbiome; Hypertension; Losarta | 2020 |
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com | 2020 |
Angiotensin receptor blockade with Losartan attenuates pressor response to handgrip contraction and enhances natriuresis in salt loaded hypertensive subjects: a quasi-experimental study among Nigerian adults.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Case-Contro | 2019 |
[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].
Topics: Adult; Antihypertensive Agents; Cytochrome P-450 CYP2C9; Female; Gene Frequency; Genotype; Humans; H | 2019 |
Facts and reflections on COVID-19 and anti-hypertensives drugs.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.
Topics: Angiotensin Receptor Antagonists; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Diseas | 2020 |
Clinical efficacy of various anti-hypertensive regimens in hypertensive women of Punjab; a longitudinal cohort study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Diuretics; | 2020 |
Hypogonadal hypertension in male Sprague-Dawley rats is renin-angiotensin system-dependent: role of endogenous androgens.
Topics: Androgens; Animals; Antihypertensive Agents; Aorta; Gene Expression Regulation, Enzymologic; GTPase- | 2020 |
Calcitriol inhibits COX-1 and COX-2 expressions of renal vasculature in hypertension: Reactive oxygen species involved?
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Calcitriol; Cyclic N-Oxides; Cyclo | 2021 |
Effects of maternal protein restriction on central and peripheral renin-angiotensin systems in male rat offspring.
Topics: Animals; Arterial Pressure; Diet, Protein-Restricted; Female; Heart Rate; Hypertension; Lactation; L | 2020 |
The Possible Regulatory Mechanisms of Aqueous, Ethyl Acetate and NHexane Fractions of the Ribes khorassanicum Extract on Acute Hypertension in Rats.
Topics: Acetates; Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiovas | 2021 |
β-Arrestin-Biased Agonist Targeting the Brain AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; beta-Arrestins; Blood Pressure; Cell Line; Choice | 2021 |
Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.
Topics: Aged; Aged, 80 and over; Angioedema; Antihypertensive Agents; Blood Pressure; Dose-Response Relation | 2020 |
Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Losartan; Male; Malondialdehyde; Oxi | 2021 |
Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; COVID-19; Female; Humans; Hypertensio | 2020 |
Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Humans; Hypertensi | 2021 |
Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diet, High-Fat; Human Umbilical Vein En | 2021 |
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2021 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Losartan modifies mesh integration after abdominal wall repair: an experimental study.
Topics: Abdominal Wall; Animals; Herniorrhaphy; Humans; Hypertension; Losartan; Prostheses and Implants; Rat | 2022 |
Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial | 2021 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Smal | 2021 |
Renoprotective and therapeutic effects of newly water, ethanol, and butanol ginseng fractions in hypertensive and chronic kidney disease with L-NAME.
Topics: Animals; Butanols; Disease Models, Animal; Ethanol; Female; Gas Chromatography-Mass Spectrometry; Ge | 2021 |
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.
Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiovascular Disea | 2017 |
Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats.
Topics: Angiotensin II; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydro | 2017 |
Association of obstructive sleep apnea with arterial stiffness and nondipping blood pressure in patients with hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2017 |
Renal denervation decreases blood pressure and renal tyrosine hydroxylase but does not augment the effect of hypotensive drugs.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Hypertension; Indapamide; Losartan; Male; Metop | 2017 |
Aliskiren reduces albuminuria after kidney transplantation.
Topics: Adult; Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Double-Blind Method; Female; Fumarates | 2017 |
Sub-chronic lead exposure produces β
Topics: Animals; Arterial Pressure; Cardiovascular Diseases; Down-Regulation; Heart Rate; Hexamethonium; Hyp | 2017 |
Angiotensin II induces calcium/calcineurin signaling and podocyte injury by downregulating microRNA-30 family members.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Calcium; Calcium Sign | 2017 |
Nitric oxide pathway presumably does not contribute to antianxiety and memory retrieval effects of losartan.
Topics: Angiotensins; Animals; Anti-Anxiety Agents; Behavior, Animal; Hypertension; Hypothalamo-Hypophyseal | 2017 |
Innate And Adaptive Immunity are Progressively Activated in Parallel with Renal Injury in the 5/6 Renal Ablation Model.
Topics: Acute Kidney Injury; Adaptive Immunity; Animals; Catheter Ablation; Creatinine; Disease Models, Anim | 2017 |
The role of losartan in preventing vascular remodeling in spontaneously hypertensive rats by inhibition of the H
Topics: Animals; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Hydrogen Peroxide; Hyper | 2017 |
Chronic high-sodium diet intake after weaning lead to neurogenic hypertension in adult Wistar rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure Determination; Heart Rate; Hexamethonium; Hypertens | 2017 |
Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Cyclooxygenase 2; Disease Models, Animal; Humans; Hypertension; Inflammatio | 2017 |
Farmácia Popular Program: pharmaceutical market analysis of antihypertensive acting on the renin-angiotensin system medicines.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Brazil; Commerce; Cost Sharing; Dr | 2017 |
Cerebrovascular recovery after stroke with individual and combined losartan and captopril treatment of SHRsp.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2017 |
Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms.
Topics: Animals; Blood Pressure; Creatinine; Diastole; Ginkgo biloba; Glutathione; Hypercholesterolemia; Hyp | 2017 |
Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Datab | 2017 |
Effects of losartan on vasomotor function and canonical transient receptor potential channels in the aortas of sinoaortic denervation rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Denervation; Endot | 2018 |
Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combi | 2018 |
Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2018 |
A Pitfall in Suspected (refractory) Celiac Disease: Losartan-Induced Enteropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biopsy; Celiac Disease; Diagnosis, Differential; Diarrhea; | 2017 |
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea | 2018 |
Losartan suppresses the kainate-induced changes of angiotensin AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Pressure; Como | 2018 |
The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Collagen; Drug Therapy, Combination; Female; Hyperten | 2018 |
Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats.
Topics: Adipose Tissue; Animals; Antihypertensive Agents; Diet, High-Fat; DNA Methylation; Epigenesis, Genet | 2018 |
Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Cardiovascular Agents; Ginkgo biloba; Glutathio | 2018 |
Danhong Injection Protects Against Hypertension-Induced Renal Injury Via Down-Regulation of Myoglobin Expression in Spontaneously Hypertensive Rats.
Topics: Animals; Cell Adhesion Molecules; Down-Regulation; Drugs, Chinese Herbal; Gene Expression Regulation | 2018 |
Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.
Topics: Animals; Blood Pressure; Collagen Type I; Collagen Type III; Compliance; Cytochrome P-450 CYP4A; Cyt | 2018 |
Hypotensive and neurometabolic effects of intragastric Reishi (Ganoderma lucidum) administration in hypertensive ISIAH rat strain.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Cerebral Cortex; Cerebrovascular | 2018 |
Effects and Mechanism of SO2 Inhalation on Rat Myocardial Collagen Fibers.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weights and Measures; Collagen; Heart; Heart Ventricle | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2018 |
Comparative effects of avocado oil and losartan on blood pressure, renal vascular function, and mitochondrial oxidative stress in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, | 2018 |
Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Birth Weight; Blood | 2018 |
Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism.
Topics: Adult; Aged; Atorvastatin; Captopril; Case-Control Studies; Coronary Artery Disease; Female; Genotyp | 2018 |
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
Topics: Antihypertensive Agents; Atenolol; Brazil; Captopril; Cell Survival; Cells, Cultured; DNA Damage; Do | 2018 |
Exosome-Mediated Transfer of ACE (Angiotensin-Converting Enzyme) From Adventitial Fibroblasts of Spontaneously Hypertensive Rats Promotes Vascular Smooth Muscle Cell Migration.
Topics: Adventitia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aniline Comp | 2018 |
Cathepsin B-Mediated NLRP3 Inflammasome Formation and Activation in Angiotensin II -Induced Hypertensive Mice: Role of Macrophage Digestion Dysfunction.
Topics: Angiotensin II; Animals; Cathepsin B; Cell Line; Cell Membrane Permeability; Chalcones; Escherichia | 2018 |
Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2018 |
Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism.
Topics: Atorvastatin; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; | 2019 |
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Age | 2019 |
Reversal of Aortic Enlargement Induced by Increased Biomechanical Forces Requires AT1R Inhibition in Conjunction With AT2R Activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Ao | 2019 |
Standardized ethanol-water extract of Ficus deltoidea Angustifolia reduces blood pressure in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Calcium; Endothelin-1; Ethanol; Ficu | 2019 |
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Topics: Administration, Intranasal; Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Animals; | 2019 |
Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Topics: Angiotensin II Type 1 Receptor Blockers; Dimethylnitrosamine; Drug Contamination; Drug Recalls; Huma | 2019 |
Reduction of blood pressure elevation by losartan in spontaneously hypertensive rats through suppression of LARG expression in vascular smooth muscle cells.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Gene Expression Regulation; Hypertension; Losartan | 2020 |
Blood pressure lowering effect of Ficus deltoidea var kunstleri in spontaneously hypertensive rats: possible involvement of renin-angiotensin-aldosterone system, endothelial function and anti-oxidant system.
Topics: Angiotensin II; Animals; Antioxidants; Blood Pressure; Captopril; Disease Models, Animal; Drugs, Chi | 2019 |
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Co | 2019 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Irreversible renal damage after transient renin-angiotensin system stimulation: involvement of an AT1-receptor mediated immune response.
Topics: Animals; Biomarkers; Hemodynamics; Hydralazine; Hypertension; Kidney; Losartan; Rats; Rats, Transgen | 2013 |
Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.
Topics: Adipokines; Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ce | 2013 |
Toward a personalized chronotherapy of high blood pressure and a circadian overswing.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2013 |
Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cost Savings; Drug Utilization Review; Dr | 2013 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe | 2013 |
Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2013 |
Can dabigatran improve blood pressure control?
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Antithrombins; Atrial Fib | 2013 |
Long-term effect of prazosin and losartan administration on blood pressure, heart, carotid artery, and acetylcholine induced dilation of cardiovascular system of young Wistar rats and SHR.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Heart; Hypertensi | 2013 |
Impact of antihypertensive medication adherence on blood pressure control in hypertension: the COMFORT study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazid | 2013 |
Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
Topics: Antihypertensive Agents; Drug Utilization Review; Drugs, Generic; Humans; Hypertension; Losartan; Pr | 2013 |
Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth | 2013 |
Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Aortic Aneurysm, T | 2013 |
Effect of angiotensin II type I receptor blocker losartan on bone deterioration in orchiectomized male hypertensive and normotensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bone and Bones; Bone Density; Hypertension; Losart | 2013 |
Intravital Förster resonance energy transfer imaging reveals elevated [Ca2+]i and enhanced sympathetic tone in femoral arteries of angiotensin II-infused hypertensive biosensor mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biosensing Techniques; Calcium; Calcium Signaling; | 2013 |
Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats.
Topics: Adaptive Immunity; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD; Antigens, Differe | 2014 |
Differential effects of antihypertensive treatments on apoptosis, oxidative stress, and expression of angiotensin receptors in the cerebral cortex from the onset of prehypertension and hypertension in stroke-prone spontaneous hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Blotting, Western; Cerebral Cortex; Hyperte | 2013 |
Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Autonomic Nervous System; Brain | 2013 |
Is validation of non-invasive hemodynamic measurement devices actually required?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; Female | 2014 |
Effects of antihypertensive drugs on central blood pressure: new evidence, more challenges.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; Female | 2014 |
Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; B | 2013 |
Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Denmark; Drug Costs; D | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mel | 2013 |
Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system.
Topics: Ammonium Compounds; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2014 |
Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood | 2013 |
Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relatio | 2013 |
Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.
Topics: Acute Disease; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Case-Control S | 2014 |
Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Cell Enlarg | 2014 |
Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Apoptosis; Blood Pressure; Brain; Hypertension; Lo | 2014 |
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
Topics: Angiotensin II; Animals; Cardiomegaly; Chemokine CCL2; Enalaprilat; gamma-Aminobutyric Acid; Glutami | 2014 |
Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost Savings; Costs and Cost Analysis; Drug Utilization; Dr | 2014 |
Roles of hypertension in the rupture of intracranial aneurysms.
Topics: Aneurysm, Ruptured; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Desoxycorticosteron | 2014 |
Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients.
Topics: Acidosis; Adolescent; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2014 |
Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Blood Pressure; Dendritic Spin | 2014 |
Hypertension, inflammation and atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Female; Humans; Hypertension; Hypertrophy, Left Ventri | 2014 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2014 |
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Co | 2014 |
American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antibodies, Monoclonal, Mur | 2014 |
Long‑term treatment of spontaneously hypertensive rats with losartan and molecular basis of modulating Ito of ventricular myocytes.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Gene Expression; Heart Ventricles; Hypertension; K | 2014 |
Does angiotensin receptor blockade ameliorate the prothrombotic tendency in hypertensive patients with atrial fibrillation? Breaking the vicious cycle.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; H | 2014 |
Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2014 |
Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction.
Topics: Amides; Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Arginine; Blood Pressure; Blotti | 2015 |
Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension & arterial remodelling in spontaneously hypertensive rats (SHR).
Topics: Analysis of Variance; Animals; Antibodies; Blood Pressure Determination; Enzyme-Linked Immunosorbent | 2014 |
The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.
Topics: Aldosterone; Captopril; Demography; Female; Humans; Hyperaldosteronism; Hypertension; Losartan; Male | 2015 |
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H | 2014 |
[Intraoperative anaphylaxis due to beta-lactams in a hypertensive patient on angiotensin ii receptor antagonists and beta-blockers].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anaphylaxis; Angiotensin II Type 1 Receptor Blockers; | 2015 |
[Microalbuminuria as a marker of endothelial dysfunction in the long-term follow-up patients after surgical correction of aortic coarctation].
Topics: Adolescent; Adult; Albuminuria; Antihypertensive Agents; Aorta, Thoracic; Aortic Coarctation; Biomar | 2013 |
Novel mechanism of intra‑renal angiotensin II-induced sodium/proton exchanger 3 expression by losartan in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Female; Gene Expression; Hypertension; Immediate-E | 2014 |
Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.
Topics: Angiotensin II; Animals; Arterial Pressure; Extracellular Signal-Regulated MAP Kinases; Humans; Hype | 2014 |
Vascular effects of a tripeptide fragment of novokinine in hypertensive rats: Mechanism of the hypotensive action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease M | 2014 |
Therapeutic impact of the single fixed-dose combination with a high-dose angiotensin-receptor blocker and a low-dose thiazide diuretic in the management of hypertension: awaiting further accumulation of clinical evidence.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Female; Humans; Hydroch | 2014 |
Healing process of autogenous bone graft in spontaneously hypertensive rats treated with losartan: an immunohistochemical and histomorphometric study.
Topics: Animals; Antihypertensive Agents; Bone Transplantation; Hypertension; Losartan; Male; Rats; Rats, In | 2014 |
Activation of upregulated angiotensin II type 2 receptors decreases carotid pulse pressure in rats with suprarenal abdominal aortic coarctation.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Aortic Coarctation; Blood Pressure; Blotting, West | 2015 |
Recurrent angioedema after naproxen use in a patient stabilized with losartan.
Topics: Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Drug Antagonism; | 2014 |
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Topics: Aged; Antihypertensive Agents; Electrocardiography; Female; Heart Failure; Humans; Hypertension; Hyp | 2014 |
Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; A | 2015 |
Antihypertensive effectiveness of combination therapy with losartan/hydrochlorothiazide for 'real world' management of isolated systolic hypertension.
Topics: Adult; Aged; Cross-Sectional Studies; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypert | 2015 |
An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Bradykinin B1 Receptor Anta | 2014 |
Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium-Calmodulin-Dependent Protein | 2014 |
Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Binding, Competitive; Blood Pressure; | 2015 |
Elevated pressure causes endothelial dysfunction in mouse carotid arteries by increasing local angiotensin signaling.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2015 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arterie | 2013 |
Inhibition of secretory activity of atrial myocytes in hypertensive rats after losartan treatment.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Heart | 2015 |
Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Hypertension; Inflammation; Interl | 2015 |
[Changes of right atrial myoendocrine cells during hypertension and after arterial pressure decrease].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood | 2014 |
Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Female; Gene Expression Regulation; Hear | 2015 |
Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress.
Topics: Alcohol Drinking; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arteries; | 2015 |
Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Forkhead Transcription Factors; Hypertension; Interleukin-2; | 2015 |
Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Cell Line; Epithelial Cells; HMGB1 Protein; Hypert | 2015 |
Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Rela | 2015 |
URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia.
Topics: Aged; Female; Genetic Association Studies; Genotype; Humans; Hypertension; Hyperuricemia; Losartan; | 2015 |
Quiz page: an unusual cause of nephrotic syndrome.
Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension | 2015 |
Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension.
Topics: Aged; Aged, 80 and over; Apelin; Blood Pressure; Female; Genotype; Humans; Hypertension; Intercellul | 2015 |
The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Blood Pressure; Coronary Vess | 2016 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomark | 2015 |
Induction of hypertension blunts baroreflex inhibition of vasopressin neurons in the rat.
Topics: Adrenergic alpha-1 Receptor Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Baroreflex; | 2015 |
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Hippocampus; Hypertension; Losartan; Male; Neuron | 2016 |
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene | 2015 |
An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
Topics: Albuminuria; Animals; Blood Pressure; Drug Combinations; Furosemide; Hydrochlorothiazide; Hypertensi | 2016 |
Norepinephrine-evoked salt-sensitive hypertension requires impaired renal sodium chloride cotransporter activity in Sprague-Dawley rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease M | 2016 |
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2015 |
Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Animals; Blood Pressure; Gene Expression Regulation; Humans; Hypertension; Losartan; Mal | 2016 |
NADPH oxidase activity and reactive oxygen species production in brain and kidney of adult male hypertensive Ren-2 transgenic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Hypertension; Kidney; Lipid Peroxidation; L | 2015 |
Effect of losartan with folic acid on plasma homocysteine and vascular ultrastructural changes in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Endothelial Cells; Folic Acid; Hematinics; Homocysteine; Hypertens | 2015 |
Hypotensive and antihypertensive effects of a hydroalcoholic extract from Senecio nutans Sch. Bip. (Compositae) in mice: Chronotropic and negative inotropic effect, a nifedipine-like action.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiogra | 2016 |
Mechanisms responsible for postmenopausal hypertension in a rat model: Roles of the renal sympathetic nervous system and the renin-angiotensin system.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Female; Hypertension; Kidn | 2016 |
Is Continuous Positive Airway Pressure an Effective and Practical Antihypertensive Agent?
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Continuous Positive Airway Pressure; Female; Human | 2016 |
COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diabetic Nephropathies; Enalapril; Female; Humans; | 2014 |
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2016 |
Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study.
Topics: Acrylates; Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Female | 2016 |
Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors.
Topics: Aldosterone; Analysis of Variance; Animals; Disease Models, Animal; Endothelium, Vascular; Hypertens | 2016 |
Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension.
Topics: Angiotensins; Animals; Blood Pressure; Disease Models, Animal; Growth Disorders; Hypertension; Lepti | 2016 |
Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy.
Topics: Antihypertensive Agents; Electrocardiography; Humans; Hypertension; Hypertrophy, Left Ventricular; L | 2016 |
Whey peptide Isoleucine-Tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptides; Disease Models, Anima | 2016 |
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Fe | 2016 |
20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR.
Topics: Angiotensins; Animals; Blood Pressure; Cytochrome P-450 CYP4A; Female; Humans; Hydroxyeicosatetraeno | 2016 |
Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Genotype; Haplotypes; Humans; Hypertension; | 2016 |
Protective effects of MCR-1329, a dual α1 and angII receptor antagonist, in mineralocorticoid-induced hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2016 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi | 2017 |
Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; A | 2016 |
Effect of p22phox depletion on sympathetic regulation of blood pressure in SHRSP: evaluation in a new congenic strain.
Topics: Acetophenones; Animals; Animals, Congenic; Antioxidants; Blood Pressure; Brain Stem; Cold Temperatur | 2016 |
Sudden Severe Bleeding in a Patient with Hemochromatosis: Liver Failure or Something Else?
Topics: Antihypertensive Agents; Chlorthalidone; Hemochromatosis; Hemoglobins; Humans; Hypertension; Liver F | 2016 |
Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Chemo | 2017 |
Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; DNA Methylation; Fibrosis; Hypertension; Hypertrop | 2017 |
Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy.
Topics: Aged; Antihypertensive Agents; Cough; Diagnosis, Differential; Factor Xa Inhibitors; Hematoma; Human | 2016 |
AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice.
Topics: Adipocytes, Beige; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Gl | 2017 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglut | 2016 |
Impaired Aortic Contractility to Uridine Adenosine Tetraphosphate in Angiotensin II-Induced Hypertensive Mice: Receptor Desensitization?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Blood Pr | 2017 |
Physical training associated with Enalapril but not to Losartan, results in better cardiovascular autonomic effects.
Topics: Animals; Antihypertensive Agents; Atropine; Autonomic Nervous System; Baroreflex; Blood Pressure; Co | 2017 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Gene Expression Regula | 2017 |
Chlorothiazide-induced photoaggravation of psoriatic lesion during narrowband ultraviolet B treatment in a case of psoriasis vulgaris.
Topics: Aged; Disease Progression; Drug Combinations; Female; Ficusin; Humans; Hydrochlorothiazide; Hyperten | 2017 |
[The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydrop | 2016 |
Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzazepines; Bosentan; Endothelin-Converting Enzy | 2017 |
Losartan reduced connexin43 expression in left ventricular myocardium of spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Connexin 43; Hy | 2008 |
Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Th | 2008 |
Agonistic AT(1) receptor autoantibody increases in serum of patients with refractory hypertension and improves Ca(2+) mobilization in cultured rat vascular smooth muscle cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Calcium; Cell Prol | 2008 |
Area-specific differences in transmitter release in central catecholaminergic neurons of spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Brain Stem; Catecholamines; Disease Models, Animal; Dopamine beta-Hydroxyla | 2008 |
Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Determination; Dose-Response Relati | 2008 |
Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Autoantibodies; Dose-Respo | 2008 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; Franc | 2008 |
Comparative analysis of renal protein expression in spontaneously hypertensive rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Blotting, Western; Disease Models, Ani | 2008 |
Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiomeg | 2009 |
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compou | 2008 |
Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Aged; Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Male; Metabolic | 2008 |
[Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].
Topics: Acute Kidney Injury; Adult; Angiotensin II Type 1 Receptor Blockers; Creatinine; Female; Gestational | 2008 |
Inhibition of Ang II and renal sympathetic nerve influence dopamine-and isoprenaline-induced renal haemodynamic changes in normal Wistar-Kyoto and spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Dopamine; Hemodyna | 2008 |
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 1995 |
Losartan in the treatment of hypertension: mechanism, efficacy and safety. Proceedings of a meeting. November 19-20, 1993. Lisbon, Portugal.
Topics: Animals; Antihypertensive Agents; Humans; Hypertension; Losartan | 1995 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2008 |
Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.
Topics: Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Crystallography; Cytochr | 2008 |
Renal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure | 2009 |
[Effects of fosinopril and losartan on the expression of Toll- like receptor 4 in renal tubular epithelia cells].
Topics: Animals; Cell Line; Epithelial Cells; Fosinopril; Hypertension; Kidney Diseases; Kidney Tubules; Los | 2008 |
Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Experime | 2008 |
Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats.
Topics: Aldosterone; Amiloride; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic | 2009 |
Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat.
Topics: Acetophenones; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agen | 2008 |
Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Conver | 2009 |
Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure.
Topics: Animals; Blood Pressure; Eplerenone; Heart; Hypertension; Losartan; Male; Rats; Rats, Inbred SHR; So | 2009 |
Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Body We | 2009 |
Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats.
Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Bl | 2009 |
Cardiovascular and autonomic phenotype of db/db diabetic mice.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B | 2009 |
[The pleiotropic effects of losartan--the importance of decreasing uric acid level].
Topics: Antihypertensive Agents; Humans; Hypertension; Losartan; Uric Acid; Uricosuric Agents | 2008 |
Cerebral vasomotor reactivity before and after blood pressure reduction in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; F | 2009 |
Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Complications; Drug Therapy, Com | 2009 |
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, HD | 2009 |
Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; DN | 2009 |
[Effects of losartan on left ventricular hypertrophy and plasma transforming growth factor-beta1 in elderly patients with hypertension].
Topics: Aged; Antihypertensive Agents; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan | 2009 |
Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies.
Topics: Animals; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Gene Expression; Gene Expres | 2009 |
Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cytoc | 2009 |
Antihypertensive effects of central ablations in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Baroreflex; Blood Pressur | 2009 |
Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Citrulline; Enzyme Inhibito | 2009 |
AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats.
Topics: Amidohydrolases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arginase; Arterio | 2009 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
Late renal medullary effects of transient angiotensin II receptor blockade in immature spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Hypertension; | 2009 |
Angiotensin II receptor blockers in pregnancy: a report of five cases.
Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2009 |
Losartan and tempol treatments normalize the increased response to hydrogen peroxide in resistance arteries from hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Antioxidants; Cyclic N-Oxides; Hydrogen Peroxide; H | 2009 |
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, | 2009 |
Na(+)-ATPase in spontaneous hypertensive rats: possible AT(1) receptor target in the development of hypertension.
Topics: Angiotensin II; Animals; Enzyme Activation; Hypertension; Kidney Tubules, Proximal; Kinetics; Losart | 2010 |
Angiotensin-(1-7) antagonist, A-779, microinjection into the caudal ventrolateral medulla of renovascular hypertensive rats restores baroreflex bradycardia.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Bradyca | 2009 |
Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C.
Topics: Aged; Antihypertensive Agents; Asian People; Case-Control Studies; Data Interpretation, Statistical; | 2009 |
Comparative evaluation of the antihypertensive activities of losartan and HM70186 during liver dysfunction.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2009 |
Comparative antihypertensive activities of losartan and HM70186 in rats with hepatic dysfunction.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Carbon Tetra | 2009 |
Chlorthalidone - a renaissance in use?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug Co | 2009 |
AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Calcito | 2009 |
[Hypertension and the heart].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Cardiovascula | 2009 |
Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Collagen; Connective Tissue; Diur | 2009 |
Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Hypertension; Losartan; Matrix Metalloproteinase 9; | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Block | 2010 |
Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Experim | 2009 |
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).
Topics: Aged; Antihypertensive Agents; Blood Flow Velocity; Echocardiography, Doppler; Female; Follow-Up Stu | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
[Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program].
Topics: Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle A | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly; | 2009 |
Role of caveolin and heat shock protein 70 interaction in the antioxidative effects of an angiotensin II type 1 receptor blocker in spontaneously hypertensive rats proximal tubules.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Caveolin 1; Disease Models, Animal; | 2010 |
Caveolin-1 and Hsp70 interaction in microdissected proximal tubules from spontaneously hypertensive rats as an effect of Losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Caveolin 1; Cell Fractionation; Cell | 2010 |
Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Hyperplasia | 2010 |
Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Endothelium, Vascular; | 2010 |
Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxida | 2010 |
Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System Diseases; | 2010 |
Astroglia are a possible cellular substrate of angiotensin(1-7) effects in the rostral ventrolateral medulla.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Astrocytes; Biosens | 2010 |
Pharmacodynamics of a losartan transdermal system for the treatment of hypertension.
Topics: Acrylates; Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Delayed-Acti | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfa | 2010 |
AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pre | 2010 |
Does enhanced respiratory-sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II-salt hypertension?
Topics: Angiotensin II; Animals; Hypertension; Losartan; Medulla Oblongata; Rats; Receptor, Angiotensin, Typ | 2010 |
Hypertension study in anaesthetized rabbits: protocol proposal for AT1 antagonists screening.
Topics: Anesthesia; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Hypertension; Imidazol | 2010 |
Effect of losartan on vascular function in fructose-fed rats: the role of perivascular adipose tissue.
Topics: Acetylcholine; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Di | 2010 |
Health-care costs of losartan and candesartan in the primary treatment of hypertension.
Topics: Acute Coronary Syndrome; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2010 |
Correction of endothelial dysfunction with impaza preparation in complex with enalapril and losartan during modeling of NO deficiency.
Topics: Animals; Antibodies; Enalapril; Hypertension; Losartan; Male; NG-Nitroarginine Methyl Ester; Nitric | 2009 |
Effect of impaza on cardiovascular system.
Topics: Animals; Antibodies; Antihypertensive Agents; Blood Pressure; Cardiovascular System; Erectile Dysfun | 2009 |
Experimental study of hypotensive effect of kardos in rats with inherited hypertension.
Topics: Animals; Antibodies; Antihypertensive Agents; Hypertension; Losartan; Male; Rats; Rats, Inbred SHR; | 2009 |
Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice.
Topics: Analysis of Variance; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Hypertension; Immuno | 2010 |
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2011 |
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, | 2010 |
Blockade of calcium channels and AT1 receptor prevents the hypertensive effect of calcilytic NPS 2143 in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Calcium Channel Blockers; Calcium | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticonvulsants; Behavior, Animal; Benzimidazoles; | 2010 |
Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2010 |
Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Atherosclerosis; Cell Line | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Blood Pressure; Cardiomegaly; Echocardiography; Electrocardiography; Fema | 2010 |
An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT(1) angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Drug Design; Hum | 2010 |
Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
Topics: Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Mode | 2010 |
Postmenopausal hypertension: role of the Renin-Angiotensin system.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Press | 2010 |
Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Atenolol; Hypertension; Losartan; Male; Mal | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Losartan associated anaphylaxis and angioneurotic oedema.
Topics: Adult; Anaphylaxis; Angioedema; Antihypertensive Agents; Epinephrine; Female; Humans; Hypertension; | 2010 |
Generic ARBs are coming.
Topics: Antihypertensive Agents; Drugs, Generic; Health Knowledge, Attitudes, Practice; Humans; Hypertension | 2010 |
Losartan attenuates vascular remodeling of the aorta in spontaneously hypertensive rats and the underlying mechanism.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Catalase; Hydrogen Peroxide; Hypertension; | 2010 |
CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent.
Topics: Amidines; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2010 |
Role of the organum vasculosum of the lamina terminalis for the chronic cardiovascular effects produced by endogenous and exogenous ANG II in conscious rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressu | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Losartan and hypertensive children. Another option for a small number of children.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Child; Clinical Trials | 2010 |
Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothia | 2011 |
Chronic infusion of angiotensin receptor antagonists in the hypothalamic paraventricular nucleus prevents hypertension in a rat model of sleep apnea.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2011 |
[Effects of combination therapy with losartan/hydrochlorothiazide on the relationships between base blood pressure, autonomic function, and health-related QOL].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autonomic Nervous System; Bl | 2010 |
Changes in angiotensin receptors expression play a pivotal role in the renal damage observed in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Collagen; Cyclic AMP-Dependent Protein | 2011 |
Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies.
Topics: Administration, Oral; alpha-Cyclodextrins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2011 |
Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Blood Pressure; Calcium Channel Blockers; Drug Therapy | 2010 |
[The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon | 2010 |
[Losartan's effects on the protein expression of the kidney of spontaneous hypertension rat].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chromatography, Liquid; Electrophoresis, Gel, Two- | 2008 |
Getting better value from the NHS drug budget.
Topics: Angiotensin II Type 1 Receptor Blockers; Budgets; Drugs, Generic; Health Care Reform; Heart Failure; | 2010 |
Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Azotemia | 2011 |
Waste not, want not: free money, moral hazard and value-based prescribing.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Capto | 2011 |
Effects of fosinopril and losartan on renal Klotho expression and oxidative stress in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Fosinopril; Glucuronidase; Hypertension; Kidney; Klotho Proteins; | 2011 |
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2011 |
Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Hemodynamics; Hyp | 2011 |
Chronic angiotensin II infusion modulates angiotensin II type I receptor expression in the subfornical organ and the rostral ventrolateral medulla in hypertensive rats.
Topics: Angiotensin II; Animals; Blood Pressure; Gene Expression Regulation; Hypertension; Losartan; Male; M | 2011 |
Arterial tortuosity syndrome with multiple intracranial aneurysms: a case report.
Topics: Aged; Angiography; Antihypertensive Agents; Aorta; Aspirin; Circle of Willis; Connective Tissue Dise | 2011 |
Heart failure prevention is the best option to stem high costs and disease burden: research for more effective heart failure treatment is needed.
Topics: Antihypertensive Agents; Black or African American; Cost of Illness; Health Care Costs; Heart Failur | 2011 |
Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Dr | 2011 |
Altered regulation of the rostral ventrolateral medulla in hypertensive obese Zucker rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain Stem; Excita | 2011 |
Angiotensin II receptor blocker pretreatment of rats undergoing sudden renal ablation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Glomerular Filtration Rate; Hypertension; Kidney D | 2012 |
Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats.
Topics: Animals; Disease Progression; Fosinopril; Gene Expression Regulation, Enzymologic; Glucuronidase; Hy | 2011 |
Managing erectile dysfunction in hypertensive patients.
Topics: Amides; Antihypertensive Agents; Benzopyrans; Chlorthalidone; Ethanolamines; Fumarates; Humans; Hydr | 2011 |
Phosphoproteomic analysis of AT1 receptor-mediated signaling responses in proximal tubules of angiotensin II-induced hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cells, Cultured; C | 2011 |
Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension.
Topics: Aged; Blood Pressure; Body Weight; Diastole; Dose-Response Relationship, Drug; Female; Follow-Up Stu | 2012 |
Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2011 |
Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Female; Heart Failure; Humans; Hypertension | 2011 |
Antihypertensive treatment using an angiotensin receptor blocker and a thiazide diuretic improves patients' quality of life: the Saga Challenge Antihypertensive Study (S-CATS).
Topics: Age Factors; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Chemical | 2011 |
Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension.
Topics: 4-Aminopyridine; Adipocytes; Adipose Tissue; Angiotensin II; Animals; Aorta; Calcium; Cells, Culture | 2011 |
Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pre | 2011 |
Increased oxidative stress, the renin-angiotensin system, and sympathetic overactivation induce hypertension in kidney androgen-regulated protein transgenic mice.
Topics: Angiotensin II; Animals; Blood Pressure; Captopril; Cyclic N-Oxides; Hypertension; Kidney; Losartan; | 2011 |
Renin-angiotensin and sympathetic nervous system contribution to high blood pressure in Schlager mice.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Blood Pressure; Heart Rate; Humans; Hypertension | 2011 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Respons | 2011 |
Gαq-protein carboxyl terminus imitation polypeptide GCIP-27 attenuates proliferation of vascular smooth muscle cells and vascular remodeling in spontaneously hypertensive rats.
Topics: 3T3 Cells; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; | 2011 |
[Young patient with mild hypertension: angiotensin inhibitor or beta blocker?].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2011 |
STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men.
Topics: Adult; Alleles; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Moni | 2012 |
Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study).
Topics: Aged; Blood Pressure; Drug Combinations; Drug Substitution; Female; Humans; Hydrochlorothiazide; Hyp | 2011 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compou | 2011 |
The pharmacokinetic-pharmacodynamic assessment of the hypotensive effect after coadministration of losartan and hydrochlorothiazide in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Hydrochlorothiazide; Hypertension; Losa | 2012 |
Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Substitution; Fees, Ph | 2012 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2012 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug | 2012 |
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, A | 2012 |
Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Coarctation; Benzazepines; Cell Membrane; C | 2012 |
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enz | 2012 |
The therapeutic tradeoff between the adverse impacts of a lower GFR and long-term renal protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients.
Topics: Antihypertensive Agents; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Flow C | 2012 |
An economic evaluation of antihypertensive therapies based on clinical trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination | 2012 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
Decreased anandamide transporter activity and calcitonin gene-related peptide production in spontaneously hypertensive rats: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arachidonic Acids; B | 2012 |
Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Blood Pre | 2012 |
Have we observed the implications of the acute fall in eGFR during treatment with losartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Pre-renal success.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Angiotensin II receptor antagonist reduces subsequent uterine arterial dysfunction in pregnant offspring of protein-restricted rat dams.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II Type 1 Receptor B | 2012 |
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy.
Topics: Animals; Biomarkers; Blood Pressure; Cell Adhesion Molecules; Disease Progression; Gene Expression R | 2012 |
Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Topics: Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2012 |
Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Occlusive Di | 2012 |
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Echocardiography; Electrocardiogra | 2012 |
Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice.
Topics: 3T3-L1 Cells; Adipocytes; Adiposity; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor B | 2012 |
Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats.
Topics: Adoptive Transfer; Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Blood Pressure; | 2012 |
Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.
Topics: Amides; Animals; Antihypertensive Agents; Aorta; Fumarates; Hypertension; Losartan; Male; Random All | 2013 |
Impact of the combination of an angiotensin II receptor blocker and low-dose hydrochlorothiazide on patients with morning hypertension.
Topics: Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male | 2012 |
Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Pressure; Diet, Protein-Restrict | 2012 |
Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP1A1; Hydrochlo | 2012 |
Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascul | 2012 |
Clinical efficacy and safety of losartan/hydrochlorothiazide combination therapy.
Topics: Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male | 2012 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothe | 2012 |
Angiotensin II type 2 receptor-mediated inhibition of NaCl absorption is blunted in thick ascending limbs from Dahl salt-sensitive rats.
Topics: Absorption; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Hypertension; | 2012 |
Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial | 2012 |
[Inhibitory effect of losartan on prostatic hyperplasia in spontaneous hypertension rats and its pathophysiological mechanism].
Topics: Angiotensin II; Animals; Antihypertensive Agents; Hypertension; Insulin-Like Growth Factor I; Interl | 2012 |
Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C-Reactive | 2012 |
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardioton | 2012 |
Oxidative stress exaggerates skeletal muscle contraction-evoked reflex sympathoexcitation in rats with hypertension induced by angiotensin II.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Afferent Pathways; Angiotensin II; Angiotens | 2013 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Effects of a fixed combination of losartan with hydrochlorothiazide on glucose tolerance in hypertensive patients uncontrolled with angiotensin ii receptor blockers alone.
Topics: Aged; Angiotensin Receptor Antagonists; Drug Combinations; Female; Glucose Tolerance Test; Humans; H | 2013 |
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Calcinosis; Cardiomyopathies; Echocardiography; Female; Humans; Hypertensio | 2013 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-R | 2002 |
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Diabetic Nephropathies; | 2002 |
A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Follow-Up Studies; H | 2002 |
Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2002 |
N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Enzyme Inhibitors; Gene Expres | 2002 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
Dissociation between the circulating renin-angiotensin system and angiotensin II receptors in central losartan-induced hypertension.
Topics: Adrenergic alpha-Agonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[Preventing stroke. Which antihypertensive drugs can do it better?].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as T | 2002 |
[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Los | 2002 |
Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Case-Control Studi | 2002 |
Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Diseas | 2002 |
Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pr | 2002 |
Activation of hypothalamic angiotensin receptors produces pressor responses via cholinergic inputs to the rostral ventrolateral medulla in normotensive and hypertensive rats.
Topics: Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Carbachol; Choliner | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losart | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losart | 2002 |
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cl | 2002 |
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
[What are the consequences of the LIFE Study for general practice].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Fibrosis; Fosinopril; H | 2002 |
Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study).
Topics: Antihypertensive Agents; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized C | 2002 |
Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2002 |
Irbesartan substitution for valsartan or losartan in treating hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Irb | 2002 |
Differential effects of antihypertensive drug therapy on arterial compliance.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
[Changed guidelines of the German High Blood Pressure League. AT(1) blocker in the first league now].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol | 2003 |
Best bang for the buck?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[Lowering blood pressure with sartans. Are there differences?].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Cross-Over Stu | 2002 |
The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2002 |
[Is one antihypertensive agent as good as another?].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Drug Therapy, Combination; Humans; Hypertension; Hy | 2002 |
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Cardiotonic Agents; Female; Fosinopril; Hyp | 2001 |
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].
Topics: Angiotensin II; Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Hypertension; Losartan; Male | 2001 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Resolving the composite trait of hypertension into its pharmacogenetic determinants by acute pharmacological modulation of blood pressure regulatory systems.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Enzyme Inhibitors; Hypertension; Lod Score; Losart | 2003 |
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hype | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Indus | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Autoradiography; Blood P | 2003 |
[Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihyper | 2003 |
Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antihypertensive Agents; Aorta; Apoptosis; bcl-2-Associate | 2003 |
[Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
Topics: Aged; Antihypertensive Agents; Atenolol; Cause of Death; Double-Blind Method; Humans; Hypertension; | 2003 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Glome | 2003 |
AT1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2003 |
Persistent lowering of arterial pressure after continuous and intermittent therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug The | 2003 |
Assessment of effect of angiotensin II receptor antagonist losartan on aortic distensibility in patients with essential hypertension by echocardiography.
Topics: Angiotensin Receptor Antagonists; Aorta; Echocardiography; Elasticity; Female; Humans; Hypertension; | 2002 |
[Relationship of hypertensive microalbuminuria and endothelial and glomerular impairment].
Topics: Albuminuria; Animals; Antihypertensive Agents; Endothelium, Vascular; Glomerular Mesangium; Hyperten | 2002 |
Hypertension, angiotensin II, aldosterone, and race.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Eplerenone; Hu | 2003 |
Effect of losartan on the Na+/Ca2+ exchanger in left ventricle of the insulin resistant and hypertensive hHTg rat.
Topics: Animals; Biological Transport, Active; Gene Expression Regulation; Heart Ventricles; Hypertension; H | 2002 |
The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats.
Topics: 4-Aminopyridine; Adrenalectomy; Adrenergic Antagonists; Amifampridine; Angiotensin Receptor Antagoni | 2003 |
[Scleroderma renal crisis following withdrawal of therapy with losartan].
Topics: Acute Disease; Anti-Inflammatory Agents; Antihypertensive Agents; Causality; Female; Humans; Hyperte | 2003 |
NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Blood Pressure; Disease Model | 2003 |
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diabetes | 2003 |
Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Bu | 2003 |
Fenofibrate and losartan.
Topics: Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Losa | 2003 |
[Hemodynamics and cell membrane effects of angiotensin II receptor antagonists in treatment of hypertension].
Topics: Adenosine Triphosphatases; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive | 2003 |
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide.
Topics: Acute Kidney Injury; Antihypertensive Agents; Benzbromarone; Blood Cell Count; Creatinine; Diuretics | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; | 2003 |
Brain nitric oxide synthase activity in spontaneously hypertensive rats during the development of hypertension.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2003 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Losartan and atenolol on hypertension induced by adenosine receptor blockade.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 2 Receptor Blocker | 2003 |
Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular risk.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardio | 2003 |
Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cardiomeg | 2004 |
Acute renal failure secondary to angiotensin II receptor blockade in a patient with bilateral renal artery stenosis.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Con | 2003 |
Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blood-Brain Barrier; Diabetes Mellitus, Experiment | 2003 |
Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2003 |
Effects of losartan combined with exercise training in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Heart Rate; Hypertension; Losartan; Ma | 2003 |
Impaired substance P release from renal sensory nerves in SHR involves a pertussis toxin-sensitive mechanism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Calcium; Dinoprostone; Do | 2004 |
Prostacyclin and thromboxane A2 production in nitric oxide-deficient hypertension in vivo. Effects of high calcium diet and angiotensin receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Calcium, Dietary; Enzyme Inhibit | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
[Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochl | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2003 |
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives.
Topics: Adenine; Adult; Aged; Alleles; Antihypertensive Agents; Atenolol; Collagen Type I; Cytosine; Elastic | 2003 |
Proportion of treatment effect (PTE) explained by a surrogate marker.
Topics: Antihypertensive Agents; Atenolol; Biomarkers; Confidence Intervals; Data Interpretation, Statistica | 2003 |
Gender-specific genetic determinants of blood pressure and organ weight: pharmacogenetic approach.
Topics: Animals; Blood Pressure; Body Weight; Chromosomes, Mammalian; Crosses, Genetic; Disease Models, Anim | 2003 |
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study.
Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia; | 2003 |
Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Endotheli | 2003 |
Ganglionic action of angiotensin contributes to sympathetic activity in renin-angiotensinogen transgenic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; C | 2004 |
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Los | 2003 |
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2004 |
Endogenous angiotensin and pressure modulate brain angiotensinogen and AT1A mRNA expression.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; B | 2004 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Achieved vs initial blood pressure in predicting renal outcomes.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cyclic GM | 2003 |
Effects of losartan in hypertension without vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp | 2004 |
Fingernail clubbing and chromonychia associated with the use of angiotensin II receptor blockers.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Fingers; Humans; Hypertension; Losartan; Mal | 2004 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
Losartan-induced attenuation of blood pressure in L-NAME hypertensive rats is associated with reversal of the enhanced expression of Gi alpha proteins.
Topics: Adenylyl Cyclases; Animals; Antihypertensive Agents; Blood Pressure; Colforsin; Disease Models, Anim | 2004 |
Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2004 |
Aspirin, superoxide anions and development of hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Cells, Cultured; Hyp | 2004 |
Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Body Weight; Cells, | 2004 |
Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2004 |
Treatment of Wilms tumor-related hypertension with losartan and captopril.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans | 2004 |
The LIFE Trial in 2004.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Human | 2004 |
Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system.
Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Chemistry; Car | 2004 |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; | 2004 |
[A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diospyros; Heart | 2004 |
Valsartan treatment of hypertension--does VALUE add value?
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2004 |
In vivo effect of losartan on platelet aggregation in patients with hypertension.
Topics: Adenosine Diphosphate; Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Male; Middle | 2004 |
Ouabain-induced hypertension alters the participation of endothelial factors in alpha-adrenergic responses differently in rat resistance and conductance mesenteric arteries.
Topics: Animals; Antihypertensive Agents; Blotting, Western; Cardiotonic Agents; Cyclooxygenase Inhibitors; | 2004 |
[Characteristics of hypotensive effect in patients with arterial hypertension and desaturation signs of obstructive sleep apnea syndrome during sleep].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Pressu | 2004 |
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; | 2004 |
Multiple pheochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Angiotensin II Type 1 Recep | 2004 |
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; | 2004 |
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Topics: Adult; Angiotensin Receptor Antagonists; Biomarkers; Fatty Liver; Female; Ferritins; Hepatitis; Huma | 2004 |
Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Diastole; Echocardiography, | 2004 |
Salt-induced ANG II suppression impairs the response of cerebral artery smooth muscle cells to prostacyclin.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Calcium; Cerebral Arteries; Epopro | 2005 |
Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; A | 2004 |
Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Acetophenones; Amino Acid Sequence; Angioten | 2004 |
AT1 receptor in rostral ventrolateral medulla mediating blunted baroreceptor reflex in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Baroreflex; Blood Pressure; Heart | 2004 |
[Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2004 |
Neurohumoral mechanisms involved in the hypertensive response elicited by bilateral carotid occlusion in conscious intact or chronically sympathectomized rats.
Topics: Adrenal Glands; Adrenergic alpha-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bloo | 2004 |
Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Hypertension; Losartan; Male; Middle Aged; Muscle, | 2005 |
Losartan-ramipril combination treatment.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Rate; Humans; H | 2004 |
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Combined Modality Therapy; Disease | 2005 |
Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
Topics: Aged; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; H | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity?
Topics: Adult; Antihypertensive Agents; Baroreflex; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2005 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Bl | 2005 |
Keeping tabs on your heart while treating BP.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan | 2005 |
Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2005 |
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left | 2005 |
[Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2005 |
[A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Clinical Tria | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Bli | 2005 |
Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
Topics: 6-Ketoprostaglandin F1 alpha; Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2005 |
Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
Topics: Adult; Anemia; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers; Creatinine; Eryth | 2005 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Rec | 2005 |
Effects of losartan on blood pressure, oxidative stress, and nitrate/nitrite levels in the nitric oxide deficient hypertensive rats.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Weight; C | 2004 |
Pulse pressure and antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2005 |
Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Cell Adhe | 2005 |
Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressu | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
Antihypertensive treatment and sympathetic excitation.
Topics: Antihypertensive Agents; Baroreflex; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; | 2005 |
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta, Thoracic; Blood Pressure; Blott | 2005 |
Long-term inhibition of angiotensin prevents reduction of periarterial innervation of calcitonin gene-related peptide (CGRP)-containing nerves in spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; C | 2005 |
[Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
Topics: Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Humans; | 2005 |
Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihyper | 2005 |
Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; B | 2005 |
Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
Topics: Acetylcholine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; | 2005 |
Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Hemodynamics; H | 2005 |
Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; An | 2006 |
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys | 2006 |
Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism.
Topics: 6-Ketoprostaglandin F1 alpha; Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2006 |
Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Apomorphine; Blood Pressure; Enalapril; Hydralazine; Hydroc | 2006 |
Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood P | 2005 |
Differential effect of losartan in female and male spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Estrous Cycle; Female; Gene Expression | 2006 |
Study of efficacy and safety of losartan (losar) in Asian Indian hypertensives.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; India; Losartan; Male; Middle Aged; Product S | 2005 |
Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Catechols; Hypertension; Ki | 2006 |
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2005 |
[Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine.
Topics: Actins; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Calcium Channe | 2006 |
Watchdog rules that Merck violated the UK industry code of practice.
Topics: Antihypertensive Agents; Drug Industry; Humans; Hypertension; Losartan; Practice Guidelines as Topic | 2006 |
Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats.
Topics: Age Factors; Aging; Algorithms; Animals; Antihypertensive Agents; Blotting, Western; Cardiomegaly; D | 2006 |
RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; | 2006 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr | 2006 |
Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Diseases in Twins; Fema | 2006 |
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Flow Velocity; Cardiac Output; Echocardiogra | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
Arteriolar remodeling in essential hypertension: are connective tissue growth factor and transforming growth factor involved?
Topics: Amlodipine; Antihypertensive Agents; Arterioles; Connective Tissue Growth Factor; Humans; Hypertensi | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
[AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2006 |
Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
Topics: Anal Canal; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2006 |
The contribution of brain angiotensin II to the baroreflex regulation of renal sympathetic nerve activity in conscious normotensive and hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Baroreflex; Blood Pressure; Brain | 2006 |
Abnormal renovascular parathyroid hormone-1 receptor in hypertension: Primary defect or secondary to angiotensin ii type 1 receptor activation?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Cells, Cultured; Desoxyc | 2006 |
[Hypertensive patient with enlarged heart. Caution, risk of atrial fibrillation!].
Topics: Antihypertensive Agents; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; E | 2006 |
Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Inf | 2006 |
Modulation of kinin B1 receptor expression by endogenous angiotensin II in hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Gene Expression Regulation; Hypert | 2006 |
Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cyclohexanecarboxylic Acids; Heart | 2006 |
Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Topics: Anti-Inflammatory Agents; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Infla | 2006 |
In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Contraindications; Diabetes Mellitus, Type 2; Female; Fetal | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Aut | 2006 |
Hypertension, diuretics, and uric acid.
Topics: Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cardiovascular System; Di | 2006 |
[Effect of asymmetric dimethylarginine on platelet-aggregation and losartan intervention in spontaneous hypertensive rat models].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arginine; Hypertension; L | 2006 |
[Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor.
Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Age | 2007 |
Increased sympathetic activity in rats submitted to chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Chronic Disease; Disease Models, A | 2007 |
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood | 2007 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Hea | 2007 |
Treating hypertension in older people: Practical implications of achieving targets.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; European Union; Geriatrics; Humans; Hypertension; | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Ben | 2007 |
Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Blotting, W | 2007 |
Investigation of the mechanisms by which chronic infusion of an acutely subpressor dose of angiotensin II induces hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; | 2007 |
Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antihypertens | 2007 |
Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension.
Topics: Adaptation, Physiological; Adult; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure | 2007 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
Enhanced activity of ventricular Na+-HCO3- cotransport in pressure overload hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Disease Models, Animal; Heart Ve | 2007 |
Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic | 2007 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Early left ventricular gene expression profile in response to increase in blood pressure.
Topics: Acute Disease; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2006 |
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
Topics: Aged; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2007 |
[Blood pressure reduction with additional benefits].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomegaly; Humans; Hypertension; Losartan | 2007 |
Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Endothelial Cells; Gene Expression Regulation; | 2007 |
Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Diabetic Retinopathy; Drug C | 2007 |
Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square Dist | 2007 |
Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arginine Vasopressin; Baroreflex; Blood Glucose; B | 2007 |
Sudden cardiac standstill during skin flap elevation in a patient undergoing craniotomy.
Topics: Aged; Amlodipine; Anesthesia, General; Anti-Arrhythmia Agents; Antihypertensive Agents; Atropine; Bl | 2007 |
The effect of diet on simvastatin and losartan enhancement of endothelial function.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diet; | 2007 |
[Peroxisome proliferator-activated receptor activator troglitazone inhibits angiotensin II-stimulated secretion of vasoactive factors by endothelial cells].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Line | 2007 |
Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Calcium Channel Blockers; D | 2007 |
Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship | 2007 |
Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?
Topics: Antihypertensive Agents; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus; Electrocardiograp | 2007 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Me | 2007 |
Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats.
Topics: Animals; Arginine; Blood Pressure; Hypertension; Losartan; Male; Nitric Oxide; Rats; Rats, Inbred SH | 2007 |
Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Administration S | 2007 |
Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodie | 2007 |
[Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Confidence Intervals; D | 2007 |
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; Collag | 2007 |
Conceptual basis and methodology of the SOPHIA study.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Clinical Trials as Topic | 2007 |
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Blood Pr | 2007 |
A novel adipokine CTRP1 stimulates aldosterone production.
Topics: Adipokines; Aldosterone; Angiotensin II; Animals; Calcium; Cytochrome P-450 CYP11B2; DNA-Binding Pro | 2008 |
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidaz | 2008 |
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease Models, Animal; D | 2007 |
Hyperinsulinemic rats are normotensive but sensitized to angiotensin II.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2008 |
Delayed effects of hypotensive drugs on structural characteristics of the renal glomerular system in hypertensive NISAG rats.
Topics: Animals; Antihypertensive Agents; Enalapril; Hypertension; Kidney Glomerulus; Losartan; Male; Nifedi | 2007 |
Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio".
Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bendroflumethiazide; Cross-Over Studies; Double-Bli | 2008 |
The renin-Angiotensin system: a potential modulator of endothelial progenitor cells.
Topics: Endothelium, Vascular; Humans; Hypertension; Losartan; Neovascularization, Pathologic; Renin-Angiote | 2007 |
Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cyclic N-Oxides; Endothelium, Vascul | 2007 |
Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2008 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bl | 2008 |
A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2008 |
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Animals; Antihypertensive Agents; Blood Pressure; Calcium; | 2008 |
Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
Topics: Aldehydes; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzylamines; D | 2008 |
A case of parkinsonism worsened by losartan: a probable new adverse effect.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dopamine Agonists; Drug Interactions; Humans; Hyperte | 2008 |
Cough induced by losartan with resolution after substitution with enalapril.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cough; Ena | 2008 |
Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Benzoates; | 2008 |
Effects of long-term losartan and L-arginine treatment on haemodynamics, glomerular filtration, and SOD activity in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Abdominal; Arginin | 2008 |
Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bone Marrow Cells; Cell Differentiation; Disease M | 2008 |
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2008 |
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Brachial Arter | 2008 |
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Ventricles; Humans; Hypert | 2008 |
Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Femal | 2008 |
Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Disease Models, A | 2008 |
Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1995 |
A new class of antihypertensive: angiotensin II receptor antagonists.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Dose-Response | 1995 |
Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1995 |
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
Topics: Amino Acid Oxidoreductases; Analysis of Variance; Animals; Antihypertensive Agents; Arginine; Biphen | 1995 |
[Effects of chronic losartan treatment on myocardial, vascular structure and reactivity with aging in spontaneously hypertensive rats (SHR): its effects compared with those of captopril].
Topics: Aging; Animals; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Captopril; Coronary C | 1995 |
Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1995 |
Losartan improves baroreflex control of heart rate of coarcted hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aortic Coarctation; Baroreflex; Biphenyl Com | 1995 |
In vivo pharmacology of L-159,913, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 1995 |
Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study.
Topics: Aged; Angiotensin II; Biphenyl Compounds; Blood Circulation; Blood Viscosity; Female; Hematocrit; Hu | 1995 |
Control of carotid vasomotor tone by local renin-angiotensin system in normotensive and spontaneously hypertensive rats. Role of endothelium and flow.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 1995 |
Effect of acute and chronic treatment with the angiotensin II subtype 1 receptor antagonist EXP 3174 on baroreflex function in conscious spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Baroreflex; Blood Pressure; Heart Rate; Hypertension; Imi | 1995 |
Antihypertensive therapy targeted to the needs of the patient: focus on the renin-angiotensin system; older and newer agents.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood | 1995 |
Angiotensin receptors: physiology and pharmacology.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl | 1995 |
Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.
Topics: Animals; Antihypertensive Agents; Arginine; Biphenyl Compounds; Blood Pressure; Bradykinin; Drug Int | 1995 |
Cardiovascular effects after the intracerebroventricular administration of peptide and nonpeptide angiotensin antagonists in Dahl salt-sensitive rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Brain; Heart Rate; Hypertension; Imidaz | 1995 |
Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1995 |
Losartan in patients with renal insufficiency.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 1995 |
The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1995 |
[Medical angiotensin II-receptor blockade in hypertension and heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1995 |
Sympathoinhibitory effects of losartan in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Agonists; Anesthetics; Animals; Antihypertensive Agents; Biphenyl Compounds; Decere | 1993 |
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 1993 |
Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells.
Topics: Aldosterone; Androstanols; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compo | 1995 |
Angiotensin II receptors and potassium channels: targets for new cardiovascular drugs.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Hypertension; Imidazoles; Losartan; Potassium | 1995 |
Angiotensinogen depletion by high renin levels in hypertensive rats: no evidence for tonic stimulation of angiotensinogen by angiotensin II.
Topics: Administration, Oral; Angiotensin II; Angiotensinogen; Animals; Biphenyl Compounds; Diet; Hypertensi | 1995 |
Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Captopril; Diabetes M | 1995 |
Losartan for hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1995 |
Anomalous effects of losartan on aminopeptidase-induced reductions of blood pressure in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; CD13 Antigens; Hypert | 1995 |
Angiotensin receptor blockers in essential hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; | 1993 |
Chronic effects of central and systemic administration of losartan on blood pressure and baroreceptor reflex in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Heart | 1994 |
Glomerular losartan (DuP 753)-sensitive angiotensin II receptor density is increased in young spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Hypertension; Imidazo | 1994 |
Enhanced pressor response to angiotensin III in spontaneously hypertensive rats: effects of losartan.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bloo | 1994 |
Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Brain Stem; He | 1994 |
ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atrial N | 1994 |
Effect of chronic losartan potassium treatment on fructose-induced hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Dietary Carb | 1994 |
The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Blood Pressure; Fe | 1994 |
Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressur | 1994 |
Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1994 |
Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Cells, Cultured; Hypertension; Hypothalamus, Anterior; | 1994 |
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1994 |
Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Binding, Competitive; Biphenyl Compounds; B | 1993 |
Altered pressure natriuresis in chronic angiotensin II hypertension in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Chron | 1994 |
Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Arginine; Biphenyl | 1994 |
Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine; Biphenyl | 1994 |
Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Aortic Coarctation; Arginine; Biphenyl Compounds; | 1994 |
Angiotensin II alters aortic fibronectin independently of hypertension.
Topics: Angiotensin II; Animals; Aorta; Biphenyl Compounds; Blood Pressure; Fibronectins; Humans; Hydralazin | 1994 |
The neurogenic origin of hypertension in SHR may be mediated by angiotensin II through a receptor different from AT1 and AT2.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Hyper | 1993 |
Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Biphenyl Compounds; Blood Pressure; Blood Vessels; | 1993 |
Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1993 |
Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Doxorubicin; H | 1994 |
DuP 753 is more effective than captopril on baroreceptor function in high-renin hypertension.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Captopril; Heart Rate; Hypertension; Im | 1994 |
Chronic converting enzyme inhibition facilitates baroreceptor resetting to hypertensive levels.
Topics: Angiotensin I; Angiotensin II; Animals; Aorta; Biphenyl Compounds; Blood Pressure; Bradykinin; Capto | 1994 |
Angiotensin receptor sites in renal vasculature of rats developing genetic hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Biphenyl Compounds; | 1993 |
Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Cerebrovascu | 1993 |
Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; | 1993 |
Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Hydra | 1993 |
Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Proteins; Body Weight; Brain; Chlorides; Creatini | 1993 |
In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Depre | 1993 |
Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 1993 |
Nonpeptide angiotensin AT1 and AT2 receptor ligands modulate the upper limit of cerebral blood flow autoregulation in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cerebrovascular Circu | 1993 |
Effect of chronic treatment with losartan potassium (DuP 753) on the elevation of blood pressure during chronic exposure of rats to cold.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1993 |
Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1993 |
Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade.
Topics: Angiotensin II; Animals; Arginine; Biphenyl Compounds; Diet, Sodium-Restricted; Electrolytes; Hemody | 1993 |
Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Ant | 1995 |
Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 1995 |
Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade?
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans | 1995 |
Losartan: the first angiotensin receptor antagonist in clinical use.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Human | 1995 |
Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity?
Topics: Adult; Analysis of Variance; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Gluc | 1995 |
Nitric oxide and the depressor response to angiotensin blockade in hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Coarctation; Arginine; Bip | 1996 |
Losartan and angina pectoris.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles | 1995 |
New angiotensin-II blocker.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; | 1996 |
Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl | 1996 |
Reversible ageusia associated with losartan.
Topics: Aged; Ageusia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans | 1996 |
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
Topics: Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Arginine; Biphenyl Compounds | 1996 |
Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1996 |
Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl C | 1996 |
Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin-deficient, genetically hypertensive rats.
Topics: Adrenergic Antagonists; Angiotensin II; Animals; Biphenyl Compounds; Endothelins; Hemodynamics; Hype | 1996 |
Losartan protects the rat kidney from ischemic injury.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Hypertension; Imid | 1996 |
Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1996 |
Regulation of ANG II receptor in hypertension: role of ANG II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1996 |
Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronary Circulation; | 1996 |
Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats.
Topics: Alkaloids; Angiotensin II; Animals; Antihypertensive Agents; Benzophenanthridines; Biphenyl Compound | 1996 |
Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Enalapril; Hyp | 1996 |
Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pithed spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Cyclooxygenase Inhibitors; Decerebrate State; | 1996 |
ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats.
Topics: Angiotensin II; Angiotensinogen; Animals; Biphenyl Compounds; Hypertension; Imidazoles; Kidney; Losa | 1996 |
[Losartan].
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Re | 1996 |
Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Pharmacodynamic, pharmacokinetic and clinical profile of the first orally active angiotensin II receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; | 1995 |
Renal function in one-kidney, one clip sodium-restricted rats: influence of enalapril and losartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Enal | 1995 |
Acute renal excretory actions of losartan in spontaneously hypertensive rats: role of AT2 receptors, prostaglandins, kinins and nitric oxide.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 1995 |
Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Feedback; Hypertensio | 1996 |
Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cerebral Arteries; Ce | 1996 |
Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Renin secretion in conscious Lyon hypertensive rats.
Topics: Adrenergic beta-Agonists; Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 1996 |
[Contribution of the renin-angiotensin system to the variability of blood pressure in hypertensive rat after blockade of nitric oxide synthesis].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Brain "ouabain" and angiotensin II in salt-sensitive hypertension in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Brain; Guanabenz; Hemodynamics | 1996 |
[Angiotensin II antagonists: a distinct therapeutic class].
Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losar | 1996 |
Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
Losartan (Cozaar)
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Human | 1996 |
The renin angiotensin system and nociception in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1995 |
Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Biphenyl | 1997 |
[Angiotensin-II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Bradykinin; Bradykinin Recept | 1997 |
Increased brain transcription factor expression by angiotensin in genetic hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Biphenyl Compounds; | 1997 |
Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Capt | 1995 |
Enhanced cardiac preconditioning in the isolated heart of the transgenic ((mREN-2) 27) hypertensive rat.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; Hypertension; I | 1997 |
Interaction between endothelin and nitric oxide in sympathetic nerve modulation in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azepines; Biphenyl Compounds; Blood Pressure; Electrodes, Implante | 1997 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1997 |
Angioedema associated with angiotensin II receptor antagonist losartan.
Topics: Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Female; H | 1997 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose | 1997 |
Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
Role for endothelin-1 in angiotensin II-mediated hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1997 |
Angiotensin II receptor antagonists, elite drugs (or not) for patients with heart failure or hypertension?
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Heart Failure; Human | 1997 |
Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion.
Topics: Acetylcholine; Aldosterone; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pre | 1997 |
Effects of captopril, losartan, and nifedipine on cell hypertrophy of cultured vascular smooth muscle from hypertensive Ren-2 transgenic rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Biphenyl Compounds; Captopril; Cells, Cultur | 1997 |
Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat.
Topics: Adenylyl Cyclases; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Antihypertensive | 1997 |
Renal effects of an angiotensin II antagonist in stroke-prone spontaneously hypertensive rat.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood | 1997 |
Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antisense Elements (Genetics); DNA, Complementary; Gene Transfer T | 1997 |
Involvement of renin-angiotensin system in hypertensive effect of cadmium in rats.
Topics: Animals; Antihypertensive Agents; Cadmium; Captopril; Hypertension; Losartan; Male; Rats; Renin; Ren | 1997 |
Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Antihypertensiv | 1997 |
Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Ao | 1997 |
[Losartan (LORZAAR) and Losartan/hydrochlorothiazide (LORZAAR-PLUS)--their value in hypertension therapy. Symposium on the occasion of the 103rd Session of the German Society. Wiesbaden, 7 April 1997].
Topics: Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Tetrazoles | 1997 |
[Angiotensin II antagonists].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Humans; Hypert | 1995 |
Lithium intoxication in an elderly patient after combined treatment with losartan.
Topics: Aged; Antidepressive Agents; Antihypertensive Agents; Antimanic Agents; Ataxia; Bipolar Disorder; Co | 1997 |
Actions of angiotensin and lisinopril on thalamic somatosensory neurons in normotensive, non-transgenic and hypertensive, transgenic rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; An | 1997 |
Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Azoles; Biphenyl | 1997 |
Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Area Under Curve; Blood Pr | 1997 |
Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1997 |
Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A | 1997 |
[New antihypertensive drugs: reasons for hope].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, C | 1997 |
Losartan and renal transplantation.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Erythrocyte Count; | 1998 |
AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Cerebro | 1998 |
Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Bradykinin; Dipepti | 1998 |
Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 1997 |
[Physiopathology of angiotensin II and vascular lesion].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; | 1997 |
Sympathetic functions in NG-nitro-L-arginine-methyl-ester-induced hypertension: modulation by the renin-angiotensin system.
Topics: Adenylyl Cyclases; Animals; Antihypertensive Agents; Enalaprilat; Enzyme Inhibitors; Epinephrine; GT | 1998 |
Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 1998 |
Chronic AT1 receptor blockade alters aortic nerve activity in hypertension.
Topics: Afferent Pathways; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Blood | 1998 |
I'm a 57-year-old man with high blood pressure and high cholesterol. I had a hard time regulating my pressure until I went on Vasotec, which was great. But I developed a cough, so my doctor switched me to Cozaar. My cough stopped and my pressure seems oka
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Humans; Hypercholester | 1998 |
Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Calcium Channel B | 1998 |
Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Endothelins; Fema | 1998 |
Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Topics: Acrylamides; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Bl | 1998 |
Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; | 1998 |
Hypothalamic angiotensin receptor subtypes in normotensive and hypertensive rats.
Topics: Angiotensin II; Animals; Binding, Competitive; Hypertension; Hypothalamus; Imidazoles; Kinetics; Los | 1998 |
[Organ protection in hypertension therapy: Losartan--tested for effect on heart and kidney. 104th Congress of the German Society for Internal Medicine. Wiesbaden, 19 April 1998].
Topics: Antihypertensive Agents; Heart; Humans; Hypertension; Kidney; Losartan | 1998 |
Candesartan vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Confounding Factors, Epidemiologic; Hum | 1998 |
Angiotensin II receptor antagonists: what future?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Enalapril; Humans; Hypert | 1998 |
Angiotensin receptor blockade blunts hyperinsulinemia-induced hypertension in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; H | 1998 |
Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan.
Topics: Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Heart Ventricles; Hypertens | 1998 |
Effects of losartan and enalapril on small artery structure in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arteries; Blood Pressure; Cell Division; Dose-Response Relationshi | 1998 |
Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Capi | 1998 |
Mechanisms of spontaneous baroreflex impairment in lyon hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Barorefl | 1998 |
Losartan and renal transplantation.
Topics: Antihypertensive Agents; Erythrocyte Count; Erythropoiesis; Hematocrit; Humans; Hypertension; Kidney | 1998 |
Effects of angiotensin II and losartan in the forearm of patients with essential hypertension.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Enzyme Inhibitors; Female; Forearm; Humans; Hyperten | 1998 |
[Renal alterations in L-NAME hypertension: influence of losartan and bosentan].
Topics: Albuminuria; Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Enzyme Inh | 1998 |
AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; | 1998 |
Aphtous ulcers of the mouth associated with losartan.
Topics: Antihypertensive Agents; Dysgeusia; Female; Humans; Hypertension; Kidney Failure, Chronic; Lisinopri | 1998 |
Candesartan cilexetil vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Randomi | 1998 |
Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Hypertension; Losartan; Male; Rats; | 1998 |
Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Arginine Vasopressi | 1998 |
The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes.
Topics: Angiotensins; Animals; Antihypertensive Agents; Arginine Vasopressin; Blood Pressure; Brain Chemistr | 1998 |
Is uric acid really an independent cardiovascular risk factor?
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Male; Risk Factors; Ticrynafen; Uri | 1998 |
[Effects of angiotensin II receptors antagonist losartan on metabolism and morphofunctional condition myocardium in hypertensive patients].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; E | 1998 |
Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan.
Topics: Administration, Oral; Animals; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Myocardi | 1998 |
The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study.
Topics: Acrylates; Adult; Antihypertensive Agents; Black People; Enalapril; Female; Humans; Hypertension; Im | 1998 |
Role of angiotensin II in hyperinsulinemia-induced hypertension in rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pr | 1998 |
Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; An | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1998 |
Renal afferent arteriolar structure in the genetically hypertensive (GH) rat and the ability of losartan and enalapril to cause structural remodelling.
Topics: Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Enalapril; Heart Ventricles; Hypertens | 1998 |
Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Cardiomegaly; Desoxycorticosterone; Endothelium, V | 1998 |
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Cell Nucleus; Diastole; DNA; | 1999 |
Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modif | 1999 |
Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Imid | 1999 |
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel | 1999 |
Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the prague hypertensive rat.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bl | 1998 |
Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pr | 1999 |
[Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension].
Topics: Aged; Antihypertensive Agents; Circadian Rhythm; Drug Evaluation; Drug Therapy, Combination; Female; | 1998 |
Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypert | 1999 |
In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1999 |
Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decis | 1999 |
Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 1999 |
Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1999 |
Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Blotting, Northern; Cardiomyopathies; | 1999 |
Losartan and enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diclofenac; Enalapril; Endothelium; E | 1999 |
Treatment of moderate or severe arterial hypertension with losartan.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Humans; Hy | 1998 |
Differential response of angiotensin peptides in the urine of hypertensive animals.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anima | 1999 |
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; | 1999 |
An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Hypertension; Losartan; M | 1999 |
p53-mediated upregulation of BAX gene transcription is not involved in Bax-alpha protein overexpression in the left ventricle of spontaneously hypertensive rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Fluorescent Antibody Technique, Direct; Gene Express | 1999 |
Gout: beyond the stereotype.
Topics: Aged; Algorithms; Allopurinol; Chronic Disease; Diagnosis, Differential; Female; Gout; Gout Suppress | 1999 |
Vascular mitogen-activated protein kinase activity is enhanced via angiotensin system in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Calcium-Calmodulin-Dependent Protein Kinase | 1999 |
Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Female; Fenofibrate; Humans; Hyperten | 1999 |
Blockade of AT(1) receptors and Na(+)/H(+) exchanger and LV dysfunction after myocardial infarction in rats.
Topics: Amiloride; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blood Volume; Drug Combination | 1999 |
Renin activity and blood pressure in response to chronic episodic hypoxia.
Topics: Adrenal Medulla; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chem | 1999 |
Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan.
Topics: Adipocytes; Animals; Antihypertensive Agents; Biological Transport; Enalapril; Glucose; Hypertension | 1999 |
Salt-sensitive hypertension in ANP knockout mice is prevented by AT1 receptor antagonist losartan.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuret | 1999 |
Losartan-induced angioedema.
Topics: Angioedema; Antihypertensive Agents; Gout; Humans; Hypertension; Losartan; Male; Middle Aged | 1999 |
Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cells, C | 1999 |
Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Drug Interactions; Hypertension; I | 1999 |
Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cromakalim; Cyclooxygenase Inhibitors; Di | 1999 |
Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Aorta; Blood Pressure; DNA, Antisense; Fibrosis; | 1999 |
Efficacy of angiotensin II antagonists in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Aging; Angiotensin II; Animals; Antihypertensive Agents | 1999 |
Timed inhibition of the renin-angiotensin system suppresses the rise in blood pressure upon awakening in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Hemo | 2000 |
Blood pressure variability in established L-NAME hypertension in rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Enzyme Inhibitors; Hypertension; Losartan; Male; N | 1999 |
Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats.
Topics: Adrenomedullin; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Body Mass Index; Electrocardiography; Female; Humans; Hypertension; H | 2000 |
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; B | 2000 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart | 2000 |
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Apolipop | 1999 |
Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats : possible role in renoprotection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Transformed; Disease Mo | 2000 |
Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes.
Topics: Action Potentials; Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Electric Conductivity; H | 2000 |
[Antihypertensive efficacy of monotherapy in increasing doses versus therapy associated in low doses].
Topics: Antihypertensive Agents; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Losar | 1999 |
Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; | 2000 |
[Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis].
Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypert | 2000 |
Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypert | 2000 |
Changes in plasma norepinephrine and endothelin levels and metabolic profile after AT1-receptor blockade in human hypertension.
Topics: Aged; Antihypertensive Agents; Endothelin-1; Female; Hemodynamics; Humans; Hypertension; Losartan; M | 2000 |
[Clinical efficacy of losartan: are there any differences between angiotensin II type I receptor antagonists and other drugs?].
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Humans; Hypertension; Losar | 2000 |
Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cell Division; Enalapril; Hypertension; | 2000 |
Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Increased central AT(1)-receptor activation, not systemic vasopressin, sustains hypertension in ANP knockout mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arginine Vasopressin; Atrial Natriuretic Factor; B | 2000 |
Role of bradykinins and nitric oxide in the AT2 receptor-mediated hypotension.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blo | 2000 |
Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Collagen; Collagenases; Extracellular Mat | 2000 |
An angiotensin system in the anterior hypothalamic area anterior is involved in the maintenance of hypertension in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensins; Animals; Anterior Hypothalamic Nucleus; Antihypertensive Agents; Blood | 2000 |
[Differential approach to administration of cosaar].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Microc | 2000 |
ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimid | 2000 |
Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Desoxycorticoste | 2000 |
[Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 2000 |
Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Hypertension; Imidazoles; Los | 2000 |
Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice.
Topics: Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; | 1999 |
Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Blotting, Western | 2000 |
Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats.
Topics: Albuminuria; Animals; Blood Pressure; Blood Proteins; Creatinine; Desoxycorticosterone; Enzyme Inhib | 2000 |
Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Collagen; E | 2000 |
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens | 2000 |
Angiotensin II infused intrarenally causes preglomerular vascular changes and hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Respo | 2000 |
Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Echocardiography; Erythropoiesis; | 2000 |
Antihypertensive monotherapy and cardiovascular responses to an acoustic startle stimulus.
Topics: Acoustic Stimulation; Adrenergic alpha-Agonists; Analysis of Variance; Antihypertensive Agents; Aten | 2001 |
AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline.
Topics: Air Movements; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 2001 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Brain Edema; Drug Admini | 2001 |
Role of the central nervous system in the development of hypertension produced by chronic nitric oxide blockade in rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Nervous System; Enzyme Inhibi | 2001 |
[Treating not only blood pressure. Advantages for microcirculation].
Topics: Adult; Aged; Blood Pressure; Humans; Hypertension; Losartan; Microcirculation; Middle Aged; Randomiz | 2001 |
[Well tolerated sartans. More normal blood pressure finally?].
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Losartan; Randomized Controlled Trial | 2001 |
Mannitol-induced toxicity in a diabetic patient receiving losartan.
Topics: Acute Kidney Injury; Antihypertensive Agents; Diabetes Mellitus, Type 1; Diuretics, Osmotic; Drug Hy | 2001 |
[Pleasant added effect. Losartan improves sex in hypertension].
Topics: Humans; Hypertension; Impotence, Vasculogenic; Losartan; Male; Treatment Outcome | 2001 |
[When hypertension damages microcirculation. A-II-antagonist corrects damage, beta blocker does not].
Topics: Atenolol; Clinical Trials as Topic; Follow-Up Studies; Humans; Hypertension; Losartan; Microcirculat | 2001 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2001 |
Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Platelets; Bone Marrow | 2001 |
Antihypertensive effects of losartan and candesartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hype | 2001 |
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2001 |
[Evaluation of the evenness of the antihypertensive effect of losartan and captopril by using a 24-hour monitoring of arterial pressure].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2001 |
Differential effect of chronic antihypertensive treatment on vascular smooth muscle cell phenotype in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Cell Cycle; Cell Division; Cells, Cultu | 2001 |
Losartan use in mild to moderate hypertension--adverse effects in moderate to severe renal failure.
Topics: Antihypertensive Agents; Humans; Hypertension; Losartan; Renal Insufficiency | 2001 |
Sexual dimorphism in the response of thoracic aorta from SHRs to losartan.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, An | 2000 |
Endothelial and myocyte apoptosis--role of angiotensin II.
Topics: Angiotensin II; Apoptosis; Endothelium, Vascular; Humans; Hypertension; In Vitro Techniques; Losarta | 2001 |
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].
Topics: Adult; Antihypertensive Agents; Atenolol; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy | 2001 |
Angiotensin-II-receptor inhibitors in pregnancy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Antihypertensive Agents; Cesarean Secti | 2001 |
Tolerability of antihypertensive drugs in a community-based setting.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Canada; | 2001 |
Role of brain angiotensin II on somatosensory-induced antinatriuresis in hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Brain; Capsaicin; Diuresis; Hypert | 2001 |
Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Apolipoproteins E; Arteriosclerosi | 2001 |
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; D | 2001 |
Structural changes in the kidney induced by coarctation hypertension.
Topics: Animals; Antihypertensive Agents; Aortic Coarctation; Body Weight; Disease Models, Animal; Heart Rat | 2001 |
Fetal toxic effects and angiotensin-II-receptor antagonists.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensi | 2001 |
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trial | 1999 |
Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter.
Topics: Angiotensinogen; Animals; Astrocytes; Blood Pressure; Brain; Dose-Response Relationship, Drug; Drink | 2001 |
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Endothelin-1; En | 2001 |
Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice.
Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Animals; Antidiuretic Hormone Recept | 2001 |
Chronic AT(1) receptor blockade alters autonomic balance and sympathetic responses in hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Autonomic Nervous System; Blood | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Heart Rate; Hypertension; In | 2001 |
Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.
Topics: Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperten | 2001 |
Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy.
Topics: Animals; Anti-Bacterial Agents; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetic N | 2001 |
The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure Determination; Female; | 2001 |
Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
Topics: Aged; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2001 |
Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Endothelial factors and microvascular hypertensive disease.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |
Effects of angiotensin blockade in the rostral ventrolateral medulla on maintenance of hypertension induced by chronic L-NAME treatment.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Enzyme Inh | 2002 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetra | 2002 |
[Losartan and the kidney protection. The RENAAL study].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2001 |
Role of central angiotensin II receptors in cold-induced hypertension.
Topics: Animals; Antihypertensive Agents; Cold Temperature; Drinking Behavior; Gene Expression; Hypertension | 2002 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; El | 2002 |
[Stress intolerance in diastolic dysfunction. A case for AT1 blocker?].
Topics: Antihypertensive Agents; Diastole; Exercise Test; Heart Failure; Humans; Hypertension; Hypertrophy, | 2002 |
Altered balance of main vasopressor and vasodepressor systems in rats with genetic hypertension and hypertriglyceridaemia.
Topics: Analysis of Variance; Animals; Cyclic N-Oxides; Enzyme Inhibitors; Female; Hypertension; Hypertrigly | 2002 |
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiomegaly; Circadian | 2002 |
Dysregulation of angiotensin II synthesis is associated with salt sensitivity in the spontaneous hypertensive rat.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting | 2002 |
Angiotensin blockade for hypertension: a promise fulfilled.
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Humans; Hypertension; Losartan | 2002 |
Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Bl | 2002 |
[Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Drug Administration Schedule; Drug Ther | 2002 |
Interaction of ACE inhibitors and AT(1)-receptor blockers on maximum blood pressure response in spontaneous hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2002 |
Reversible ageusia induced by losartan: a case report.
Topics: Aged; Ageusia; Antihypertensive Agents; Female; Humans; Hypertension; Losartan | 2002 |
Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Case-Control Studi | 2002 |
Losartan potassium (Cozaar).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2002 |
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Topics: Administration, Oral; Allopurinol; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Con | 2002 |
Contemporary medical options for treating patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood | 1996 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pr | 2002 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |
Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; D | 2002 |
A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged | 2001 |
ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Humans; Hyp | 2002 |
[LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Risk Factors | 2002 |
Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Aging; Animals; Aorta, Thoracic; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activatio | 2002 |
[Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Rate; Hum | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
Glia- and neuron-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference.
Topics: Animals; Blood Pressure; Brain; DNA, Complementary; Green Fluorescent Proteins; Hypertension; Immuno | 2002 |
Losartan and the meaning of LIFE.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Losartan; Prognosis | 2002 |
Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diure | 2002 |
Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Disease Mo | 2002 |
Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cerebrovascular Disorders; Hypertension | 1992 |
Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1992 |
Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardi | 1992 |
Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive A | 1992 |
Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension.
Topics: Animals; Antihypertensive Agents; Arginine; Biphenyl Compounds; Blood Pressure; Hemodynamics; Hypert | 1992 |
Effects of renin-angiotensin system blockade in guinea pigs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Bradykinin; C | 1992 |
Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1992 |
[Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Com | 1992 |
Role of tissue renin in the pathophysiology of hypertension in TGR(mREN2)27 rats.
Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; B | 1992 |
Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.
Topics: Acrylates; Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphen | 1992 |
Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Analysis of Variance; Angiotensin II; Angiotensin-Convertin | 1990 |
Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Biphenyl Compo | 1992 |
Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Comp | 1991 |
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1991 |
Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Hypertension; Imidazoles; Kidney; Losartan; Rats; Rats, Inbred SHR | 1991 |
Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; Dogs; Dose-Respon | 1991 |
DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cerebrovascular Disorders; D | 1991 |
Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Hypertension; Imidazoles; Lo | 1991 |
Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1991 |
Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1990 |